{
    "results": [
        [
            0,
            "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.",
            [
                " {}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"],\"DRUGS\": [\"mentions of drugs, compounds, or substances found in text\"], \"DISEASES\": [\"mentions of diseases or conditions found in text\"], \"PROTEINS\": [\"mentions of proteins or biological molecules found in text\"], \"CELLS\": [\"mentions of cells found in text\"], \"GENES\": [\"mentions of genes found in text\"]}\n\nThere are no mentions of ages, drugs, diseases, proteins, cells, or genes in the provided text. Therefore, the output should be an empty dictionary.\n\n{\"AGE\": [], \"DRUGS\": [], \"DISEASES\": [], \"PROTEINS\": [], \"CELLS\": [], \"GENES\": []}",
                {}
            ]
        ],
        [
            1,
            "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.",
            [
                " {\"AGE\": [\"patient\"], \"disease\": [\"liposarcoma\"], \"medication_1\": [\"trabectedin\"], \"event\": [\"toxicity\", \"heavy toxicity\", \"rhabdomyolysis\"], \"time\": [\"fourth course\"], \"other_medication\": [\"alternative herbal medicine\"]}",
                {
                    "Pathology": [
                        "rhabdomyolysis",
                        "retroperitoneal liposarcoma",
                        "adverse event"
                    ],
                    "Drug": [
                        "trabectedin"
                    ]
                }
            ]
        ],
        [
            2,
            "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.",
            [
                " {}\n\nIn May 2009 he underwent surgical removal of the abdominal mass:\n{\"Surgery\": [\"surgical removal\"], \"Abdominal mass\": [\"abdominal mass\"]}\n\nachieving a complete margin negative (R0) resection:\n{\"Resection\": [\"achieving a complete margin negative\"], \"R0\": [\"R0 resection\"]}",
                {}
            ]
        ],
        [
            3,
            "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.",
            [
                " {\"LESION\": [\"lesion\"], \"SIZE\": [\"16 \u00d7 10 cm\"]}\n\nIn spite of chemotherapy, the lesion progressed rapidly and reached a size of 16 \u00d7 10 cm, extending into the pre-aortic seat of the retro-peritoneum space.",
                {}
            ]
        ],
        [
            4,
            "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.",
            [
                " {\"AGE\": [\"patient\", \"during\"]}\n\n\"trabectedin\"",
                {
                    "Drug": [
                        "trabectedin"
                    ]
                }
            ]
        ],
        [
            5,
            "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].",
            [
                " {\"AGE\": [\"cancer patients\", \"prolonged life expectancy\"]}\n\nThe Cytochrome P450 (CYP) system plays a crucial role in the metabolism of most chemotherapeutic drugs [9].\n\n{\"CYTOCHROME P450\": [\"CYP system\"]}\n\nThe CYP3A4 isoform is the most abundant and widely studied CYP isoform involved in drug metabolism in humans [10].\n\n{\"CYTOCHROME P450 ISFORMS\": [\"CYP3A4\"]}\n\nThe interaction between CYP3A4 and chemotherapeutic drugs can lead to increased drug toxicity, decreased drug efficacy, or both [11].\n\n{\"DRUGS\": [\"chemotherapeutic drugs\"]}\n\nThe interaction between CYP3A4 and paclitaxel, a widely used chemotherapeutic drug, has been extensively studied [12].\n\n{\"PACLITAXEL\": []}\n\nThe interaction between CYP3A4 and docetaxel, another chemotherapeutic drug, has also been reported [13].\n\n{\"DOCETAXEL\": []}\n\nThe interaction between CYP3A4 and irinotecan, a topoisomerase I inhibitor, has been shown to increase the risk of severe diarrhea and neutropenia [14].\n\n{\"IRINOTECAN\": []}\n\nThe interaction between CYP3A4 and 5-fluorouracil, a pyrimidine antimetabolite, can lead to increased toxicity and decreased efficacy [15].\n\n{\"5-FLUOROURACIL\": []}\n\nThe interaction between CYP3A4 and capecitabine, an oral prodrug of 5-fluorouracil, can also result in increased toxicity [16].\n\n{\"CAPECITABINE\": []}\n\nThe interaction between CYP3A4 and gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, can lead to decreased efficacy [17].\n\n{\"GEFITINIB\": []}\n\nThe interaction between CYP3",
                {
                    "Pathology": [
                        "cancer",
                        "cancer-related syndromes",
                        "treatment-induced toxicity"
                    ]
                }
            ]
        ],
        [
            6,
            "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.",
            [
                " {\"AGE\": []}\n\n\"The following format must be followed:\", \"format\"\n\n\"This is a scientific article about pharmacology.\", \"pharmacology\"\n\n\"We need to parse all the cited entities.\", \"entities\"\n\n\"Find every word refering to the described entities.\", \"described entities\"\n\n\"The patient took a commercial preparation of chokeberry juice\", \"commercial preparation\", \"chokeberry juice\"\n\n\"which did not provide information on the amounts of its compounds.\", \"compounds\"\n\n\"It cannot be excluded that other interactions might have occurred\", \"interactions\"\n\n\"such as the inhibition of transport mechanisms, the activation of the death receptor\", \"transport mechanisms\", \"death receptor\"\n\n\"and other unknown mechanisms.\", \"unknown mechanisms\"",
                {
                    "Extraction process": [
                        "chokeberry juice"
                    ]
                }
            ]
        ],
        [
            7,
            "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.",
            [
                " {\"AGE\": []}\n\nThis case report emphasizes the intricacy surrounding medicinal cannabis and the health hazards linked to its utilization.",
                {
                    "Herb name": [
                        "cannabis"
                    ]
                }
            ]
        ],
        [
            8,
            "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.",
            [
                " {\"AGE\": [],\n \"cannabis\": [\"patient took cannabis\"],\n \"chronic back pain\": [],\n \"PGx\": [\"test indicated the presence of variants\"],\n \"COMT\": [\"variants for the COMT gene\"],\n \"HTR2A\": [\"variants for the HTR2A gene\"]}",
                {
                    "Herb name": [
                        "cannabis"
                    ],
                    "Pathology": [
                        "chronic back pain"
                    ]
                }
            ]
        ],
        [
            9,
            "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].",
            [
                " {\"AGE\": [],\n \"Disease PD\": [\"Parkinson's disease\"],\n \"Region\": [\"this region\"],\n \"Neuronal death\": [\"Neuronal death in this region\"],\n \"Dopamine\": [\"dopamine concentrations\", \"concentrations of dopamine\"],\n \"Treatment\": [\"treatment strategies\", \"initiating medications\"],\n \"Carbidopa-levodopa\": [\"carbidopa-levodopa\"],\n \"Ropinirole\": [\"ropinirole\"],\n \"Entacapone\": [\"entacapone\"],\n \"Improve movement control\": [\"improve movement control\"]}",
                {
                    "Pathology": [
                        "PD"
                    ],
                    "Drug": [
                        "carbidopa-levodopa",
                        "ropinirole",
                        "entacapone"
                    ]
                }
            ]
        ],
        [
            10,
            "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.",
            [
                " {\"AGE\": [],\n \"cannabis\": [\"cannabis\"],\n \"pharmacokinetic\": [\"pharmacokinetic\"],\n \"pharmacodynamic\": [\"pharmacodynamic\"],\n \"effects\": [\"effects\"],\n \"individual\u2019s\": [\"individual's\"],\n \"pharmacogenomic\": [\"pharmacogenomic\"],\n \"PGx\": [\"PGx\"],\n \"patient\u2019s\": [\"patient's\"],\n \"medication\": [\"medication\"],\n \"regimen\": [\"regimen\"],\n \"therapeutic\": [\"therapeutic\"],\n \"response\": [\"response\"],\n \"adverse\": [\"adverse\"],\n \"drug\": [\"drug\"],\n \"events\": [\"events\"]}",
                {
                    "Herb name": [
                        "cannabis"
                    ],
                    "Pathology": [
                        "adverse drug events"
                    ]
                }
            ]
        ],
        [
            11,
            "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.",
            [
                " {\"AGE\": [\"patient's\", \"history includes\"]}\n{\"SPINAL STENOSIS\": []}\n{\"VITAMIN D DEFICIENCY\": []}\n{\"FREQUENT FALLS\": []}\n{\"NICOTINE\": []}\n{\"ALCOHOL DEPENDENCE\": []}\n{\"MILD KIDNEY DISEASE\": []}\n{\"CHRONIC NECK\": []}\n{\"BACK\": []}\n{\"SHOULDER PAIN\": []}",
                {
                    "Pathology": [
                        "PD",
                        "spinal stenosis",
                        "vitamin D deficiency",
                        "frequent falls",
                        "mild kidney disease",
                        "chronic neck, back, and shoulder pain"
                    ]
                }
            ]
        ],
        [
            12,
            "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).",
            [
                " {\"AGE\": [\"his\"]}\n\n\"The clinical pharmacist recommended dose increases of carbidopa-levodopa\": {\"carbidopa-levodopa\": [\"carbidopa-levodopa\"]}}",
                {
                    "Drug": [
                        "carbidopa-levodopa"
                    ],
                    "Pathology": [
                        "tremors"
                    ]
                }
            ]
        ],
        [
            13,
            "However, his PCP determined that additional medication for pain control was warranted.",
            [
                " {\"AGE\": []}\n\nhis PCP determined that additional medication for pain control was warranted.\n- his\n- his PCP\n- pain control\n- additional medication",
                {}
            ]
        ],
        [
            14,
            "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].",
            [
                " {\"AGE\": []}\n\nfactors: [\"numerous factors\"],\ndiscrepancies: [\"discrepancies\"],\nstudy results: [\"study results\"],\npain models: [\"pain models\"],\nhealthy subjects: [\"healthy subjects\"],\npatients: [\"patients\"],\nroutes of administration: [\"routes of administration\"],\ninhalation: [\"inhalation\"],\noral: [\"oral\"],\nsources: [\"sources\"]",
                {
                    "Pathology": [
                        "pain",
                        "healthy"
                    ]
                }
            ]
        ],
        [
            15,
            "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].",
            [
                " {\"CB1Rs\": [\"CB1Rs on presynaptic neurons\"]}\n{\"AGE\": [], \"dopamine\": [\"dopamine levels\"], \"neurotransmitter\": [\"inhibitory neurotransmitter levels\"]}",
                {
                    "Target": [
                        "CB1Rs"
                    ],
                    "Parameter": [
                        "dopamine levels"
                    ]
                }
            ]
        ],
        [
            16,
            "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.",
            [
                " {\"PGx\": [\"patient's PGx results\"], \"COMT\": [\"COMMT Met/Met\"]}",
                {}
            ]
        ],
        [
            17,
            "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].",
            [
                " {\"PD\": [\"patients with PD\"]}\n\nOne out of five patients experienced hallucinations [12].",
                {
                    "Pathology": [
                        "PD",
                        "hallucinations"
                    ],
                    "Herb name": [
                        "cannabis"
                    ]
                }
            ]
        ],
        [
            18,
            "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].",
            [
                " {\"CYP2D6\": [\"does not utilize for metabolism\"]}\n\nThe clinical pharmacist suggested morphine as an alternative for this patient. [No mentions of ages or other specific entities found in this text.]",
                {
                    "Pathology": [
                        "pain"
                    ],
                    "Drug": [
                        "morphine"
                    ]
                }
            ]
        ],
        [
            19,
            "The authors want to thank Katie Meyer for her assistance.",
            [
                " {\"Catie Meyer\": [\"the authors want to thank\", \"Katie Meyer\"]}\n\nThe present investigation was designed to elucidate the molecular mechanisms underlying the cardioprotective effects of [l-arginine](http://en.wikipedia.org/wiki/L-arginine) in the setting of ischemia-reperfusion injury.\n\n{\"l-arginine\": [\"the present investigation was designed to elucidate the molecular mechanisms underlying the cardioprotective effects of\", \"l-arginine\"]}\n\nIschemia-reperfusion injury was induced by ligating the left coronary artery for 30 minutes followed by reperfusion for 2 hours.\n\n{\"ischemia-reperfusion injury\": [\"was induced by ligating the left coronary artery for 30 minutes followed by reperfusion for 2 hours\"]}\n\nThe cardioprotective effects of [l-arginine](http://en.wikipedia.org/wiki/L-arginine) were assessed by measuring infarct size, left ventricular function, and oxidative stress markers.\n\n{\"infarct size\": [\"were assessed by measuring\"], [\"left ventricular function\": [\"were assessed by measuring\"]], [\"oxidative stress markers\": [\"were assessed by measuring\"]]}\n\n[Nitric oxide](http://en.wikipedia.org/wiki/Nitric_oxide) production was increased in the [l-arginine](http://en.wikipedia.org/wiki/L-arginine)-treated group, as evidenced by a significant increase in nitrite/nitrate levels.\n\n{\"nitrite/nitrate levels\": [\"was evidenced by a significant increase in\"], [\"nitric oxide\": [\"production was increased in the l-arginine-treated group\"]]}\n\nMoreover, [l-arginine](http://en.wikipedia.org/wiki/L-arginine) pretreatment attenuated myocardial [apoptosis](http://en.wikipedia.org/wiki/Apoptosis), as indicated by a decrease in apoptotic index.\n\n{\"apoptotic index\": [\"was indicated by a decrease in\"], [\"myocardial apoptosis\": [\"attenuated by l-arginine pretreatment",
                {}
            ]
        ],
        [
            20,
            "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.",
            [
                " {\"CAM\": [\"conventional medicines integrated with\", \"Complementary and Alternative Medicine\"]}\n{\"DECADES\": [\"the past two decades\"]}\n{\"RATE\": [\"increased rate\"]}\n{\"WORLD\": [\"the world\"]}\n{\"CONVENTIONAL MEDICINES\": [\"conventional medicines\"]}\n{\"CAM\": [\"CAM\"]}\n{\"TREATMENT\": [\"for treatment\"]}",
                {
                    "Duration": [
                        "the past two decades"
                    ]
                }
            ]
        ],
        [
            21,
            "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].",
            [
                " {\"CHINA\": [\"In China\"], \"PERCENTAGE\": [\"93.4%\"], \"YEAR\": [\"2009-2010\"], \"PATIENTS\": [\"cancer patients\"]}\n\nReferences:\n[4]: {\"REFERENCE\": [\"[4]\"]}\n\nNote: No specific entities were mentioned in the given text related to the pharmacological aspect of the article.",
                {
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            22,
            "In South Korean population reported a range from 29% to 83% [5].",
            [
                " {\"AGE\": [\"29%\", \"83%\", \"South Korean population\"]}\n\nReferences:\n[5]: {\"Publication\": [], \"Authors\": [], \"Year\": [], \"Title\": [], \"Journal\": [], \"Volume\": [], \"Issue\": [], \"Pages\": [], \"DOI\": [], \"PMID\": [], \"CitedEntities\": {}}\n\"The prevalence of hypertension in South Korea was reported to be between 29% and 83% in the South Korean population\"[5].",
                {
                    "Ethnic group": [
                        "South Korean"
                    ]
                }
            ]
        ],
        [
            23,
            "An important fact is that most of these affected drugs have very narrow therapeutic indices.",
            [
                " {\"AGE\": [],\n \"drugs\": [\"affected drugs\", \"most of these affected drugs\"]}",
                {}
            ]
        ],
        [
            24,
            "To date an increasing number of studies in evaluating HDIs have been reported [11].",
            [
                " {\"HDIs\": [\"hydrosoluble isoflavones\", \"an increasing number of studies\"]}\n\nTo date an increasing number of studies in evaluating HDIs have been reported [11]. In particular, HDIs have been shown to exhibit a wide range of pharmacological activities, including [12]:\n\n{\"ANTIOXIDANT\": [\"pharmacological activities\", \"have been shown to exhibit a wide range of\", \"include\"], \"ANTI-INFLAMMATORY\": [\"pharmacological activities\"], \"ANTI-CANCER\": [\"pharmacological activities\"], \"NEUROPROTECTIVE\": [\"pharmacological activities\"]}\n\n1. Antioxidant activity: HDIs have been reported to scavenge free radicals and inhibit lipid peroxidation [13, 14].\n2. Anti-inflammatory activity: HDIs have been shown to inhibit the production of inflammatory cytokines and inhibit the activity of cyclooxygenase-2 (COX-2) [15, 16].\n3. Anti-cancer activity: HDIs have been reported to inhibit the growth of various types of cancer cells, including breast cancer, colon cancer, and prostate cancer [17-19].\n4. Neuroprotective activity: HDIs have been shown to protect neurons from oxidative stress and excitotoxicity, and improve cognitive function [20-22].\n\nTherefore, HDIs represent a promising class of natural compounds with a wide range of therapeutic applications.\n\n{\"HDIs\": [\"hydrosoluble isoflavones\", \"an increasing number of studies\", \"have been reported to scavenge free radicals and inhibit lipid peroxidation\", \"have been shown to inhibit the production of inflammatory cytokines and inhibit the activity of cyclooxygenase-2 (COX-2)\", \"have been reported to inhibit the growth of various types of cancer cells, including breast cancer, colon cancer, and prostate cancer\", \"have been shown to protect neurons from oxidative stress and excitotoxicity, and improve cognitive function\"]}",
                {}
            ]
        ],
        [
            25,
            "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.",
            [
                " {\"PHARMACOGENOMICS\": [\"pharmacogenomics studies\"], \"CLINIC STUDY\": [\"clinic study\"], \"HERB PRODUCTS\": [\"some important herb products\"], \"HDIs\": [\"have been reported to have HDIs\"]}",
                {
                    "Study": [
                        "pharmacogenomics studies",
                        "clinic study"
                    ]
                }
            ]
        ],
        [
            26,
            "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).",
            [
                " {\"TPMT gene\": [\"thiopurine S-methyltransferase gene\"], \"rs1142345 (A>G) SNP\": [\"rs1142345\", \"SNP\"]}",
                {
                    "Parameter": [
                        "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"
                    ],
                    "Pathology": [
                        "hypoglycemic"
                    ]
                }
            ]
        ],
        [
            27,
            "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.",
            [
                " {\"rs1142345\": [\"was associated with\", \"clinical effect of traditional hypoglycemic herbs\"]}",
                {
                    "Parameter": [
                        "rs1142345"
                    ],
                    "Pathology": [
                        "hypoglycemic"
                    ]
                }
            ]
        ],
        [
            28,
            "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.",
            [
                " {\"AGE\": [],\n \"AUC\": [\"concentration-time curve\"],\n \"EMs\": [\"extensive metabolizer\"],\n \"PM\": [\"poor metabolizer\"]}",
                {
                    "Parameter": [
                        "AUC: concentration-time curve"
                    ]
                }
            ]
        ],
        [
            29,
            "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nWith the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications have increased tremendously over the last decade [1,2].\n\n{\"AGE\": []}\n\ndecade - not a mention of age.\nboom - not an entity.\nconventional therapeutic drugs - not an entity.\nutilization - not an entity.\nherbal remedies - not an entity.\nin combination with other medications - not an entity.\nover the last decade - not an entity.",
                {}
            ]
        ],
        [
            30,
            "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.",
            [
                " {\"Cameroon\": [\"Faangum\"], \"Cameroon, Cameroonian\": [], \"Ghana\": [\"Sasanemasa\", \"Sesemasa\", \"Esisimansa\"], \"Togo\": [\"Lifui\"], \"Nigeria\": [\"Akoko\"], \"shrub\": []}\n\nThe Faangum shrub is indigenous to Cameroon.\n\nLocal names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.\n\nThe active principles of the Sesamum indicum L. (Sesame) seeds were investigated for their anti-inflammatory and analgesic activities.\n\n{\"Sesame\": [\"Sesamum indicum L.\"], \"Sesame seeds\": [\"Sesame indicum L.\"], \"L\": [\"Linnaeus\"]}\n\nThe active principles of the Sesame seeds were investigated for their anti-inflammatory and analgesic activities.\n\nThe methanolic extract of the seeds of Sesamum indicum L. (Sesame) was used for the study.\n\n{\"methanolic extract\": [], \"seeds\": [\"seeds of Sesame\"], \"Sesame\": [\"Sesamum indicum L.\"], \"L\": [\"Linnaeus\"]}\n\nThe methanolic extract of the Sesame seeds was used for the study.\n\nThe methanolic extract was subjected to column chromatography using silica gel as the stationary phase.\n\n{\"methanolic extract\": [], \"column chromatography\": [], \"silica gel\": []}\n\nThe methanolic extract was subjected to column chromatography using silica gel as the stationary phase.\n\nThe active compounds were identified by comparing their spectral data with those reported in the literature.\n\n{\"active compounds\": [], \"spectral data\": []}\n\nThe active compounds were identified by comparing their spectral data with those reported in the literature.\n\nThe major active compounds identified were sesamin, sesamolin, sesamol, and sesaminol.\n\n{\"sesamin\": [], \"sesamolin\": [], \"sesamol\": [],",
                {
                    "Herb name": [
                        "Faangum",
                        "Sasanemasa/Sesemasa",
                        "Esisimansa",
                        "Lifui",
                        "Akoko"
                    ]
                }
            ]
        ],
        [
            31,
            "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].",
            [
                " {\"CYP450\": [\"cytochrome P450\", \"CYP450 family\"]}\n\nThe biotransformation of about 70% of xenobiotics and other endogenous substances [14]:\n{\"xenobiotics\": [\"xenobiotics and other endogenous substances\"]}",
                {
                    "Target": [
                        "cytochrome P450 (CYP450)"
                    ]
                }
            ]
        ],
        [
            32,
            "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.",
            [
                " {\"CYP1A2\": [\"effects on\", \"activities of\"],\n \"CYP2C9\": [\"activities of\"],\n \"CYP2C19\": [\"activities of\"],\n \"Newbouldia laevis\": [],\n \"Cassia abbreviata\": []}",
                {
                    "Extraction process": [
                        "extracts"
                    ],
                    "Herb name": [
                        "Newbouldia laevis",
                        "Cassia abbreviata"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C9",
                        "CYP2C19"
                    ]
                }
            ]
        ],
        [
            33,
            "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.",
            [
                " {\"LINEAR REGRESSION ANALYSIS\": [\"used to determine the K A\"],\n \"K A\": [\"determined\"],\n \"TIME COURSE\": [\"used for linear regression analysis\"],\n \"NON-TARGETED APPROACH\": [\"used\"],\n \"METABOLITES\": [\"present in the analysed samples\"]}",
                {}
            ]
        ],
        [
            34,
            "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.",
            [
                " {\"AGE\": [],\n \"herbal extracts\": [\"herbal extracts\"],\n \"bioavailability\": [\"bioavailability\"],\n \"intestinal absorption\": [\"intestinal absorption\"],\n \"plasma concentration\": [\"plasma concentration\"],\n \"test compounds\": [\"test compounds\"],\n \"GIT tract\": [\"GIT tract\"],\n \"soluble extract\": [\"soluble extract\"]}",
                {
                    "Extraction process": [
                        "extracts",
                        "soluble extract"
                    ],
                    "Parameter": [
                        "bioavailability",
                        "bioavailable concentration"
                    ]
                }
            ]
        ],
        [
            35,
            "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.",
            [
                " {\"HERBAL MEDICINAL REMEDIES\": [\"herbal medicinal remedies\"],\n \"RESEARCHERS\": [\"researchers\"],\n \"GUIDELINES\": [\"guidelines\"],\n \"OPINIONS\": [\"opinions\"],\n \"DDI\": [\"DDI\"],\n \"HDI\": [\"herb-drug interactions\"]}",
                {
                    "Study": [
                        "DDI studies"
                    ]
                }
            ]
        ],
        [
            36,
            "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.",
            [
                " {\"TDI\": [\"the TDI effects\"], \"herbals\": [\"these herbals\"], \"patients\": [\"patients chronically use them\"], \"sufficient intermediary metabolites\": [\"sufficient intermediary metabolites may be generated\"], \"consumers\": [\"consumers concomitantly taking conventional medications\"]}",
                {}
            ]
        ],
        [
            37,
            "Extraction was performed using water to mimic the indigenous mode of extraction.",
            [
                " {\"Water\": [\"was used\", \"to mimic the indigenous mode of extraction\"]}",
                {}
            ]
        ],
        [
            38,
            "[44].",
            [
                " {\"AGE\": []}\n\nThe following entities were identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"scientific article\"\n4. \"parsing\"\n5. \"entities\"\n6. \"find\"\n7. \"every word\"\n8. \"referring\"\n9. \"described entities\"\n\n{\"entities\": [\"pharmacology\", \"cited entities\", \"scientific article\", \"parsing\", \"entities\", \"find\", \"every word\", \"referring\", \"described entities\"]}",
                {}
            ]
        ],
        [
            39,
            "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.",
            [
                " {\"Waters Corporation\": [\"Milford, MA, USA\"],\n \"Acquity BEH C18 column\": [\"2.1 mm \u00d7 100 mm\", \"1.7 \u00b5m particle size\"],\n \"binary pump\": [],\n \"vacuum degasser\": [],\n \"autosampler\": [],\n \"column oven\": [],\n \"Micromass Xevo tandem quadrupole mass spectrometric detector\": [\"QTOF xevo G2\"],\n \"Waters micromass\": [\"Manchester, UK\"],\n \"ESI probe\": []}",
                {
                    "Extraction process": [
                        "extracts",
                        "extracts"
                    ],
                    "Target": [
                        "NADP"
                    ]
                }
            ]
        ],
        [
            40,
            "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.",
            [
                " {\"HDI\": [], \"IVIVE\": [], \"Drug-Drug Interaction\": [], \"in vitro\": [], \"in vivo\": [], \"extrapolation\": [], \"pharmacological tool\": [], \"predict\": [], \"currently\": [], \"specific\": [], \"almost all\": [], \"deal\": [], \"one\": [\"inhibitor\", \"drug\"], \"and\": [], \"one\": [\"victim-drug\"]}",
                {}
            ]
        ],
        [
            41,
            "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.",
            [
                " {\"SLC22 family members\": [\"29 putative\", \"18 of which are believed to be\"]}\n{\"OATs\": [\"18 of which are believed to be\"]}",
                {
                    "Parameter": [
                        "SLC22",
                        "OATs"
                    ]
                }
            ]
        ],
        [
            42,
            "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].",
            [
                " {\"Oat1\": [\"have been identified\", \"interact with\"], \"Oat3\": [\"have been identified\", \"interact with\"], \"none\": [\"mentions of ages found in text\"]}",
                {
                    "Parameter": [
                        "Oat1",
                        "Oat3"
                    ]
                }
            ]
        ],
        [
            43,
            "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.",
            [
                " {\"Danshen components\": [\"These latter two transporter families and the OATs have fairly distinct substrate interactions with Danshen components.\"],\n \"transporter families\": [],\n \"OATs\": [\"These latter two transporter families and the OATs\"]}",
                {
                    "Parameter": [
                        "transporter families",
                        "the OATs"
                    ],
                    "Herb name": [
                        "Danshen components"
                    ]
                }
            ]
        ],
        [
            44,
            "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.",
            [
                " {\"AGE\": []}\n\nIntroduction: The incidence of type 2 diabetes is increasing in the community.\n\n(No mentions of specific entities found in this section)",
                {
                    "Drug": [
                        "gliclazide"
                    ],
                    "Herb name": [
                        "St John's wort"
                    ],
                    "Target": [
                        "CYP2C9"
                    ],
                    "Pathology": [
                        "type 2 diabetes"
                    ]
                }
            ]
        ],
        [
            45,
            "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).",
            [
                " {\"AGE\": [\"31%\"], \"diabetic patients\": [\"31%\"], \"alternative medicines\": [\"31%%\"], \"conventional medicines\": [\"31%\"]}",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            46,
            "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).",
            [
                " {\"AGE\": [],\n \"Oida\": [\"Oida et al.\"],\n \"metabolites\": [\"metabolites\", \"four of these metabolites\", \"identified in urine\", \"represented\"],\n \"positions\": [\"6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions\"],\n \"mentions of ages\": [],\n \"dose\": [\"dose\"],\n \"96\u2009h\": [\"96 hours\"],\n \"respectively\": []}",
                {}
            ]
        ],
        [
            47,
            "Elliot et al.",
            [
                " {\"Authors\": [\"Elliot\", \"et\", \"al.\"], \"Year\": [], \"Journal\": [], \"Title\": [], \"Subject Area\": [], \"Drugs\": [], \"Dosage\": [], \"Route\": [], \"Population\": [], \"Animal Model\": [], \"Disease\": [], \"Findings\": [], \"Methods\": []}\n\nThe given text does not provide enough information to extract any entities related to age, year, journal title, title, subject area, drugs, dosage, route, population, animal model, disease, findings, or methods. The given text only provides the authors' names.",
                {}
            ]
        ],
        [
            48,
            "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.",
            [
                " {\"CYP2C9\": [\"CYP2C9*2\", \"CYP2C9*3\"]}\n\nPolymerase chain reaction-RFLP analysis: {}",
                {
                    "Target": [
                        "CYP2C9*2",
                        "CYP2C9*3"
                    ]
                }
            ]
        ],
        [
            49,
            "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).",
            [
                " {\"PCR\": [\"PCR was performed\"], \"HotMasterMix\": [\"2.5 \u00d7 HotMasterMix\"], \"Eppendorf\": [\"Eppendorf, Westbury, NY, USA\"]}",
                {}
            ]
        ],
        [
            50,
            "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.",
            [
                " {\"Gliclazide\": [\"gliclazide\"]}\n{\"Day\": [\"day\", \"days\"], \"Participants\": []}",
                {
                    "Herb name": [
                        "caffeine",
                        "grapefruit"
                    ],
                    "Drug": [
                        "gliclazide"
                    ]
                }
            ]
        ],
        [
            51,
            "(2003).",
            [
                " {\"AGE\": []}\n\n{\"CITED\\_ENTITIES\": [\n{\"ADENOSINE\\_RECEPTORS\": [\"adenosine receptors\"]},\n{\"AMPA\\_RECEPTORS\": [\"AMPA receptors\"]},\n{\"ANESTHETICS\": [\"anesthetics\"]},\n{\"BENZODIAZEPINE\\_RECEPTORS\": [\"benzodiazepine receptors\"]},\n{\"BINDING\\_SITES\": [\"binding sites\"]},\n{\"CANNABINOID\\_RECEPTORS\": [\"cannabinoid receptors\"]},\n{\"CHLORIDE\\_IONS\": [\"chloride ions\"]},\n{\"DOPAMINE\\_RECEPTORS\": [\"dopamine receptors\"]},\n{\"GABA\\_RECEPTORS\": [\"GABA receptors\"]},\n{\"GLUTAMATE\\_RECEPTORS\": [\"glutamate receptors\"]},\n{\"GTP\": [\"GTP\"]},\n{\"ION\\_CHANNELS\": [\"ion channels\"]},\n{\"KETAMINE\": [\"ketamine\"]},\n{\"LIGANDS\": [\"ligands\"]},\n{\"MUSCARINIC\\_ACETYLCHOLINE\\_RECEPTORS\": [\"muscarinic acetylcholine receptors\"]},\n{\"NMDA\\_RECEPTORS\": [\"NMDA receptors\"]},\n{\"NICOTINIC\\_ACETYLCHOLINE\\_RECEPTORS\": [\"nicotinic acetylcholine receptors\"]},\n{\"OPIOID\\_RECEPTORS\": [\"opioid receptors\"]},\n{\"PHARMACOLOGY\": [\"pharmacology\"]},\n{\"PROTEINS\": [\"proteins\"]},\n{\"RECEPTORS\": [\"receptors\"]},\n{\"SEROTONIN\\_RECEPTORS\": [\"serotonin receptors\"]},\n{\"SODIUM\\_IONS\": [\"sodium ions\"]}\n]}\n\n{\"2003\": []}",
                {}
            ]
        ],
        [
            52,
            "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.",
            [
                " {\"AGE\": [],\n \"CYP2C9\": [\"CYP2C9*3\", \"CYP2C9\"],\n \"CL/F\": [\"CL/Fs\"],\n \"glipizide\": [\"glipizide\", \"Kidd et al., 1999\"],\n \"tolbutamide\": [\"tolbutamide\", \"Kirchheiner et al., 2002a\"]}",
                {
                    "Target": [
                        "CYP2C9*3 allele"
                    ],
                    "Parameter": [
                        "CL/Fs"
                    ],
                    "Drug": [
                        "glipizide",
                        "tolbutamide"
                    ]
                }
            ]
        ],
        [
            53,
            "Park et al.",
            [
                " {\n\"AGE\": [],\n\"AUTHORS\": [\"Park\"],\n\"ET_AL\": [\"et al.\"],\n\"JOURNAL\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGE_START\": [],\n\"PAGE_END\": [],\n\"YEAR\": []\n}",
                {}
            ]
        ],
        [
            54,
            "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.",
            [
                " {\"CMV\": [\"acute cytomegalovirus\"], \"EBV\": [\"Epstein Barr virus\"]}",
                {
                    "Pathology": [
                        "acute cytomegalovirus (CMV",
                        "Epstein Barr virus (EBV"
                    ]
                }
            ]
        ],
        [
            55,
            "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.",
            [
                " {\"ANA\": [\"Antinuclear antibody\"], \"smooth muscle antibody\": [\"smooth muscle antibody\"]}\n\nThe titers of ANA and smooth muscle antibody were:\n- ANA: 1 : 40\n- smooth muscle antibody: 1 : 80.",
                {
                    "Parameter": [
                        "Antinuclear antibody (ANA",
                        "smooth muscle antibody"
                    ],
                    "Amount": [
                        "1 : 40",
                        "1 : 80"
                    ]
                }
            ]
        ],
        [
            56,
            "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).",
            [
                " {\"AGE\": [],\n \"Liver\": [\"liver\", \"livers\", \"hepatitis\", \"portal tracts\", \"hepatocyte\", \"cholangiolar\"],\n \"Disease\": [\"hepatitis\"],\n \"Histology\": [\"histology\"],\n \"Chronic\": [\"chronic\"],\n \"Fibroinflammatory\": [\"fibroinflammatory\"],\n \"Expansion\": [\"expansion\"],\n \"Portal tracts\": [\"portal tracts\"],\n \"Moderate\": [\"moderate\"],\n \"Plasma cell rich\": [\"plasma cell rich\"],\n \"Interface hepatitis\": [\"interface hepatitis\"],\n \"Rare\": [\"rare\"],\n \"Periportal\": [\"periportal\"],\n \"Hepatocyte\": [\"hepatocyte\"],\n \"Apoptosis\": [\"apoptosis\"],\n \"Mild\": [\"mild\"],\n \"Cholangiolar\": [\"cholangiolar\"],\n \"Proliferation\": [\"proliferation\"],\n \"Figures\": [\"figures\"],\n \"1\": [\"1(a)\", \"1(b)\"]}",
                {
                    "Pathology": [
                        "chronic hepatitis",
                        "interface hepatitis"
                    ],
                    "Parameter": [
                        "periportal hepatocyte"
                    ]
                }
            ]
        ],
        [
            57,
            "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.",
            [
                " {\"AGE\": []}\n\nThe clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.\n\n(No specific entities were mentioned in this excerpt.)",
                {}
            ]
        ],
        [
            58,
            "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.",
            [
                " {\"AGE\": [\"she\", \"by the time of her presentation\"]}\n\nAlthough she was initially asymptomatic, she developed:\n{\"SYMPTOMS\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"]}\n\nby the time of her presentation.",
                {
                    "Pathology": [
                        "right upper quadrant abdominal pain",
                        "fatigue",
                        "lower extremity edema"
                    ]
                }
            ]
        ],
        [
            59,
            "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].",
            [
                " {\"American College of Obstetrics and Gynecology\": [\"included\"], \"black cohosh\": [\"mentioned as a possible remedy\"]}\n\nThe phytochemical constituents of black cohosh, Actaea racemosa (L.), have been studied extensively for their potential therapeutic effects [16, 17, 18].\n\n{\"Actaea racemosa\": [\"mentioned as the source of phytochemical constituents\"], \"phytochemical constituents\": [\"studied extensively\"]}\n\nThe major active compounds of black cohosh are triterpene glycosides, specifically actein and 27-deoxyactein, and isoflavones, such as formononetin and 2'-hydroxymethylactein [16, 17, 18].\n\n{\"actein\": [\"mentioned as a major active compound\"], \"27-deoxyactein\": [\"mentioned as a major active compound\"], \"formononetin\": [\"mentioned as an isoflavone\"], \"2'-hydroxymethylactein\": [\"mentioned as an isoflavone\"]}\n\nThe mechanism of action of black cohosh in the treatment of menopausal symptoms is not fully understood, but it is believed to act through modulation of estrogen receptors and neurotransmitter systems [19].\n\n{\"menopausal symptoms\": [\"mentioned as the condition treated by black cohosh\"], \"estrogen receptors\": [\"mentioned as a potential target of black cohosh\"], \"neurotransmitter systems\": [\"mentioned as a potential target of black cohosh\"]}\n\nSeveral studies have investigated the effects of black cohosh on vasomotor symptoms, such as hot flashes and night sweats, in menopausal women [20, 21, 22].\n\n{\"vasomotor symptoms\": [\"mentioned as the symptoms studied\"], \"hot flashes\": [\"mentioned as a vasomotor symptom\"], \"night sweats\": [\"mentioned as a vasomotor symptom\"]}\n\nA randomized, double-blind, placebo-controlled trial involving 125 men",
                {
                    "Ethnic group": [
                        "American"
                    ],
                    "Herb name": [
                        "black cohosh"
                    ],
                    "Pathology": [
                        "menopause"
                    ]
                }
            ]
        ],
        [
            60,
            "This case culminated in liver failure despite discontinuation of the herbal supplement [4].",
            [
                " {\"AGE\": []}\n\nThis case culminated in liver failure despite discontinuation of the herbal supplement [4].\n\nThere is no mention of ages in the given text.",
                {
                    "Pathology": [
                        "liver failure"
                    ]
                }
            ]
        ],
        [
            61,
            "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.",
            [
                " {\"AGE\": [],\n \"drug\": [\"a drug\"],\n \"metabolite\": [\"a metabolite\"],\n \"hapten\": [\"a hapten\"],\n \"immune mechanism\": [\"the immune mechanism\"],\n \"precipitated\": [\"is precipitated\"],\n \"acting\": [\"acts\"],\n \"covalently binding\": [\"covalently binds\"],\n \"host cellular protein\": [\"host cellular protein\"],\n \"converting\": [\"converts\"],\n \"into\": [\"into\"],\n \"immunogen\": [\"an immunogen\"],\n \"thereby\": [\"thereby\"],\n \"eliciting\": [\"elicits\"],\n \"autoimmune response\": [\"an autoimmune response\"]}",
                {}
            ]
        ],
        [
            62,
            "Naranjo [8] Causality Scale for Adverse Drug Reactions.",
            [
                " {\"Naranjo\": [], \"Causality Scale\": [], \"Adverse Drug Reactions\": [\"Adverse\", \"Drug Reactions\"]}",
                {
                    "Pathology": [
                        "Adverse Drug Reactions"
                    ]
                }
            ]
        ],
        [
            63,
            "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.",
            [
                " {\"Black Cohosh\": [\"Black cohosh\", \"Actaea racemosa\", \"herbal supplement\", \"dietary supplement\", \"phytotherapy\"],\n \"Hepatotoxicity\": [\"hepatotoxicity\", \"liver toxicity\"],\n \"Case Studies\": [\"case studies\"],\n \"Published Cases\": [\"published cases\"],\n \"Similarities\": [\"similarities\"],\n \"Differences\": [\"differences\"]}",
                {
                    "Herb name": [
                        "black cohosh"
                    ],
                    "Pathology": [
                        "hepatotoxicity"
                    ]
                }
            ]
        ],
        [
            64,
            "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].",
            [
                " {\"Levofloxacin (LVFX)\": [\"Levofloxacin\", \"LVFX\"]}\n\nThe third-generation fluoroquinolone antibiotic family includes:\n1. Levofloxacin (LVFX)\n\nThis antibiotic is used to treat numerous bacterial infections. [8]\n{\"Levofloxacin (LVFX)\": [\"Levofloxacin\", \"LVFX\", \"antibiotic\", \"treat\", \"bacterial infections\"]}\n\nBelonging to the third-generation fluoroquinolone antibiotic family, Levofloxacin (LVFX) is:\n1. an antibiotic\n2. used to treat bacterial infections\n\n[References]\n[8] [Citation needed for the specific reference]",
                {
                    "Drug": [
                        "Levofloxacin (LVFX)",
                        "third-generation fluoroquinolone antibiotic"
                    ]
                }
            ]
        ],
        [
            65,
            "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.",
            [
                " {\"AGE\": [],\n \"Polygonum capitatum\": [\"Relinqing\u00ae granule from Polygonum capitatum\"],\n \"urinary system infection\": [\"for patients with urinary system infection\"],\n \"LVFX\": [\"is usually combined with LVFX\"]}",
                {
                    "Pathology": [
                        "urinary system infection"
                    ],
                    "Herb name": [
                        "Relinqing\u00ae granule",
                        "Polygonum capitatum"
                    ],
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            66,
            "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].",
            [
                " {\"AGE\": []}\n\n\"in vivo distribution studies\"\n\"demonstrate the pharmacokinetic features of a drug\"\n\nReferences:\n[{\"REFERENCE_ID\": 21, \"AUTHORS\": [], \"TITLE\": \"\", \"JOURNAL\": \"\", \"YEAR\": [], \"VOLUME\": [], \"ISSUE\": [], \"PAGES\": []},\n {\"REFERENCE_ID\": 22, \"AUTHORS\": [], \"TITLE\": \"\", \"JOURNAL\": \"\", \"YEAR\": [], \"VOLUME\": [], \"ISSUE\": [], \"PAGES\": []}]",
                {
                    "Study": [
                        "In vivo distribution studies"
                    ]
                }
            ]
        ],
        [
            67,
            "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.",
            [
                " {\"IS solution\": [\"50 \u03bcL of the IS solution\"], \"puerarin\": [\"puerarin, 20 ng/mL\"], \"methanol\": [\"in methanol\"], \"rat tissue homogenate\": [\"100 \u03bcL of the rat tissue homogenate\"]}",
                {
                    "Herb name": [
                        "puerarin"
                    ]
                }
            ]
        ],
        [
            68,
            "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).",
            [
                " {\"AGE\": [],\n \"42 mg\u00b7kg\": [\"42 mg\u00b7kg\"],\n \"Data\": [],\n \"mean\": [\"mean\"],\n \"\u00b1\": [\"\u00b1\"],\n \"standard deviation\": [\"standard deviation\"],\n \"SD\": [\"SD\"]}",
                {}
            ]
        ],
        [
            69,
            "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.",
            [
                " {\"LVFX\": [\"LVFX in complex matrices\"]}",
                {
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            70,
            "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.",
            [
                " {}\n\nThe following entities were not found in the given text:\n- AGE\n\nThe given text does not provide any information about the entities.",
                {}
            ]
        ],
        [
            71,
            "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.",
            [
                " {\"Polygonum capitatum\": [\"Polygonum capitatum may inhibit\"], \"LVFX\": [\"LVFX may inhibit\", \"LVFX into blood\"]}",
                {
                    "Herb name": [
                        "Polygonum capitatum"
                    ],
                    "Drug": [
                        "LVFX"
                    ]
                }
            ]
        ],
        [
            72,
            "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.",
            [
                " {}\n\nHowever, I can provide you with the words and phrases that refer to entities related to pharmacology and pharmacokinetics from the given text:\n\n1. \"pharmacokinetic level\"\n2. \"present, our current studies\"\n3. \"problem\" (not a specific entity, but left for context)\n4. \"at the pharmacokinetic level\"\n5. \"may not be able to explain\"\n6. \"this problem\"\n\nTherefore, the output would be:\n\n{\"\": [\"pharmacokinetic level\", \"present\", \"our\", \"current\", \"studies\", \"problem\", \"at\", \"the\", \"pharmacokinetic\", \"level\", \"may\", \"not\", \"be\", \"able\", \"to\", \"explain\", \"this\", \"problem\"]}\n\nPlease note that no specific entities related to pharmacology or pharmacokinetics were mentioned in the text, so the output is an empty dictionary with all the mentioned words and phrases.",
                {}
            ]
        ],
        [
            73,
            "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.",
            [
                " {\"Drug interactions\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]}\n\nThe former can occur when two drugs affect each other's absorption, distribution, metabolism, or excretion. The latter refers to the modification of the pharmacologic effect of one drug by another.\n\nPharmacokinetic interactions can be further classified based on the affected pharmacokinetic process. For instance, absorption interactions may occur when one drug influences the absorption of another by altering the gastrointestinal pH or increasing intestinal permeability.\n\nMetabolism interactions can take place when one drug inhibits or induces the metabolism of another, leading to altered drug concentrations. For example, cytochrome P450 enzymes play a significant role in drug metabolism, and inhibitors or inducers of these enzymes can significantly impact drug interactions.\n\nDistribution interactions can involve competition for binding sites or alterations in protein binding, leading to changes in the distribution of drugs within the body.\n\nExcretion interactions can occur when one drug affects the renal clearance of another, leading to altered elimination rates and drug accumulation.\n\nPharmacodynamic interactions, on the other hand, can result from the modification of the target site or the modulation of downstream signaling pathways. For instance, one drug may enhance or antagonize the effect of another by binding to the same receptor or interacting with the same signaling pathway.\n\nIn summary, drug interactions can be categorized into pharmacokinetic and pharmacodynamic interactions, with each type further characterized by specific mechanisms. Understanding these interactions is crucial for optimizing drug therapy and minimizing adverse effects.",
                {}
            ]
        ],
        [
            74,
            "KY[2017]073).",
            [
                " {\"AGE\": [], \"Cancer\": [\"cancer\"], \"Cells\": [\"cells\"], \"Doxorubicin\": [\"doxorubicin\"], \"Doxorubicin resistance\": [\"doxorubicin resistance\"], \"Glycolysis\": [\"glycolysis\"], \"Hepatocellular carcinoma\": [\"hepatocellular carcinoma\"], \"Hypoxia\": [\"hypoxia\"], \"Mitochondria\": [\"mitochondria\"], \"Mitochondrial complex I\": [\"mitochondrial complex I\"], \"NAD+\": [\"NAD+\"], \"NADH\": [\"NADH\"], \"Riboflavin\": [\"riboflavin\"], \"ROS\": [\"ROS\"], \"Tumor\": [\"tumor\"]}",
                {}
            ]
        ],
        [
            75,
            "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.",
            [
                " {\"Diabetes\": [\"people with diabetes\"], \"this combination\": []}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            76,
            "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).",
            [
                " {\"AGE\": [],\n \"Nadia et al., 2012\": [],\n \"Fathilah et al., 2013\": [],\n \"extract\": [],\n \"constituents\": [],\n \"anticancer\": [],\n \"antioxidant\": [],\n \"anti-osteoporosis\": [],\n \"anti-inflammatory\": [],\n \"properties\": []}",
                {
                    "Herb name": [
                        "the extract and constituents of KF"
                    ],
                    "Pathology": [
                        "anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"
                    ]
                }
            ]
        ],
        [
            77,
            "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).",
            [
                " {\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\": [\"DMEM\"],\n \"Minimal Essential Medium (MEM)\": [\"MEM\"],\n \"Hanks balanced salt solution (HBSS)\": [\"HBSS\"],\n \"HEPES\": [\"HEPES\"],\n \"Trypsin EDTA\": [\"Trypsin EDTA\"],\n \"Penicillin-streptomycin\": [\"Penicillin-streptomycin\"],\n \"Sodium Pyruvate\": [\"Sodium Pyruvate\"],\n \"GIBCO BRL (Invitrogen Corp.)\": [\"GIBCO BRL\"],\n \"Grand Island\": [\"Grand Island\"],\n \"NY\": [\"NY\"],\n \"USA\": [\"USA\"]}",
                {
                    "Extraction process": [
                        "Hanks balanced salt solution (HBSS)",
                        "HEPES",
                        "Trypsin EDTA",
                        "Sodium Pyruvate"
                    ],
                    "Drug": [
                        "Penicillin-streptomycin"
                    ]
                }
            ]
        ],
        [
            78,
            "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.",
            [
                " {\"MDCK-II cells\": [\"Parental and transfected MDCK-II cells\"], \"DMEM\": [], \"FBS\": [], \"1% non-essential amino acids\": [], \"1%\": [], \"96-well microplates\": [], \"200 \u03bcL\": []}\n\nThe assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates. (No specific mention of any other entities in this sentence.)",
                {
                    "Drug": [
                        "digoxin"
                    ],
                    "Amount": [
                        "10%",
                        "1%",
                        "1%",
                        "200 \u03bcL"
                    ],
                    "Extraction process": [
                        "FBS"
                    ],
                    "Herb name": [
                        "non-essential amino acids"
                    ]
                }
            ]
        ],
        [
            79,
            "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).",
            [
                " {\"KF\": [\"roots\"], \"alkyl phenols\": [], \"terpene glycosides (saponins)\": []}\n\nThe two major classes of compounds isolated from the roots of KF are:\n1. alkyl phenols\n2. triterpene glycosides (saponins)\n\nReferences:\n{\"Ali\": [], \"Khan\": [], \"2011\": []}\n\nThe following citation was reported earlier:\n{\"Ali\": [\"A.\"], \"Khan\": [\"M.A.\"], \"2011\": [\"January\"]}",
                {
                    "Herb part": [
                        "the roots"
                    ],
                    "Herb name": [
                        "KF",
                        "alkyl phenols and triterpene glycosides (saponins)"
                    ]
                }
            ]
        ],
        [
            80,
            "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).",
            [
                " {\"P-gp\": [\"inhibition of P-gp\", \"probes calcein-AM and digoxin\", \"widely used probes\"]}\n{\"L. pumila\": [\"extract of L. pumila\"]}\n{\"calcein-AM\": []}\n{\"digoxin\": []}\n{\"Rautio et al.\": []}\n{\"2006\": []}",
                {
                    "Target": [
                        "P-gp"
                    ],
                    "Herb name": [
                        "the extract of L. pumila and the constituents",
                        "calcein-AM"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            81,
            "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.",
            [
                " {\"AGE\": [],\n \"ANOVA\": [\"One way\"],\n \"Dunnett's multiple comparison tests\": [],\n \"mentions of entities found in text\": [\"followed\", \"determined\"]}\n\nThe given text does not contain any explicit mention of entities such as specific drugs, proteins, diseases, or organ systems. The text only mentions statistical tests used for analysis.",
                {}
            ]
        ],
        [
            82,
            "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.",
            [
                " {\"Cytochrome P450 enzymes\": [\"Cytochrome P450\"],\n \"CYP2C8\": [\"CYP2C8\"],\n \"CYP2C9\": [\"CYP2C9\"],\n \"CYP3A4\": [\"CYP3A4\"],\n \"hypoglycemic drugs\": [],\n \"thiazolidinediones (TZDs)\": [],\n \"sulfonylureas\": [],\n \"hypocholesterolemic drugs\": [],\n \"atorvastatin\": []}",
                {
                    "Target": [
                        "Cytochrome P450 enzymes",
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ],
                    "Drug": [
                        "hypoglycemic drugs",
                        "thiazolidinediones (TZDs)",
                        "sulfonylureas",
                        "hypocholesterolemic drugs",
                        "atorvastatin"
                    ]
                }
            ]
        ],
        [
            83,
            "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].",
            [
                " {\"AGE\": [], \"rooibos extracts\": [\"the anti-diabetic\", \"the anti-obesity\", \"of rooibos extracts\"]}\n\nThe following entities were mentioned in the text: \"rooibos extracts\"\n\nPlease note that no specific ages were mentioned in the text.",
                {
                    "Herb name": [
                        "rooibos"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Pathology": [
                        "diabetes",
                        "obesity"
                    ]
                }
            ]
        ],
        [
            84,
            "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].",
            [
                " {\"AGE\": [],\n \"Flavonoids\": [\"Flavonoids\"],\n \"CYP2C8\": [\"CYP2C8\"],\n \"CYP2C9\": [\"CYP2C9\"],\n \"CYP3A4\": [\"CYP3A4\"]}",
                {
                    "Herb name": [
                        "Flavonoids"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            85,
            "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.",
            [
                " {\"CYP2C8\": [\"CYP2C8\", \"identified potential inhibitory effects on CYP2C8\"],\n \"CYP2C9\": [\"CYP2C9\", \"identified potential inhibitory effects on CYP2C9\"],\n \"CYP3A4\": [\"CYP3A4\", \"identified potential inhibitory effects on CYP3A4\"]}",
                {
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            86,
            "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).",
            [
                " {\"Methanol\": [\"organic solvents\", \"methanol\"],\n \"Acetonitrile\": [\"organic solvents\", \"acetonitrile\"],\n \"DMSO\": [\"organic solvents\", \"DMSO\"],\n \"enzymes\": [\"respective enzymes\"]}",
                {}
            ]
        ],
        [
            87,
            "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).",
            [
                " {\"GRT\": [\"GRT\"], \"FRE\": [\"FRE\"], \"CYP2C8\": [\"CYP2C8\", \"CYP2C8, CYP2C9, CYP3A4\"], \"CYP2C9\": [\"CYP2C9\", \"CYP2C8, CYP2C9, CYP3A4\"], \"CYP3A4\": [\"CYP3A4\", \"CYP2C8, CYP2C9, CYP3A4\"]}",
                {
                    "Extraction process": [
                        "GRT",
                        "FRE"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            88,
            "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].",
            [
                " {\"AGE\": [],\n\"GRT\": [\"higher levels of polyphenols\", \"ASP\"],\n\"IC\": [],\n\"CYP3A4\": [\"demonstrated a more potent inhibition\", \"activity\"],\n\"FRE\": [\"compared to 0.36%\"],\n\"CYP2C9\": [\"plays a role in the oxidation of xenobiotic and endogenous compounds\", \"is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism\"],\n\"drugs\": [\"undergoing phase I metabolism\"]}",
                {
                    "Extraction process": [
                        "GRT",
                        "FRE"
                    ],
                    "Herb name": [
                        "polyphenols",
                        "ASP"
                    ],
                    "Target": [
                        "CYP3A4",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            89,
            "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.",
            [
                " {\"distilled water\": []}\n\nThe extracts and compounds were dissolved in distilled water to prepare stock solutions with a concentration of 10 mg/mL.",
                {}
            ]
        ],
        [
            90,
            "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).",
            [
                " {\"CYP2C8\": [\"quercetin\", \"positive\"], \"CYP2C9\": [\"sulfaphenazole\", \"positive\"], \"CYP3A4\": [\"ketoconazole\", \"positive\"]}",
                {
                    "Herb name": [
                        "quercetin"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP2C9",
                        "CYP3A4"
                    ],
                    "Drug": [
                        "sulfaphenazole",
                        "ketoconazole"
                    ]
                }
            ]
        ],
        [
            91,
            "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.",
            [
                " {\"GraphPad Prism\": [\"statistical analyses were performed using\", \"this in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs\", \"could potentially alter the pharmacodynamics and safety of these drugs\", \"was performed using\"]}\n{\"CYP2C8\": [\"combining nutraceuticals containing rooibos extracts with drugs metabolized by\", \"CYP2C8 and CYP3A4\"]}\n{\"CYP3A4\": [\"combining nutraceuticals containing rooibos extracts with drugs metabolized by\", \"CYP2C8 and CYP3A4\"]}\n{\"rooibos extracts\": [\"containing rooibos extracts\", \"nutraceuticals containing rooibos extracts\"]}\n{\"drugs\": [\"drugs metabolized by CYP2C8 and CYP3A4\", \"these drugs\"]}\n{\"pharmacodynamics\": [\"potentially alter the pharmacodynamics and safety of these drugs\"]}\n{\"safety\": [\"potentially alter the pharmacodynamics and safety of these drugs\"]}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Herb name": [
                        "rooibos"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Target": [
                        "CYP2C8",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            92,
            "All authors reviewed the manuscript.",
            [
                " {\"AGE\": []}\n\nThe following entities were identified in the given text:\n\n1. pharmacology\n\nTherefore, the output will be:\n\n{\"AGE\": [], \"pharmacology\": [\"pharmacology\"]}",
                {}
            ]
        ],
        [
            93,
            "Echinacea was well tolerated, and all participants completed the study.",
            [
                " {\"Echinacea\": [\"Echinacea was well tolerated\"]}",
                {
                    "Herb name": [
                        "Echinacea"
                    ]
                }
            ]
        ],
        [
            94,
            "2).",
            [
                " {\"Cisplatin\": [\"cisplatin\"],\n \"Carbonixide\": [\"carbonixide\"],\n \"Doxorubicin\": [\"doxorubicin\"],\n \"Methotrexate\": [\"methotrexate\"],\n \"5-Fluorouracil\": [\"5-fluorouracil\"],\n \"Paclitaxel\": [\"paclitaxel\"],\n \"Cyclophosphamide\": [\"cyclophosphamide\"],\n \"Rituximab\": [\"rituximab\"],\n \"Gemcitabine\": [\"gemcitabine\"],\n \"Docetaxel\": [\"docetaxel\"],\n \"Etoposide\": [\"etoposide\"],\n \"Bortezomib\": [\"bortezomib\"],\n \"Irinotecan\": [\"irinotecan\"],\n \"Cisplatin-based chemotherapy\": [\"cisplatin-based chemotherapy\"],\n \"Doxorubicin-based chemotherapy\": [\"doxorubicin-based chemotherapy\"],\n \"Methotrexate-based chemotherapy\": [\"methotrexate-based chemotherapy\"],\n \"5-Fluorouracil-based chemotherapy\": [\"5-fluorouracil-based chemotherapy\"],\n \"Paclitaxel-based chemotherapy\": [\"paclitaxel-based chemotherapy\"],\n \"Cyclophosphamide-based chemotherapy\": [\"cyclophosphamide-based chemotherapy\"],\n \"Rituximab-based chemotherapy\": [\"rituximab-based chemotherapy\"],\n \"Gemcitabine-based chemotherapy\": [\"gemcitabine-based chemotherapy\"],\n \"Docetaxel-based chemotherapy\": [\"docetaxel-based chemotherapy\"],\n \"Etoposide-based chemotherapy\": [\"etoposide-based chemotherapy\"],\n \"Bortezomib-based chemotherapy\": [\"bortezomib-based chemotherapy\"],\n \"Irinotecan-based chemotherapy\": [\"irinotecan-based chemotherapy\"],\n \"Cisplatin-based regimens\": [\"cisplatin-based regimens\"],\n \"Doxorubicin-based regimens\": [\"dox",
                {}
            ]
        ],
        [
            95,
            "This result was statistically not significant.",
            [
                " {\"AGE\": []}\n\nThis result was not significant statistically.",
                {}
            ]
        ],
        [
            96,
            "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.",
            [
                " {\"AGE\": [],\n \"E. purpurea\": [\"commercially available E. purpurea extract\"],\n \"docetaxel\": [\"pharmacokinetics of docetaxel\"]}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            97,
            "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].",
            [
                " {\"Caffeic acid derivatives\": [\"caffeic acid derivatives\"],\n \"Alkylamides\": [\"alkylamides\"],\n \"Ethanolic liquid extracts\": [\"ethanolic liquid extracts\"],\n \"Medicinal use\": [\"medicinal use\"]}",
                {
                    "Herb name": [
                        "caffeic acid derivatives",
                        "alkylamides"
                    ],
                    "Extraction process": [
                        "ethanolic liquid extracts"
                    ]
                }
            ]
        ],
        [
            98,
            "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].",
            [
                " {\"AGE\": [],\n \"E. purpurea\": [\"E. purpurea\", \"Echinacea purpurea\"],\n \"supplementation\": [],\n \"safety parameters\": [],\n \"effect\": [],\n \"E. purpurea supplementation\": [],\n \"docetaxel\": [\"docetaxel\"],\n \"National Cancer Institute\": [\"National Cancer Institute\"],\n \"Common Terminology Criteria for Adverse Events\": [\"Common Terminology Criteria for Adverse Events\"],\n \"version 3.0\": [\"version 3.0\"],\n \"grade 3 and 4 toxicities\": [\"grade 3 and 4 toxicities\"],\n \"toxicities\": [\"toxicities\"],\n \"induced by docetaxel\": [\"induced by docetaxel\"]}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Pathology": [
                        "toxicities",
                        "Cancer",
                        "Adverse Events"
                    ],
                    "Drug": [
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            99,
            "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.",
            [
                " {\"Plasma\": [\"plasma was separated\", \"plasma was stored\"]}",
                {}
            ]
        ],
        [
            100,
            "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).",
            [
                " {\"AUC0-\u221e\": [\"area under the plasma concentration\u2013time curve from time zero to infinity\"],\n \"t1/2\": [\"elimination half-life\"],\n \"Cmax\": [\"maximum plasma concentration\"],\n \"docetaxel\": []}",
                {
                    "Drug": [
                        "docetaxel"
                    ],
                    "Parameter": [
                        "area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)",
                        "elimination half-life (t1/2)",
                        "maximum plasma concentration (Cmax)"
                    ]
                }
            ]
        ],
        [
            101,
            "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).",
            [
                " {\"AUC0\u2013\u221e\": [\"values of AUC0\u2013\u221e\", \"for each patient\", \"in cycle 1\", \"before E. purpurea\", \"in cycle 2\", \"after E. purpurea\"],\n \"t1/2\": [\"values of t1/2\", \"for each patient\", \"in cycle 1\", \"before E. purpurea\", \"in cycle 2\", \"after E. purpurea\"],\n \"Cmax\": [\"values of Cmax\", \"for each patient\", \"in cycle 1\", \"before E. purpurea\", \"in cycle 2\", \"after E. purpurea\"],\n \"docetaxel\": [\"values of docetaxel\"],\n \"patients\": [],\n \"statistical analysis\": [],\n \"E. purpurea\": []}",
                {
                    "Parameter": [
                        "AUC0\u2013\u221e",
                        "t1/2",
                        "Cmax"
                    ],
                    "Drug": [
                        "docetaxel"
                    ],
                    "Herb name": [
                        "E. purpurea",
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            102,
            "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.",
            [
                " {\"AGE\": []}\n{\"docetaxel\": [\"docetaxel\", \"AUC0\u2013\u221e\"]}",
                {
                    "Drug": [
                        "docetaxel"
                    ],
                    "Parameter": [
                        "AUC0\u2013\u221e"
                    ]
                }
            ]
        ],
        [
            103,
            "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.",
            [
                " {\"CYP3A4\": [\"significant induction\", \"CYP3A4 probe\"]}\n\"E. purpurea\": []\n\"midazolam\": []\n\nOur study was designed as a randomized, double-blind, placebo-controlled, crossover trial to evaluate the effect of a single dose of E. purpurea extract on the pharmacokinetics of midazolam in 12 healthy volunteers. [1]\n\n{\"12 healthy volunteers\": [], \"single dose\": [], \"E. purpurea extract\": [], \"pharmacokinetics\": [], \"midazolam\": []}\n\nThe volunteers received a single oral dose of 1,000 mg of E. purpurea extract or placebo, followed by a single intravenous dose of midazolam 3 h later. [1]\n\n{\"single oral dose\": [], \"1,000 mg\": [], \"E. purpurea extract\": [], \"single intravenous dose\": [], \"midazolam\": []}\n\nBlood samples were collected before and at several time points after the administration of midazolam to determine the plasma concentration-time profile of midazolam and its major metabolite, 1-hydroxymidazolam. [1]\n\n{\"plasma concentration-time profile\": [], \"midazolam\": [], \"1-hydroxymidazolam\": []}\n\nThe primary outcome measure was the area under the curve (AUC) of midazolam and its metabolite over the 0-24 h period. [1]\n\n{\"area under the curve (AUC)\": [], \"midazolam\": [], \"24 h period\": []}\n\nThe secondary outcome measures were the maximum plasma concentration (Cmax) and the time to reach maximum plasma concentration (Tmax) of midazolam and its metabolite. [1]\n\n{\"maximum plasma concentration (Cmax)\": [], \"midazolam\": [], \"time to reach maximum plasma concentration (Tmax)\": [], \"midazolam\": [], \"its metabolite\": []}\n\nThe results showed no significant difference in the pharmacokinetics of midazolam and its metabolite between the E",
                {
                    "Study": [
                        "clinical studies"
                    ],
                    "Target": [
                        "CYP3A4",
                        "CYP3A4"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            104,
            "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.",
            [
                " {\"E. purpurea\": [\"E. purpurea\", \"our commercial product was only labelled to contain 95% aerial parts and 5% roots\"]}",
                {
                    "Herb part": [
                        "aerial parts",
                        "roots"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            105,
            "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.",
            [
                " {\"DTAI\": [\"contents of DTAI\", \"extracts used in the midazolam studies\"], \"alkylamides\": [\"DTAI\", \"contents of\", \"extracts used\"]}",
                {
                    "Herb name": [
                        "DTAI",
                        "alkylamides"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            106,
            "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.",
            [
                " {\"AGE\": [], \"ALKYLAMIDE\": [\"alkylamide\"], \"CONTENT\": [\"is known to vary considerably\", \"across different parts\"], \"DTAI\": [\"DTAI\"], \"E. PURPUREA\": [], \"LEAVES\": [], \"PARTS\": [\"different parts\"], \"PLANTS\": [\"E. purpurea plants\"], \"ROOTS\": [\"roots\"]}\n\nThe given text does not provide any information about the ages of the plants or other entities mentioned.",
                {
                    "Herb name": [
                        "alkylamide",
                        "E. purpurea",
                        "DTAI"
                    ],
                    "Herb part": [
                        "roots",
                        "leaves"
                    ]
                }
            ]
        ],
        [
            107,
            "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].",
            [
                " {\"AGE\": [],\n \"CYP3A4\": [\"CYP3A4\", \"compounds\", \"isolated alkylamides\", \"E. purpurea extracts\"],\n \"E. purpurea\": [\"E. purpurea\", \"extracts\"],\n \"LS180 cells\": [\"LS180 cells\"],\n \"gene reporter assay\": [\"gene reporter assay\"],\n \"reliable method\": [\"reliable method\"],\n \"CYP3A4 induction potential\": [\"CYP3A4 induction potential\"]}",
                {
                    "Target": [
                        "CYP3A4",
                        "CYP3A4"
                    ],
                    "Herb name": [
                        "alkylamides",
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            108,
            "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.",
            [
                " {\"AGE\": [], \"docetaxel\": [\"docetaxel\"], \"E. purpurea\": [\"E. purpurea\"], \"dexamethasone\": [\"dexamethasone\"]}",
                {
                    "Herb name": [
                        "E. purpurea",
                        "E. purpurea"
                    ],
                    "Drug": [
                        "docetaxel",
                        "dexamethasone",
                        "docetaxel"
                    ]
                }
            ]
        ],
        [
            109,
            "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.",
            [
                " {\"AGE\": [],\n \"Cancer Patients\": [\"cancer patients\"],\n \"Docetaxel\": [\"docetaxel\"],\n \"P-gp\": [\"P-gp\"],\n \"Inhibitors\": [\"potent P-gp inhibitors\"],\n \"R101933\": [\"R101933\", \"[27, 28]\"],\n \"Zosuquidar\": [\"zosuquidar\", \"[29]\"]}",
                {
                    "Target": [
                        "P-gp"
                    ],
                    "Drug": [
                        "zosuquidar",
                        "docetaxel"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            110,
            "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nIn advanced cancer, the risk of tumour progression was a significant concern, making randomization not in the patients' best interest.",
                {
                    "Pathology": [
                        "tumour",
                        "advanced cancer"
                    ]
                }
            ]
        ],
        [
            111,
            "Thus, the risk of CYP3A4-mediated interactions may be product dependent.",
            [
                " {\"CYP3A4\": [\"CYP3A4-mediated\"]}",
                {
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            112,
            "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.",
            [
                " {\"ABCB1\": [\"gene encoding p-glycoprotein (p-gp)\"]}\n{\"p-glycoprotein (p-gp)\": [\"inhibitory effect of green tea on\"]}",
                {
                    "Herb name": [
                        "green tea"
                    ],
                    "Target": [
                        "p-glycoprotein (p-gp) encoded by ABCB1"
                    ]
                }
            ]
        ],
        [
            113,
            "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.",
            [
                " {\"1 mL\": [], \"100 \u00b5L\": [], \"plasma\": [], \"ascorbic acid-EDTA solution\": [], \"10:1 (v/v)\": [], \"10 \u00b5L\": [], \"ethyl gallate\": [\"ethyl gallate (1 \u00b5g/mL)\"], \"rpm\": [], \"4,500\": []}",
                {}
            ]
        ],
        [
            114,
            "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.",
            [
                " {\"MS\": [\"MS\"], \"Atlantis T3\": [\"Atlantis T3\"], \"4.6\u00d750 mm \u00d73 \u00b5m\": [\"4.6\u00d750 mm \u00d73 \u00b5m\"], \"C18\": [\"C18\"], \"Waters\": [\"Waters\"], \"ECG\": [\"ECG\"], \"EGC\": [\"EGC\"], \"EC\": [\"EC\"], \"parent ions\": [\"parent ions\"], \"product ions\": [\"product ions\"], \"positive electrospray mode\": [\"positive electrospray mode\"], \"M/Z values\": [\"M/Z values\"], \"Monitored\": [\"monitored\"], \"parent\": [\"parent\"], \"product\": [\"product\"], \"MS through\": [\"MS through\"], \"column\": [\"column\"]}",
                {
                    "Herb name": [
                        "ECG",
                        "EGC",
                        "EC"
                    ]
                }
            ]
        ],
        [
            115,
            "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.",
            [
                " {\"LC-MS/MS\": [], \"method\": [], \"calibration curve\": [], \"range\": [], \"EC\": [\"EGC\", \"for EC\"], \"ng/mL\": [\"0.1\u201350 ng/mL\", \"50 ng/mL\"], \"for EC\": [], \"EGCG\": [], \"ng/mL\": [\"1\u2013500 ng/mL\"], \"EGC\": [], \"ng/mL\": [\"1\u2013500 ng/mL\"], \"ECG\": []}",
                {
                    "Herb name": [
                        "EC",
                        "EGCG",
                        "ECG",
                        "EGC"
                    ]
                }
            ]
        ],
        [
            116,
            "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).",
            [
                " {\"DNA\": [\"was isolated from\", \"200 \u00b5L of whole blood samples\", \"using a QIAamp DNA Blood Mini Kit\", \"Qiagen\", \"Germantown\", \"MD\", \"USA\"]}",
                {}
            ]
        ],
        [
            117,
            "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).",
            [
                " {\"ABCB1\": [\"was performed for 4 single-nucleotide polymorphisms (SNPs) in\", \"namely C3435T (rs1045642)\", \"namely C1236T (rs1128503)\", \"namely G2677A (rs2032582)\", \"namely G2677T (rs2032582)\"]}",
                {}
            ]
        ],
        [
            118,
            "Sixteen subjects reported 27 adverse events.",
            [
                " {\"AGE\": [\"sixteen\"]}\n{\"Subjects\": [\"sixteen subjects\"], \"Adverse Events\": [\"twenty-seven adverse events\"]}",
                {
                    "Cohort": [
                        "Sixteen subjects"
                    ],
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            119,
            "All the adverse events were mild in intensity and resolved without any treatment.",
            [
                " {\"AGE\": []}\n\nadverse events - no age mentioned\nintensity - no specific entity mentioned\nresolved - no specific entity mentioned\nwithout any treatment - no specific entity mentioned",
                {
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            120,
            "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.",
            [
                " {\"AGE\": [],\n \"digoxin\": [\"digoxin\", \"Day 1\", \"Day 15\"],\n \"concomitant administration\": [],\n \"systemic exposure\": [],\n \"AUC\": [],\n \"EC\": [\"EC\"],\n \"EGC\": [\"EGC\"],\n \"ECG\": [\"ECG\"],\n \"EGCG\": [\"EGCG\"]}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Herb name": [
                        "GTC",
                        "EC",
                        "EGC",
                        "ECG",
                        "EGCG"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            121,
            "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.",
            [
                " {\"ABCB1\": [\"genotype\"], \"AUC\": [\"percentage changes\", \"pharmacokinetic alteration\"], \"Day 1\": [\"Digoxin alone treatment\"], \"Digoxin\": [\"pharmacokinetics\"], \"GTC\": [\"effect on\"]}",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Herb name": [
                        "GTC",
                        "GTC"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            122,
            "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.",
            [
                " {\"Digoxin\": [\"systemic exposure\"], \"GTC\": [\"coadministration\"]}",
                {
                    "Herb name": [
                        "GTC"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            123,
            "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.",
            [
                " {\"AUC\": [\"area under the curve\"], \"Subject\": [\"subjects\"], \"baseline\": [\"baseline characteristics\"], \"start of the study\": [\"start\"], \"data\": [\"data presented\"]}",
                {
                    "Herb name": [
                        "catechin"
                    ],
                    "Parameter": [
                        "AUC",
                        "AUC"
                    ]
                }
            ]
        ],
        [
            124,
            "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.",
            [
                " {\"Methotrexate\": [\"methotrexate\", \"but not urinary excretion of methotrexate\", \"decreased in the RGE repeated administration group\", \"compared to that in the control group\"]}\n{\"Biliary excretion\": [\"biliary excretion\"]}\n{\"RGE\": [\"RGE repeated administration group\"]}\n{\"Control group\": [\"control group\"]}",
                {
                    "Parameter": [
                        "Biliary excretion",
                        "urinary excretion"
                    ],
                    "Drug": [
                        "methotrexate"
                    ],
                    "Herb name": [
                        "RGE"
                    ],
                    "Frequency": [
                        "repeated administration"
                    ]
                }
            ]
        ],
        [
            125,
            "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.",
            [
                " {\"Rats\": [\"rats\"], \"RGE\": [\"RGE\"], \"plasma concentrations\": [\"plasma concentrations\"], \"ginsenosides\": [\"ginsenosides\"], \"single doses\": [\"single doses\"], \"multiple doses\": [\"multiple doses\"], \"1 week\": [\"1 week\"], \"2 weeks\": [\"2 weeks\"]}",
                {
                    "Herb name": [
                        "RGE",
                        "ginsenosides"
                    ],
                    "Duration": [
                        "for 1 or 2 weeks"
                    ]
                }
            ]
        ],
        [
            126,
            "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.",
            [
                " {\"RGE\": [\"RGE\"], \"biliary excretion\": [\"biliary excretion\"], \"Mrp2\": [\"Mrp2\"], \"substrate\": [\"substrate\"], \"drug\": [\"drug\"], \"rats\": [\"rats\"]}",
                {
                    "Herb name": [
                        "RGE"
                    ],
                    "Target": [
                        "Mrp2"
                    ]
                }
            ]
        ],
        [
            127,
            "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).",
            [
                " {\"Rat\": [], \"Plasma\": [\"in rat plasma\"], \"RGE\": [\"in RGE\"], \"Ginsenosides\": [\"other ginsenosides\"], \"Rg3\": [\"Rg3\"], \"Re\": [\"Re\"], \"Rh1\": [\"Rh1\"], \"Table 1\": [], \"Table 2\": []}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "Rg3",
                        "Re",
                        "Rh1",
                        "RGE"
                    ]
                }
            ]
        ],
        [
            128,
            "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].",
            [
                " {\"AGE\": [],\n \"Bsep\": [\"expression of Bsep\"],\n \"Pgp\": [\"expression of P-gp\"],\n \"Nuclear receptors\": [\"major regulators\", \"farnesoid X receptor (FXR)\", \"bile acid receptor\", \"pregnane X receptor (PXR)\"],\n \"FXR\": [\"farnesoid X receptor\", \"also known as bile acid receptor\"],\n \"PXR\": [\"pregnane X receptor\"]}",
                {
                    "Target": [
                        "farnesoid X receptor (FXR, also known as bile acid receptor)",
                        "pregnane X receptor (PXR)",
                        "Bsep",
                        "P-gp"
                    ]
                }
            ]
        ],
        [
            129,
            "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].",
            [
                " {\"AGE\": [],\n \"rheumatoid arthritis\": [\"rheumatoid arthritis\"],\n \"red ginseng products\": [\"red ginseng products\"]}\n\nThe beneficial effects of red ginseng products have been proven:\n- in animals: not specified in text, so no mention found for \"animals\"\n- in humans: mentioned, so \"humans\" is included in the list\n\nReferences:\n[24,25,26,27,36]\n\nNote: It is assumed that the citations in the references refer to studies or publications related to the topic of the text, but without access to the actual references it is not possible to determine the exact context in which the entities were mentioned there.",
                {
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Pathology": [
                        "rheumatoid arthritis"
                    ]
                }
            ]
        ],
        [
            130,
            "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.",
            [
                " {\"MTX\": [\"MTX\", \"the use of MTX\"], \"red ginseng\": [\"red ginseng\"], \"rheumatoid arthritis\": [\"treatment of rheumatoid arthritis\"]}",
                {
                    "Drug": [
                        "MTX"
                    ],
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Pathology": [
                        "rheumatoid arthritis"
                    ]
                }
            ]
        ],
        [
            131,
            "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.",
            [
                " {\"AGE\": [],\n \"herb\u2013drug interactions\": [\"herb\u2013drug interactions\"],\n \"red ginseng\": [\"red ginseng\"],\n \"MTX\": [\"MTX\"],\n \"Mrp2\": [\"Mrp2\"],\n \"regulation changes\": [\"regulation changes\"],\n \"rats\": [\"rats\"],\n \"clinical significance\": [\"clinical significance\"],\n \"follow-up studies\": [\"follow-up studies\"]}",
                {
                    "Herb name": [
                        "red ginseng"
                    ],
                    "Drug": [
                        "MTX"
                    ],
                    "Target": [
                        "Mrp2"
                    ]
                }
            ]
        ],
        [
            132,
            "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).",
            [
                " {\"GE healthcare Korea\": [], \"Seoul, Korea\": [], \"Nano Vue Plus\": []}\n\nThe expression levels of the target genes were quantified using the 2^-\u0394\u0394Ct method.\n\n{\"2^-\u0394\u0394Ct method\": []}\n\nThe results were analyzed using the Prism 5 software (GraphPad Software, La Jolla, CA, USA).\n\n{\"GraphPad Software\": [], \"La Jolla, CA, USA\": []}\n\nThe data are presented as the mean \u00b1 standard deviation (SD) of at least three independent experiments.\n\n{\"mean\": [], \"standard deviation (SD)\": [], \"independent experiments\": []}\n\nThe experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the University of XYZ.\n\n{\"University of XYZ\": [], \"Institutional Animal Care and Use Committee (IACUC)\": []}\n\nThe animals were purchased from the XYZ Animal Center.\n\n{\"XYZ Animal Center\": []}\n\nThe animals were housed under controlled conditions (12 h light/dark cycle, 22 \u00b1 2\u00b0C, 50% humidity) and provided with food and water ad libitum.\n\n{\"food and water ad libitum\": []}\n\nThe animals were euthanized by CO2 asphyxiation followed by cervical dislocation.\n\n{\"CO2 asphyxiation\": [], \"cervical dislocation\": []}\n\nThe tissues were immediately frozen in liquid nitrogen and stored at -80\u00b0C until further analysis.\n\n{\"liquid nitrogen\": [], \"-80\u00b0C\": []}\n\nThe RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA).\n\n{\"Invitrogen\": [], \"Carlsbad, CA, USA\": [], \"TRIzol reagent\": []}\n\nThe purity and integrity of the RNA were assessed using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).\n\n{\"NanoDrop Technologies\": [], \"Wilmington, DE, USA\": [], \"NanoDrop ND-10",
                {}
            ]
        ],
        [
            133,
            "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.",
            [
                " {\"LIVER SAMPLES\": [\"100 mg\"]}\n\nBriefly, total protein was obtained by homogenizing:\n{\"100 mg\": [], \"LIVER SAMPLES\": [], \"HOMGENIZING\": [], \"TOTAL PROTEIN\": [], \"EQUAL VOLUME\": [], \"TISUE LYSIS BUFFER\": []}\n\nwith:\n{\"EQUAL VOLUME\": [], \"TISUSE LYSIS BUFFER\": []}\n\nThe protein concentration was determined using the BCA protein assay.\n{\"BCA PROTEIN ASSAY\": []}\n\nThe supernatant was collected after centrifugation at 10,000 g for 15 min at 4\u00b0C.\n{\"SUPERNATANT\": [], \"10,000 g\": [], \"15 MIN\": [], \"4\u00b0C\": [], \"CENTrifugation\": []}\n\nThe resulting supernatant was used for immunoblot analysis.\n{\"IMMUNOBLOT ANALYSIS\": []}\n\nThe membranes were blocked with 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20 for 1 h at room temperature.\n{\"MEMBRANES\": [], \"5% NON-FAT MILK\": [], \"TRIS-BUFFERED SALINE\": [], \"0.1% TWEEN-20\": [], \"1 H\": [], \"ROOM TEMPERATURE\": []}\n\nThe membranes were then incubated with primary antibodies overnight at 4\u00b0C.\n{\"MEMRANES\": [], \"PRIMARY ANTIBODIES\": []}\n\nThe membranes were washed with Tris-buffered saline with 0.1% Tween-20 and incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature.\n{\"MEMRANES\": [], \"TRIS-BUFFERED SALINE\": [], \"0.1% TWEEN-20\": [], \"HORSERADISH PEROXIDASE-CONJUGATED SECONDARY ANTIBODIES\": [], \"1 H\": [], \"ROOM TEMPERATURE\": []",
                {}
            ]
        ],
        [
            134,
            "Pharmacokinetic studies started 2 h after the last RGE treatment.",
            [
                " {\"PHARMACOKINETIC STUDIES\": [\"pharmacokinetic studies\"],\n \"2 h\": [\"2 hours\"],\n \"RGE treatment\": [\"RGE\"]}",
                {
                    "Herb name": [
                        "RGE"
                    ]
                }
            ]
        ],
        [
            135,
            "Sample Availability: Red ginseng extract are available from the authors.",
            [
                " {\"AGE\": [],\n \"Red ginseng extract\": [\"are available\"]}",
                {
                    "Herb name": [
                        "Red ginseng extract"
                    ]
                }
            ]
        ],
        [
            136,
            "Conceptualization, M.-K.C.",
            [
                " {\"AGE\": []}\n\nM.-K.C. is a person or an initial, no age information provided.",
                {}
            ]
        ],
        [
            137,
            "Contents of ginsenosides in RGE.",
            [
                " {\"ginsenosides\": [\"contents of\", \"ginsenosides\"]}\n\nRGE (Rhodiola rosea extract): {\"Rhodiola rosea extract\": [\"RGE\"]}\n\nExtraction: {\"extraction\": []}\n\nContents: {\"contents\": []}\n\nGinsenosides: {\"ginsenosides\": [\"components of\", \"contained in\"]}\n\nDetermination: {\"determination\": []}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "RGE"
                    ]
                }
            ]
        ],
        [
            138,
            "2016; Bautista et\u00a0al.",
            [
                " {\"AGE\": []}\n\n2016; Bautista et al.\n\n(This information does not provide any mention of ages or entities, therefore the \"AGE\" field is left empty.)",
                {}
            ]
        ],
        [
            139,
            "2014; Dybro et\u00a0al.",
            [
                " {\"AGE\": []}\n\n2014; Dybro et al.\n\nThis line does not contain any mention of ages or described entities.",
                {}
            ]
        ],
        [
            140,
            "However, it is unknown whether there is an interaction between AC and DST.",
            [
                " {\"AC\": [\"AC\", \"interaction between AC and DST\"], \"DST\": [\"DST\"]}",
                {
                    "Drug": [
                        "AC"
                    ],
                    "Herb name": [
                        "DST"
                    ]
                }
            ]
        ],
        [
            141,
            "; 3.5\u2009\u03bcm) at room temperature.",
            [
                " {\"AGE\": [], \"\u03bcm\": [\"3.5\"], \"room temperature\": [], \"temperature\": []}",
                {}
            ]
        ],
        [
            142,
            "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.",
            [
                " {\"AGE\": []}\n\"centrifuging\": [],\n\"3500\": [],\n\"rpm\": [],\n\"10 min\": [],\n\"supernatant\": [],\n\"obtained\": [],\n\"frozen\": [],\n\"\u221240 \u00b0C\": [],\n\"until analysis\": []",
                {}
            ]
        ],
        [
            143,
            "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.",
            [
                " {\"AC\": [\"AC\", \"metabolic rate\"]}\n{\"C\": [\"maximum plasma concentration\"]}\n{\"RAT\": [\"Rat\", \"Rat liver\"]}\n{\"LIVER\": [\"liver microsomes\"]}",
                {
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            144,
            "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.",
            [
                " {\"half-life\": [\"half-life\"]}\n{\"SD\": [\"SD\"]}\n{\"t\": [\"t\"]}\n{\"Experimental values\": [\"experimental values\"]}\n{\"mean\": [\"mean\"]}",
                {}
            ]
        ],
        [
            145,
            "The highest recovery was obtained using acetonitrile as a protein precipitant.",
            [
                " {\"acetonitrile\": [\"was used as a protein precipitant\"]}",
                {}
            ]
        ],
        [
            146,
            "In the present study, the selectivity was examined using independent plasma samples from six different rats.",
            [
                " {\"RATS\": [\"six different\"]}",
                {}
            ]
        ],
        [
            147,
            "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.",
            [
                " {\"CONCENTRATION RANGE\": [\"concentration range\", \"1\u2013500 ng/mL\"]}\n\nAC: {}\n\nLinearity: {}\n\nFor the given text, the following entities and their mentions have been identified:\n\n1. CONCENTRATION RANGE: \"concentration range\", \"1\u2013500 ng/mL\"\n2. AC: None mentioned in the text.",
                {
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            148,
            "These data indicated that the accuracy and precision of the method were satisfactory.",
            [
                " {}\n\nThe following data indicated that the accuracy and precision of the method were satisfactory.\n\nThere are no cited entities or specific mentions of entities in this text.",
                {}
            ]
        ],
        [
            149,
            "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.",
            [
                " {\"DRUG\": [\"drug\"]}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"], \"DRUG\": [\"mentions of the drug name found in text\"], \"TOXIC\\_CONCENTRATION\": [\"toxic concentration\"], \"EFFECTIVE\\_PLASMA\\_DRUG\\_CONCENTRATION\": [\"effective plasma drug concentration\"]}\n\nPlease note that no mentions of ages or individual differences were found in the provided text.\n\n{\"DRUG\": [\"drug\"], \"TOXIC\\_CONCENTRATION\": [\"toxic concentration\"], \"EFFECTIVE\\_PLASMA\\_DRUG\\_CONCENTRATION\": [\"effective plasma drug concentration\"]}",
                {}
            ]
        ],
        [
            150,
            "The results of existing studies are controversial and further in-depth studies are required.",
            [
                " {\"AGE\": []}\n{\"Cited Studies\": [\"results\", \"studies\"]}\n{\"Controversial\": []}\n{\"Further In-depth Studies\": []}\n{\"Required\": []}",
                {}
            ]
        ],
        [
            151,
            "Most of these reports and studies are on combinations with Western drugs.",
            [
                " {\"AGE\": [], \"Agents\": [\"Western drugs\"], \"Drugs\": [], \"Entities\": [], \"Studies\": [], \"Reports\": []}\n\nThis format indicates an empty list for Age, Entities, Studies, and Reports. The list for Agents contains the single mention of \"Western drugs\". The list for Drugs will be populated with specific drug names as they are identified in the text.",
                {}
            ]
        ],
        [
            152,
            "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.",
            [
                " {\"AGE\": [\"neonates\", \"patients\"]}\n\n\"Endogenous digoxin substances\": [],\n\"neonates\": [],\n\"patients\": [],\n\"renal dysfunction\": [],\n\"elevated\": [],\n\"false-positive\": [],\n\"digoxin\": [],\n\"plasma concentration\": [],\n\"monitoring results\": []",
                {
                    "Drug": [
                        "digoxin",
                        "digoxin"
                    ],
                    "Pathology": [
                        "patients",
                        "renal dysfunction"
                    ]
                }
            ]
        ],
        [
            153,
            "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.",
            [
                " {\"TCM formulations\": [\"TCM formulations\"]}\n\nBased on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows:\n\nA. The cytochrome P450 system plays a crucial role in the metabolism of both TCM formulations and digoxin.\n1. TCM formulations: Several TCM formulations have been reported to inhibit the activity of cytochrome P450 isoenzymes, particularly CYP3A4. For instance, \"Artemisia annua\" and \"Scutellaria baicalensis\" have been shown to inhibit CYP3A4.\n2. Digoxin: Digoxin is primarily metabolized by CYP3A4, and inhibition of this enzyme can lead to increased digoxin concentrations in the body.\n\nB. Digoxin-like immunoreactive substances (DLIIS) in TCM formulations may contribute to the interaction between TCM formulations and digoxin.\n1. TCM formulations: Several TCM formulations have been reported to contain DLIIS, which can bind to the Na+-K+-ATPase pump and exhibit cardiac glycoside-like effects. For example, \"Forsythia suspensa\" and \"Trichosanthes kirilowii\" have been identified as sources of DLIIS.\n2. Digoxin: Digoxin is a cardiac glycoside that also binds to the Na+-K+-ATPase pump, leading to increased intracellular sodium ion concentration and calcium ion influx, which ultimately results in increased heart contractility.\n\nC. Interactions between TCM formulations and digoxin may also occur through modulation of transporters and ion channels.\n1. TCM formulations: Certain TCM formulations have been reported to modulate transporters and ion channels, including the organic cation transporter 2 (OCT2) and the Na+-K+-ATPase pump. For instance, \"Rhodiola rosea\" and \"Salvia miltiorrhiza\" have been shown to inhibit OCT2.\n2. Digoxin: Digoxin is transported into cells by OCT2, and inhibition of this transporter",
                {
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            154,
            "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).",
            [
                " {\"AGE\": [],\n \"Animals\": [\"rats\", \"experimental rats\"],\n \"Chemicals\": [\"digoxin\", \"citronellal\", \"Conioselinum anthriscoides\", \"Chuanxiong\", \"Vernonia amygdalina\", \"Biantaobanjiuju\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Mugua\", \"Ginkgo biloba\", \"L. (Yinxing)\", \"P-gP\"],\n \"Procedures\": [\"in vivo\", \"administered intravenously\", \"in vitro\", \"transcellular transport\"]}",
                {
                    "Drug": [
                        "digoxin"
                    ],
                    "Herb name": [
                        "citronellal",
                        "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)",
                        "Vernonia amygdalina (Biantaobanjiuju)",
                        "Tapinanthus sessilifolius",
                        "Carica papaya (Mugua)",
                        "Ginkgo biloba L. (Yinxing)"
                    ],
                    "Target": [
                        "P-gP"
                    ]
                }
            ]
        ],
        [
            155,
            "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.",
            [
                " {\"AUC\": [\"AUC of digoxin\"], \"digoxin\": [\"digoxin\"], \"mice\": [\"mice\"]}",
                {
                    "Parameter": [
                        "AUC"
                    ],
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            156,
            "Li Xin et al.",
            [
                " {\"AUTHORS\": [\"Li Xin\", \"et al.\"]},\n{\"DOI\": []},\n{\"JOURNAL\": []},\n{\"MONTH\": []},\n{\"PAGE_NUMBER\": []},\n{\"TITLE\": []},\n{\"VOLUME\": []},\n{\"YEAR\": []},\n{\"ENTITIES\": {\n\"Li Xin\": [],\n\"et al\": []\n}}\n\nThe given text does not contain any entities related to age, DOI, journal, month, page number, title, volume, year. The entities are the authors of the article.",
                {}
            ]
        ],
        [
            157,
            "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).",
            [
                " {\"AGE\": [],\n\"C. pinnatifida Bunge (Shanzha)\": [\"C. pinnatifida Bunge (Shanzha) extract\", \"C. pinnatifida Bunge\"],\n\"arrhythmias\": [\"ventricular arrhythmias\", \"digoxin-induced arrhythmias\"],\n\"duration of QRS interval\": [],\n\"ventricular precontraction\": [],\n\"ventricular tachycardia\": [],\n\"ventricular fibrillation\": [],\n\"digoxin\": [],\n\"rats\": [],\n\"flavonoid glycoside\": [],\n\"flavane polymers\": [],\n\"blood vessels\": [],\n\"blood pressure\": [],\n\"heart rhythm\": [],\n\"cardiovascular system\": []}",
                {
                    "Pathology": [
                        "ventricular precontraction, ventricular tachycardia,",
                        "ventricular fibrillation",
                        "arrhythmia",
                        "arrhythmias",
                        "ventricular arrhythmias",
                        "arrhythmias"
                    ],
                    "Herb name": [
                        "C. pinnatifida Bunge (Shanzha)",
                        "C. pinnatifida Bunge (Shanzha)",
                        "flavonoid glycoside",
                        "flavane polymers",
                        "C. pinnatifida Bunge (Shanzha)"
                    ],
                    "Drug": [
                        "digoxin",
                        "digoxin",
                        "digoxin"
                    ],
                    "Parameter": [
                        "blood pressure",
                        "heart rhythm"
                    ]
                }
            ]
        ],
        [
            158,
            "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).",
            [
                " {\"AGE\": []}\n\nWhen: [\"when\", \"it\"]\nthe bias of medicine: []\nis greater than that of food: []\nit: []\nwill inevitably affect: []\nthe balance of: [\"balance\"]\nqi: [\"qi\"]\nblood: [\"blood\"]\nyin and yang: [\"yin and yang\"]\nof the human body: [\"human body\"]\n\nJia et al., 2021: []",
                {}
            ]
        ],
        [
            159,
            "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.",
            [
                " {\"AGE\": []}\n\nAlthough a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.\n\nDigoxin: {\"Digoxin\": [\"digoxin\"]}\n\nTCM formulations: {\"TCM formulations\": [\"TCM formulations\"]}\n\nclinical application: {\"clinical application\": [\"clinical application\"]}\n\nyears: {\"years\": [\"years\"]}\n\nresearch: {\"research\": [\"research\"]}\n\npossible interactions: {\"possible interactions\": [\"possible interactions\"]}\n\nDigoxin and TCM formulations: {}\n\nAccording to the literature, the interactions between digoxin and TCM formulations mainly involve herbs that inhibit P-glycoprotein (PGP) or organic cation transporter 2 (OCT2), leading to increased digoxin levels in the body.\n\ninteractions: {\"interactions\": [\"interactions\"]}\n\nliterature: {\"literature\": [\"literature\"]}\n\nmainly involve: {\"mainly involve\": [\"mainly involve\"]}\n\nherbs: {\"herbs\": [\"herbs\"]}\n\ninhibit P-glycoprotein (PGP) or organic cation transporter 2 (OCT2): {\"inhibit P-glycoprotein (PGP) or organic cation transporter 2 (OCT2)\": [\"inhibit P-glycoprotein (PGP)\", \"inhibit organic cation transporter 2 (OCT2)\"]}\n\nleading to increased digoxin levels in the body: {\"leading to increased digoxin levels in the body\": [\"leading to increased digoxin levels in the body\"]}\n\nDigoxin levels: {\"Digoxin levels\": [\"digoxin levels\"]}\n\nbody: {\"body\": [\"body\"]}\n\nThe following herbs have been reported to inhibit P-glycoprotein (PGP) or organic cation transporter 2 (OCT2):\n\nfollowing: {\"following\": [\"following\"]}\n\nherbs: {\"herbs\": [\"herbs\"]}\n\nhave been reported: {\"have been reported\": [\"have been reported\"]}\n",
                {
                    "Drug": [
                        "digoxin"
                    ]
                }
            ]
        ],
        [
            160,
            "The composition of TCM formulations is complex.",
            [
                " {\"TCM\": [\"Traditional Chinese Medicine\", \"formulations\"]}\n\nThe identification of active components in TCM formulations is a challenging task.\n\n{\"CHINESE_HERBS\": [\"TCM formulations\", \"Chinese herbs\"]}\n\nThe pharmacological effects of Chinese herbs are often attributed to their complex chemical compositions.\n\n{\"CHEMICAL_COMPOSITIONS\": [\"complex chemical compositions\"]}\n\nThe isolation and identification of active compounds from Chinese herbs have been achieved through various methods, including:\n\n{\"EXTRACTION\": [\"extraction\"]}\n{\"CHROMATOGRAPHY\": [\"chromatography\"]}\n{\"MASS_SPECTROMETRY\": [\"mass spectrometry\"]}\n{\"NMR\": [\"NMR\"]}\n{\"GC-MS\": [\"GC-MS\"]}\n{\"LC-MS\": [\"LC-MS\"]}\n{\"HPLC\": [\"HPLC\"]}\n\nThe pharmacological activities of these active compounds have been studied extensively using in vitro and in vivo approaches.\n\n{\"IN_VITRO\": [\"in vitro\"]}\n{\"IN_VIVO\": [\"in vivo\"]}\n{\"PHARMACOLOGICAL_ACTIVITIES\": [\"pharmacological activities\"]}\n{\"ACTIVE_COMPOUNDS\": [\"active compounds\"]}\n\nThe mechanisms of action of these active compounds are diverse and can involve various targets, including:\n\n{\"RECEPTORS\": [\"targets\", \"receptors\"]}\n{\"ENZYMES\": [\"targets\", \"enzymes\"]}\n{\"ION_CHANNELS\": [\"targets\", \"ion channels\"]}\n{\"TRANSPORT_PROTEINS\": [\"targets\", \"transport proteins\"]}\n{\"GENES\": [\"targets\", \"genes\"]}\n{\"DNA\": [\"targets\", \"DNA\"]}\n{\"RNA\": [\"targets\", \"RNA\"]}\n{\"PROTEINS\": [\"targets\", \"proteins\"]}\n{\"CELLS\": [\"targets\", \"cells\"]}\n{\"ORGANS\": [\"targets\", \"organs\"]}\n{\"SYSTEMS\": [\"targets\", \"systems\"]}\n\nThe therapeutic applications of these",
                {}
            ]
        ],
        [
            161,
            "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.",
            [
                " {\"TCM formulations\": [\"TCM formulations\", \"interactions between TCM formulations and digoxin\"]}",
                {}
            ]
        ],
        [
            162,
            "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.",
            [
                " {\"AGE\": []}\n\nMany: [\"many\"]\nthese medicines: [] (generic term for herbal remedies or supplements)\nbenign: []\nbecause they are of natural origin: []\nhowever: []\nbecause: []\ntheir constituents: [] (chemical compounds found in herbs)\nmay be metabolized: [] (process by which a substance is chemically changed in the body)\nthrough the same enzymatic pathways: [] (series of biochemical reactions catalyzed by enzymes)\nas pharmaceutical agents: [] (traditional medicines vs. synthetic drugs)\nthere is a potential: []\nfor herb-drug interactions: []",
                {}
            ]
        ],
        [
            163,
            "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).",
            [
                " {\"CYTOCHROME P450 (P450)\": [\"most important class of enzymes involved in human drug metabolism\", \"superfamily of related monooxygenase forms\", \"responsible for oxidative metabolism of xenobiotics and endogenous compounds\"]}",
                {
                    "Parameter": [
                        "cytochrome P450 (P450)",
                        "monooxygenase forms"
                    ]
                }
            ]
        ],
        [
            164,
            "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).",
            [
                " {\"AGE\": []}\n\n\"Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug\"\n\nNo mentions of ages found in the text.",
                {}
            ]
        ],
        [
            165,
            "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.",
            [
                " {\"CAW\": [\"extract\", \"botanical drug\"],\n \"NCT03929250\": [],\n \"NCT03937908\": [],\n \"phase I\": [],\n \"clinical trials\": [],\n \"cognitive decline\": []}",
                {
                    "Herb name": [
                        "CAW",
                        "CAW"
                    ],
                    "Study": [
                        "preclinical studies",
                        "phase II clinical trials"
                    ],
                    "Pathology": [
                        "cognitive decline"
                    ]
                }
            ]
        ],
        [
            166,
            "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).",
            [
                " {\"AGE\": [], \"Hepatocytes\": [\"Hepatocytes cultured\"], \"nuclear receptor agonists\": [], \"transporter function\": [], \"proper drug disposition\": []}\n\nReferences:\n{\"Yang et al., 2016\": []}",
                {
                    "Parameter": [
                        "nuclear receptor"
                    ]
                }
            ]
        ],
        [
            167,
            "C. asiatica Plant Material and Preparation of CAW-R61J.",
            [
                " {\"C. asiatica\": [\"Plant Material\", \"CAW-R61J\"]}",
                {
                    "Herb name": [
                        "C. asiatica Plant"
                    ]
                }
            ]
        ],
        [
            168,
            "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).",
            [
                " {\"CA\": [\"CAW-R61F\", \"CAW-R61H\"], \"Oregon Health & Science University (OHSU)\": [], \"Portland\": [], \"OR\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nThe text does not provide any information related to age.",
                {
                    "Amount": [
                        "21.4%",
                        "23.9%"
                    ],
                    "Herb name": [
                        "dried CA for CAW-R61F",
                        "dried CA for CAW-R61H"
                    ]
                }
            ]
        ],
        [
            169,
            "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.",
            [
                " {\"DMSO\": [\"0.1% (v/v)\"]}",
                {
                    "Parameter": [
                        "DMSO",
                        "DMSO"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ],
                    "Amount": [
                        "0.1% (v/v)",
                        "0.1%"
                    ]
                }
            ]
        ],
        [
            170,
            "Plates were thawed at ambient temperature.",
            [
                " {}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nPlates were thawed at ambient temperature.\n\nThere are no mentions of entities or ages in this text.",
                {}
            ]
        ],
        [
            171,
            "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.",
            [
                " {\"P450 enzyme activity\": [\"P450 enzyme activity by CAW-R61J\"], \"IC50 values\": [\"IC50 values between 30-minute preincubations\"], \"NADPH\": [\"NADPH in the presence and absence\"]}",
                {
                    "Parameter": [
                        "Potential TDI of P450 enzyme activity",
                        "IC50",
                        "NADPH"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ],
                    "Duration": [
                        "30-minute"
                    ]
                }
            ]
        ],
        [
            172,
            "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Dogs\": [\"dogs\"], \"Dose\": [\"dose\", \"5 mg/kg\", \"10 mg/kg\"], \"Euthanasia\": [\"euthanasia\"], \"Heart\": [\"heart\"], \"Heartbeats\": [\"heartbeats\"], \"Isoflurane\": [\"isoflurane\"], \"Mortality\": [\"mortality\"], \"Nitrous Oxide\": [\"nitrous oxide\"], \"Oxygen\": [\"oxygen\"], \"Respiratory Rate\": [\"respiratory rate\"], \"Sodium Thiopental\": [\"sodium thiopental\"], \"Survival\": [\"survival\"], \"Thiopental\": [\"thiopental\"], \"Vasopressors\": [\"vasopressors\"]}",
                {}
            ]
        ],
        [
            173,
            "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.",
            [
                " {\"IC50\": [\"IC50 values\", \"concentration-response curves\", \"four-parameter sigmoid (Hill) model\"]}\n\nThe expression of the recombinant human receptor, hERG, was stably transfected into HEK293 cells, and the functional characterization was performed using the patch-clamp technique.\n\n{\"hERG\": [\"recombinant human receptor\", \"HEK293 cells\", \"functional characterization\", \"patch-clamp technique\"]}\n\nThe hERG channel was inhibited by several drugs, including E-4031, dofetilide, and astemizole.\n\n{\"E-4031\": [\"inhibited hERG channel\"], \"dofetilide\": [\"inhibited hERG channel\"], \"astemizole\": [\"inhibited hERG channel\"]}\n\nThe IC50 values for E-4031, dofetilide, and astemizole were determined to be 0.21 \u00b5M, 0.05 \u00b5M, and 1.2 \u00b5M, respectively.\n\n{\"IC50\": [\"IC50 values\", \"E-4031\", \"0.21 \u00b5M\", \"dofetilide\", \"0.05 \u00b5M\", \"astemizole\", \"1.2 \u00b5M\"]}\n\nThe results suggest that dofetilide is the most potent inhibitor of the hERG channel among the three drugs tested.\n\n{\"dofetilide\": [\"most potent inhibitor\"], \"hERG channel\": [\"inhibitor\"]}\n\nIn conclusion, the IC50 values for E-4031, dofetilide, and astemizole were determined using a sigmoid model, and the results indicate that dofetilide is the most potent inhibitor of the hERG channel.\n\n{\"IC50\": [\"IC50 values\", \"determined using a sigmoid model\", \"results indicate\", \"dofetilide\", \"most potent inhibitor\", \"hERG channel\": [\"inhibitor\"]}",
                {
                    "Parameter": [
                        "the IC50 values",
                        "the concentration-response (percentage control value)"
                    ]
                }
            ]
        ],
        [
            174,
            "2 above (substituting logEC50 for logIC50).",
            [
                " {\"AGE\": [],\n \"Chemical Compounds\": [\"logEC50\", \"logIC50\"],\n \"Entities\": [],\n \"Drugs\": [],\n \"Proteins\": [],\n \"Doses\": [],\n \"Receptors\": [\"receptors\"],\n \"Ligands\": [\"ligands\"],\n \"Agonists\": [],\n \"Antagonists\": [],\n \"Inhibitors\": [],\n \"Enzymes\": [],\n \"Tissues\": [],\n \"Cells\": [],\n \"Organisms\": [],\n \"Studies\": [],\n \"Research\": [],\n \"Methods\": [],\n \"Techniques\": []}",
                {
                    "Parameter": [
                        "logEC50",
                        "logIC50"
                    ]
                }
            ]
        ],
        [
            175,
            "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).",
            [
                " {\"Prism 8.0.2\": [\"GraphPad Software\", \"San Diego\", \"CA\"]}",
                {}
            ]
        ],
        [
            176,
            "Object name is dmd.120.090860f1.jpg Fig.",
            [
                " {\"Fig\": [\"Fig.\", \"figure\"]}\n\nThe following entities were identified in the given text:\n\n{\"Adenosine Receptors\": [\"adenosine receptors\"],\n \"Adenosine\": [\"adenosine\"],\n \"Agonist\": [\"agonist\"],\n \"Antagonist\": [\"antagonist\"],\n \"Binding\": [\"binding\"],\n \"Brain\": [\"brain\"],\n \"Cerebral Cortex\": [\"cerebral cortex\"],\n \"Cyclic AMP\": [\"cyclic AMP\"],\n \"Dopamine\": [\"dopamine\"],\n \"Drug\": [\"drug\"],\n \"G Protein-Coupled Receptors\": [\"G protein-coupled receptors\"],\n \"G Proteins\": [\"G proteins\"],\n \"GABA\": [\"GABA\"],\n \"Glutamate\": [\"glutamate\"],\n \"GTP\": [\"GTP\"],\n \"Heart\": [\"heart\"],\n \"Hippocampus\": [\"hippocampus\"],\n \"Intracellular Signaling\": [\"intracellular signaling\"],\n \"Ion Channels\": [\"ion channels\"],\n \"Ligand\": [\"ligand\"],\n \"Membrane\": [\"membrane\"],\n \"Molecule\": [\"molecule\"],\n \"NMDA Receptors\": [\"NMDA receptors\"],\n \"Neuron\": [\"neuron\"],\n \"Neurotransmitter\": [\"neurotransmitter\"],\n \"Nucleotide\": [\"nucleotide\"],\n \"Pharmacology\": [\"pharmacology\"],\n \"Protein\": [\"protein\"],\n \"Receptor\": [\"receptor\"],\n \"Signaling\": [\"signaling\"],\n \"Synapse\": [\"synapse\"],\n \"Thyroid Hormone\": [\"thyroid hormone\"],\n \"Tissue\": [\"tissue\"]}",
                {}
            ]
        ],
        [
            177,
            "Mean\tS.D.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Dose\": [], \"Mean\": [\"Mean\"], \"S.D\": [\"S.D\"], \"Pharmacokinetics\": [\"pharmacokinetics\"], \"Plasma\": [\"plasma\"], \"Concentration\": [\"concentration\"], \"Time\": [\"time\"], \"Peak\": [\"peak\"], \"Clearance\": [\"clearance\"], \"Volume\": [\"volume\"], \"Half-life\": [\"half-life\"], \"Subjects\": [\"subjects\"]}",
                {}
            ]
        ],
        [
            178,
            "Mean\tS.D.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Dose\": [], \"Mean\": [\"Mean\"], \"S.D\": [\"S.D\"], \"Pharmacokinetics\": [\"pharmacokinetics\"], \"Plasma\": [\"plasma\"], \"Concentration\": [\"concentration\"], \"Time\": [\"time\"], \"Peak\": [\"peak\"], \"Clearance\": [\"clearance\"], \"Volume\": [\"volume\"], \"Half-life\": [\"half-life\"], \"Subjects\": [\"subjects\"]}",
                {}
            ]
        ],
        [
            179,
            "***P < 0.0001.",
            [
                " {\"AGE\": [], \"entities_pharmacological_compounds\": [\"P\"], \"doses\": [], \"drugs\": [\"P\"], \"conditions\": [], \"diseases\": [], \"proteins\": [], \"genes\": [], \"organisms\": [], \"locations\": []}\n\nIn this text, there is only one entity mentioned which is \"P\" representing a statistical value with a p-value less than 0.0001. No other entities such as ages, proteins, genes, locations, diseases, or conditions have been mentioned in the provided text.",
                {}
            ]
        ],
        [
            180,
            "; data not shown).",
            [
                " {\"AGE\": []}\n{\"ANESTHETIC\": [\"anesthetic\"]}\n{\"BENZODIAZEPINE\": [\"benzodiazepine\"]}\n{\"BLOOD-ALCOHOL CONCENTRATION\": [\"blood-alcohol concentration\"]}\n{\"CARDIAC\": [\"cardiac\"]}\n{\"CARDIAC ARREST\": [\"cardiac arrest\"]}\n{\"CARDIOPULMONARY RESUSCITATION\": [\"cardiopulmonary resuscitation\"]}\n{\"CARDIOTOXIC\": [\"cardiotoxic\"]}\n{\"CITRIC ACID\": [\"citric acid\"]}\n{\"CLINICAL TRIAL\": [\"clinical trial\"]}\n{\"CONSCIOUSNESS\": [\"consciousness\"]}\n{\"CONTRAST MEDIA\": [\"contrast media\"]}\n{\"CORONARY ARTERY\": [\"coronary artery\"]}\n{\"CORONARY DISEASE\": [\"coronary disease\"]}\n{\"CORONARY SINUS\": [\"coronary sinus\"]}\n{\"DIABETES\": [\"diabetes\"]}\n{\"DIASTOLE\": [\"diastole\"]}\n{\"DIASTOLIC PRESSURE\": [\"diastolic pressure\"]}\n{\"DIASTOLIC VOLUME\": [\"diastolic volume\"]}\n{\"DIASTOLIC VOLUME REDUCTION\": [\"diastolic volume reduction\"]}\n{\"DIASTOLIC VOLUMES\": [\"diastolic volumes\"]}\n{\"DIASTOLY\": [\"diastoly\"]}\n{\"DIASTOLYSIS\": [\"diastolysis\"]}\n{\"DIASTOLYSIS CARDIA\": [\"diastolysis cardia\"]}\n{\"DIASTOLYSIS CARDIA PROCEDURE\": [\"diastolysis cardia procedure\"]}\n{\"DIASTOLYSIS CARDIA TECHNIQUE\": [\"diastolysis cardia technique\"]}\n{\"DIASTOLYSIS TECHNIQUE\": [\"diastolysis technique\"]}\n{\"DIASTOLYSIS-INDUCED DIAPHORETIC RESPONSE\": [\"diastolysis-induced diaphoresis response\"]",
                {}
            ]
        ],
        [
            181,
            "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nThis article does not provide any information about ages. Therefore, the \"AGE\" field should be left empty.\n\nThe cited references are: Ring et al. (1996), Suzuki et al. (2002), Emoto et al. (2003), Walsky et al. (2006), VandenBrink et al. (2011), Zhao et al. (2012), and Thu et al. (2017). These are sources that are consistent with the literature on the topic. However, the article does not provide any information about the specific content of these references related to ages.",
                {}
            ]
        ],
        [
            182,
            "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).",
            [
                " {\"CYP1A2\": [\"least inhibition\"], \"CYP2B6\": [\"least inhibition\"], \"CYP2C9\": [\"strongest reversible inhibition\", \"IC50 330 \u00b5g/ml\"]}",
                {
                    "Target": [
                        "CYP2C9",
                        "CYP1A2",
                        "CYP2B6"
                    ],
                    "Parameter": [
                        "IC50",
                        "IC50"
                    ],
                    "Amount": [
                        "330 \u00b5g/ml",
                        "> 1000 \u00b5g/ml"
                    ]
                }
            ]
        ],
        [
            183,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\"Caffeine\": [\"caffeine\", \"theophylline\", \"theobromine\"],\n \"Dopamine\": [\"dopamine\", \"dopaminergic\", \"dopaminergic system\"],\n \"Serotonin\": [\"serotonin\", \"serotonergic\"],\n \"Norepinephrine\": [\"norepinephrine\"],\n \"Adrenaline\": [\"adrenaline\"],\n \"Histamine\": [\"histamine\"],\n \"Acetylcholine\": [\"acetylcholine\"],\n \"GABA\": [\"GABA\"],\n \"Glutamate\": [\"glutamate\"],\n \"Morphine\": [\"morphine\"],\n \"Fentanyl\": [\"fentanyl\"],\n \"Ibuprofen\": [\"ibuprofen\"],\n \"Aspirin\": [\"aspirin\"],\n \"Paracetamol\": [\"paracetamol\"],\n \"Codeine\": [\"codeine\"],\n \"Morphine derivatives\": [\"morphine derivatives\"],\n \"Opioid receptors\": [\"opioid receptors\"],\n \"NMDA receptors\": [\"NMDA receptors\"],\n \"G protein\": [\"G protein\"],\n \"GABA receptors\": [\"GABA receptors\"],\n \"Nicotinic acetylcholine receptors\": [\"nicotinic acetylcholine receptors\"],\n \"Serotonin receptors\": [\"serotonin receptors\"],\n \"Dopamine receptors\": [\"dopamine receptors\"],\n \"Adrenergic receptors\": [\"adrenergic receptors\"],\n \"Histamine receptors\": [\"histamine receptors\"],\n \"Muscarinic acetylcholine receptors\": [\"muscarinic acetylcholine receptors\"],\n \"5-HT1A receptors\": [\"5-HT1A receptors\"],\n \"5-HT2A receptors\": [\"5-HT2A receptors\"],\n \"5-HT3 receptors\": [\"5-HT3 receptors\"],\n \"5-HT4 receptors\": [\"5-HT4 receptors\"],\n \"D1 receptors\": [\"D",
                {}
            ]
        ],
        [
            184,
            "Object name is dmd.120.090860f3.jpg Fig.",
            [
                " {\"Fig\": [\"Fig.\", \"figure\"]}\n\nThe following entities were identified in the given text:\n\n{\"Adenosine Receptors\": [\"adenosine receptors\"],\n \"Adenosine\": [\"adenosine\"],\n \"Agonist\": [\"agonist\"],\n \"Antagonist\": [\"antagonist\"],\n \"Binding\": [\"binding\"],\n \"Brain\": [\"brain\"],\n \"Cerebral Cortex\": [\"cerebral cortex\"],\n \"Cyclic AMP\": [\"cyclic AMP\"],\n \"Dopamine\": [\"dopamine\"],\n \"Drug\": [\"drug\"],\n \"G Protein-Coupled Receptors\": [\"G protein-coupled receptors\"],\n \"G Proteins\": [\"G proteins\"],\n \"GABA\": [\"GABA\"],\n \"Glutamate\": [\"glutamate\"],\n \"GTP\": [\"GTP\"],\n \"Heart\": [\"heart\"],\n \"Hippocampus\": [\"hippocampus\"],\n \"Intracellular Signaling\": [\"intracellular signaling\"],\n \"Ion Channels\": [\"ion channels\"],\n \"Ligand\": [\"ligand\"],\n \"Membrane\": [\"membrane\"],\n \"Molecule\": [\"molecule\"],\n \"NMDA Receptors\": [\"NMDA receptors\"],\n \"Neuron\": [\"neuron\"],\n \"Neurotransmitter\": [\"neurotransmitter\"],\n \"Nucleotide\": [\"nucleotide\"],\n \"Pharmacology\": [\"pharmacology\"],\n \"Protein\": [\"protein\"],\n \"Receptor\": [\"receptor\"],\n \"Signaling\": [\"signaling\"],\n \"Synapse\": [\"synapse\"],\n \"Thyroid Hormone\": [\"thyroid hormone\"],\n \"Tissue\": [\"tissue\"]}",
                {}
            ]
        ],
        [
            185,
            "Data shown are the means \u00b1 S.D.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\"], \"Buprenorphine\": [\"buprenorphine\"], \"Cisapride\": [\"cisapride\"], \"Diazepam\": [\"diazepam\"], \"Fentanyl\": [\"fentanyl\"], \"Gastrointestinal\": [\"gastrointestinal\"], \"Heart rate\": [\"heart rate\"], \"Ibuprofen\": [\"ibuprofen\"], \"Morphine\": [\"morphine\"], \"Naloxone\": [\"naloxone\"], \"Nitrous oxide\": [\"nitrous oxide\"], \"Opioids\": [\"opioids\"], \"Pain\": [\"pain\"], \"Propofol\": [\"propofol\"], \"Rats\": [\"rats\"], \"Sedation\": [\"sedation\"], \"Seizures\": [\"seizures\"], \"Sodium chloride\": [\"sodium chloride\"], \"Temperature\": [\"temperature\"], \"Thiopental\": [\"thiopental\"], \"Vasopressors\": [\"vasopressors\"]}",
                {}
            ]
        ],
        [
            186,
            "of triplicate determinations.",
            [
                " {\"AGE\": []}\n{\"CITED\\_ENTITIES\": [\"triplicate determinations\"]}\n{\"DRUGS\": []}\n{\"DOSES\": []}\n{\"ENTITIES\": []}\n{\"EXPERIMENTS\": []}\n{\"GENES\": []}\n{\"PROTEINS\": []}\n{\"SPECIES\": []}\n{\"SYSTEMS\": []}\n{\"TECHNIQUES\": []}\n{\"TREATMENTS\": []}\n{\"LOCATIONS\": []}\n{\"ORGANS\": []}\n{\"CELL\\_LINES\": []}\n{\"COMPOUNDS\": []}\n{\"DISEASES\": []}\n{\"SYNDROMES\": []}\n{\"TOXINS\": []}\n{\"DRUG\\_CLASS\": []}\n{\"DRUG\\_NAMES\": []}\n{\"GENE\\_NAMES\": []}\n{\"PROTEIN\\_NAMES\": []}\n{\"SPECIES\\_NAMES\": []}\n{\"SYSTEMS\\_NAMES\": []}\n{\"TECHNIQUE\\_NAMES\": []}\n{\"TREATMENT\\_NAMES\": []}\n{\"LOCATION\\_NAMES\": []}\n{\"ORGAN\\_NAMES\": []}\n{\"CELL\\_LINE\\_NAMES\": []}\n{\"COMPOUND\\_NAMES\": []}\n{\"DISEASE\\_NAMES\": []}\n{\"SYNDROME\\_NAMES\": []}\n{\"TOXIN\\_NAMES\": []}\n{\"DRUG\\_DOSES\": []}\n{\"GENE\\_DOSES\": []}\n{\"PROTEIN\\_DOSES\": []}\n{\"CONCENTRATIONS\": []}\n{\"FREQUENCIES\": []}\n{\"DURATIONS\": []}\n{\"TEMPERATURES\": []}\n{\"PRESSURES\": []}\n{\"VOLUMES\": []}\n{\"WEIGHTS\": []}\n{\"DIMENSIONS\": []}\n{\"FREQUENCY\\_UNITS\": []}\n{\"CONCENTRATION\\_UNITS\": []}\n{\"DOSE\\_UNITS\": []}\n{\"TEMPERATURE\\_UNITS\": []}\n{\"PRESSURE\\_UNITS\": []}\n{\"VOLUME\\_UNITS\": []",
                {}
            ]
        ],
        [
            187,
            "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.",
            [
                " {\"AGE\": [],\n \"human\": [\"human liver microsoms\", \"human P450 forms\"],\n \"entities\": [\"centelloids\", \"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\"],\n \"locations\": [\"in human liver microsoms and human P450 forms expressed by E. coli\"]\n}",
                {
                    "Herb name": [
                        "centelloids"
                    ],
                    "Parameter": [
                        "P450",
                        "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"
                    ]
                }
            ]
        ],
        [
            188,
            "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.",
            [
                " {\"CAW-R61J\": [\"CAW-R61J\", \"this extract\"]}\n{\"centelloid\": [\"centelloid\"]}",
                {
                    "Herb name": [
                        "the centelloid content of CAW-R61J"
                    ],
                    "Parameter": [
                        "plasma concentrations for these compounds"
                    ],
                    "Study": [
                        "clinical studies"
                    ]
                }
            ]
        ],
        [
            189,
            "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.",
            [
                " {\"IC50\": [\"IC50 values of the as yet unknown inhibitory CAW-R61J compounds\"],\n \"CAW-R61J\": [\"CAW-R61J compounds\"],\n \"P450\": [\"weak P450 inhibition\"],\n \"in vivo\": [\"in vivo concentration achieved in humans\"]}",
                {
                    "Target": [
                        "P450"
                    ],
                    "Parameter": [
                        "IC50",
                        "in vivo concentration"
                    ],
                    "Herb name": [
                        "CAW-R61J"
                    ]
                }
            ]
        ],
        [
            190,
            "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.",
            [
                " {\"CA derivatives\": [\"CA derivatives\", \"CA derivatives will be\", \"CA derivatives it will also be important to examine possible interactions of CA derivatives\"]}\n\nIt will be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.\n\nPlease note that no specific mentions of ages or other entities were found in the provided text.",
                {
                    "Herb name": [
                        "CA"
                    ],
                    "Parameter": [
                        "phase II drug-metabolizing enzymes"
                    ]
                }
            ]
        ],
        [
            191,
            "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.",
            [
                " {\"AGE\": []}\n\n\"The following format must be followed:\nThe tolerability and safety of combination drugs were evaluated in the context of their DDI potential.\"\n\nNo entities related to age were mentioned in the given text.",
                {}
            ]
        ],
        [
            192,
            "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].",
            [
                " {\"AGE\": [], \"fimasartan\": [\"fimasartan\"], \"patients\": [\"patients\"], \"with\": [\"with\"], \"hypertension\": [\"hypertension\"], \"and\": [\"and\"], \"chronic kidney disease\": [\"chronic kidney disease\"], \"clinical outcomes\": [\"clinical outcomes\"], \"recommended\": [\"recommended\"]}",
                {
                    "Drug": [
                        "fimasartan"
                    ],
                    "Pathology": [
                        "hypertension",
                        "chronic kidney disease"
                    ]
                }
            ]
        ],
        [
            193,
            "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).",
            [
                " {\"Fimasartan\": [\"Fimasartan\", \"fimasartan-amide\"],\n \"Amlodipine\": [\"Amlodipine\"],\n \"Hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n \"Agilent\": [\"Agilent\"],\n \"Wilmington\": [\"Wilmington\"],\n \"DE\": [\"DE\"],\n \"USA\": [\"USA\"],\n \"Agilent 6470 Triple Quadrupole LC-MS/MS system\": [\"Agilent 6470 Triple Quadrupole LC-MS/MS system\"]}",
                {
                    "Drug": [
                        "Fimasartan",
                        "fimasartan-amide",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            194,
            "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.",
            [
                " {\"CONCENTRATIONS\": [\"low\", \"medium\", \"high\"]}\n\nThree samples of quality control (QC) were prepared.",
                {}
            ]
        ],
        [
            195,
            "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.",
            [
                " {\"berberine (IS)\": [\"1 ng/mL\"]}\n\n\"acetonitrile\": []\n\n\"150 \u03bcL\" : []\n\n\"mL\" : []\n\n\"reconstituted standard curves\" : []",
                {}
            ]
        ],
        [
            196,
            "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).",
            [
                " {\"AGE\": [],\"Post-preparative stability\": [\"Post-preparative stability\"],\"evaluated\": [], \"comparing\": [], \"extracted QC samples\": [], \"maintained\": [], \"at\": [], \"6 \u00b0C\": [], \"for\": [], \"24 h\": [], \"compared with\": [], \"untreated QC samples\": []}",
                {}
            ]
        ],
        [
            197,
            "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.",
            [
                " {\"rat\": [\"each rat\", \"combination group\"], \"fimasartan\": [\"fimasartan\"], \"3 mg/kg\": [\"3 mg/kg\"], \"amlodipine\": [\"amlodipine\"], \"5 mg/kg\": [\"5 mg/kg\"], \"hydrochlorothiazide\": [\"hydrochlorothiazide\"], \"5 mg/kg\", \"saline\": [\"containing 10% DMSO\", \"dissolved in salane\"]}",
                {
                    "Drug": [
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ],
                    "Amount": [
                        "3 mg/kg",
                        "5 mg/kg",
                        "5 mg/kg"
                    ]
                }
            ]
        ],
        [
            198,
            "The jejunal segments were then isolated and rinsed using pre-warmed saline.",
            [
                " {\"jejunal segments\": []}",
                {}
            ]
        ],
        [
            199,
            "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).",
            [
                " {\"Age\": [], \"amlodipine\": [\"for amlodipine analysis\"], \"acetonitrile\": [\"150 \u03bcL acetonitrile\"], \"berberine\": [\"1 ng/mL berberine (IS)\"]}",
                {
                    "Drug": [
                        "amlodipine"
                    ]
                }
            ]
        ],
        [
            200,
            "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).",
            [
                " {\"Figure 1\": [], \"IONIZATION MODE\": [], \"mass transition\": [], \"Q1\": [], \"Q3\": []}\n\nThe product ion scan results of authentic standards were used to select the ionization mode and mass transition from Q1 to Q3 (Figure 1).",
                {}
            ]
        ],
        [
            201,
            "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.",
            [
                " {\"AGE\": [],\n \"fimasartan\": [\"fimasartan\", \"fimasartan-amide\"],\n \"amlodipine\": [\"amlodipine\"],\n \"hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n \"LLOQ\": [\"LLOQ\"],\n \"rat plasma samples\": [\"rat plasma\"],\n \"oral administration\": [],\n \"1 h\": []}",
                {
                    "Drug": [
                        "fimasartan",
                        "fimasartan-amide",
                        "amlodipine",
                        "hydrochlorothiazide",
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            202,
            "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].",
            [
                " {\"QC sample\": [\"response of a QC sample\"], \"inter-day accuracy\": [], \"intra-day accuracy\": [], \"acceptance criteria for accuracy\": [], \"Guideline of Bioanalytical method validation\": [], \"FDA\": [], \"EMA\": [], \"ICH\": []}",
                {}
            ]
        ],
        [
            203,
            "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.",
            [
                " {\"AGE\": [],\n \"fimasartan\": [\"is an attractive candidate\", \"suggests the increasing use\"]}",
                {
                    "Drug": [
                        "fimasartan",
                        "fimasartan"
                    ],
                    "Pathology": [
                        "hypertension"
                    ]
                }
            ]
        ],
        [
            204,
            "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).",
            [
                " {\"AGE\": [],\n \"fimasartan\": [\"fimasartan\"],\n \"amlodipine\": [\"amlodipine\"],\n \"hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n \"product ion mass spectra\": [\"product ion mass spectra\"],\n \"Figure 1\": []}",
                {
                    "Drug": [
                        "fimasartan",
                        "amlodipine",
                        "hydrochlorothiazide"
                    ]
                }
            ]
        ],
        [
            205,
            "and M.P.",
            [
                " {\"AGE\": []}\n{\"Cancer\": [\"cancer\"]}\n{\"Doxorubicin\": [\"doxorubicin\"]}\n{\"Cardiotoxicity\": [\"cardiotoxicity\"]}\n{\"Heart\": [\"heart\"]}\n{\"Myocardium\": [\"myocardium\"]}\n{\"DNA\": [\"DNA\"]}\n{\"Topoisomerase II\": [\"topoisomerase II\"]}\n{\"Anthracyclines\": [\"anthracyclines\"]}\n{\"Breast cancer\": [\"breast cancer\"]}\n{\"Cardiomyocytes\": [\"cardiomyocytes\"]}\n{\"Apoptosis\": [\"apoptosis\"]}\n{\"Mitochondria\": [\"mitochondria\"]}\n{\"Reactive oxygen species\": [\"reactive oxygen species\"]}\n{\"NADPH\": [\"NADPH\"]}\n{\"NADP+\": [\"NADP+\"]}\n{\"NADPH oxidase\": [\"NADPH oxidase\"]}\n{\"ROS\": [\"ROS\"]}\n{\"Mitochondrial membrane\": [\"mitochondrial membrane\"]\n}",
                {}
            ]
        ],
        [
            206,
            "Data represented as mean and CV from five or six independent experiments.",
            [
                " {\"AGE\": [],\n \"Agonists\": [\"agonists\"],\n \"Antagonists\": [\"antagonists\"],\n \"CV\": [\"coefficient of variation\"],\n \"Experiments\": [\"experiments\"],\n \"Independent\": [\"independent\"],\n \"Pharmacology\": [\"pharmacology\"],\n \"Receptors\": [\"receptors\"]}",
                {}
            ]
        ],
        [
            207,
            "However, there are several challenges associated with the chronic nature of HAART administration.",
            [
                " {\"HAART\": [\"chronic nature of HAART administration\"]}",
                {
                    "Drug": [
                        "HAART"
                    ]
                }
            ]
        ],
        [
            208,
            "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].",
            [
                " {}\n\nPeople taking ART: {\"ART\": [\"people taking ART\"]}\n\n[1,2].: {}\n\nThe following format must be followed:\n{\"AGE\": [\"mentions of ages found in text\"]}\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART\n\n{\"ART\": [\"attention\", \"shifted\", \"from\", \"reduction\", \"mortality\", \"to\", \"improvement\", \"quality\", \"life\", \"for\", \"people\", \"taking\"]}",
                {
                    "Drug": [
                        "ART"
                    ]
                }
            ]
        ],
        [
            209,
            "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].",
            [
                " {\"EFV\": [\"EFV\", \"efavirenz\"], \"NVP\": [\"NVP\", \"nevirapine\"], \"liver damage\": [\"liver damage\"], \"nausea\": [\"nausea\"], \"vomiting\": [\"vomiting\"], \"fever\": [\"fever\"], \"diarrhoea\": [\"diarrhea\"], \"dyslipidemia\": [\"dyslipidemia\"], \"headache\": [\"headache\"]}",
                {
                    "Drug": [
                        "EFV",
                        "NVP"
                    ],
                    "Pathology": [
                        "side effects",
                        "liver damage",
                        "nausea",
                        "vomiting",
                        "fever",
                        "diarrhoea",
                        "dyslipidemia",
                        "headache"
                    ]
                }
            ]
        ],
        [
            210,
            "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"ENTITY\": [\"mentions of the entity found in text\"]}\n\nThere is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].\n\nEntities:\n{\"MEDICINAL PLANTS\": [\"potential of medicinal plants\", \"combatting diseases\", \"developing countries\"]}\n{\"DISEASES\": [\"diseases\"]}\n{\"DEVELOPING COUNTRIES\": [\"developing countries\"]}",
                {}
            ]
        ],
        [
            211,
            "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nAlthough effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.\n\nThere are no mentions of ages in this text.",
                {}
            ]
        ],
        [
            212,
            "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].",
            [
                " {\"CYP2B6\": [\"genetic polymorphism in CYP2B6\"]}\n\nThe activity of CYP2C19 is influenced by genetic polymorphism and drug-drug interactions [27].\n\n{\"CYP2C19\": [\"activity\", \"genetic polymorphism\"]}\n\nThe role of CYP3A4 in drug metabolism is significant due to its extensive expression in various tissues and high catalytic activity [28].\n\n{\"CYP3A4\": [\"role\", \"drug metabolism\", \"extensive expression\", \"various tissues\", \"high catalytic activity\"]}\n\nThe inhibition of CYP3A4 by grapefruit juice is a well-known drug-drug interaction that can lead to increased bioavailability of certain drugs [29].\n\n{\"CYP3A4\": [\"inhibition\", \"grapefruit juice\", \"drug-drug interaction\", \"increased bioavailability\"]}\n\nThe expression of CYP1A2 is regulated by various factors, including xenobiotics, hormones, and genetic polymorphisms [30].\n\n{\"CYP1A2\": [\"expression\", \"regulated\", \"xenobiotics\", \"hormones\", \"genetic polymorphisms\"]}\n\nThe metabolism of codeine to morphine is catalyzed by CYP2D6, and genetic polymorphisms in this enzyme can affect the therapeutic response to codeine [31].\n\n{\"CYP2D6\": [\"metabolism\", \"codeine\", \"morphine\", \"genetic polymorphisms\", \"therapeutic response\"]}\n\nThe inhibition of CYP2D6 by quinidine is a well-known drug-drug interaction that can lead to increased plasma concentrations of quinidine and its metabolites [32].\n\n{\"CYP2D6\": [\"inhibition\", \"quinidine\", \"drug-drug interaction\", \"increased plasma concentrations\"]}\n\nThe role of CYP2E1 in the metabolism of ethanol and other xenobiotics is well established [33].\n\n{\"CYP2E1\":",
                {
                    "Target": [
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            213,
            "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.",
            [
                " {\"AGE\": [],\n \"test compounds\": [\"each test compound\"],\n \"intestinal absorption\": [],\n \"plasma concentrations\": [],\n \"herbal extracts\": [\"herbal extracts\"],\n \"bioavailability\": [\"bioavailability\"],\n \"% yield\": [\"% yield\"],\n \"soluble extract\": [\"soluble extract\"],\n \"GI tract\": [\"GI tract\"]}",
                {
                    "Extraction process": [
                        "extracts",
                        "soluble extract"
                    ],
                    "Parameter": [
                        "bioavailability",
                        "bioavailable concentration"
                    ]
                }
            ]
        ],
        [
            214,
            "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.",
            [
                " {\"Caffeic acid\": [\"Caffeic acid\"],\n \"Catechin\": [\"Catechin\"],\n \"Chlorogenic acid\": [\"Chlorogenic acid\"],\n \"Epicatechin\": [\"Epicatechin\"],\n \"p-Coumaric acid\": [\"p-Coumaric acid\"],\n \"Structures\": []}",
                {
                    "Herb name": [
                        "phenolic compounds",
                        "Caffeic acid",
                        "Catechin",
                        "Chlorogenic acid",
                        "Epicatechin",
                        "p-Coumaric acid"
                    ],
                    "Extraction process": [
                        "crude herbal extracts"
                    ]
                }
            ]
        ],
        [
            215,
            "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.",
            [
                " {\"phytochemical profiling\": [], \"advantage\": [], \"similar drug interacting constituents\": [], \"related herbs\": [], \"therapeutic purposes\": [], \"necessary mechanistic studies\": []}",
                {}
            ]
        ],
        [
            216,
            "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.",
            [
                " {\"CYP2B6\": [\"CYP2B6\", \"extracts caused a concentration-dependent inhibition in CYP2B6\"]}\n\nLaunaea taraxacifolia: {}, Hyptis suaveolens: {}, Boerhavia diffusa: {}, Myrothamnus flabellifolius: {}",
                {
                    "Herb name": [
                        "Launaea taraxacifolia",
                        "Hyptis suaveolens",
                        "Boerhavia diffusa",
                        "Myrothamnus flabellifolius"
                    ],
                    "Extraction process": [
                        "extracts"
                    ],
                    "Target": [
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            217,
            "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.",
            [
                " {\"University of Cape Town\": [\"obtained from\"], \"Human Research Ethics committee\": [\"obtained from\"], \"HREC\": [\"REF:\"], \"826/2014\": []}",
                {}
            ]
        ],
        [
            218,
            "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.",
            [
                " {}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\n[--]\nThe material was allowed to extract for 72 h at room temperature [--]\n{\"TIME\": [\"72 hours\", \"room temperature\"]}\n\nduring which [--]\n{\"TIME\": [\"during which\"]}\n\nsupernatant was decanted [--]\n{\"PROCESS\": [\"decanted\"], \"FLUID\": [\"supernatant\"]}\n\nevery 24 h [--]\n{\"TIME\": [\"every 24 hours\"]}\n\nand the solid residue [--]\n{\"MATERIAL\": [\"solid residue\"]}\n\nwas reconstituted [--]\n{\"PROCESS\": [\"reconstituted\"]}\n\nin the same volume [--]\n{\"QUANTITY\": [\"same volume\"]}\n\nof purified water [--]\n{\"FLUID\": [\"purified water\"]}\n\nfor the extraction process [--]\n{\"PROCESS\": [\"extraction process\"]}\n\nto be repeated. [--]\n{\"PROCESS\": [\"to be repeated\"]}",
                {
                    "Duration": [
                        "for 72 h"
                    ],
                    "Frequency": [
                        "every 24 h"
                    ]
                }
            ]
        ],
        [
            219,
            "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.",
            [
                " {\"AUTHORS\": [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"]}",
                {}
            ]
        ],
        [
            220,
            "All authors reviewed the final manuscript.",
            [
                " {\"AGE\": []}\n\nThe following entities were identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"parsed\"\n4. \"scientific article\"\n5. \"entities\"\n6. \"find\"\n7. \"every word\"\n8. \"referring\"\n9. \"described\"\n10. \"entities\"\n\n{\"ENTITIES\": [\"pharmacology\", \"cited entities\", \"parsed\", \"scientific article\", \"entities\", \"find\", \"every word\", \"referring\", \"described\"]}",
                {}
            ]
        ],
        [
            221,
            "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.",
            [
                " {\"GGT\": [\"GGT with five major ingredients\"]}",
                {
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            222,
            "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.",
            [
                " {\"AGE\": [\"7 \u00b1 1-day\"]}",
                {}
            ]
        ],
        [
            223,
            "Therefore, we applied this dose of GGT in our study.",
            [
                " {\"GGT\": [\"this dose of GGT\"]}",
                {
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            224,
            "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].",
            [
                " {\"AAP\": [\"AAP dose\"], \"dose\": [\"recommended dose\", \"suggested dose\"], \"patients\": [], \"mentions of ages\": [], \"common cold\": [\"treatment of the common cold\"]}",
                {
                    "Drug": [
                        "AAP"
                    ],
                    "Amount": [
                        "1000 mg",
                        "1000 mg"
                    ],
                    "Frequency": [
                        "4 times (8 tablets) per day"
                    ],
                    "Pathology": [
                        "common cold"
                    ]
                }
            ]
        ],
        [
            225,
            "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.",
            [
                " {\"AAP\": [\"AAP 1000 mg\", \"AAP 1000 mg \u00d7 4 times daily\"],\n \"GGT\": [\"GGT 7680 mg\", \"GGT 7680 mg once daily\"]}",
                {
                    "Drug": [
                        "AAP",
                        "AAP"
                    ],
                    "Amount": [
                        "1000 mg",
                        "7680 mg",
                        "1000 mg",
                        "7680 mg"
                    ],
                    "Frequency": [
                        "once daily",
                        "once daily",
                        "4 times daily",
                        "once daily"
                    ],
                    "Herb name": [
                        "GGT",
                        "GGT"
                    ],
                    "Duration": [
                        "week"
                    ]
                }
            ]
        ],
        [
            226,
            "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.",
            [
                " {\"AAP\": [\"AAP at\", \"AAP was\"], \"mg\": [\"1000 mg\", \"1000 mg \u00d7 4 times\"], \"daily\": [\"\"], \"presence\": [\"\"], \"absence\": [\"in the absence of\"], \"GGT\": [\"GGT (7680 mg)\"], \"daily\": [\"daily\"]}",
                {
                    "Drug": [
                        "AAP"
                    ],
                    "Frequency": [
                        "once a day",
                        "4 times a day",
                        "daily"
                    ],
                    "Amount": [
                        "1000 mg",
                        "7680 mg"
                    ],
                    "Herb name": [
                        "GGT"
                    ]
                }
            ]
        ],
        [
            227,
            "and Y.C.P.",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BLOOD-BRAIN BARRIER\": [\"blood-brain barrier\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC ARREST\": [\"cardiac arrest\"], \"CARDIAC GLYCOSIDES\": [\"cardiac glycosides\"], \"CARDIAC OUTPUT\": [\"cardiac output\"], \"CARDIAC STIMULANT\": [\"cardiac stimulant\"], \"CARDIAC TACHYCARDIA\": [\"cardiac tachycardia\"], \"CARDIAC VASCULATURE\": [\"cardiac vascularature\"], \"CATECHOLAMINE\": [\"catecholamine\"], \"CELL MEMBRANE\": [\"cell membrane\"], \"CHEMOTHERAPY\": [\"chemotherapy\"], \"CHLORIDE\": [\"chloride\"], \"CHOLINERGIC AGENTS\": [\"cholinergic agents\"], \"CHOLINERGIC RECEPTORS\": [\"cholinergic receptors\"], \"CONTRACTION\": [\"contraction\"], \"CORONARY ARTERIES\": [\"coronary arteries\"], \"CORONARY VESSELS\": [\"coronary vessels\"], \"DIABETES\": [\"diabetes\"], \"DIURETIC\": [\"diuretic\"], \"DRUG INTERACTIONS\": [\"drug interactions\"], \"ELECTROLYTES\": [\"electrolytes\"], \"ENDOTHELIUM\": [\"endothelium\"], \"EXCITABILITY\": [\"excitability\"], \"HEART\": [\"heart\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HYPERKALEMIA\": [\"hyperkalemia\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"HYPERVOLAEMIA\": [\"hypervolaemia\"], \"HYPOGLYCEMIA\": [\"hypoglycemia\"], \"HYPOKALEMIA\": [\"hypokalemia\"], \"HYPOXIA\": [\"hypoxia\"], \"INFARCTION\": [\"infarction\"], \"INTRAVENOUS\": [\"intravenous\"], \"ISCHEMIA",
                {}
            ]
        ],
        [
            228,
            "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.",
            [
                " {\"AGE\": []}\n\n\"performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.\"\n\nThe mentioned entities are acronyms, so it is not clear what they represent without additional context. Therefore, no entities have been identified in this text.",
                {}
            ]
        ],
        [
            229,
            "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.",
            [
                " {\"AAP\": [\"AAP.s\", \"the described entities\", \"AAP.s\"],\n \"non-compartmental analysis\": [],\n \"pharmacokinetic\": [\"pharmacokinetic\", \"PK\"]}",
                {
                    "Drug": [
                        "AAP"
                    ]
                }
            ]
        ],
        [
            230,
            "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.",
            [
                " {\"AGE\": [\"elderly subjects\"]}\n\n\"St. John\u2019s wort\": [], \"garlic oil\": [], \"Panax ginseng\": [], \"Ginkgo biloba\": [],\n\"CYP1A2\": [\"CYP1A2, activity\"], \"CYP2D6\": [\"CYP2D6, activity\"], \"CYP2E1\": [\"CYP2E1, activity\"], \"CYP3A4\": [\"CYP3A4, activity\"]",
                {
                    "Herb name": [
                        "St. John\u2019s wort",
                        "garlic oil",
                        "Panax ginseng",
                        "Ginkgo biloba"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2D6",
                        "CYP2E1",
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            231,
            "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.",
            [
                " {\"AGE\": [\"individuals greater than 65 years of age\"]}\n\n[1\u20133,8,9]: {}\n[10\u201312]: {}",
                {
                    "Study": [
                        "surveys"
                    ],
                    "Age": [
                        "greater than 65 years of age"
                    ]
                }
            ]
        ],
        [
            232,
            "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.",
            [
                " {\"AGE\": [\"mentions of ages found in text\": [\"elders\", \"elderly\"]]}\n\nThe following citations were not included in the provided text, but they may contain additional information regarding age and pharmacology:\n[28\u201330]\n\nTo parse the cited literature, you would need to read the full text of the cited articles and extract any mentions of age or age-related changes in relation to pharmacology and botanical supplements.",
                {
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            233,
            "Adherence to these restrictions was further emphasized five days before each probe drug administration.",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nAdherence to these restrictions was further emphasized five days before each probe drug administration.\n\nNo mentions of ages found in the given text.",
                {}
            ]
        ],
        [
            234,
            "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.",
            [
                " {}\n\nPeaks: [\"peaks\"]\n\nThe following format must be followed:\n{\"AGE\": [\"mentions of ages found in text\"]}\n\nAssignment of peaks was performed by:\nComparison: [\"comparison\"],\nRetention times: [\"retention times\"],\nUltraviolet absorption spectra: [\"ultraviolet absorption spectra\"]",
                {}
            ]
        ],
        [
            235,
            "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.",
            [
                " {\"AGE\": []}\n\nRESULTS General Experimental Observations - All:\n{\"AGE\": []}\n\nAll subjects completed the study and no serious adverse events occurred during the course of the investigation. (No mentions of ages or specific entities found in this text.)",
                {}
            ]
        ],
        [
            236,
            "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.",
            [
                " {\"CYP\": [\"CYP (Phenotypic Ratio)\"]}\n\"CYP\": [\"CYP (Pre- and Postsupplementation)\"]\n\nThe table does not provide any information about the entities related to ages, so the output will only include the \"CYP\" entity.",
                {}
            ]
        ],
        [
            237,
            "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.",
            [
                " {\"St. John\u2019s wort\": [\"St. John\u2019s wort when more conventional \u2018area-under-the-curve\u2019 methods were utilized to determine midazolam clearance\", \"St. John\u2019s wort with single-time point phenotypic ratio approach\"]}\n\n[1] The following format must be followed:\n{\"ENTITY\": [\"mentions of entities found in text\"]}\n\n[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.\n\n{\"St. John\u2019s wort\": [\"St. John\u2019s wort\", \"St. John\u2019s wort when more conventional \u2018area-under-the-curve\u2019 methods were utilized to determine midazolam clearance\", \"St. John\u2019s wort with single-time point phenotypic ratio approach\"]}",
                {
                    "Herb name": [
                        "St. John\u2019s wort"
                    ],
                    "Parameter": [
                        "area-under-the-curve",
                        "clearance"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            238,
            "This finding also corroborates the results of an earlier study in young individuals.",
            [
                " {\"AGE\": [\"young individuals\"]}",
                {}
            ]
        ],
        [
            239,
            "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.",
            [
                " {\"St. John\u2019s wort\": [\"St. John\u2019s wort\"]}\n\nAgents:\n{\"agents\": [\"these agents\"]}\n\nInteraction:\n{\"interaction\": [\"potential interaction\"]}\n\nAgents and interaction:\n{\"agents_and_interaction\": [\"agents\", \"interaction\"]}\n\nAgents and St. John\u2019s wort:\n{\"agents_and_St_John_s_wort\": [\"agents\", \"St. John\u2019s wort\"]}",
                {
                    "Herb name": [
                        "St. John\u2019s wort"
                    ]
                }
            ]
        ],
        [
            240,
            "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.",
            [
                " {\"AGE\": [\"ages\", \"two age groups\"]}\n\nThe difference... hints at... age-related diminution... or dissimilarity... garlic supplements.",
                {
                    "Target": [
                        "CYP2E1"
                    ],
                    "Herb name": [
                        "allyl sulfide",
                        "garlic"
                    ]
                }
            ]
        ],
        [
            241,
            "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.",
            [
                " {\"AGE\": [\"elderly\"]}\n\nsuch an interaction is particularly relevant to { \"AGE\": [\"elderly\"] } patients on anticoagulant therapy.",
                {
                    "Drug": [
                        "anticoagulant therapy"
                    ]
                }
            ]
        ],
        [
            242,
            "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.",
            [
                " {\"AGE\": [],\n \"ginkgolides\": [\"various ginkgolides\"],\n \"platelet activating factor\": [\"platelet activating factor\"]}",
                {
                    "Target": [
                        "platelet activating factor"
                    ],
                    "Herb name": [
                        "ginkgolides"
                    ]
                }
            ]
        ],
        [
            243,
            "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.",
            [
                " {\"G. biloba\": [\"herb-drug interactions\", \"findings\"]}\n{\"CYP isoforms\": [\"phytochemical-mediated effects\"]}",
                {
                    "Herb name": [
                        "G. biloba"
                    ],
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            244,
            "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.",
            [
                " {\"G. biloba\": [\"G. biloba\"], \"Panax ginseng\": [\"Panax ginseng\"], \"CYP isoforms\": [\"specific CYP isoforms\"]}",
                {
                    "Herb name": [
                        "G. biloba",
                        "Panax ginseng"
                    ],
                    "Target": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            245,
            "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.",
            [
                " {\"CYP2C9\": [\"principal isoform\", \"involved in the biotransformation of warfarin\", \"biotransformation of warfarin (more particularly the active enantiomer, S-warfarin)\", \"aforementioned reports\", \"hint strongly at a ginseng-mediated induction\"]}",
                {
                    "Target": [
                        "CYP2C9"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Study": [
                        "reports"
                    ],
                    "Herb name": [
                        "ginseng"
                    ]
                }
            ]
        ],
        [
            246,
            "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.",
            [
                " {\"AGE\": []}\n\nbotanical supplements\nconventional medications\nserious\nherb-drug interactions",
                {}
            ]
        ],
        [
            247,
            "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.",
            [
                " {\"Plasma\": [\"was collected\", \"was analyzed\"], \"Quinine\": [\"blood samples\", \"plasma\", \"analyzed\"], \"(3-hydroxyquinine)\": [\"metabolite\"], \"HPLC method\": [\"used\"]}",
                {
                    "Drug": [
                        "quinine",
                        "3-hydroxyquinine"
                    ]
                }
            ]
        ],
        [
            248,
            "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.",
            [
                " {\"G. kola\": [\"phytochemical analysis of G. kola seeds\", \"reveal\", \"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"kolaviron\", \"biflavonoid complex\", \"metallic ions\", \"aluminum\", \"magnesium\", \"calcium\", \"copper\"]}",
                {
                    "Herb name": [
                        "G. kola",
                        "benxophenones",
                        "xanthones",
                        "alkaloids",
                        "phenols",
                        "tannins",
                        "saponins",
                        "kolaviron",
                        "biflavonoid complex",
                        "G. kola"
                    ],
                    "Herb part": [
                        "seeds"
                    ]
                }
            ]
        ],
        [
            249,
            "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.",
            [
                " {\"Pregnancy\": [\"pregnancy\"], \"breastfeeding\": [\"breastfeeding\"], \"hypersensitivity\": [\"hypersensitivity to quinine\", \"similar agents\"], \"G. kola seeds\": [\"G. kola seeds\"]}",
                {
                    "Pathology": [
                        "Pregnancy",
                        "breastfeeding",
                        "hypersensitivity",
                        "adverse side effects"
                    ],
                    "Drug": [
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ],
                    "Herb part": [
                        "seeds"
                    ]
                }
            ]
        ],
        [
            250,
            "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.",
            [
                " {\"AGE\": [\"mentions of ages not found in given text\"]}\n\n\"participants\" : [\"participants\"],\n\"were\" : [\"were\"],\n\"certified\" : [\"certified\"],\n\"healthy\" : [\"healthy\"],\n\"by\" : [\"by\"],\n\"a\" : [\"a\"],\n\"physician\" : [\"physician\"],\n\"based\" : [\"based\"],\n\"on\" : [\"on\"],\n\"medical history\" : [\"medical history\"],\n\"clinical examination\" : [\"clinical examination\"],\n\"and\" : [\"and\"],\n\"lab\" : [\"lab\"],\n\"tests\" : [\"tests\"],\n\"gave\" : [\"gave\"],\n\"their\" : [\"their\"],\n\"written\" : [\"written\"],\n\"informed\" : [\"informed\"],\n\"consent\" : [\"consent\"],\n\"to comply\" : [\"to comply\"],\n\"with\" : [\"with\"],\n\"the\" : [\"the\"],\n\"study protocol\" : [\"study protocol\"]",
                {
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            251,
            "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).",
            [
                " {\"QUININE SULPHATE\": [\"600 mg quinine sulphate tablets\", \"quinine sulphate\"]}\n{\"MADERICHT LTD\": []}\n{\"ENGLAND\": []}\n\nIn the second phase, 2 hours after quinine sulphate administration, each subject received a single intravenous dose of 10 mg/kg verapamil hydrochloride (Reckitt and Colman, Harlow, England).\n\n{\"VERAPAMIL HYDROCHLORIDE\": [\"10 mg/kg verapamil hydrochloride\"]}\n{\"RECKITT AND COLMAN\": []}\n{\"HARLOW\": []}\n\nThe plasma concentration of quinine was determined at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours after quinine administration.\n\n{\"QUININE\": [\"plasma concentration of quinine\"]}\n\nThe plasma concentration of verapamil was determined at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours after verapamil administration.\n\n{\"VERAPAMIL\": [\"plasma concentration of verapamil\"]}\n\nThe study was carried out in accordance with the Declaration of Helsinki, and all subjects gave their informed consent before participation.\n\n{\"\": []}\n{\"DECLARATION OF HELSINKI\": []}\n{\"INFORMED CONSENT\": []}\n{\"SUBJECTS\": []}\n\nEach subject weighed between 50 and 80 kg.\n\n{\"SUBJECTS\": [\"each subject\"]}\n{\"50 KG\": []}\n{\"80 KG\": []}\n\nThe study was designed and coordinated by Dr. A. Smith (University of London, London, England).\n\n{\"DR. A. SMITH\": []}\n{\"UNIVERSITY OF LONDON\": []}\n{\"LONDON\": []}\n\nThe data were analyzed by Dr. J. Doe (University of Cambridge, Cambridge, England).\n\n{\"DR. J. DOE\": []}\n{\"UNIVER",
                {
                    "Amount": [
                        "600 mg"
                    ],
                    "Drug": [
                        "quinine sulphate"
                    ]
                }
            ]
        ],
        [
            252,
            "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.",
            [
                " {\"TIME\": [\"time zero\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"]}\n\nVenous blood samples - {\"BLOOD\": [\"venous blood samples\"], \"VOLUME\": [\"5ml\"]}\n\nwere collected - {}\n\ninto heparinised tubes - {\"CONTAINER\": [\"heparinised tubes\"]}\n\nat time zero - {\"TIME\": [\"time zero\"]}\n\n(just before the administration of quinine sulphate tablets) - {}\n\nand at - {\"TIME\": [\"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"]}\n\nafter each participant received - {\"PERSON\": [\"each participant\"]}\n\nquinine alone or concurrently with the scheduled dose of G. kola - {}",
                {
                    "Drug": [
                        "quinine sulphate",
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ]
                }
            ]
        ],
        [
            253,
            "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.",
            [
                " {\"QUININE\": [\"quinine\", \"limit of quantitation\", \"0.37\u00b5g/ml\"],\n \"3-HYDROXYQUININE\": [\"3-hydroxyquinine\", \"limit of quantitation\", \"0.5\u00b5g/ml\"]}",
                {
                    "Drug": [
                        "quinine",
                        "3-hydroxyquinine"
                    ]
                }
            ]
        ],
        [
            254,
            "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.",
            [
                " {\"AUC0\u2013\u221e\": [\"AUC0\u2013\u221e of quinine\"]}",
                {
                    "Parameter": [
                        "AUC0\u2013\u221e"
                    ],
                    "Drug": [
                        "quinine"
                    ]
                }
            ]
        ],
        [
            255,
            "Precisely, only 3 participants complained of very light dizziness.",
            [
                " {\"AGE\": [\"participants\"]}",
                {
                    "Pathology": [
                        "light dizziness"
                    ]
                }
            ]
        ],
        [
            256,
            "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.",
            [
                " {\"AGE\": [],\n \"quinine\": [\"The exact mechanism responsible for the delayed and decreased absorption of quinine\", \"quinine may have interacted through complex formation\", \"The reduction in the Cmax and tmax of quinine\"],\n \"G. kola\": [\"in this current study\", \"usually found in G. kola\"],\n \"trace metals\": [\"it is possible that quinine may have interacted through complex formation with the trace metals\"],\n \"flavonoids\": [\"as evidenced from a significant reduction in the Cmax and tmax of quinine\", \"usually found in G. kola\"]}",
                {
                    "Drug": [
                        "quinine",
                        "quinine",
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola",
                        "flavonoids",
                        "G. kola"
                    ],
                    "Parameter": [
                        "Cmax",
                        "tmax"
                    ]
                }
            ]
        ],
        [
            257,
            "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.",
            [
                " {\"Quinine\": [\"the described entity throughout the article\"],\n \"G. kola\": [\"G. kola\", \"the presence of G. kola\"],\n \"study groups\": [\"both study groups\"],\n \"parameters\": [\"T1/2\", \"CL/F\"],\n \"mentions of ages\": []}",
                {
                    "Parameter": [
                        "T1/2",
                        "CL/F"
                    ],
                    "Drug": [
                        "quinine"
                    ],
                    "Herb name": [
                        "G. kola"
                    ]
                }
            ]
        ],
        [
            258,
            "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.",
            [
                " {\"Cisapride\": [\"Cisapride was used in this study.\"],\n \"Ranitidine\": [\"Ranitidine was used in this study.\"],\n \"Diazepam\": [\"Diazepam was used in this study.\"],\n \"Midazolam\": [\"Midazolam was used in this study.\"],\n \"Fentanyl\": [\"Fentanyl was used in this study.\"],\n \"Ibuprofen\": [\"Ibuprofen was used in this study.\"],\n \"Diclofenac\": [\"Diclofenac was used in this study.\"],\n \"Indomethacin\": [\"Indomethacin was used in this study.\"],\n \"Ketorolac\": [\"Ketorolac was used in this study.\"],\n \"Paracetamol\": [\"Paracetamol was used in this study.\"],\n \"Morphine\": [\"Morphine was used in this study.\"],\n \"Buprenorphine\": [\"Buprenorphine was used in this study.\"],\n \"Fentanyl citrate\": [\"Fentanyl citrate was used in this study.\"],\n \"Morphine sulfate\": [\"Morphine sulfate was used in this study.\"],\n \"Buprenorphine hydrochloride\": [\"Buprenorphine hydrochloride was used in this study.\"],\n \"Naloxone\": [\"Naloxone was used in this study.\"],\n \"Pentazocine\": [\"Pentazocine was used in this study.\"],\n \"Nalbuphine\": [\"Nalbuphine was used in this study.\"],\n \"Fentanyl transdermal system\": [\"Fentanyl transdermal system was used in this study.\"],\n \"Morphine transdermal system\": [\"Morphine transdermal system was used in this study.\"],\n \"Buprenorphine transdermal system\": [\"Buprenorphine transdermal system was used in this study.\"],\n \"Oxycodone\": [\"Oxycodone was used in this study.\"],\n \"Hydromorphone\": [\"Hydromorphone was used in this study.\"],\n \"Fentanyl patch\": [\"Fentany",
                {}
            ]
        ],
        [
            259,
            "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.",
            [
                " {\"AGE\": [\"77 participants\"], \"S. frutescens\": [\"1,200 mg S. frutescens\"]}",
                {
                    "Amount": [
                        "1,200 mg"
                    ],
                    "Herb name": [
                        "S. frutescens"
                    ]
                }
            ]
        ],
        [
            260,
            "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].",
            [
                " {\"ADULTS\": [\"more than 50% of adults\"], \"KwaZulu-Natal\": [], \"attending\": [], \"public sector facilities\": [], \"for ART initiation\": [], \"disclose using TCAM\": []}\n\n[10] : {\"ADULTS\": [\"more than 50% of adults\"], \"KwaZulu-Natal\": [\"attending public sector facilities for ART initiation\"], \"disclose\": [], \"using TCAM\": []}\n\n[11] : {\"ADULTS\": [\"HIV positive individuals\"], \"similar levels\": [], \"worldwide\": []}",
                {
                    "Drug": [
                        "ART"
                    ],
                    "Pathology": [
                        "HIV positive"
                    ]
                }
            ]
        ],
        [
            261,
            "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.",
            [
                " {\"MOS-HIV\": [\"MOS-HIV\", \"placebo\", \"1200 mg\"]}",
                {
                    "Amount": [
                        "1200 mg",
                        "1200mg"
                    ]
                }
            ]
        ],
        [
            262,
            "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).",
            [
                " {\"PR interval\": [\"PR interval\"], \"QRS duration\": [\"QRS duration\"], \"corrected QT interval (QTc)\": [\"corrected QT interval\", \"QTc\"]}",
                {
                    "Parameter": [
                        "the PR interval",
                        "QRS duration",
                        "corrected QT interval (QTc)"
                    ],
                    "Study": [
                        "both arms"
                    ]
                }
            ]
        ],
        [
            263,
            "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.",
            [
                " {\"AGE\": [],\n \"HDL\": [\"high density lipoprotein\"],\n \"LDL\": [\"low density lipoprotein\"],\n \"P-value\": [\"P-value for interaction effect of groups over time\"]}",
                {
                    "Parameter": [
                        "HDL (high density lipoprotein)",
                        "LDL (low density lipoprotein)"
                    ]
                }
            ]
        ],
        [
            264,
            "(PDF) Click here for additional data file.",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BLOOD-BRAIN BARRIER\": [\"blood-brain barrier\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC ARREST\": [\"cardiac arrest\"], \"CARDIAC OUTPUT\": [\"cardiac output\"], \"CARDIOPULMONARY\": [\"cardiopulmonary\"], \"CARDIOPULMONARY RESUSCITATION\": [\"cardiopulmonary resuscitation\"], \"CELLS\": [\"cells\"], \"CHLORIDE\": [\"chloride\"], \"CHLORIDE CONCENTRATION\": [\"chloride concentration\"], \"CHLORIDE SHIFT\": [\"chloride shift\"], \"CLINICAL TRIAL\": [\"clinical trial\"], \"CONSCIOUSNESS\": [\"consciousness\"], \"CONTRACTILE FORCE\": [\"contractile force\"], \"CORONARY ARTERIES\": [\"coronary arteries\"], \"CORONARY DISEASE\": [\"coronary disease\"], \"CORONARY VESSELS\": [\"coronary vessels\"], \"DEPOLARIZATION\": [\"depolarization\"], \"DIABETES\": [\"diabetes\"], \"DIABETIC PATIENTS\": [\"diabetic patients\"], \"DIURETIC\": [\"diuretic\"], \"DRUG\": [\"drug\"], \"ELECTROLYTE\": [\"electrolyte\"], \"ELECTROLYTE IMBALANCE\": [\"electrolyte imbalance\"], \"ENDOTHELIUM\": [\"endothelium\"], \"EXCITABILITY\": [\"excitability\"], \"EXTRACELLULAR FLUID\": [\"extracellular fluid\"], \"HEART\": [\"heart\"], \"HEART RATE\": [\"heart rate\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HYPERKALEMIA\": [\"hyperkalemia\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"HYPOGLYCEMIA\": [\"hypoglycemia\"], \"HYPOXIA\": [\"hypoxia\"], \"INFARCTION\": [\"infarction\"], \"INTRAVENOUS\": [\"intravenous\"], \"ISC",
                {}
            ]
        ],
        [
            265,
            "Thabethe, D.A.",
            [
                " {\"AGE\": []}\n\nD.A. Thabethe,\n\n...\n\nThe following entities were identified in the given text:\n\n1. Thabethe, D.A.\n\nTherefore, the output will be:\n\n{\"AGE\": [], \"AUTHOR\": [\"Thabethe, D.A.\"], \"COMPOUND\": [], \"CONDITION\": [], \"DOSE\": [], \"DRUG\": [], \"ENTITY\": [], \"FORM\": [], \"MECHANISM\": [], \"ROUTE\": [], \"STUDY\": [], \"SYMPTOM\": [], \"TIME\": [], \"TREATMENT\": []}",
                {}
            ]
        ],
        [
            266,
            "Data were reported as prevalence (percent) of the occurrence.",
            [
                " {\"AGE\": []}\n\nThe following entities were mentioned in the text:\n\n1. \"data\"\n2. \"prevalence\"\n3. \"percent\"\n\nThere was no explicit mention of any age or age-related information in the provided text.",
                {}
            ]
        ],
        [
            267,
            "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.",
            [
                " {\"CKD\": [\"chronic kidney disease\"]}\n\nThe progression of CKD is characterized by a decline in the glomerular filtration rate (GFR) and the development of structural damage in the kidneys. [\n\n{\"GFR\": [\"glomerular filtration rate\"]}\n\n]\n\nCKD is a complex and heterogeneous condition, and its pathogenesis involves various factors, including inflammation, oxidative stress, fibrosis, and vascular damage. [\n\n{\"inflammation\": [], \"oxidative stress\": [], \"fibrosis\": [], \"vascular damage\": []}\n\n]\n\nOne of the key factors in the development and progression of CKD is the renin-angiotensin-aldosterone system (RAAS). [\n\n{\"RAAS\": [\"renin-angiotensin-aldosterone system\"]}\n\n]\n\nThe RAAS is a complex hormonal system that plays a crucial role in regulating blood pressure and fluid balance. In CKD, the RAAS is activated in response to various stimuli, including decreased renal blood flow, hypovolemia, and inflammation. [\n\n{\"hypovolemia\": []}\n\n]\n\nActivation of the RAAS leads to increased production of angiotensin II, which in turn leads to vasoconstriction, increased sodium reabsorption, and increased production of aldosterone. [\n\n{\"angiotensin II\": [\"angiotensin II\"], \"vasoconstriction\": [], \"sodium reabsorption\": [], \"aldosterone\": []}\n\n]\n\nThese effects contribute to the development of hypertension, proteinuria, and fibrosis in CKD. [\n\n{\"hypertension\": [], \"proteinuria\": [], \"fibrosis\": []}\n\n]\n\nPharmacological interventions that target the RAAS have been shown to be effective in slowing the progression of CKD. [\n\n{}\n\n]\n\nAngiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are two classes of drugs that are commonly used to inhibit the RAAS.",
                {
                    "Pathology": [
                        "Chronic kidney disease (CKD)"
                    ]
                }
            ]
        ],
        [
            268,
            "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.",
            [
                " {\"THERAPIES\": [\"therapies\"]}\n{\"DRUGS\": [\"drugs\"]}\n{\"INTERACTIONS\": [\"interactions\"]}\n{\"SAFE\": [\"safe\"]}\n{\"HARMFUL\": [\"harmful\"]}",
                {}
            ]
        ],
        [
            269,
            "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.",
            [
                " {\"AGE\": [\"age\", \"ages\"]}\n{\"ETHICS\\_COMMITTEE\": [\"ethics committee\", \"university research affairs\"], \"PROJECT\\_NUMBER\": [], \"ETHICS\\_CODE\": []}\n{\"PATIENTS\": [], \"DEMOGRAPHIC\\_INFORMATION\": [], \"SEX\": [], \"EDUCATIONAL\\_STATUS\": [], \"OCCUPATIONAL\\_STATUS\": [], \"MARITAL\\_STATUS\": []}\n{\"HOSPITAL\\_RECORDS\": [], \"DIRECT\\_INTERVIEWING\": [], \"SPECIALLY\\_DESIGNED\\_FORM\": []}",
                {}
            ]
        ],
        [
            270,
            "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.",
            [
                " {\"AGE\": [\"20-60 years\", \"age group\"]}",
                {
                    "Age": [
                        "20\u201360 years"
                    ],
                    "Sex": [
                        "male",
                        "female"
                    ]
                }
            ]
        ],
        [
            271,
            "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.",
            [
                " {\"AGE\": [],\n \"Congenital kidney disease\": [\"congenital\"],\n \"Polycystic kidney disease\": [\"polycystic\"],\n \"Drug-induced renal failure\": [\"drug-induced\"],\n \"Renal failure\": [],\n \"Acute kidney injury\": [\"acute kidney\"]}",
                {
                    "Pathology": [
                        "congenital kidney disease",
                        "polycystic kidney disease",
                        "drug-induced renal failure",
                        "acute kidney injury"
                    ]
                }
            ]
        ],
        [
            272,
            "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.",
            [
                " {\"AGE\": [\"fifty-zero\", \"seventy\"]}",
                {
                    "Age": [
                        "50\u201370 years"
                    ]
                }
            ]
        ],
        [
            273,
            "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.",
            [
                " {\"AGE\": [\"fifty\u2013six\", \"sixty\u2013four\", \"middle-aged\"]}",
                {
                    "Age": [
                        "50\u201364"
                    ]
                }
            ]
        ],
        [
            274,
            "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.",
            [
                " {\"Iranian borage (E. amoenum)\": [\"Iranian borage\", \"E. amoenum\"],\n \"our study population\": [],\n \"unformulated and anticough syrups\": [\"unformulated and anticough syrups\"],\n \"main indications\": [\"main indications\"],\n \"common cold\": [\"common cold\"],\n \"respiratory problems\": [\"respiratory problems\"]}",
                {
                    "Herb name": [
                        "Iranian borage (E. amoenum)"
                    ]
                }
            ]
        ],
        [
            275,
            "[27] In the study performed by Roozbeh et al.",
            [
                " {\"Roozbeh\": [], \"et\": [], \"al\": [], \"study\": [], \"performed\": []}\n\nIn the study performed by Roozbeh et al., the effects of the novel compound X on the hERG channel were investigated. The hERG channel is a potassium channel that plays a crucial role in the repolarization of cardiac action potentials.\n\n{\"hERG\": [\"hERG channel\"], \"channel\": [\"potassium channel\", \"hERG channel\"], \"plays\": [], \"crucial\": [], \"role\": [], \"repolarization\": [], \"cardiac\": [], \"action\": [], \"potentials\": []}\n\nThe compound X was administered intravenously to anesthetized guinea pigs.\n\n{\"compound X\": [], \"administered\": [], \"intravenously\": [], \"anesthetized\": [], \"guinea pigs\": []}\n\nThe electrocardiogram (ECG) recordings were obtained before and after the administration of the compound X.\n\n{\"ECG\": [\"electrocardiogram\"], \"recordings\": [], \"obtained\": [], \"before\": [], \"after\": []}\n\nThe ECG recordings revealed that the compound X caused a significant prolongation of the QT interval.\n\n{\"QT interval\": [\"prolongation of the QT interval\"], \"revealed\": []}\n\nFurthermore, the compound X also caused a significant increase in the duration of the QTc interval.\n\n{\"QTc interval\": [\"duration of the QTc interval\"], \"increase\": []}\n\nThese findings suggest that the compound X may have the potential to cause life-threatening arrhythmias, particularly in patients with underlying heart conditions.\n\n{\"life-threatening arrhythmias\": [], \"particularly\": [], \"patients\": [], \"underlying\": [], \"heart conditions\": []}\n\nIn conclusion, the study by Roozbeh et al. investigated the effects of the novel compound X on the hERG channel in guinea pigs and found that it caused a significant prolongation and increase in the duration of the QT and QTc intervals, respectively. These findings suggest that the compound X may have the potential to cause life-threatening arrhythmias.\n",
                {}
            ]
        ],
        [
            276,
            "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).",
            [
                " {\"Karnofsky performance status scale\": [\"Karnofsky performance status scale of 90%\"]}\n{\"TEM\": [\"temozolomide\"]}\n{\"PATIENT\": []}\n{\"AGE\": []}\n{\"NEUROLOGICAL DEFICIENCIES\": [\"neurological deficiencies\"]}\n{\"RESECTION\": []}\n{\"SCALE\": []}\n{\"PERFORMANCE STATUS\": [\"performance status scale\"]}\n{\"KARNOFSKY\": [\"Karnofsky\"]}\n{\"SCALE VALUE\": [\"90%\"]}\n{\"RADIOTHERAPY\": []}\n{\"DEPARTMENT\": []}\n{\"TEXT\": [\"The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM)\"]}",
                {
                    "Pathology": [
                        "neurological deficiencies"
                    ],
                    "Drug": [
                        "temozolomide"
                    ]
                }
            ]
        ],
        [
            277,
            "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.",
            [
                " {\"AGE\": [\"2 months\"]}\n\n\"[18 F]-fluorethylenthyrosin\": []\n\"positron emission tomography\": []\n\"residual tumor\": []\n\"end of radiotherapy\": []",
                {
                    "Pathology": [
                        "tumor"
                    ]
                }
            ]
        ],
        [
            278,
            "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.",
            [
                " {\"AGE\": []}\n\nOur article focuses on the risk of interactions between pharmaceutical drugs and herbal formulas. Therefore, no specific mentions of ages were found in the given text.",
                {}
            ]
        ],
        [
            279,
            "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.",
            [
                " {\"AGE\": [], \"whole blood\": [\"whole blood\"], \"normal saline\": [\"normal saline\"], \"37\u00b0C\": [\"37\u00b0C\"]}",
                {}
            ]
        ],
        [
            280,
            "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.",
            [
                " {\"International normalized ratio\": [\"International normalized ratio was measured\", \"International normalized ratio was measured before warfarin dosing\", \"International normalized ratio was measured after warfarin dosing\"]}",
                {
                    "Parameter": [
                        "International normalized ratio",
                        "International normalized ratio"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            281,
            "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.",
            [
                " {\"AGE\": [],\n \"human plasma\": [\"standard human plasma\"],\n \"factor activity\": [\"percentage factor activity\", \"known factor activity\"],\n \"clotting time\": []}",
                {
                    "Parameter": [
                        "clotting time"
                    ]
                }
            ]
        ],
        [
            282,
            "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.",
            [
                " {\"half-life\": [\"half-life\", \"ln2/kel\"],\n \"apparent clearance (CL/F)\": [\"apparent clearance\", \"dose/AUC0\u2212\u221e\"],\n \"apparent volume of distribution (V/F)\": [\"apparent volume of distribution\"],\n \"kel\": [\"kel\"]}",
                {
                    "Parameter": [
                        "half-life",
                        "CL/F",
                        "AUC0\u2212\u221e",
                        "CL/kel"
                    ]
                }
            ]
        ],
        [
            283,
            "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.",
            [
                " {\"S-warfarin\": [\"concentration-time data\"], \"PCA\": [\"percentage of prothrombin complex activity\"], \"INR\": [\"derived from the INR data\"]}",
                {
                    "Drug": [
                        "S-warfarin",
                        "S-warfarin"
                    ],
                    "Parameter": [
                        "prothrombin complex activity (PCA",
                        "INR"
                    ]
                }
            ]
        ],
        [
            284,
            "However, this did not reach statistical significance (data not shown).",
            [
                " {\"AGE\": []}\n\nThis article does not provide any mention of ages.",
                {}
            ]
        ],
        [
            285,
            "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.",
            [
                " {\"AGE\": [],\n \"Warfarin\": [\"Warfarin only\", \"Warfarin and cranberry\", \"Warfarin and garlic\", \"Warfarin and cranberry/warfarin only\", \"Warfarin and garlic/warfarin only\"],\n \"S-warfarin\": [\"S-warfarin\", \"S-warfarin tmax\", \"S-warfarin Cmax\", \"S-warfarin t1/2\", \"S-warfarin AUC\", \"S-warfarin CL/F\", \"S-warfarin fraction unbound\"],\n \"R-warfarin\": [\"R-warfarin\", \"R-warfarin tmax\", \"R-warfarin Cmax\", \"R-warfarin t1/2\", \"R-warfarin AUC\", \"R-warfarin CL/F\", \"R-warfarin fraction unbound\"],\n \"Cranberry\": [\"Warfarin and cranberry\", \"Cranberry/warfarin only\"],\n \"Garlic\": [\"Warfarin and garlic\", \"Garlic/warfarin only\"]}",
                {
                    "Drug": [
                        "S-warfarin",
                        "R-warfarin",
                        "Warfarin",
                        "Warfarin",
                        "Warfarin",
                        "Warfarin",
                        "warfarin",
                        "Warfarin",
                        "warfarin",
                        "S-warfarin",
                        "R-warfarin"
                    ],
                    "Herb name": [
                        "cranberry",
                        "garlic",
                        "cranberry",
                        "garlic"
                    ],
                    "Parameter": [
                        "tmax",
                        "Cmax",
                        "AUC",
                        "CL/F",
                        "tmax",
                        "Cmax",
                        "t1/2",
                        "AUC",
                        "CL/F",
                        "AUC, area under the plasma concentration\u2013time curve",
                        "CL, clearance",
                        "CL/F, apparent clearance",
                        "Cmax, maximum concentration",
                        "F, bioavailability",
                        "tmax, time to Cmax"
                    ]
                }
            ]
        ],
        [
            286,
            "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.",
            [
                " {\"Table 3\": [\"the parameter estimates for warfarin are presented in this table\"], \"warfarin\": [\"warfarin\"]}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            287,
            "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.",
            [
                " {\"AGE\": [\"for 5 days\"], \"cranberry juice\": [], \"S-warfarin\": [], \"AUC\": []}\n\n(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.\n\nNote: No mentions of ages, cranberry, or warfarin were found in the given context other than what is explicitly stated. Therefore, the \"mentions of ages found in text\" field is set to [\"for 5 days\"] based on the information provided. The other fields are empty as no other mentions of the described entities were found.",
                {
                    "Herb name": [
                        "cranberry"
                    ],
                    "Extraction process": [
                        "juice"
                    ],
                    "Duration": [
                        "for 5 days"
                    ],
                    "Drug": [
                        "warfarin",
                        "S-warfarin"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            288,
            "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.",
            [
                " (2006b) included 7 patients with atrial fibration.\n{\"ATRIAL FIBRILLATION\": [\"patients with atrial fibrillation\"]}",
                {
                    "Cohort": [
                        "7 patients"
                    ],
                    "Pathology": [
                        "atrial fibrillation"
                    ]
                }
            ]
        ],
        [
            289,
            "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.",
            [
                " {\"AGE\": [], \"warfarin\": [\"warfarin\"], \"cranberry juice\": [\"cranberry juice\"]}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Herb name": [
                        "cranberry"
                    ],
                    "Extraction process": [
                        "juice"
                    ],
                    "Amount": [
                        "10\u2009mg"
                    ]
                }
            ]
        ],
        [
            290,
            "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.",
            [
                " {\"AGE\": [],\n \"Drug Metabolism and Pharmacokinetics\": [\"Drug Metabolism and Pharmacokinetics\"],\n \"Covance Laboratories Inc.\": [\"Covance Laboratories Inc.\"],\n \"Madison, WI, USA\": [\"Madison, WI, USA\"],\n \"Patients\": [\"Patients\"],\n \"complementary medicines\": [\"complementary medicines\"],\n \"warfarin\": [\"warfarin\"],\n \"herb\u2013drug interaction\": [\"herb\u2013drug interaction\"]}",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            291,
            "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.",
            [
                " {\"Valerian\": [\"valerian root\", \"valerian\"]}\n\n\"In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.\"\n\nAcademic Editor: Igho J. Onakpoya\n{\"Igho J. Onakpoya\": [\"Igho J. Onakpoya\"]}",
                {
                    "Pathology": [
                        "cancer patients"
                    ],
                    "Herb name": [
                        "valerian"
                    ],
                    "Drug": [
                        "anticancer drugs"
                    ]
                }
            ]
        ],
        [
            292,
            "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.",
            [
                " {\"CYP 3A4\": [\"may stimulate CYP 3A4\"]}\n\nValeriana officinalis\": []\n\nAge\": []\n\nOther entities: []",
                {
                    "Herb name": [
                        "valerian",
                        "Valeriana officinalis"
                    ],
                    "Target": [
                        "CYP 3A4"
                    ]
                }
            ]
        ],
        [
            293,
            "It therefore was recommended that they should be avoided in the elderly [10, 12].",
            [
                " {\"AGE\": [\"elderly\"]}",
                {}
            ]
        ],
        [
            294,
            "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.",
            [
                " {\"Valerian root extracts\": [\"recommended daily doses\", \"about 600 mg\"]}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Herb name": [
                        "valerian"
                    ],
                    "Herb part": [
                        "root"
                    ],
                    "Amount": [
                        "600\u2009mg"
                    ]
                }
            ]
        ],
        [
            295,
            "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).",
            [
                " {\"VALERIAN\": [\"valerian\", \"Valeriana\"], \"DATABASES\": [\"MEDLINE\", \"TOXLIT\"], \"SEARCH\": [\"search terms\", \"was conducted\"], \"DIMDI\": [\"Cologne\", \"Germany\"]}",
                {
                    "Herb name": [
                        "valerian",
                        "valeriana"
                    ]
                }
            ]
        ],
        [
            296,
            "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.",
            [
                " {}\n\nStudies were assessed for:\n{\"Studies\": [\"studies\"]}\n\nfor completeness and validity of data on:\n{\"Data\": [\"data\"]}\n\nmaterial and methods:\n{\"Materials and Methods\": [\"materials and methods\"]}\n\non the potential clinical relevance of the results:\n{\"Clinical Relevance\": [\"clinical relevance\"]}\n\nand on potential bias in the presentation of results and conclusions:\n{\"Bias\": [\"bias\"], \"Presentation of Results and Conclusions\": [\"presentation of results and conclusions\"]}",
                {}
            ]
        ],
        [
            297,
            "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Animals\": [\"rats\", \"male rats\", \"Wistar rats\"], \"Benzodiazepines\": [\"benzodiazepines\", \"midazolam\"], \"Brain\": [\"brain\"], \"Dose\": [\"doses\", \"dose-dependent\"], \"Fentanyl\": [\"fentanyl\"], \"Fentanyl Citrate\": [\"fentanyl citrate\"], \"Fentanyl Solution\": [\"fentanyl solution\"], \"Fentanyl Transdermal\": [\"fentanyl transdermal\"], \"Fentanyl Transdermal Patch\": [\"fentanyl transdermal patch\"], \"Fentanyl-Induced\": [\"fentanyl-induced\"], \"Fentanyl-Induced Seizures\": [\"fentanyl-induced seizures\"], \"Fentanyl-Induced Seizure Threshold\": [\"fentanyl-induced seizure threshold\"], \"Fentanyl-Induced Status Epilepticus\": [\"fentanyl-induced status epilepticus\"], \"Fentanyl-Induced Tonic-Clonic Seizures\": [\"fentanyl-induced tonic-clonic seizures\"], \"Fentanyl-Induced Tonic Seizures\": [\"fentanyl-induced tonic seizures\"], \"Fentanyl-Induced Status Epilepticus Rats\": [\"fentanyl-induced status epilepticus rats\"], \"Fentanyl-Induced Status Epilepticus Model\": [\"fentanyl-induced status epilepticus model\"], \"Fentanyl-Induced Status Epilepticus Rats' Brains\": [\"fentanyl-induced status epilepticus rats' brains\"], \"Fentanyl-Induced Status Epilepticus Rats' Hippocampus\": [\"fentanyl-induced status epilepticus rats' hippocampus\"], \"Fentanyl-Induced Status Epilepticus Rats' Hippocampal CA1 Region\": [\"fentanyl-induced status ep",
                {}
            ]
        ],
        [
            298,
            "[36].",
            [
                " {\"AGE\": []}\n\nThe following entities were identified in the given text:\n\n1. [36].: This is a citation and does not provide any information about entities.\n\nTherefore, the output will be:\n{\"AGE\": []}",
                {}
            ]
        ],
        [
            299,
            "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.",
            [
                " {\"Daily\": [], \"before going to bed\": [], \"participants\": [], \"took\": [], \"two tablets\": [], \"with\": [], \"500\u224dm\": [], \"valerian extract\": [], \"each\": [], \"extraction solvent\": [\"ethanol\"], \"70%\": [], \"valerenic acid content\": [\"5.51\u224dmg/tablet\"], \"for\": [], \"14 subsequent days\": []}",
                {
                    "Frequency": [
                        "Daily"
                    ],
                    "Amount": [
                        "500\u2009mg"
                    ],
                    "Herb name": [
                        "valerian",
                        "valerenic acid"
                    ],
                    "Duration": [
                        "14 subsequent days"
                    ]
                }
            ]
        ],
        [
            300,
            "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.",
            [
                " {\"CYP 3A4/5\": [\"activities\", \"1-hydroxymidazolam/midazolam serum ratio\"],\n \"CYP 1A2\": [\"activities\", \"paraxanthine/caffeine serum ratio\"],\n \"CYP 2E1\": [\"activities\", \"hydroxychlorzoxazone/chlorzoxazone serum ratio\"],\n \"CYP 2D6\": [\"activities\", \"debrisoquine urinary recovery ratio\"]}",
                {
                    "Drug": [
                        "midazolam",
                        "paraxanthine",
                        "caffeine",
                        "chlorzoxazone",
                        "debrisoquine"
                    ]
                }
            ]
        ],
        [
            301,
            "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].",
            [
                " {\"Haloperidol\": [\"Haloperidol (38\u2009mg/kg bw)\"]}\n{\"AGE\": []}\n{\"bw\": [\"bw\"]}\n{\"mg\": []}\n{\"kg\": []}\n{\"Valerian\": []}\n{\"intramuscularly\": []}\n{\"once\": []}\n{\"every\": []}\n{\"4 weeks\": []}\n{\"over\": []}\n{\"12 weeks\": []}\n{\"beginning\": []}\n{\"after\": []}\n{\"15 days\": []}\n{\"treatment\": []}",
                {
                    "Drug": [
                        "Haloperidol"
                    ],
                    "Amount": [
                        "38\u2009mg/kg bw"
                    ],
                    "Frequency": [
                        "once",
                        "every 4 weeks"
                    ],
                    "Duration": [
                        "12 weeks",
                        "15 days"
                    ],
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            302,
            "The results were not presented in detail but indicated that the two drugs act independently from each other.",
            [
                " {\"Drugs\": [\"the two drugs\"]}",
                {}
            ]
        ],
        [
            303,
            "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.",
            [
                " {\"VALERIAN PREPARATIONS\": [\"valerian preparations\"]}\n{\"CASE REPORTS\": [\"two case reports\"]}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            304,
            "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.",
            [
                " {\"AGE\": [],\n \"herbal medicines\": [\"none of these herbal medicines\"],\n \"MAO-inhibitory properties\": [\"none of these herbal medicines has been proven to have\"],\n \"delirium\": [\"induction of delirium\"],\n \"valerian preparation\": [\"assumption of an involvement of the valerian preparation\"]}",
                {
                    "Target": [
                        "MAO"
                    ],
                    "Pathology": [
                        "delirium"
                    ],
                    "Drug": [
                        "opioids"
                    ],
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            305,
            "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.",
            [
                " {\"Drug-drug interactions\": [\"mechanisms of drug-drug interactions\", \"essential for assessing and minimizing clinical risks\"]}\n\nThe interaction between cytochrome P450 (CYP) enzymes and drugs is a major contributor to drug-drug interactions. [\n\n{\"Cytochrome P450 (CYP) enzymes\": [\"interaction between cytochrome P450 (CYP) enzymes and drugs\", \"major contributor to drug-drug interactions\"]}\n\nThe inhibition of CYP enzymes by certain drugs can lead to increased plasma concentrations of other drugs that are metabolized by the same enzymes. [\n\n{\"CYP enzymes\": [\"inhibition of CYP enzymes\", \"drugs can lead to increased plasma concentrations\", \"other drugs that are metabolized by the same enzymes\"]}\n\nThe inhibition of CYP3A4, the most abundant isoform of CYP enzymes in the liver, is a common cause of drug-drug interactions. [\n\n{\"CYP3A4\": [\"inhibition of CYP3A4\", \"most abundant isoform of CYP enzymes in the liver\"]}\n\nThe interaction between warfarin and cyclosporine is a well-known example of drug-drug interactions caused by the inhibition of CYP enzymes. [\n\n{\"Warfarin\": [\"interaction between warfarin and cyclosporine\"]}\n\nCyclosporine is a potent inhibitor of CYP2C9 and CYP3A4, leading to increased plasma concentrations of warfarin and an increased risk of bleeding. [\n\n{\"Cyclosporine\": [\"potent inhibitor of CYP2C9 and CYP3A4\", \"leading to increased plasma concentrations of warfarin\", \"increased risk of bleeding\"]}\n\nThe interaction between grapefruit juice and drugs is another common example of drug-drug interactions caused by the inhibition of CYP enzymes. [\n\n{\"Grapefruit juice\": [\"interaction between grapefruit juice and drugs\"]}\n\nGrapefruit juice is a known inhibitor of CYP3A4, leading to increased plasma concentrations of many",
                {}
            ]
        ],
        [
            306,
            "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.",
            [
                " {\"AGE\": []}\n{\"Cited Entities\": [\n\"extract components\",\n\"in vitro data\",\n\"in vivo data\",\n\"open questions\",\n\"bioavailability\",\n\"metabolism\"\n]}",
                {
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            307,
            "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.",
            [
                " {\"AGE\": []}\n\nAt present, { \"relevant risk\": [\"relevant risk of pharmacodynamic interactions\"], \"pharmacodynamic interactions\": [\"pharmacodynamic interactions\"], \"clinical observations\": [\"clinical observations\"]}",
                {}
            ]
        ],
        [
            308,
            "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].",
            [
                " {\"AGE\": []}\n\n\"regarding interactions is high in valerian\"\n\n{\"VALERIAN\": [\"valerian\"]}\n\n\"is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].\"}\n\n{\"HMPC\": [\"respective monograph\"], \"OFFICE\\_OF\\_DIETARY\\_SUPPLEMENTS\": [\"fact sheet\"], \"NIH\": [\"NIH\"]}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            309,
            "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.",
            [
                " {\"CYP-isoenzymes\": [\"CYP-isoenzymes\"],\n \"P-gp\": [\"P-gp\"],\n \"UGT\": [\"UGT\"]}",
                {
                    "Target": [
                        "CYP-isoenzymes",
                        "P-gp",
                        "UGT"
                    ]
                }
            ]
        ],
        [
            310,
            "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.",
            [
                " {\"Valerian\": [\"valerian\"]}",
                {
                    "Herb name": [
                        "valerian"
                    ]
                }
            ]
        ],
        [
            311,
            "The authors declare that there is no conflict of interests regarding the publication of this paper.",
            [
                " {\"CITED\\_ENTITIES\": []}\n\n{\"AGE\": []}\n{\"AUTHORS\": [\"authors\", \"declare\"]}\n{\"CONFLICT\\_OF\\_INTERESTS\": [\"declare\"]}\n{\"PUBLICATION\": []}\n\nThe following is the list of entities found in the given text:\n\n{\"CITED\\_ENTITIES\": [\"authors\", \"paper\", \"publication\"]}\n{\"AGE\": []}\n{\"AUTHORS\": [\"authors\"]}\n{\"CONFLICT\\_OF\\_INTERESTS\": [\"declare\"]}\n{\"PUBLICATION\": [\"publication\"]}",
                {}
            ]
        ],
        [
            312,
            "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.",
            [
                " {\"AGE\": [],\n \"rifampin\": [\"600 mg\", \"for 7 days\", \"as positive controls for CYP3A induction\"],\n \"clarithromycin\": [\"1000 mg\", \"for 7 days\", \"as positive controls for CYP3A inhibition\"],\n \"CYP3A\": [\"for CYP3A induction and inhibition\"]}",
                {
                    "Drug": [
                        "rifampin",
                        "clarithromycin"
                    ],
                    "Amount": [
                        "600 mg",
                        "1000 mg"
                    ],
                    "Duration": [
                        "7 days"
                    ],
                    "Target": [
                        "CYP3A"
                    ]
                }
            ]
        ],
        [
            313,
            "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.",
            [
                " {\"Venlafaxine\": [\"Venlafaxine is\", \"a serotonin-norepinephrine reuptake inhibitor\", \"used as an antidepressant\"]}",
                {
                    "Drug": [
                        "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"
                    ]
                }
            ]
        ],
        [
            314,
            "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.",
            [
                " {\"AGE\": []}\n\n\"after venlafaxine discontinuation\" refers to the discontinuation of a medication called venlafaxine.\n\n\"rapid improvement\" refers to a quick recovery or progress.\n\n\"regression of the radiological abnormalities\" refers to the reduction or reversal of abnormalities seen on radiological imaging.\n\n\"normalization of the LVEF\" refers to the restoration of a normal left ventricular ejection fraction (LVEF), which is a measure of the heart's ability to pump blood effectively.",
                {
                    "Drug": [
                        "venlafaxine"
                    ],
                    "Pathology": [
                        "the radiological abnormalities"
                    ],
                    "Parameter": [
                        "LVEF"
                    ]
                }
            ]
        ],
        [
            315,
            "This was an important case of drug-induced cardiopulmonary toxicity.",
            [
                " {\"Drug-induced cardiopulmonary toxicity\": [\"drug-induced\", \"cardiopulmonary\", \"toxicity\"]}",
                {
                    "Pathology": [
                        "drug-induced cardiopulmonary toxicity"
                    ]
                }
            ]
        ],
        [
            316,
            "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.",
            [
                " {\"DIP\": [\"DIP\", \"Another typical feature\", \"its reversibility\"]}",
                {
                    "Pathology": [
                        "DIP",
                        "DIP"
                    ],
                    "Duration": [
                        "hours to months"
                    ]
                }
            ]
        ],
        [
            317,
            "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.",
            [
                " {\"AGE\": [],\n \"venlafaxine\": [\"venlafaxine\"],\n \"cardiopulmonary toxicity\": [\"cardiopulmonary toxicity\"]}",
                {
                    "Pathology": [
                        "cardiopulmonary toxicity"
                    ],
                    "Drug": [
                        "venlafaxine"
                    ]
                }
            ]
        ],
        [
            318,
            "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.",
            [
                " {\"AGE\": []}\n\nAn extensive investigation was conducted, including LBA, imaging studies, autoimmune disease detection, right heart catheterization, and myocardial biopsy.",
                {}
            ]
        ],
        [
            319,
            "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.",
            [
                " {\"CYP2D6\": [\"inhibitors of CYP2D6\", \"isoenzyme CYP2D6\", \"presence of a phenotype of metabolization slow of CYP2D6\"]}\n\n\"The circumstantial administration of inhibitors of CYP2D6 and the presence of a phenotype of slow metabolization of CYP2D6 may have resulted in the toxic accumulation of venlafaxine and the subsequent clinical manifestation.\"",
                {}
            ]
        ],
        [
            320,
            "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.",
            [
                " {\"AGE\": []}\n\nOs par\u00e2metros renais: [\"parameters renal\"]\nhep\u00e1ticos: [\"hepatic\"]\nprote\u00ednas do complemento: [\"complement proteins\"]\nestavam: [\"were\"]\ntodos: [\"all\"]\nnormais: [\"normal\"]",
                {}
            ]
        ],
        [
            321,
            "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.",
            [
                " {\"AGE\": []}\n\nThe majority of cardiac medicaments were, therefore, discontinued.",
                {}
            ]
        ],
        [
            322,
            "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.",
            [
                " {\"AGE\": [\"previamente h\u00edgida de 35 anos de idade\"]}",
                {}
            ]
        ],
        [
            323,
            "Apoio financeiro: Nenhum.",
            [
                " {\"Cited Entities\": {}}\n\nThe given text does not contain any scientific entities or substances to be parsed. The provided text is in Portuguese and the first line translates to \"Financial support: None.\" which is a statement about funding for the research and not related to any entities or substances in pharmacology.",
                {}
            ]
        ],
        [
            324,
            "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.",
            [
                " {\"RED GINSENG\": [\"red ginseng\"], \"RHC\": [\"red ginseng and herb extract complex\"], \"MENOPAUSAL SYMPTOMS\": [\"menopausal symptoms\"]}",
                {
                    "Herb name": [
                        "red ginseng",
                        "herb extract complex (RHC)"
                    ],
                    "Pathology": [
                        "menopausal symptoms"
                    ]
                }
            ]
        ],
        [
            325,
            "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.",
            [
                " {\"AGE\": [\"women\"], \"menopause\": [\"women who became menopausal\", \"after 1 year of menopause\"], \"surgery\": [\"women who underwent\"], \"hysterectomy\": [\"women who underwent\"], \"endometrial hyperplasia\": [\"women with a history of\"], \"endometrial cancer\": [\"women with a history of\"], \"breast cancer\": [\"women with a history of\"], \"sex hormone\u2013related cancers\": [\"women with a history of\"], \"hypertension\": [\"uncontrolled hypertension\", \"160/100 mmHg or higher\"], \"diabetes mellitus\": [\"uncontrolled diabetes mellitus\", \"fasting blood sugar 180 mg/dL or higher\", \"cases of starting or changing medication due to diabetes within 3 mo\"], \"thyroid patients\": [\"uncontrolled thyroid patients\"], \"migraines\": [\"women who have had severe migraines within the last year\", \"women who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease\"], \"atypical uterine bleeding\": [\"women who have taken sleep inducers\", \"antidepressants\", \"selective estrogen receptor modulators\", \"antihyperlipidemic drugs\", \"antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel)\", \"bisphosphonates\", \"calcitonin\"], \"within 4 wk\": [11, 12], \"plant hormones\": [\"isoflavone\", \"flaxseed\", \"pomegranate\", \"horseradish\", \"white sorghum\", \"red shamrock\", \"red ginseng products\"], \"supplements\": [10, 12], \"medicines\": [10, 12], \"functional foods\": [11, 12], \"herbal medicines\": [11, 12], \"bone health\": [11], \"blood lipid lipids\": [11], \"triglyceride\": [11], \"cholesterol\": [11], \"female hormone formulations\": [12], \"ALT",
                {
                    "Sex": [
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "female",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women",
                        "women"
                    ],
                    "Pathology": [
                        "menopausal",
                        "surgery",
                        "hysterectomy",
                        "endometrial hyperplasia",
                        "endometrial, breast, or sex hormone\u2013related cancers",
                        "uncontrolled hypertension",
                        "uncontrolled diabetes mellitus",
                        "diabetes",
                        "uncontrolled thyroid",
                        "severe migraines",
                        "thromboembolism",
                        "cerebrovascular disease",
                        "cardiovascular disease",
                        "uterine bleeding",
                        "menopause",
                        "drug or alcohol abuse",
                        "hypersensitivity"
                    ],
                    "Drug": [
                        "chemotherapy",
                        "sleep inducers",
                        "antidepressants",
                        "selective estrogen receptor modulators",
                        "antihyperlipidemic drugs",
                        "antithrombotic drugs",
                        "Aspirin",
                        "Warfarin",
                        "Clopidogrel",
                        "bisphosphonates",
                        "calcitonin"
                    ],
                    "Amount": [
                        "160/100\u00a0mmHg",
                        "180\u00a0mg/dL"
                    ],
                    "Parameter": [
                        "fasting blood sugar",
                        "triglyceride",
                        "cholesterol",
                        "alanine aminotransferase (ALT)",
                        "aspartate aminotransferase (AST)",
                        "creatinine"
                    ],
                    "Duration": [
                        "within 3\u00a0mo",
                        "within the last year",
                        "after 1\u00a0yr",
                        "within 4\u00a0wk",
                        "within 4\u00a0wk",
                        "within 4\u00a0wk",
                        "within 6\u00a0mo",
                        "more than 10\u00a0h",
                        "within 3\u00a0mo",
                        "women",
                        "within 1\u00a0mo"
                    ],
                    "Herb name": [
                        "isoflavone",
                        "flaxseed",
                        "pomegranate",
                        "horseradish",
                        "white sorghum",
                        "red shamrock",
                        "red ginseng"
                    ],
                    "Study": [
                        "clinical trials",
                        "clinical trial"
                    ]
                }
            ]
        ],
        [
            326,
            "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.",
            [
                " {\"DATE OF ONSET AND DISAPPEARANCE\": [\"date of onset\", \"date of disappearance\"],\n \"DEGREE AND RESULT OF ADVERSE REACTION\": [\"degree\", \"result\"],\n \"MEASURES TAKEN\": [\"measures\"],\n \"TEST SUBSTANCE\": [\"test substance\"],\n \"CAUSAL RELATIONSHIP\": [\"causal relationship\"],\n \"NAME OF DRUG\": [\"name of drug\"]}",
                {
                    "Pathology": [
                        "adverse reactions",
                        "adverse reaction",
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            327,
            "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.",
            [
                " {\"AGE\": []}\n\nThe examination of demographic information and characteristics before consumption: (no specific entities mentioned)\n\nshowed no statistically significant difference between the intake groups: (\"intake groups\")",
                {}
            ]
        ],
        [
            328,
            "p-value by Fisher's exact test.",
            [
                " {\"AGE\": [], \"p-value\": [\"p-value\"], \"Fisher's exact test\": [\"Fisher's exact test\"]}",
                {}
            ]
        ],
        [
            329,
            "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.",
            [
                " {\"AGE\": [\"mentions of ages not specified in text\"], \"pruritus\": [\"pruritus\"], \"hot flash\": [\"hot flash\"], \"subject\": [\"subjects\"], \"placebo group\": [\"placebo group\"], \"recovered\": [\"recovered\"]}",
                {
                    "Pathology": [
                        "pruritus",
                        "hot flash",
                        "headache"
                    ]
                }
            ]
        ],
        [
            330,
            "It is noteworthy that no severe adverse reactions were observed in this study.",
            [
                " {\"AGE\": []}\n\nThis study:\nno information found for specific ages.",
                {
                    "Pathology": [
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            331,
            "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.",
            [
                " {\"RHC\": [\"RHC intake\"]}",
                {
                    "Herb name": [
                        "RHC"
                    ],
                    "Pathology": [
                        "menopausal"
                    ]
                }
            ]
        ],
        [
            332,
            "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.",
            [
                " {\"AGE\": [],\n \"celastrol\": [\"celastrol\"],\n \"UGT1A1\": [\"UGT1A1-mediated\", \"UGT1A1\"],\n \"UGT2B7\": [\"UGT2B7-catalyzed\"],\n \"4-MU\": [\"4-MU glucuronidation\"]}",
                {
                    "Study": [
                        "inhibition kinetic study"
                    ],
                    "Herb name": [
                        "celastrol"
                    ],
                    "Target": [
                        "UGT1A1-mediated 4-MU glucuronidation",
                        "UGT2B7-catalyzed 4-MU glucuronidation"
                    ]
                }
            ]
        ],
        [
            333,
            "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].",
            [
                " {\"AGE\": [],\n \"Compounds\": [\"compounds\", \"inhibition of compounds\", \"isoforms\"],\n \"UGTs\": [\"UGTs\", \"recombinant UGTs\"]}",
                {
                    "Target": [
                        "UGT isoforms",
                        "UGTs"
                    ]
                }
            ]
        ],
        [
            334,
            "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.",
            [
                " {\"Dixon\": [], \"Lineweaver-Burk\": [], \"plots\": [], \"intersection\": [], \"quadrant\": [], \"inhibition\": [], \"type\": [], \"competitive\": []}\n\nThe given text does not provide any information regarding the specified entities. Therefore, all fields are left empty.",
                {}
            ]
        ],
        [
            335,
            "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.",
            [
                " {\"Celastrol\": [\"celastrol concentration\"], \"Ki\": [\"inhibition kinetic parameter\"], \"MicroM\": [\"0.49 \u03bcM\"]}",
                {
                    "Herb name": [
                        "celastrol"
                    ]
                }
            ]
        ],
        [
            336,
            "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].",
            [
                " {\"AGE\": [], \"Animal\": [\"human\"], \"Fold\": [\"120-fold\", \"13-fold\"], \"Expression\": [\"UGT1A6\"], \"Glucuronidation\": [\"serotonin\"], \"Liver\": [\"human liver\"]}",
                {
                    "Target": [
                        "UGT1A6"
                    ]
                }
            ]
        ],
        [
            337,
            "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].",
            [
                " {\"AGE\": [], \"clofibric acid\": [\"clofibric acid\"], \"valproic acid\": [\"valproic acid\"]}",
                {
                    "Drug": [
                        "valproic acid"
                    ]
                }
            ]
        ],
        [
            338,
            "The previous study performed by Du et al.",
            [
                " {\"Du\": [\"Du et al.\"], \"study\": [\"previous study\"]}",
                {}
            ]
        ],
        [
            339,
            "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.",
            [
                " {\"Celastrol (Cela)\": [\"inhibition kinetic analysis of\", \"towards UGT2B7-catalyzed 4-MU glucuronidation\"]}\n{\"UGT2B7\": [\"UGT2B7-catalyzed\"]}\n{\"4-MU\": [\"4-MU glucuronidation\"]}",
                {
                    "Herb name": [
                        "celastrol (Cela)"
                    ],
                    "Target": [
                        "UGT2B7-catalyzed 4-MU glucuronidation"
                    ]
                }
            ]
        ],
        [
            340,
            "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].",
            [
                " {\"AGE\": [],\n \"ginseng\": [\"the therapeutic benefits of ginseng\", \"ginseng include\", \"mentions of ginseng\"],\n \"anti-diabetic\": [\"include anti-diabetic\"],\n \"effect\": [\"include anti-diabetic\", \"effect\"],\n \"anti-inflammatory\": [\"include anti-inflammatory\"],\n \"response\": [\"and anti-oxidative response\", \"response\"],\n \"chronic liver disease\": [\"on chronic liver disease\"],\n \"disease\": [\"chronic liver disease\"]}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Pathology": [
                        "chronic liver disease"
                    ]
                }
            ]
        ],
        [
            341,
            "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].",
            [
                " {\"AGE\": [],\n \"Korean red ginseng extract (RGE)\": [\"Korean red ginseng extract (RGE)\"],\n \"single oral dose\": [\"single oral dose\"],\n \"0.5\u20132.0 g/kg\": [\"0.5\u20132.0 g/kg\"],\n \"probe substrates\": [\"probe substrates\"],\n \"cytochrome P450 (CYP)\": [\"cytochrome P450 (CYP)\"],\n \"i.e.\": [\"i.e.\"],\n \"CYP1A2\": [\"CYP1A2\"],\n \"CYP2C9\": [\"CYP2C9\"],\n \"CYP2C19\": [\"CYP2C19\"],\n \"CYP2D6\": [\"CYP2D6\"],\n \"CYP3A\": [\"CYP3A\"]\n}",
                {
                    "Herb name": [
                        "ginseng",
                        "red ginseng extract (RGE)"
                    ],
                    "Ethnic group": [
                        "Korean"
                    ],
                    "Amount": [
                        "0.5\u20132.0 g/kg"
                    ],
                    "Target": [
                        "cytochrome P450 (CYP) enzymes",
                        "CYP1A2, 2C9, 2C19, 2D6, 3A"
                    ]
                }
            ]
        ],
        [
            342,
            "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.",
            [
                " {\"valsartan\": [\"could be used as a model drug\", \"for investigating\", \"OATP (in human)\", \"or Oatp (in rats)\"],\n \"OATP\": [\"OATP (in human)\"],\n \"Oatp\": [\"Oatp (in rats)\"],\n \"RGE\": [\"herb\u2013drug interaction between valsartan and\"],\n \"ginsenosides\": [\"herb\u2013drug interaction between valsartan and\"]}",
                {
                    "Drug": [
                        "valsartan",
                        "valsartan"
                    ],
                    "Target": [
                        "OATP",
                        "Oatp"
                    ],
                    "Herb name": [
                        "RGE",
                        "ginsenosides"
                    ]
                }
            ]
        ],
        [
            343,
            "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).",
            [
                " {\"AGE\": [],\n \"RGE\": [\"repeated administration of RGE\"],\n \"Rc\": [\"high dose of Rc\"],\n \"herb\u2013drug interactions\": [\"herb\u2013drug interactions involving valsartan\"],\n \"valsartan\": [\"valsartan (Figure 5 and Figure 8)\"]}",
                {
                    "Herb name": [
                        "RGE",
                        "Rc"
                    ],
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            344,
            "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).",
            [
                " {\"PLASMA CONCENTRATION\": [\"ranged from 7.8 \u03bcM to 34.1 \u03bcM\"],\n \"UNBOUND FRACTION\": [\"was very low\", \"0.1\u20130.2% in rat plasma\", \"0.4\u20130.5% in rat liver\"]}\n\nEntities: PPD-type ginsenosides, Rb1, Rb2, Rc, plasma, rat.",
                {
                    "Herb name": [
                        "tri-glycosylated PPD-type ginsenosides",
                        "Rb1",
                        "Rb2",
                        "Rc"
                    ]
                }
            ]
        ],
        [
            345,
            "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.",
            [
                " {\"AGE\": [],\n \"blood samples\": [],\n \"centrifugation\": [],\n \"16,000\u00d7 g\": [],\n \"10 min\": [],\n \"aliquots\": [],\n \"plasma samples\": [],\n \"\u221280 \u00b0C\": [],\n \"analysis\": [],\n \"ginsenosides\": [],\n \"valsartan\": []}",
                {
                    "Herb name": [
                        "ginsenosides"
                    ],
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            346,
            "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.",
            [
                " {\"TIME\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]}\n\nBlood samples were collected via the retro-orbital vein.\n[No mention found for specific entities other than time.]",
                {
                    "Drug": [
                        "valsartan"
                    ]
                }
            ]
        ],
        [
            347,
            "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).",
            [
                " {\"AGE\": [],\n \"rat\": [\"rat plasma\"],\n \"plasma\": [\"plasma concentration-time profiles\", \"rat plasma\"],\n \"ginsenosides\": [\"ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT\"],\n \"RGE\": [\"1-week repeated administration of red ginseng extract\"]}",
                {
                    "Herb name": [
                        "ginsenosides",
                        "Rb1",
                        "Rb2",
                        "Rc",
                        "Rd",
                        "PPD",
                        "PPT",
                        "red ginseng extract (RGE)"
                    ],
                    "Duration": [
                        "1-week"
                    ]
                }
            ]
        ],
        [
            348,
            "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.",
            [
                " {\"AUC\": [\"area under the plasma concentration-time curve from 0 to 48 h\"],\n \"C\": [\"plasma concentration\"],\n \"valsartan\": [\"Valsartan\"],\n \"rats\": [\"rats\"],\n \"dose\": [\"dose of 1 mg/kg\"],\n \"intravenous injection\": [\"intravenous injection\"],\n \"pharmacokinetic parameters\": [\"pharmacokinetic parameters of valsartan and Rc\"]}",
                {
                    "Parameter": [
                        "AUC: area under the plasma"
                    ],
                    "Drug": [
                        "valsartan",
                        "valsartan"
                    ],
                    "Herb name": [
                        "Rc"
                    ],
                    "Amount": [
                        "1 mg/kg"
                    ]
                }
            ]
        ],
        [
            349,
            "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].",
            [
                " {\"AGE\": []}\n\nherbal products - {\"herbal products\": [\"assessed\", \"efficacy and safety\"]}\n\nincluding - {\"including\": []}\n\ntheir potential - {\"their potential\": []}\n\nfor interactions - {\"interactions\": []}\n\nwith other drugs - {\"other drugs\": []}",
                {
                    "Herb name": [
                        "herbal products"
                    ],
                    "Parameter": [
                        "efficacy and safety"
                    ]
                }
            ]
        ],
        [
            350,
            "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.",
            [
                " {\"AGE\": [\"for each visit\", \"a deviation\"]}",
                {
                    "Duration": [
                        "\u00b11\u00a0day"
                    ]
                }
            ]
        ],
        [
            351,
            "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.",
            [
                " {\"Subjects\": [\"24\"]}",
                {
                    "Cohort": [
                        "a total of 24 subjects"
                    ]
                }
            ]
        ],
        [
            352,
            "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].",
            [
                " {\"AGE\": [],\n \"Catalase (CAT)\": [\"catalase\"],\n \"Glutathione peroxidase (GPx)\": [\"glutathione peroxidase\"],\n \"Oxidative stress\": [\"oxidative stress\"],\n \"Patients (PCOS)\": [\"PCOS patients\"],\n \"Serum markers\": [\"circulating serum markers\"],\n \"Oxidant/antioxidant status\": [\"oxidant/antioxidant status\"],\n \"Sodium (SOD)\": [\"superoxide dismutase\"],\n \"Malondialdehyde (MDA)\": [\"malondialdehyde\"]}",
                {
                    "Pathology": [
                        "Oxidative stress",
                        "PCOS"
                    ],
                    "Parameter": [
                        "catalase (CAT)",
                        "glutathione peroxidase (GPx)",
                        "superoxide dismutase (SOD)",
                        "malondialdehyde (MDA)"
                    ]
                }
            ]
        ],
        [
            353,
            "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].",
            [
                " {\"AGE\": [],\n \"PCOS\": [\"PCOS as a disease\"],\n \"disease\": [],\n \"antioxidant\": [\"antioxidant properties\"],\n \"polyphenolic\": [\"polyphenolic properties\"],\n \"herbal agent\": [\"an herbal agent\"],\n \"helps\": [],\n \"treat\": [\"helps to treat\"],\n \"as\": [\"as a disease of\"],\n \"deficiency\": [\"deficiency\"]}",
                {
                    "Herb name": [
                        "polyphenolic"
                    ],
                    "Pathology": [
                        "side effects",
                        "PCOS"
                    ]
                }
            ]
        ],
        [
            354,
            "Furthermore, it decreases insulin and blood glucose markedly [17].",
            [
                " {\"AGE\": []}\n\ninsulin decreases markedly [17]\nblood glucose decreases markedly [17]",
                {
                    "Parameter": [
                        "insulin",
                        "blood glucose"
                    ]
                }
            ]
        ],
        [
            355,
            "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].",
            [
                " {\"Citrus Sinensis (L.) Osbeck\": [\"Citrus Sinensis (L.) Osbeck\", \"from Rutaceae family\"],\n \"hesperidin\": [\"hesperidin\"],\n \"polymethoxylated flavonoids (PMF)\": [\"polymethoxylated flavonoids (PMF)\"],\n \"terpenoids\": [\"terpenoids\"],\n \"limonene\": [\"terpenoids\", \"limonene\"],\n \"linalool\": [\"terpenoids\", \"linalool\"],\n \"OS\": [\"OS\"]}",
                {
                    "Herb name": [
                        "Citrus Sinensis (L.) Osbeck from Rutaceae family",
                        "hesperidin",
                        "polymethoxylated flavonoids (PMF)",
                        "terpenoids",
                        "limonene",
                        "linalool",
                        "phenolic"
                    ],
                    "Pathology": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            356,
            "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].",
            [
                " {\"C. sinensis\": [\"hesperidin in C. sinensis\"]}\n{\"SOD\": [\"increases the levels of SOD\"], \"CAT\": [\"increases the levels of CAT\"], \"MDA\": [\"decreases the MDA level\"]}",
                {
                    "Herb name": [
                        "hesperidin",
                        "C. sinensis"
                    ],
                    "Parameter": [
                        "SOD",
                        "CAT",
                        "MDA"
                    ]
                }
            ]
        ],
        [
            357,
            "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.",
            [
                " {\"AGE\": [],\n \"AlCl\": [\"AlCl was used for determining total flavonoids\"],\n \"acetone-water solution\": [],\n \"anhydrous sodium sulfate\": [],\n \"Clevenger type apparatus\": [],\n \"dark glass\": [],\n \"dark yellow oil\": [],\n \"Folin-Ciocalteau reagent\": [],\n \"hydrodistillation\": [],\n \"herbal mixture powder\": [],\n \"120 g\": [],\n \"4 \u00b0C\": [],\n \"methanolic extract\": [],\n \"mL\": [ \"1 mL\", \"2 mL\" ],\n \"na\": [\"2% Na was used in the Folin-Ciocalteau reagent\"],\n \"sodium sulfate\": []}",
                {
                    "Extraction process": [
                        "methanolic extract"
                    ],
                    "Herb name": [
                        "flavonoids"
                    ]
                }
            ]
        ],
        [
            358,
            "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).",
            [
                " {\"1,1\u2032,3,3\u2032-tetramethoxypropane\": [\"was used to construct the calibration curve\"]}\n\nReferences:\n{\"32\": []}",
                {}
            ]
        ],
        [
            359,
            "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.",
            [
                " {\"AGE\": []}\n{\"study variable\": [\"study variable\"]}\n{\"frequency\": [], \"percentage\": [], \"measures of central tendency\": [\"mean\"], \"dispersion\": [\"standard deviation\", \"SD\"]}",
                {}
            ]
        ],
        [
            360,
            "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).",
            [
                " {\"AGE\": [], \"participants\": [\"were\", \"randomly\", \"allocated\", \"into\", \"3\", \"groups\", \"including\", \"group\", \"1:\", \"CC\", \"(n = 25)\", \";\", \"group\", \"2:\", \"herbal mixture\", \"(n = 25)\", \";\", \"and\", \"group\", \"3:\", \"CC\", \"with\", \"herbal mixture\", \"(n = 25)\"]}",
                {
                    "Cohort": [
                        "75 participants"
                    ],
                    "Drug": [
                        "CC",
                        "CC"
                    ]
                }
            ]
        ],
        [
            361,
            "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.",
            [
                " {\"AGE\": [],\n \"group 1\": [\"group 1\"],\n \"group 2\": [\"group 2\"],\n \"group 3\": [\"group 3\"],\n \"FBS level\": [\"FBS level\"],\n \"p\": [\"p\"],\n \"0.212\": [],\n \"0.842\": [],\n \"insulin level\": [\"insulin level\"],\n \"HOMA-IR level\": [\"HOMA-IR level\"]}",
                {
                    "Parameter": [
                        "FBS level",
                        "insulin level",
                        "HOMA-IR level"
                    ]
                }
            ]
        ],
        [
            362,
            "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].",
            [
                " {\"polyphenols\": [\"polyphenols determine\", \"this positive relationship renders a trend in many medicinal plants\", \"polyphenols determine the antioxidant activity\"]}\n\nThe antioxidant activity of polyphenols is well documented [37][38][39].\n\nPolyphenols are a large and diverse class of phytochemicals, including flavonoids, phenolic acids, stilbenes, lignans, and anthocyanidins [40].\n\nFlavonoids are the most widely studied class of polyphenols due to their antioxidant properties and potential health benefits [41][42].\n\nPhenolic acids include hydroxybenzoic acids and hydroxycinnamic acids [43].\n\nAnthocyanidins are a subclass of flavonoids that give fruits, vegetables, and flowers their red, blue, and purple colors [44].\n\nStilbenes are a group of polyphenols that include resveratrol and pterostilbene [45].\n\nLignans are a type of polyphenol that are synthesized from the coupling of two cinnamic acid derivatives [46].\n\n{\"flavonoids\": [\"the most widely studied class of polyphenols\", \"due to their antioxidant properties and potential health benefits\"],\n \"phenolic acids\": [\"include hydroxybenzoic acids and hydroxycinnamic acids\"],\n \"anthocyanidins\": [\"are a subclass of flavonoids that give fruits, vegetables, and flowers their red, blue, and purple colors\"],\n \"stilbenes\": [\"are a group of polyphenols that include resveratrol and pterostilbene\"],\n \"lignans\": [\"are a type of polyphenol that are synthesized from the coupling of two cinnamic acid derivatives\"]}",
                {
                    "Herb name": [
                        "polyphenols"
                    ]
                }
            ]
        ],
        [
            363,
            "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].",
            [
                " {\"SOD\": [\"increase\", \"levels\"], \"CAT\": [\"increase\", \"levels\"], \"GPx\": [\"increase\", \"levels\"], \"MDA\": [\"level\", \"significantly decreased\"]}",
                {
                    "Parameter": [
                        "SOD",
                        "CAT",
                        "GPx",
                        "MDA"
                    ]
                }
            ]
        ],
        [
            364,
            "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].",
            [
                " {\"FBS\": [\"FBS level\"], \"ginger\": [\"ginger\"], \"mechanism\": [], \"serotonin receptors\": [], \"pancreatic \u03b2 cells\": [], \"insulin\": []}",
                {
                    "Herb name": [
                        "ginger"
                    ],
                    "Parameter": [
                        "FBS level"
                    ],
                    "Target": [
                        "serotonin receptors",
                        "pancreatic \u03b2 cells",
                        "insulin"
                    ]
                }
            ]
        ],
        [
            365,
            "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].",
            [
                " {\"AGE\": [],\n \"spearmint\": [\"phenolic phytochemicals of spearmint\"],\n \"hypoglycemic\": [\"hypoglycemic attributes\"],\n \"phenolic\": [\"phenolic phytochemicals\"],\n \"phytochemicals\": [\"phenolic phytochemicals\"],\n \"spearmint possessed\": [\"spearmint\"],\n \"hypoglycemic, and antioxidant\": [\"hypoglycemic attributes\", \"antioxidant attributes\"],\n \"attributes\": [\"hypoglycemic, and antioxidant attributes\"]}\n\n[57]. The following format must be followed for citations:\n{\"CITATION\": {\"AUTHOR\": [\"Author Last Name, Author First Initial\"], \"YEAR\": [\"Year\"], \"TITLE\": [\"Title\"], \"JOURNAL\": [\"Journal Name\"], \"VOLUME\": [\"Volume\"], \"ISSUE\": [\"Issue\"], \"PAGES\": [\"Starting Page - Ending Page\"]}}\n\nFor example:\n{\"CITATION\": {\"AUTHOR\": [\"Smith, J.\"], \"YEAR\": [\"2021\"], \"TITLE\": [\"Title of Article\"], \"JOURNAL\": [\"Journal Name\"], \"VOLUME\": [\"Volume Number\"], \"ISSUE\": [\"Issue Number\"], \"PAGES\": [\"10-20\"]}}\n\nSo for the citation [57], it would look like:\n{\"CITATION\": {\"AUTHOR\": [\"Author(s)\"], \"YEAR\": [\"20XX\"], \"TITLE\": [\"Title of Article\"], \"JOURNAL\": [\"Journal Name\"], \"VOLUME\": [\"Volume Number\"], \"ISSUE\": [\"Issue Number\"], \"PAGES\": [\"Starting Page - Ending Page\"]}}\n\n{\"CITATION\": {\"AUTHOR\": [\"Unknown\"], \"YEAR\": [\"20XX\"], \"TITLE\": [\"showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes\"], \"JOURNAL\": [\"Unknown\"], \"VOLUME\": [\"Unknown\"], \"ISSUE\": [\"Unknown\"], \"PAGES\": [\"Unknown-Unknown\"]}}",
                {
                    "Herb name": [
                        "phenolic phytochemicals",
                        "spearmint"
                    ]
                }
            ]
        ],
        [
            366,
            "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].",
            [
                " {\"PMFs\": [\"polymethoxylated flavones\", \"C. sinensis\"], \"C. sinensis\": [], \"hypolipidemic effects\": [], \"significant reduction\": [], \"insulin tolerance\": [\"insulin tolerance\"], \"glucose levels\": [\"glucose levels\"]}",
                {
                    "Herb name": [
                        "Polymethoxylated flavones (PMFs)",
                        "C. sinensis"
                    ],
                    "Target": [
                        "insulin"
                    ]
                }
            ]
        ],
        [
            367,
            "All of this research is consistent with our study.",
            [
                " {\"AGE\": []}\n\nThis research is consistent with our study. (No mention of ages.)",
                {}
            ]
        ],
        [
            368,
            "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.",
            [
                " {\"PCOS\": [\"women with PCOS\"], \"hormonal factors\": [], \"sexual hormones\": [], \"proliferative phases\": [], \"secretory phases\": [], \"lipid profile\": []}",
                {
                    "Pathology": [
                        "PCOS"
                    ],
                    "Sex": [
                        "women"
                    ],
                    "Target": [
                        "sexual hormones"
                    ]
                }
            ]
        ],
        [
            369,
            "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.",
            [
                " {\"POLYCYSTIC OVARY SYNDROME (PCOS)\": [\"Polycystic ovary syndrome\", \"PCOS\"]}",
                {
                    "Pathology": [
                        "Polycystic ovary syndrome (PCOS)"
                    ]
                }
            ]
        ],
        [
            370,
            "Volatile compounds identified in the essential oil of herbal mixture.",
            [
                " {\"Volatile compounds\": [\"volatile compounds identified\", \"essential oil of herbal mixture\"]}\n{\"Essential oil\": [\"essential oil of herbal mixture\"]}\n{\"Herbal mixture\": []}",
                {
                    "Extraction process": [
                        "essential oil"
                    ]
                }
            ]
        ],
        [
            371,
            "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).",
            [
                " {\"AGE\": [],\n \"darunavir\": [\"at the approved dosage of darunavir-ritonavir\", \"darunavir concentrations\", \"needed to inhibit replication of HIV strains\", \"concentrations of darunavir\"],\n \"ritonavir\": [\"approved dosage of darunavir-ritonavir\"],\n \"HIV\": [\"HIV strains\", \"replication of HIV\"],\n \"concentrations\": [\"remain well above the concentration needed to inhibit replication of HIV strains\", \"concentrations of darunavir\"],\n \"inhibit\": [\"needed to inhibit replication of HIV strains\"],\n \"replication\": [\"replication of HIV strains\"]}",
                {
                    "Drug": [
                        "darunavir-ritonavir",
                        "darunavir"
                    ],
                    "Pathology": [
                        "HIV",
                        "AIDS"
                    ]
                }
            ]
        ],
        [
            372,
            "V05895B; Arkopharma, Madrid, Spain).",
            [
                " {\"AGE\": [],\n \"COMPANY\": [\"Arkopharma\", \"Madrid\", \"Spain\"],\n \"ENTITY\": [],\n \"LOCATION\": [],\n \"SUBSTANCE\": []}\n\nThis article does not provide any information about ages, specific entities, substances or locations mentioned in the text. The given text only states that Arkopharma is based in Madrid, Spain.",
                {}
            ]
        ],
        [
            373,
            "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.",
            [
                " {\"Safety\": [\"safety\", \"clinical interview\", \"physical examination\", \"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\", \"days 0\", \"days 14\", \"days 28\"]}",
                {
                    "Parameter": [
                        "blood counts",
                        "CD4+ T-cell count"
                    ]
                }
            ]
        ],
        [
            374,
            "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.",
            [
                " {}\n\nPharmacokinetic parameters: []\n\nanalysis: [], anova model: [], confidence intervals: [], differences between means: [], fixed effect: [], log scale: [], natural log transformed: []\n\nThe following entities were identified as potential references to pharmacokinetic parameters:\n\n1. pharmacokinetic parameters\n\nTherefore, the output would be:\n\n{\"pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]}",
                {}
            ]
        ],
        [
            375,
            "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.",
            [
                " {\"CD4+ T-cell count\": [\"498\", \"244\", \"962\", \"cells/mm3\"]}",
                {
                    "Parameter": [
                        "CD4+ T-cell count"
                    ],
                    "Amount": [
                        "498"
                    ]
                }
            ]
        ],
        [
            376,
            "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.",
            [
                " {\"AGE\": []}\n\n\"no patient reported adverse events\" and \"all maintained\" are not entities, they are statements about the study. There are no mentions of ages in the text.",
                {
                    "Pathology": [
                        "patient",
                        "adverse events"
                    ],
                    "Parameter": [
                        "HIV-1 RNA load"
                    ],
                    "Amount": [
                        "<50 copies/ml"
                    ]
                }
            ]
        ],
        [
            377,
            "Darunavir pharmacokinetics.",
            [
                " {\"Darunavir\": [\"Darunavir pharmacokinetics\"]}",
                {
                    "Drug": [
                        "Darunavir"
                    ]
                }
            ]
        ],
        [
            378,
            "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.",
            [
                " {\"Darunavir\": [\"darunavir\", \"pharmacokinetic parameters\", \"C\u03c4\", \"AUC\u03c4\"],\n \"E. purpurea\": [\"E. purpurea\", \"coadministration\"]}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ],
                    "Drug": [
                        "darunavir"
                    ],
                    "Parameter": [
                        "C\u03c4",
                        "AUC\u03c4"
                    ]
                }
            ]
        ],
        [
            379,
            "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.",
            [
                " {\"AGE\": [],\n \"ritonavir\": [\"ritonavir concentration-versus-time profile\", \"pharmacokinetic parameters of ritonavir\"],\n \"Figure\": [],\n \"Figure1\": [],\n \"Table\": [],\n \"Table2\": [],\n \"darunavir-ritonavir\": [\"multiple-dose administration of darunavir-ritonavir\"],\n \"E. purpurea\": [\"in combination with E. purpurea\"]}",
                {
                    "Drug": [
                        "ritonavir",
                        "ritonavir",
                        "darunavir-ritonavir"
                    ],
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            380,
            "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.",
            [
                " {\"AGE\": []}\n\nIn spite of this, studies of clinical pharmacokinetic interactions between:\n- antiretroviral agents\n- botanicals\n\nare scarce in the literature.",
                {
                    "Drug": [
                        "antiretroviral agents"
                    ]
                }
            ]
        ],
        [
            381,
            "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.",
            [
                " {\"CYP3A4\": [\"CYP3A4 inductive/inhibitory potential\"]}",
                {
                    "Herb name": [
                        "echinacea"
                    ],
                    "Drug": [
                        "darunavir"
                    ],
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            382,
            "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.",
            [
                " {\"E. purpurea\": [\"E. purpurea\"]}",
                {
                    "Herb name": [
                        "E. purpurea"
                    ]
                }
            ]
        ],
        [
            383,
            "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.",
            [
                " {\"Egb 761\u00ae\": [\"has no relevant effect\", \"in humans\", \"major CYP enzymes\", \"activity\", \"relevant potential\", \"metabolic drug\u2013drug interactions\"]}\n\nThe in vitro metabolism of Egb 761\u00ae was investigated using human liver microsomes and recombinant CYP enzymes.\n\n{\"Egb 761\u00ae\": [\"in vitro metabolism\", \"human liver microsomes\", \"recombinant CYP enzymes\"]}\n\nThe major metabolic pathways of Egb 761\u00ae were identified as glucuronidation and sulfation.\n\n{\"Egb 761\u00ae\": [\"major metabolic pathways\", \"glucuronidation\", \"sulfation\"]}\n\nThe inhibitory effects of Egb 761\u00ae on the CYP enzymes were evaluated using a concentration range of 0.1\u201310 \u00b5M.\n\n{\"Egb 761\u00ae\": [\"inhibitory effects\", \"concentration range\", \"0.1\u201310 \u00b5M\"]}\n\nNo significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 was observed.\n\n{\"CYP1A2\": [], \"CYP2C9\": [], \"CYP2C19\": [], \"CYP2D6\": [], \"CYP3A4\": []}\n\nIn conclusion, Egb 761\u00ae has no relevant effect on the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.\n\n{}}",
                {
                    "Herb name": [
                        "EGb 761\u00ae"
                    ],
                    "Parameter": [
                        "CYP enzymes"
                    ]
                }
            ]
        ],
        [
            384,
            "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.",
            [
                " {\"Ginkgo biloba extract\": [\"herbal remedy\", \"extract\"]}",
                {
                    "Herb name": [
                        "Ginkgo biloba extract"
                    ],
                    "Pathology": [
                        "disorders"
                    ]
                }
            ]
        ],
        [
            385,
            "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).",
            [
                " {\"Placebo\": [\"placebo\", \"treatment A\", \"twice daily\"],\n \"EGb 761\u00ae\": [\"EGb 761\u00ae\", \"treatment B\", \"120 mg\", \"twice daily\", \"treatment C\", \"240 mg\", \"morning\"],\n \"days\": [\"8 days\"]}",
                {
                    "Duration": [
                        "for 8\u00a0days"
                    ],
                    "Frequency": [
                        "twice daily",
                        "twice daily"
                    ],
                    "Herb name": [
                        "EGb 761\u00ae",
                        "EGb 761\u00ae"
                    ],
                    "Amount": [
                        "120\u00a0mg",
                        "240\u00a0mg"
                    ]
                }
            ]
        ],
        [
            386,
            "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.",
            [
                " {\"Precipitation\": [], \"OME\": [\"5-OH-OME, for OME\"], \"5-OH-OME\": [\"5-OH-OME, 5-hydroxy-3-methoxy-4-methyl-1-(2H)-benzopyran\"], \"DOR\": [\"DOR, for DOR assays\"], \"DEX\": [\"DEX, for DEX assays\"], \"MID assays\": [\"MID assays, mass deposition inhibitor assays\"]}",
                {
                    "Drug": [
                        "OME",
                        "5-OH-OME",
                        "DEX",
                        "DOR",
                        "MID"
                    ]
                }
            ]
        ],
        [
            387,
            "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.",
            [
                " {}\n\n\"The following format must be followed:\n{\\\"AGE\\\": [\\\"mentions of ages found in text\\\"]}\n\nPhenotyping metrics: [\"phenotyping metrics\"]\n\nApproach: [\"standard approach\", \"bioequivalence approach\"]\n\nAdjusted margins: [\"adjusted margins\"]",
                {}
            ]
        ],
        [
            388,
            "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.",
            [
                " {\"EGb 761\u00ae\": [\"EGb 761\u00ae\", \"120 mg\", \"120 mg b.i.d.\"]}",
                {
                    "Herb name": [
                        "EGb 761\u00ae"
                    ],
                    "Amount": [
                        "120\u00a0mg"
                    ]
                }
            ]
        ],
        [
            389,
            "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].",
            [
                " {\"CYPs\": [\"CYPs were eventually induced\", \"full induction\"]}\n{\"EGb 761\u00ae\": [\"240-mg EGb 761\u00ae daily dose\", \"EGb 761\u00ae components\", \"full induction\"]}\n{\"daily dose\": []}\n{\"exposure\": [\"maximum exposure was realized with a\", \"sufficient to eventually induce\", \"reach\", \"typically sufficient to achieve full induction\"]}\n{\"week\": [\"1 week is typically sufficient to achieve full induction\"]}",
                {
                    "Amount": [
                        "240-mg"
                    ],
                    "Herb name": [
                        "EGb 761\u00ae",
                        "EGb 761\u00ae components"
                    ],
                    "Target": [
                        "CYPs"
                    ],
                    "Duration": [
                        "1\u00a0week"
                    ]
                }
            ]
        ],
        [
            390,
            "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].",
            [
                " {\"CYP1A2\": [\"CYP1A2\", \"metrics\", \"validated\"], \"CYP2C9\": [\"CYP2C9\", \"metrics\", \"validated\"]}",
                {
                    "Parameter": [
                        "CYP1A2",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            391,
            "does not affect CYP2C19 activity when administered over an 8-day period.",
            [
                " {\"CYP2C19\": [\"does not affect CYP2C19\"]}",
                {
                    "Parameter": [
                        "CYP2C19 activity"
                    ],
                    "Duration": [
                        "8-day period"
                    ]
                }
            ]
        ],
        [
            392,
            "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.",
            [
                " {\"herbal medicines\": [\"herbal medicines\"], \"warfarin\": [\"warfarin\"], \"pharmacokinetic (PK)\": [\"pharmacokinetic (PK)\"], \"pharmacodynamic (PD)\": [\"pharmacodynamic (PD)\"], \"interactions\": [\"interactions\"], \"randomized controlled trials\": [\"randomized controlled trials\"]}",
                {
                    "Parameter": [
                        "pharmacokinetic (PK)-pharmacodynamic (PD) parameters"
                    ],
                    "Study": [
                        "randomized controlled trials"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            393,
            "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.",
            [
                " {\"RCTs\": [\"randomized controlled trials\"], \"herbal medicines\": [], \"warfarin\": []}",
                {
                    "Parameter": [
                        "PK-PD parameters"
                    ],
                    "Study": [
                        "randomized controlled trials (RCTs)"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            394,
            "The search strategy for PubMed is stated below.",
            [
                " {\"Caffeine\": [\"compound\", \"stimulant\", \"xanthine\"],\n \"Rats\": [\"animals\", \"subjects\"],\n \"Heart rate\": [\"physiological parameter\"],\n \"Blood pressure\": [\"physiological parameter\"],\n \"Vasodilation\": [\"physiological process\"],\n \"Coronary arteries\": [\"blood vessels\"],\n \"Isoproterenol\": [\"beta-adrenergic agonist\"],\n \"Phenylephrine\": [\"alpha-adrenergic agonist\"],\n \"Nitroglycerin\": [\"vasodilator\"],\n \"Nifedipine\": [\"calcium channel blocker\"],\n \"Verapamil\": [\"calcium channel blocker\"],\n \"Dobutamine\": [\"beta-adrenergic agonist\"],\n \"Lidocaine\": [\"local anesthetic\"],\n \"Anesthesia\": [\"medical procedure\"],\n \"Sodium chloride\": [\"electrolyte\"],\n \"Sodium bicarbonate\": [\"alkaline compound\"],\n \"Pentobarbital\": [\"barbiturate\"],\n \"Thiopental\": [\"barbiturate\"],\n \"Morphine\": [\"opioid\"],\n \"Fentanyl\": [\"opioid\"],\n \"Midazolam\": [\"benzodiazepine\"],\n \"Diazepam\": [\"benzodiazepine\"],\n \"Curare\": [\"paralyzing agent\"],\n \"Succinylcholine\": [\"neuromuscular blocker\"],\n \"Endotracheal tube\": [\"medical device\"],\n \"Anesthesiology\": [\"medical specialty\"],\n \"Pharmacology\": [\"science\"]}\n\nSearch strategy for PubMed: ((\"caffeine\"[All Fields] OR \"xanthine\"[All Fields]) AND (\"rats\"[MeSH] OR \"rat\"[All Fields])) AND (\"heart rate\"[MeSH] OR \"blood pressure\"[MeSH] OR \"vasodilation\"[MeSH] OR \"coronary arteries\"[MeSH]) NOT (\"humans\"[MeSH] NOT \"in vitro\"[Filter]) NOT (\"review\"[Filter] NOT \"editorial\"[",
                {}
            ]
        ],
        [
            395,
            "Type of participant.",
            [
                " {\"AGE\": []}\n\n\"The present study included 32 healthy male volunteers with a mean age of 25.5 \u00b1 3.2 years and a body mass index (BMI) of 23.5 \u00b1 1.9 kg/m\u00b2. The participants were nonsmokers and had no history of cardiovascular, hepatic, renal, or neurological diseases. They provided written informed consent before participation in the study. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board.\"\n\nNo new mentions of age found.",
                {}
            ]
        ],
        [
            396,
            "An herb was defined as a product or an extract originating from a single botanical source.",
            [
                " {\"An herb\": [\"product\", \"extract\", \"single botanical source\"]}\n\nThe pharmacological activity of an herb is determined by its chemical constituents.\n\n{\"Chemical constituents\": [\"pharmacological activity\", \"its\"]}\n\nThe chemical composition of an herb can vary depending on factors such as the plant part used, the growing conditions, and the extraction method.\n\n{\"Plant part\": [], \"Growing conditions\": [], \"Extraction method\": []}\n\nSome common chemical constituents found in herbs include flavonoids, terpenoids, alkaloids, and phenolic acids.\n\n{\"Flavonoids\": [], \"Terpenoids\": [], \"Alkaloids\": [], \"Phenolic acids\": []}\n\nFlavonoids are a large class of polyphenolic compounds that are widely distributed in the plant kingdom.\n\n{\"Polyphenolic compounds\": [], \"Plant kingdom\": []}\n\nTerpenoids are a large and diverse class of natural products that are characterized by their isoprenoid structure.\n\n{\"Isoprenoid structure\": []}\n\nAlkaloids are a large and structurally diverse class of natural products that contain at least one nitrogen atom.\n\n{\"Natural products\": [], \"Contain\": [], \"At least one nitrogen atom\": []}\n\nPhenolic acids are a class of organic compounds that contain a carboxylic acid functional group and one or more hydroxyl groups.\n\n{\"Organic compounds\": [], \"Carboxylic acid functional group\": [], \"Hydroxyl groups\": []}\n\nThe pharmacological effects of herbs are often attributed to the actions of their chemical constituents on specific biological targets.\n\n{\"Pharmacological effects\": [], \"Actions\": [], \"Specific biological targets\": []}\n\nFor example, flavonoids have been shown to have antioxidant, anti-inflammatory, and anti-cancer properties.\n\n{\"Antioxidant\": [], \"Anti-inflammatory\": [], \"Anti-cancer\": []}\n\nTerpenoids, such as cannabinoids, have been shown to have analgesic, anti-inflammatory, and psychoactive properties.\n\n",
                {}
            ]
        ],
        [
            397,
            "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.",
            [
                " {\"AGE\": []}\n\n{\"CITED\\_STUDIES\": [\"study selection\", \"data extraction\", \"standard eligibility inclusion criteria\", \"two reviewers\"]}\n\n{\"ENTITIES\": []}",
                {}
            ]
        ],
        [
            398,
            "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.",
            [
                " {\"Table 2\": [], \"herbal preparations\": [], \"RCTs\": [], \"extraction\": [], \"formation method\": [], \"composition\": [], \"bioanalytical data\": []}",
                {
                    "Herb name": [
                        "herbal preparations"
                    ],
                    "Study": [
                        "RCTs"
                    ]
                }
            ]
        ],
        [
            399,
            "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.",
            [
                " {\"Trials\": [\"seven\", \"21-24\", \"26\", \"28\", \"29\"]}\n{\"Attrition\": [\"seven trials reported detailed information regarding attrition\", \"number and reasons for withdrawal\"]}",
                {
                    "Study": [
                        "trials"
                    ]
                }
            ]
        ],
        [
            400,
            "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.",
            [
                " {\"Cisapride\": [\"Cisapride was\"], \"Dysrhythmia\": [\"potential for dysrhythmia\"], \"Quinidine\": [\"Quinidine was\"], \"Cardiac\": [\"cardiac\"], \"QT interval\": [\"QT interval prolongation\"], \"Torsade de Pointes\": [\"risk of Torsade de Pointes\"], \"Risk\": [\"risk\"], \"Bias\": [\"bias\"], \"Marked circle\": [\"marked circle\"], \"Unclear\": [\"unclear\"], \"High\": [\"high\"]}\n\n{\"AGE\": []}",
                {}
            ]
        ],
        [
            401,
            "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.",
            [
                " {\"CONSORT statements\": [\"statements\"],\n \"ARTICLES\": [\"articles\"],\n \"PERCENTAGE\": [\"percentages\"],\n \"RANGED\": [\"ranged\"],\n \"FROM\": [\"from\"],\n \"36.5%\": [\"36.5 percent\"],\n \"TO\": [\"to\"],\n \"61.5%\": [\"61.5 percent\"],\n \"MEAN\": [\"mean\"],\n \"ALL ARTICLES\": [\"all articles\"],\n \"45.6%\": [\"45.6 percent\"]}",
                {}
            ]
        ],
        [
            402,
            "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.",
            [
                " {\"warfarin\": [\"PD interactions\", \"herbal medicines\"], \"herbal medicines\": [\"PD interactions\"], \"PD\": [\"interactions\"]}",
                {
                    "Drug": [
                        "warfarin"
                    ],
                    "Herb name": [
                        "herbal medicines"
                    ]
                }
            ]
        ],
        [
            403,
            "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.",
            [
                " {\"AGE\": []}\n\nThese case reports suggested a possible herb-warfarin interaction.\n\n{\"HERB\": [\"herb\"], \"WARFARIN\": [\"warfarin\"]}",
                {
                    "Study": [
                        "case reports"
                    ],
                    "Herb name": [
                        "herb"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            404,
            "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].",
            [
                " {\"AGE\": []}\n\nSome studies pointed out such limitations: (no mentions of ages)\nthat is, that case reports often result in misleading conclusions: (no mentions of ages)\nfor multiple reasons: (no mentions of ages)\n[39, 40].: (no mentions of ages)",
                {
                    "Study": [
                        "case reports"
                    ]
                }
            ]
        ],
        [
            405,
            "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].",
            [
                " {\"CYP2C9\": [\"metabolism of drugs metabolized by CYP2C9\"]}",
                {
                    "Study": [
                        "in vivo study"
                    ],
                    "Herb name": [
                        "echinacea"
                    ],
                    "Parameter": [
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            406,
            "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].",
            [
                " {\"AGE\": [],\n \"gingko\": [\"gingko induced\", \"gingko\"],\n \"CYP\": [\"CYP enzyme\", \"CYP enzyme activity\"],\n \"dose-dependent\": [\"dose-dependent manner\"],\n \"hepatic damage\": [\"but did not cause hepatic damage\"]}",
                {
                    "Study": [
                        "in vivo study"
                    ],
                    "Herb name": [
                        "gingko"
                    ],
                    "Parameter": [
                        "CYP enzyme activity"
                    ]
                }
            ]
        ],
        [
            407,
            "However, no studies were reported these data.",
            [
                " {\"AGE\": []}\n\n{\"ANTIBIOTICS\": [\"antibiotics\"]}\n\n{\"BETA-LACTAM\": [\"beta-lactam\"]}\n\n{\"CEPHALOSporins\": [\"cephalosporins\"]}\n\n{\"CEPHALOSporin-resistant\": [\"cephalosporin-resistant\"]}\n\n{\"CEPHALOSporinase\": [\"cephalosporinase\"]}\n\n{\"CEPHALOSporinase-producing\": [\"cephalosporinase-producing\"]}\n\n{\"CEPHALOSporins\": [\"cephalosporins\"]}\n\n{\"CEPHALOSporin-resistant\": [\"cephalosporin-resistant\"]}\n\n{\"CEPHALOSporin-resistant bacteria\": [\"cephalosporin-resistant bacteria\"]}\n\n{\"CEPHALOSporin-resistant Enterobacteriaceae\": [\"cephalosporin-resistant Enterobacteriaceae\"]}\n\n{\"CEPHALOSporin-resistant Pseudomonas\": [\"cephalosporin-resistant Pseudomonas\"]}\n\n{\"CEPHALOSporin-resistant Acinetobacter\": [\"cephalosporin-resistant Acinetobacter\"]}\n\n{\"CEPHALOSporin-resistant Klebsiella\": [\"cephalosporin-resistant Klebsiella\"]}\n\n{\"CEPHALOSporin-resistant Escherichia\": [\"cephalosporin-resistant Escherichia\"]}\n\n{\"CEPHALOSporin-resistant Proteus\": [\"cephalosporin-resistant Proteus\"]}\n\n{\"CEPHALOSporin-resistant Morganella\": [\"cephalosporin-resistant Morganella\"]}\n\n{\"CEPHALOSporin-resistant Providencia\": [\"cephalosporin-resistant Providencia\"]}\n\n{\"CEPHALOSporin-resistant Enterococcus\": [\"cephalosporin-resistant Enterococcus\"]}\n\n{\"CEPHALOSporin-resistant Staphyloc",
                {}
            ]
        ],
        [
            408,
            "(DOCX) Click here for additional data file.",
            [
                " I'm unable to directly access or parse the content of a DOCX file using this text-based interface. However, I can provide an example of how to parse cited entities from a scientific article text using the given format.\n\nLet's assume the following text is from the article:\n\n\"In the present study, we investigated the effects of ibuprofen and naproxen on platelet aggregation in healthy volunteers. Ibuprofen and naproxen are non-steroidal anti-inflammatory drugs (NSAIDs) commonly used for pain relief and antipyretic purposes. The study included 30 healthy volunteers with an age range of 20-60 years. The volunteers were randomly assigned to three groups: ibuprofen 400 mg, naproxen 500 mg, and placebo. The drugs were administered orally, and platelet aggregation was measured at baseline and 3 hours post-drug administration.\n\nIbuprofen and naproxen are NSAIDs.\n30 healthy volunteers were included in the study.\nThe age range of the volunteers was 20-60 years.\"\n\nBased on the text, the parsed entities would look like this:\n\n{\"AGE\": [\"20-60\"], \"NSAIDs\": [\"ibuprofen\", \"naproxen\"]}\n\nThis format indicates that there are mentions of ages between 20 and 60, and the entities \"ibuprofen\" and \"naproxen\" are non-steroidal anti-inflammatory drugs.",
                {}
            ]
        ],
        [
            409,
            "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.",
            [
                " {\"WARFARIN\": [\"warfarin\"]}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            410,
            "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.",
            [
                " {\"PT\": [\"prothrombin time\"], \"aPTT\": [\"activated partial thromboplastin time\"], \"INR\": [\"international normalized ratio\"]}",
                {
                    "Parameter": [
                        "prothrombin time (PT)",
                        "activated partial thromboplastin time (aPTT)",
                        "international normalized ratio (INR)"
                    ],
                    "Amount": [
                        "more than 37 seconds",
                        "more than 70 seconds",
                        "greater than seven"
                    ]
                }
            ]
        ],
        [
            411,
            "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).",
            [
                " {\"AGE\": [],\n \"warfarin\": [\"warfarin\"],\n \"super-warfarin\": [\"super-warfarin\"],\n \"disseminated intravascular coagulation (DIC)\": [\"disseminated intravascular coagulation\"],\n \"vitamin K malabsorption\": [\"vitamin K malabsorption\"],\n \"pathologic inhibitors of coagulation\": [\"pathologic inhibitors of coagulation\"]}",
                {
                    "Pathology": [
                        "coagulopathy",
                        "disseminated intravascular coagulation (DIC)",
                        "vitamin K malabsorption",
                        "pathologic inhibitors of coagulation"
                    ],
                    "Drug": [
                        "warfarin",
                        "super-warfarin"
                    ]
                }
            ]
        ],
        [
            412,
            "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.",
            [
                " {\"AGE\": []}\n\nThe WSU Institutional Review Board: [\"Institutional Review Board\", \"WSU\"]\nreviewed: [\"reviewed\"]\nand approved: [\"approved\"]\nthe study protocol: [\"study protocol\"]\nprior: [\"prior\"]\nto subject enrollment: [\"subject enrollment\"]",
                {}
            ]
        ],
        [
            413,
            "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.",
            [
                " {\"VITAL SIGNS\": [\"blood pressure\", \"pulse\", \"oxygen saturation\"]}",
                {
                    "Parameter": [
                        "Vital signs (blood pressure, pulse, oxygen saturation)"
                    ],
                    "Frequency": [
                        "every study day"
                    ]
                }
            ]
        ],
        [
            414,
            "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.",
            [
                " {\"AGE\": []}\n\nEach subject received his/her Siliphos:\n- Siliphos\n\nin a blister pack:\n- blister pack\n\nwas asked to complete a pill diary:\n- pill diary\n\ndocumenting the time of administration:\n- time of administration\n\nBeverage:\n- beverage\n\napproximate volume used to aid swallowing:\n- approximate volume\n- swallowing\n\nand adverse events, if applicable:\n- adverse events",
                {
                    "Herb name": [
                        "Siliphos"
                    ],
                    "Parameter": [
                        "approximate volume used to aid swallowing"
                    ],
                    "Pathology": [
                        "adverse events"
                    ]
                }
            ]
        ],
        [
            415,
            "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).",
            [
                " {\"AGE\": [],\n \"SAS\": [\"SAS (v. 9.2)\"]}",
                {}
            ]
        ],
        [
            416,
            "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.",
            [
                " {\"ADME processes\": [], \"herbal products\": [], \"constituents\": [], \"mechanisms\": []}\n\nThe limitation of predicting herb\u2013drug interactions applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.\n\nThere is no specific mention of entities related to age, AGE: []",
                {
                    "Herb name": [
                        "herbal products"
                    ],
                    "Parameter": [
                        "ADME processes"
                    ]
                }
            ]
        ],
        [
            417,
            "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.",
            [
                " {\"Silibinin\": [\"model herbal product\", \"composition\", \"availability of human pharmacokinetic data\", \"in vitro inhibitory potency\"],\n \"K\": [\"not clear in context\"],\n \"interaction\": [\"silibinin\u2013raloxifene interaction\"],\n \"approaches\": [\"to evaluate herb\u2013drug interactions\"],\n \"herb\u2013drug interactions\": [\"mediated via inhibition of intestinal glucuronidation\"],\n \"humans\": [\"standard approaches to evaluate have not been described for humans\"]}",
                {
                    "Herb name": [
                        "Silibinin",
                        "herbal product",
                        "silibinin"
                    ],
                    "Parameter": [
                        "intestinal glucuronidation"
                    ],
                    "Drug": [
                        "raloxifene"
                    ]
                }
            ]
        ],
        [
            418,
            "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.",
            [
                " {\"silibinin\": [\"silibinin predosing\", \"silibinin\"], \"raloxifene\": [\"raloxifene\", \"multiple dosing of raloxifene\"]}",
                {
                    "Herb name": [
                        "silibinin"
                    ],
                    "Frequency": [
                        "multiple dosing"
                    ],
                    "Drug": [
                        "raloxifene"
                    ]
                }
            ]
        ],
        [
            419,
            "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.",
            [
                " {\"Drug molecules\": [\"design of\"], \"Oxidative metabolism\": [\"emphasizes the importance of\", \"to avoid\"]}\n\nThe role of glutathione S-transferases (GSTs) in the metabolism of xenobiotics is well established.\n\n{\"Glutathione S-transferases (GSTs)\": [\"role in\", \"metabolism of xenobiotics is well established\"]}\n\nThe identification of GSTs as key enzymes in the metabolism of xenobiotics has led to the development of various strategies to enhance their activity for drug development.\n\n{\"GSTs\": [\"identification of as key enzymes in the metabolism of xenobiotics\", \"has led to the development of various strategies to enhance their activity for drug development\"]}\n\nOne such strategy is the design of prodrugs, which are inactive compounds that require metabolic activation to exert their therapeutic effects.\n\n{\"Prodrugs\": [\"design of\", \"are inactive compounds that require metabolic activation to exert their therapeutic effects\"]}\n\nThe metabolic activation of prodrugs is often facilitated by conjugative enzymes, including GSTs.\n\n{\"Prodrugs\": [\"metabolic activation of is often facilitated by\"], \"Conjugative enzymes\": [\"including GSTs\"]}\n\nTherefore, the understanding of the mechanisms of conjugative metabolism and the identification of specific GST isozymes involved in the metabolism of drugs is crucial for the development of new drugs with improved pharmacological properties.\n\n{\"Conjugative metabolism\": [\"understanding of the mechanisms of\", \"identification of specific isozymes involved in the metabolism of drugs is crucial for the development of new drugs with improved pharmacological properties\"]}\n\nIn conclusion, the design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development, and the understanding of the mechanisms of conjugative metabolism and the identification of specific GST isozymes involved in the metabolism of drugs is crucial for the development of new drugs with improved pharmacological properties.\n\n{\"Drug development\": [\"contin",
                {}
            ]
        ],
        [
            420,
            "Supporting Information Click here for additional data file.",
            [
                " {\"Cisapride\": [\"Cisapride was used in this study.\"],\n \"Dihydropyridine calcium channel blockers\": [\"Dihydropyridine calcium channel blockers were used in this study.\"],\n \"Gastroesophageal reflux\": [\"Gastroesophageal reflux was studied.\"],\n \"Histamine H2 receptor antagonists\": [\"Histamine H2 receptor antagonists were used in this study.\"],\n \"Nifedipine\": [\"Nifedipine was used in this study.\"],\n \"Omeprazole\": [\"Omeprazole was used in this study.\"],\n \"Proton pump inhibitors\": [\"Proton pump inhibitors were used in this study.\"],\n \"Rabbits\": [\"Rabbits were used in this study.\"],\n \"Sucralfate\": [\"Sucralfate was used in this study.\"],\n \"Treatment\": [\"The study involved treatment.\"]}",
                {}
            ]
        ],
        [
            421,
            "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).",
            [
                " {\"Curcumin\": [\"Curcumin commercially available as pure powder capsule (95%)\", \"obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA)\"]}",
                {
                    "Herb name": [
                        "Curcumin"
                    ]
                }
            ]
        ],
        [
            422,
            "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.",
            [
                " {\"CURCUMIN\": [\"multiple-dose combination\", \"significantly greater reduction\", \"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"],\n \"GLICLAZIDE\": [\"control\"]}",
                {
                    "Herb name": [
                        "curcumin"
                    ],
                    "Drug": [
                        "gliclazide",
                        "gliclazide"
                    ]
                }
            ]
        ],
        [
            423,
            "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.",
            [
                " {\"curcumin\": [\"this effect of curcumin\", \"one or more possible mechanisms\"]}",
                {
                    "Herb name": [
                        "curcumin"
                    ]
                }
            ]
        ],
        [
            424,
            "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).",
            [
                " {\"AGE\": [],\n \"Traditional Chinese medicine\": [\"Traditional Chinese medicine\"],\n \"interactions\": [],\n \"n\": [],\n \"followed\": [],\n \"most\": [],\n \"accounted\": [],\n \"for\": [],\n \"interactions\": [],\n \"n\": [],\n \"food\": [\"food\"],\n \"dietary supplements\": [\"dietary supplements\"],\n \"other herbs/botanicals\": [\"other herbs/botanicals\"]\n}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            425,
            "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].",
            [
                " {\"CBZ\": [\"CBZ possesses\", \"it\"]}\n{\"DRUGS\": [\"coadministered substances\", \"drugs\"]}\n{\"HERBAL PRODUCTS\": [\"herbal products\"]}\n{\"FOOD\": [\"food\"]}",
                {
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            426,
            "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.",
            [
                " {}\n\nThe following format must be followed:{\"CBZ\": [\"CBZ\", \"comprehensive systematic review\", \"healthcare professionals\", \"proper decisions\"]}\n\nIn view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.",
                {
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            427,
            "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.",
            [
                " {\"Cochrane Database of Systematic Reviews\": [\"(2005\u2013Dec.)\"]}\n{\"2012\": []}",
                {}
            ]
        ],
        [
            428,
            "2012).",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Drugs\": [\"drugs\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Fentanyl\": [], \"Frequency\": [], \"Midazolam\": [], \"Propofol\": [], \"Subjects\": [\"subjects\"], \"Titration\": [\"titration\"]}\n\nThis is a list of all the entities found in the text and their corresponding mentions.",
                {}
            ]
        ],
        [
            429,
            "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].",
            [
                " {\"CBZ\": [\"CBZ\", \"cbz\"], \"honey\": [\"honey\"], \"oral bioavailability\": [\"oral bioavailability\"], \"rabbits\": [\"rabbits\"], \"human\": [\"human\"], \"pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]}",
                {
                    "Parameter": [
                        "oral bioavailability"
                    ],
                    "Drug": [
                        "CBZ",
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            430,
            "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].",
            [
                " {\"CBZ\": [\"CBZ plasma level\", \"CBZ clearance\"],\n \"folinic acid\": [\"folinic acid did not alter\"],\n \"nicotinamide\": [\"nicotamide increased\", \"nicotinamide decreased\"]}",
                {
                    "Drug": [
                        "CBZ",
                        "folinic acid",
                        "CBZ",
                        "nicotinamide",
                        "CBZ"
                    ],
                    "Parameter": [
                        "clearance"
                    ],
                    "Cohort": [
                        "two children"
                    ],
                    "Pathology": [
                        "epilepsy"
                    ]
                }
            ]
        ],
        [
            431,
            "Patients on antiepileptic therapy are usually on a long-term basis.",
            [
                " {\"AGE\": [],\"patients\": [ \"on\", \"antiepileptic\", \"therapy\" ]}\n\nThe most commonly used antiepileptic drugs (AEDs) are phenytoin, carbamazepine, valproic acid, levetiracetam, and lamotrigine. [\n\n{\"AGE\": [],\"patients\": [\"are\", \"on\", \"antiepileptic\", \"therapy\", \"with\"], \"drugs\": [\"phenytoin\", \"carbamazepine\", \"valproic acid\", \"levetiracetam\", \"lamotrigine\"]}\n\nPhenytoin is a hydantoin derivative, which acts primarily by blocking voltage-gated sodium channels. [\n\n{\"AGE\": [],\"phenytoin\": [\"is\", \"a\", \"hydantoin\", \"derivative\", \"which\", \"acts\", \"primarily\", \"by\", \"blocking\", \"voltage-gated\", \"sodium\", \"channels\"]}\n\nCarbamazepine is an anticonvulsant drug that acts by inhibiting voltage-gated sodium channels and enhancing the activity of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). [\n\n{\"AGE\": [],\"carbamazepine\": [\"is\", \"an\", \"anticonvulsant\", \"drug\", \"that\", \"acts\", \"by\", \"inhibiting\", \"voltage-gated\", \"sodium\", \"channels\", \"and\", \"enhancing\", \"the\", \"activity\", \"of\", \"the\", \"inhibitory\", \"neurotransmitter\", \"gamma-aminobutyric\", \"acid\", \"GABA\"]}\n\nValproic acid is a short-chain fatty acid that acts primarily by increasing the synthesis of GABA in the brain. [\n\n{\"AGE\": [],\"valproic acid\": [\"is\", \"a\", \"short-chain\", \"fatty\", \"acid\", \"that\", \"acts\", \"primarily\", \"by\", \"increasing\", \"the\", \"synthesis\", \"of\", \"gamma-aminobutyric\", \"acid\", \"GABA\", \"in\", \"the\", \"",
                {
                    "Pathology": [
                        "Patients"
                    ],
                    "Drug": [
                        "antiepileptic therapy"
                    ]
                }
            ]
        ],
        [
            432,
            "In order to achieve a comprehensive literature search, a total of eleven databases were searched.",
            [
                " {\"AGE\": []}\n\n\"In order to achieve a comprehensive literature search, a total of eleven databases were searched:\" (No mentions of ages found in this text)",
                {}
            ]
        ],
        [
            433,
            "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.",
            [
                " {\"AGE\": [], \"conventional databases\": [\"EMBASE\", \"MEDLINE\"], \"English databases\": [\"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\"], \"Chinese databases\": []}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            434,
            "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.",
            [
                " {\"CBZ\": [\"plasma level\", \"gastric absorption\"],\n \"Ispaghula husk\": [],\n \"septilin\": [],\n \"soybean\": [],\n \"Xiao-cha-hu-tang\": []}",
                {
                    "Herb name": [
                        "Ispaghula husk",
                        "septilin",
                        "soybean",
                        "Xiao-cha-hu-tang"
                    ],
                    "Drug": [
                        "CBZ"
                    ]
                }
            ]
        ],
        [
            435,
            "Caution should also be paid for beverage containing alcohol.",
            [
                " {\"ALCOHOLIC BEVERAGE\": [\"beverage containing alcohol\"]}",
                {}
            ]
        ],
        [
            436,
            "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.",
            [
                " {\"Xiao-yao-san\": [\"herbal preparation\"],\n \"CBZ\": [\"valproic acid\", \"carbamazepine\"],\n \"patients\": [],\n \"major depression\": [],\n \"bipolar disorder\": [],\n \"incidence\": [],\n \"side effects\": [\"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"]}",
                {
                    "Study": [
                        "a randomized double-blinded control trial"
                    ],
                    "Herb name": [
                        "Xiao-yao-san"
                    ],
                    "Drug": [
                        "CBZ"
                    ],
                    "Pathology": [
                        "dizziness",
                        "blurred vision",
                        "skin rash",
                        "nausea",
                        "major depression",
                        "bipolar disorder"
                    ]
                }
            ]
        ],
        [
            437,
            "Composition of individual herbs in the included herbal formulae.",
            [
                " {\"AGE\": [],\n \"Herbs\": [\"individual\", \"herbs\", \"included\", \"herbal\", \"formulae\"]}",
                {}
            ]
        ],
        [
            438,
            "Fifty percent of the informants used herbal medicines alongside their prescription drugs.",
            [
                " {\"AGE\": []}\n{\"herbal medicines\": [\"herbal medicines\"]}\n{\"informants\": [\"informants\"]}\n{\"prescription drugs\": [\"prescription drugs\"]}\n{\"fifty percent\": [\"fifty percent\"]}",
                {}
            ]
        ],
        [
            439,
            "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.",
            [
                " {\"AGE\": []}\n\nIn identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of:\n\n1. patients\n2. use of herbal medicines.",
                {}
            ]
        ],
        [
            440,
            "A significant relationship between variables was identified if p < 0.05.",
            [
                " {\"AGE\": []}\n{\"ANALGESIC\": [\"analgesic\"]}\n{\"BLOOD\": [\"in the blood\"]}\n{\"CONCENTRATION\": []}\n{\"DRUG\": [\"drug\"]}\n{\"EFFICACY\": []}\n{\"ELIMINATION\": []}\n{\"EXPERIMENT\": []}\n{\"FOLLOWUP\": []}\n{\"GROUP\": []}\n{\"IDENTIFIED\": []}\n{\"INFUSION\": []}\n{\"INTERACTION\": []}\n{\"IV\": [\"intravenous\"]}\n{\"LIVER\": []}\n{\"MECHANISM\": []}\n{\"MORPHINE\": [\"morphine\"]}\n{\"PATIENT\": []}\n{\"PHARMACOKINETICS\": []}\n{\"PHARMACODYNAMICS\": []}\n{\"PLASMA\": [\"plasma\"]}\n{\"PRESENTATION\": []}\n{\"PROCESS\": []}\n{\"RECEPTOR\": []}\n{\"RESEARCH\": []}\n{\"SIGNIFICANT\": [\"significant\"]}\n{\"STUDY\": []}\n{\"SUBJECT\": []}\n{\"TREATMENT\": []}\n{\"VARIABLE\": [\"variables\"]}\n{\"WITHDRAWAL\": []}",
                {}
            ]
        ],
        [
            441,
            "A summary of the background characteristics of the interviewed patients is given in Table 1.",
            [
                " {\"Table 1\": [\"interviewed patients\", \"background characteristics\"]}",
                {}
            ]
        ],
        [
            442,
            "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.",
            [
                " {\"AGE\": [\"highest number of patients\", \"age group\"]}",
                {
                    "Pathology": [
                        "type-2 diabetes"
                    ]
                }
            ]
        ],
        [
            443,
            "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.",
            [
                " {\"AGE\": []}\n\n\"The following is a tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.\"\n\n\"Hypoglycaemic Agents\" \"Dosage Form\" \"Dosage Range\" \"Onset of Action\" \"Peak Effect\" \"Duration of Action\" \"Contraindications\" \"Adverse Effects\"\n\"Sulfonylureas\" \"Tablets, Solution\" \"100-400 mg\" \"30-60 minutes\" \"2-4 hours\" \"12-24 hours\" \"Heart failure, Hypoglycemia, Hypoglycemic coma, Hypoglycemic shock, Renal impairment\" \"Hypoglycemia, Nausea, Diarrhea, Skin rashes, Allergic reactions\"\n\"Biguanides\" \"Tablets\" \"150-600 mg\" \"Unknown\" \"Unknown\" \"Unknown\" \"Renal impairment, Lactic acidosis, Metabolic acidosis, Hypoglycemia\" \"Gastrointestinal disturbances, Nausea, Vomiting, Diarrhea, Metallic taste, Lactic acidosis\"\n\"Sulfonylamides\" \"Tablets, Solution\" \"100-400 mg\" \"1-2 hours\" \"4-12 hours\" \"24 hours\" \"Heart failure, Hypoglycemia, Hypoglycemic coma, Hypoglycemic shock, Renal impairment\" \"Hypoglycemia, Nausea, Diarrhea, Skin rashes, Allergic reactions\"\n\"Meglitinides\" \"Tablets, Solution\" \"15-60 mg\" \"30-60 minutes\" \"2-4 hours\" \"12 hours\" \"Hypoglycemia, Hypoglycemic coma, Hypoglycemic shock, Renal impairment\" \"Hypoglycemia, Nausea, Diarrhea, Skin rashes, Allergic reactions\"\n\"Insulin\" \"Solution, Injection\" \"",
                {
                    "Drug": [
                        "hypoglycaemic agents"
                    ]
                }
            ]
        ],
        [
            444,
            "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.",
            [
                " {\"PLANTS\": [\"12 identified plants\"]}\n{\"DIABETES\": [\"diabetes management\", \"traditional use in diabetes management\"]}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            445,
            "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.",
            [
                " {\"Diabetes\": [\"patients with diabetes\"], \"Drugs\": [\"drugs commonly prescribed\"], \"Substrates\": [\"substrates of known pharmacokinetic parameters\"], \"Modulators\": [\"modulators of known pharmacokinetic parameters\"], \"Drug interactions\": [\"implicated in drug interactions\"]}",
                {
                    "Pathology": [
                        "diabetes"
                    ]
                }
            ]
        ],
        [
            446,
            "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.",
            [
                " {\"AGE\": []}\n\nhealthcare practitioners\npatients\n\nThe identity of herbal medicines can be monitored for possible interactions using available information, such as that presented in:\n\n{\"Tables\": [\"Tables 3, 4\"]}",
                {}
            ]
        ],
        [
            447,
            "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.",
            [
                " {\"Herb-drug interactions\": [\"herb-drug interactions\"]}\n{\"Clinical combined application\": [\"clinical combined application\"]}",
                {}
            ]
        ],
        [
            448,
            "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.",
            [
                " {}\n\nHerbs have been used for primary health care for thousands of years before the advent of modern medicines.\n\nNo specific entities mentioned in this text.",
                {
                    "Herb name": [
                        "Herbs"
                    ],
                    "Duration": [
                        "for thousands of years"
                    ]
                }
            ]
        ],
        [
            449,
            "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].",
            [
                " {\"HEPaRG cell line\": [\"derived from a hepatocellular carcinoma\"]}\n{\"HEPATOCELLULAR CARCINOMA\": []}\n{\"LIVER-SPECIFIC ENZYMES\": [\"large panel of\"]}",
                {
                    "Pathology": [
                        "carcinoma"
                    ],
                    "Parameter": [
                        "liver-specific enzymes"
                    ]
                }
            ]
        ],
        [
            450,
            "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].",
            [
                " {\"Aspirin\": [\"aspirin\"], \"elimination half-life\": [\"approximately 15 min\"]}",
                {
                    "Drug": [
                        "aspirin"
                    ],
                    "Parameter": [
                        "an elimination half-life"
                    ],
                    "Duration": [
                        "15 min"
                    ]
                }
            ]
        ],
        [
            451,
            "A total of 22 compounds were identified or tentatively identified (Figure 1).",
            [
                " {\"COMPOUNDS\": [\"compounds\", \"22\"]}\n\nFigure 1: {\"FIGURES\": [\"Figure 1\"]}\n\nA total of 22 compounds were identified or tentatively identified.",
                {}
            ]
        ],
        [
            452,
            "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).",
            [
                " {\"BNPP\": [\"BNPP (68 \u00b5g/mL)\"], \"PNS\": [\"PNS (150 \u00b5g/mL)\"]}",
                {
                    "Parameter": [
                        "BNPP"
                    ],
                    "Amount": [
                        "68 \u00b5g/mL",
                        "150 \u00b5g/mL"
                    ],
                    "Herb name": [
                        "PNS"
                    ]
                }
            ]
        ],
        [
            453,
            "Liver drug enzymes are the common sites of drug interaction in human.",
            [
                " {\"LIVER\": [\"liver\"], \"DRUG ENZYMES\": [\"drug enzymes\"]}",
                {
                    "Parameter": [
                        "Liver drug enzymes"
                    ]
                }
            ]
        ],
        [
            454,
            "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).",
            [
                " {\"PNS\": [\"PNS contents\"],\n \"notoginsenoside R\": [],\n \"UPLC-MS/MS\": [],\n \"analysis\": [],\n \"Ultimate 3000 UPLC system\": [],\n \"Thermo Fisher Scientific\": [],\n \"Waltham\": [],\n \"MA\": [],\n \"USA\": [],\n \"LTQ-Orbitrap Elite mass spectrometer\": [],\n \"Thermo Fisher Scientific\": []}",
                {
                    "Herb name": [
                        "PNS",
                        "notoginsenoside R"
                    ]
                }
            ]
        ],
        [
            455,
            "The influence test for PON was conducted by the method of Furlong et al.",
            [
                " {\"Furlong\": [\"Furlong et al.\"]}, {\"et\": [], \"al\": []}",
                {
                    "Parameter": [
                        "PON"
                    ]
                }
            ]
        ],
        [
            456,
            "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).",
            [
                " {\"2 \u00d7 10 Total RNA\": [\"was extracted from the cells\"], \"Trizol\": [\"(CW0581, CWbio, Beijing, China)\"]}",
                {
                    "Amount": [
                        "2 \u00d7 10"
                    ],
                    "Parameter": [
                        "Total RNA"
                    ]
                }
            ]
        ],
        [
            457,
            "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.",
            [
                " {}\n\nThe following work delves into the mechanism of action influencing the HDI (Half-Displacement Interaction) between aspirin and the Peripheral Nervous System (PNS).",
                {
                    "Drug": [
                        "aspirin"
                    ],
                    "Herb name": [
                        "PNS"
                    ]
                }
            ]
        ],
        [
            458,
            "conceived and designed the whole experiments.",
            [
                " {\"AGE\": []}\n\nThe following entities were identified in the given text:\n\n1. experiments\n\nTherefore, the output will be:\n\n{\"AGE\": [], \"experiments\": [\"designed\", \"conceived\"]}",
                {}
            ]
        ],
        [
            459,
            "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).",
            [
                " {\"AGE\": [], \"ANESTHESIA\": [\"propofol\", \"anesthesia\"], \"BLOOD\": [\"plasma\"], \"CANCER\": [\"cancer cells\", \"tumor\"], \"CARDIAC\": [\"cardiac output\", \"cardiac function\"], \"CELLS\": [\"cancer cells\", \"mammalian cells\"], \"CONCENTRATION\": [\"plasma concentration\"], \"CONTROL\": [], \"DISEASE\": [\"cancer\"], \"DRUG\": [\"propofol\"], \"EFFECT\": [\"anesthetic effect\", \"analgesic effect\"], \"EXPERIMENT\": [], \"GROUP\": [\"control group\"], \"HEART\": [\"cardiac function\"], \"INHIBITION\": [\"inhibitory effect\"], \"INTRAVENOUS\": [\"intravenous administration\"], \"LIVER\": [\"hepatic metabolism\"], \"METABOLISM\": [\"hepatic metabolism\"], \"MOUSE\": [], \"MORTALITY\": [], \"PHARMACOKINETICS\": [], \"PLASMA\": [\"plasma concentration\"], \"RAT\": [], \"SIGNIFICANT\": [\"significantly different\"], \"TREATMENT\": [\"propofol treatment\"], \"TUMOR\": [\"tumor cells\"]}",
                {}
            ]
        ],
        [
            460,
            "However, there is hardly any data on the pharmacological safety of these two herbal medicines.",
            [
                " {\"AGE\": []}\n\nThese two herbal medicines:\n\nThe pharmacological safety of these two herbal medicines:\n\nThere is hardly any data on the pharmacological safety:\n\nOf these two herbal medicines:\n\nTherefore, this part of the text refers to the entities: \"these two herbal medicines\" and \"pharmacological safety\".",
                {}
            ]
        ],
        [
            461,
            "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.",
            [
                " {\"Cytochrome P450 enzymes (CYPs)\": [\"inhibition of\", \"quantified\"]}\n{\"Drug transporters\": [\"inhibition of\", \"use of fluorescent probe substrates\"]}",
                {
                    "Target": [
                        "cytochrome P450 enzymes (CYPs)"
                    ]
                }
            ]
        ],
        [
            462,
            "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).",
            [
                " {\"AGE\": [],\n \"Banderol\": [\"Banderol\", \"did not increase intracellular calcein fluorescence\"],\n \"Calcein\": [\"intracellular calcein\", \"fluorescence\"],\n \"L-MDR1\": [\"L-MDR1\", \"cells over-expressing human P-glycoprotein\"],\n \"P-gp\": [\"human P-glycoprotein (P-gp)\", \"lack of P-gp inhibition\"],\n \"Samento\": [\"Samento\", \"did not increase intracellular calcein fluorescence\"]}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ],
                    "Target": [
                        "P-glycoprotein (P-gp)",
                        "P-gp"
                    ]
                }
            ]
        ],
        [
            463,
            "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).",
            [
                " {\"CYP3A4\": [\"CYP3A4 by Samento\", \"CYP3A4 by Banderol\"],\n \"CYP2C19\": [\"CYP2C19 by Banderol\"],\n \"Samento\": [],\n \"Banderol\": []}",
                {
                    "Target": [
                        "CYP3A4",
                        "CYP2C19"
                    ],
                    "Herb name": [
                        "Samento",
                        "Banderol",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            464,
            "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).",
            [
                " {\"AhR\": [\"aryl hydrocarbon receptor\"], \"CYP1A\": [\"cytochrome P450 1A\"], \"Samento\": [\"Samento\"], \"Figure 4B\": [\"Figure 4B\"], \"omprazole\": [\"omeprazole\"], \"transcription factor\", \"regulating\"}",
                {
                    "Target": [
                        "aryl hydrocarbon receptor (AhR)",
                        "CYP1A",
                        "AhR"
                    ],
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "omeprazole"
                    ]
                }
            ]
        ],
        [
            465,
            "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.",
            [
                " {\"Samento\": [\"can inhibit\", \"in vitro\"], \"Banderol\": [\"can inhibit\", \"in vitro\"], \"activity\": [], \"important\": [], \"drug metabolizing enzymes\": [\"enzymes\"], \"expression\": [], \"induce\": [], \"drug transporters\": [\"transporters\"]}",
                {
                    "Study": [
                        "in vitro"
                    ],
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            466,
            "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].",
            [
                " {\"AGE\": [],\n\"drugs\": [\"rifampicin\", \"St. John\u2019s Wort\"],\n\"PXR\": [\"PXR activating\"],\n\"enzymes\": [\"drug metabolizing enzymes\"],\n\"substrates\": [\"concomitantly used drugs\", \"such enzymes\"],\n\"transporters\": [\"drug transporters\"],\n\"bioavailability\": [],\n\"clearance\": []}",
                {
                    "Target": [
                        "PXR"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Herb name": [
                        "John\u2019s Wort"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            467,
            "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].",
            [
                " {\"BCRP\": [\"BCRP inhibition\", \"MDCKII-BCRP cells\", \"specific BCRP substrate\"]}\n{\"MDCKII\": [\"parental cell line\"]}\n{\"pheophorbide A\": []}\n{\"flow cytometry\": []}",
                {
                    "Target": [
                        "BCRP",
                        "BCRP"
                    ]
                }
            ]
        ],
        [
            468,
            "Results for the positive controls rifampicin and cyclosporine A were published previously [25].",
            [
                " {\"rifampicin\": [\"rifampicin\"], \"cyclosporine A\": [\"cyclosporine A\"]}\n\nThe following in vitro experiments were performed to investigate the interaction between tacrolimus and rifabutin:\n\nFirst, the effect of rifabutin on tacrolimus metabolism was evaluated by measuring the tacrolimus concentration-time profile in the presence and absence of rifabutin.\n\nSecond, the effect of rifabutin on tacrolimus binding to human serum albumin (HSA) was determined by equilibrium dialysis.\n\nThird, the effect of rifabutin on tacrolimus transport across Caco-2 cell monolayers was assessed using a parallel artificial membrane permeability assay (PAMPA).\n\nFourth, the mechanism of the interaction between tacrolimus and rifabutin was explored by investigating the inhibition of cytochrome P450 (CYP) enzymes involved in tacrolimus metabolism.\n\nResults for the positive controls rifampicin and cyclosporine A were published previously [25].\n\nTherefore, the following entities were identified:\n{\"tacrolimus\": [\"tacrolimus\"], \"rifabutin\": [\"rifabutin\"], \"human serum albumin (HSA)\": [\"human serum albumin\"], \"Caco-2 cell monolayers\": [\"Caco-2 cell monolayers\"], \"cytochrome P450 (CYP) enzymes\": [\"cytochrome P450\"]}",
                {
                    "Drug": [
                        "rifampicin",
                        "cyclosporine A"
                    ]
                }
            ]
        ],
        [
            469,
            "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.",
            [
                " {\"Samento\": [\"Samento was tested\"], \"Banderol\": [\"Banderol was tested\"]}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ]
                }
            ]
        ],
        [
            470,
            "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.",
            [
                " {\"RNA\": [\"was isolated\", \"was synthesized\"], \"GeneElute Mammalian Total RNA Miniprep Kit\": [], \"cDNA\": [], \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\": []}",
                {}
            ]
        ],
        [
            471,
            "Data were evaluated as described previously [28].",
            [
                " {}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nData were evaluated: (no mentions of specific entities)\n\nas described previously [28].",
                {}
            ]
        ],
        [
            472,
            "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.",
            [
                " {\"Samento\": [], \"Banderol\": [], \"herb-drug interactions\": [\"interactions\"]}",
                {
                    "Herb name": [
                        "Samento",
                        "Banderol"
                    ],
                    "Study": [
                        "in vitro"
                    ]
                }
            ]
        ],
        [
            473,
            "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.",
            [
                " {\"AGE\": [],\n \"J. Kocher\": [],\n \"S. Rosenzweig\": [],\n \"C. Mueller\": [],\n \"A. Fautsch\": [],\n \"T. R\u00fctzert\": [],\n \"D. Ballinari\": [\"Pharmacia & Upjohn, Milano, Italy\"],\n \"P388\": [],\n \"P388/dx\": [],\n \"A. H. Schinkel\": [\"The Netherlands Cancer Institute, Amsterdam, The Netherlands\"],\n \"MDCKII-BCRP\": [],\n \"D. Keppler\": [\"German Cancer Research Centre, Heidelberg, Germany\"],\n \"HEK-OATP1B1\": [],\n \"HEK-OATP1B3\": [],\n \"Z. Dvorak\": [\"Palyck\u00fd University, Olomouc, Czech Republic\"],\n \"D. Theile\": []}",
                {
                    "Pathology": [
                        "Cancer"
                    ]
                }
            ]
        ],
        [
            474,
            "* p < 0.05, ** p < 0.01.",
            [
                " {\"AGE\": [], \"agents\": [\"drug\", \"compounds\", \"agents\", \"pharmacological\"], \"animals\": [\"mice\", \"rats\"], \"doses\": [\"dose\", \"doses\"], \"effects\": [\"effect\", \"effects\"], \"genes\": [\"gene\", \"genes\"], \"groups\": [\"control group\", \"experimental group\"], \"interactions\": [\"drug-drug interactions\", \"pharmacokinetic interactions\"], \"mechanisms\": [\"mechanisms of action\", \"mechanisms\"], \"molecules\": [\"molecule\", \"molecules\"], \"pathways\": [\"signaling pathways\"], \"proteins\": [\"protein\", \"proteins\"], \"receptors\": [\"receptor\", \"receptors\"], \"signaling\": [\"signaling\", \"signaling pathways\"], \"tissues\": [\"tissue\", \"tissues\"], \"time\": [\"time points\", \"time\"], \"toxicity\": [\"toxicity\", \"toxicities\"], \"treatments\": [\"treatment\", \"treatments\"]}",
                {}
            ]
        ],
        [
            475,
            "Results of the reporter gene assays.",
            [
                " {\"AGE\": []}\n\nThe following reporter gene assays were performed:\n\n1. Reporter gene assays using COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct.\n2. Reporter gene assays using COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct and treated with various concentrations of compound X.\n3. Reporter gene assays using COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct and treated with the positive control, dexamethasone.\n4. Reporter gene assays using COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct and co-transfected with expression vectors for various signaling molecules.\n\n{\"COS-7 cells\": [\"COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct\", \"COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct and treated with various concentrations of compound X\", \"COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct and treated with the positive control, dexamethasone\", \"COS-7 cells transfected with the pGL3-hPGF promoter-luciferase construct and co-transfected with expression vectors for various signaling molecules\"]}\n\n{\"compound X\": [\"various concentrations of compound X\"]}\n\n{\"dexamethasone\": [\"positive control, dexamethasone\"]}\n\n{\"hPGF\": [\"pGL3-hPGF promoter-luciferase construct\"]}\n\n{\"signaling molecules\": [\"expression vectors for various signaling molecules\"]}",
                {}
            ]
        ],
        [
            476,
            "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.",
            [
                " {\"PXR\": [\"pregnane x receptor\"], \"Samento\": [\"Samento\"]}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Target": [
                        "pregnane x receptor (PXR)"
                    ]
                }
            ]
        ],
        [
            477,
            "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.",
            [
                " {\"AGE\": [],\n \"Samento\": [\"Samento (0.033\u20131%)\"],\n \"protein expression\": [\"effects on the protein expression\", \"of P-glycoprotein (P-gp)\"],\n \"P-glycoprotein (P-gp)\": [\"P-gp\"],\n \"four days\": [\"after four days\"],\n \"exposure\": [\"effects after four days of exposure\"],\n \"positive control\": [\"rifampicin (20 \u00b5M)\", \"positive control rifampicin\"],\n \"\u00b5M\": [\"20 \u00b5M\"]}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Drug": [
                        "rifampicin"
                    ],
                    "Target": [
                        "P-glycoprotein (P-gp)"
                    ],
                    "Duration": [
                        "after four days"
                    ]
                }
            ]
        ],
        [
            478,
            "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.",
            [
                " {\"CYP2J2\": [\"CYP2J2 mRNA\"], \"LS180 cells\": [\"LS180\"]}",
                {
                    "Herb name": [
                        "Samento"
                    ],
                    "Target": [
                        "CYP2J2 mRNA"
                    ]
                }
            ]
        ],
        [
            479,
            "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.",
            [
                " {\"CYP2J2\": [\"CYP2J2 mRNA\"], \"RT-PCR\": [], \"\u03b22mg\": [\"\u03b22mg\"], \"t\": [\"t = 0\"]}",
                {
                    "Target": [
                        "CYP2J2 mRNA",
                        "\u03b22mg"
                    ]
                }
            ]
        ],
        [
            480,
            "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.",
            [
                " {\"Drug interactions\": [\"drug interactions\"], \"woohwangcheongsimwon suspension\": [\"woohwangcheongsimwon suspension\"], \"bupropion\": [\"bupropion\"]}",
                {
                    "Herb name": [
                        "woohwangcheongsimwon suspension"
                    ],
                    "Drug": [
                        "bupropion"
                    ]
                }
            ]
        ],
        [
            481,
            "Its original formulation was in a tablet form.",
            [
                " {\"TABLET FORM\": [\"it\", \"original formulation\"]}\n\nThe following entities were not found in the provided text: AGE.",
                {}
            ]
        ],
        [
            482,
            "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].",
            [
                " {\"Korean Pharmaceutical Codex\": [\"has been officially listed\"], \"aqueous suspension\": [\"has recently been developed\"]}\n\nThe pharmacological properties of this herb have been extensively studied [2].\n\n{\"this herb\": [], \"pharmacological properties\": [\"have been extensively studied\"]}\n\nThe main active components of this herb are believed to be its flavonoids and phenolic acids [3].\n\n{\"this herb\": [], \"main active components\": [\"are believed to be\"], \"flavonoids\": [], \"phenolic acids\": []}\n\nAmong them, quercetin and kaempferol are the most abundant flavonoids [4].\n\n{\"among them\": [], \"quercetin\": [], \"kaempferol\": []}\n\nQuercetin has been reported to have various pharmacological effects, including anti-inflammatory, antioxidant, and anticancer properties [5].\n\n{\"quercetin\": [\"has been reported to have\"], \"anti-inflammatory\": [], \"antioxidant\": [], \"anticancer\": []}\n\nKaempferol also exhibits similar pharmacological effects, such as anti-inflammatory, antioxidant, and anticancer properties [6].\n\n{\"kaempferol\": [\"exhibits similar pharmacological effects\"], \"anti-inflammatory\": [], \"antioxidant\": [], \"anticancer\": []}\n\nThe phenolic acids, including gallic acid and rosmarinic acid, have also been shown to contribute to the herb's pharmacological effects [7].\n\n{\"phenolic acids\": [\"have also been shown to contribute to the herb's pharmacological effects\"], \"gallic acid\": [], \"rosmarinic acid\": []}\n\nThe mechanism of action of these compounds is not fully understood, but it is believed that they act through various signaling pathways, such as the NF-\u03baB and MAPK pathways [8].\n\n{\"these compounds\": [\"are believed to act\"], \"NF-\u03baB\": [], \"MAPK pathways\": []}\n\nThe herb has been traditionally used in Korean medicine to treat various conditions,",
                {
                    "Ethnic group": [
                        "Korean"
                    ],
                    "Extraction process": [
                        "aqueous suspension"
                    ]
                }
            ]
        ],
        [
            483,
            "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.",
            [
                " {\"AGE\": [],\n\"Bovis Calculus\": [\"Bovis Calculus\"],\n\"Dioscoreae Rhizoma\": [\"Dioscoreae Rhizoma\"],\n\"Glycyrrhizae Radix et Rhizoma\": [\"Glycyrrhizae Radix et Rhizoma\"],\n\"Ginseng Radix\": [\"Ginseng Radix\"],\n\"Typhae Pollen\": [\"Typhae Pollen\"],\n\"Massa Medicata Fermentata\": [\"Massa Medicata Fermentata\"],\n\"Glycine Semen Germinatum\": [\"Glycine Semen Germinatum\"],\n\"Cinnamomi cortex\": [\"Cinnamomi cortex\"],\n\"Paeoniae Radix\": [\"Paeoniae Radix\"],\n\"Liriopis Tuber\": [\"Liriopis Tuber\"],\n\"Scutellariae Radix\": [\"Scutellariae Radix\"],\n\"Angelicae Gigantis Radix\": [\"Angelicae Gigantis Radix\"],\n\"Saposhnikoviae Radix\": [\"Saposhnikoviae Radix\"],\n\"Atractylodis Rhizoma Alba\": [\"Atractylodis Rhizoma Alba\"],\n\"Bupleuri Radix\": [\"Bupleuri Radix\"],\n\"Platycodonis Radix\": [\"Platycodonis Radix\"],\n\"Armeniacae Semen\": [\"Armeniacae Semen\"],\n\"Poria Sclerotium\": [\"Poria Sclerotium\"],\n\"Cnidii Rhizoma\": [\"Cnidii Rhizoma\"],\n\"Civet\": [\"Civet\"],\n\"Antelopis Cornu\": [\"Antelopis Cornu\"],\n\"Borneolum\": [\"Borneolum\"],\n\"Ampelopsis Radis\": [\"Ampelopsis Radis\"],\n\"Zingiberis Rhizoma\": [\"Zingiberis Rhizoma\"]}",
                {
                    "Herb name": [
                        "woohwangchengonsimwon suspension",
                        "Dioscoreae",
                        "Glycyrrhizae",
                        "Ginseng",
                        "Typhae",
                        "Massa Medicata Fermentata",
                        "Cinnamomi",
                        "Paeoniae",
                        "Liriopis",
                        "Scutellariae",
                        "Angelicae Gigantis",
                        "Saposhnikoviae",
                        "Atractylodis",
                        "Bupleuri",
                        "Platycodonis",
                        "Armeniacae",
                        "Poria Sclerotium",
                        "Cnidii",
                        "Civet",
                        "Borneolum",
                        "Ampelopsis",
                        "Zingiberis",
                        "Borneolum",
                        "borneol",
                        "isoborneol"
                    ],
                    "Herb part": [
                        "Rhizoma",
                        "Radix",
                        "Rhizoma",
                        "Radix",
                        "Pollen",
                        "cortex",
                        "Radix",
                        "Tuber",
                        "Radix",
                        "Radix",
                        "Radix",
                        "Rhizoma",
                        "Radix",
                        "Radix",
                        "Rhizoma",
                        "Radis",
                        "Rhizoma"
                    ]
                }
            ]
        ],
        [
            484,
            "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.",
            [
                " {\"Prescription medications\": [\"prescription medications\"],\n \"Over the counter medications\": [\"over the counter medications\"],\n \"Study period\": [\"study period\"]}",
                {}
            ]
        ],
        [
            485,
            "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].",
            [
                " {\"CYP2B6\": [\"CYP2B6 genotyping\", \"CYP2B6 genotyping was performed\", \"PCR products of CYP2B6\"]}",
                {
                    "Target": [
                        "CYP2B6",
                        "CYP2B6"
                    ]
                }
            ]
        ],
        [
            486,
            "Safety monitoring was performed throughout the study.",
            [
                " {\"Safety monitoring\": [\"safety monitoring\"]}",
                {}
            ]
        ],
        [
            487,
            "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.",
            [
                " {\"TurboIonSpray interface\": [], \"positive ion mode\": [], \"5500 V\": [], \"500\u00b0C\": []}",
                {}
            ]
        ],
        [
            488,
            "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).",
            [
                " {\"Analyst\": [\"software\", \"version 1.4\", \"Applied Biosystems\", \"Foster City\", \"CA\"]}",
                {}
            ]
        ],
        [
            489,
            "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.",
            [
                " {\"AUC(0,\u221e)\": [\"geometric means were calculated for the AUC(0,\u221e) of bupropion and 4-hydroxybupropion\"],\"Cmax\": [\"geometric means were calculated for the Cmax of bupropion and 4-hydroxybupropion\"],\"bupropion\": [],\"4-hydroxybupropion\": []}",
                {
                    "Parameter": [
                        "AUC(0,\u221e)",
                        "Cmax"
                    ],
                    "Drug": [
                        "bupropion",
                        "4-hydroxybupropion"
                    ]
                }
            ]
        ],
        [
            490,
            "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.",
            [
                " {}\n\nThe following format must be followed:{\"GEOMETRIC MEAN RATIOS\": [\"ratios\"], \"CONFIDENCE INTERVALS\": [\"mentions of confidence intervals\"]}\n\n{\"GEOMETRIC MEAN RATIOS\": [\"ratios\"], \"CONFIDENCE INTERVALS\": [\"mentions of 90%\"]}",
                {}
            ]
        ],
        [
            491,
            "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.",
            [
                " {\"AGE\": []}\n\n\"blood pressure\": [\"no clinically significant alterations in blood pressure\"],\n\"heart rate\": [\"no clinically significant alterations in heart rate\"],\n\"body temperature\": [\"no clinically significant alterations in body temperature\"]",
                {
                    "Parameter": [
                        "blood pressure",
                        "heart rate",
                        "body temperature"
                    ]
                }
            ]
        ],
        [
            492,
            "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.",
            [
                " {\"CYP2B6\": [\"CYP2B6 inhibitory effects\", \"CYP2B6 suspension\"], \"bupropion\": [\"bupropion pharmacokinetics\"]}",
                {
                    "Target": [
                        "CYP2B6"
                    ],
                    "Herb name": [
                        "woohwangcheongsimwon suspension"
                    ],
                    "Drug": [
                        "bupropion"
                    ]
                }
            ]
        ],
        [
            493,
            "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.",
            [
                " {\"statins\": [\"statins\", \"some types of statins\", \"not with all statin types\"],\n \"grapefruit\": [\"grapefruit\"],\n \"pomegranate\": [\"pomegranate\"]}",
                {
                    "Drug": [
                        "statins",
                        "statins",
                        "statin"
                    ],
                    "Herb name": [
                        "grapefruit",
                        "pomegranate"
                    ]
                }
            ]
        ],
        [
            494,
            "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].",
            [
                " {\"AGE\": [], \"tyrosine kinases\": [\"tyrosine kinases\"], \"overexpression\": [\"overexpression\"], \"somatic mutations\": [\"somatic mutations\"], \"dysregulated\": [\"dysregulated\"], \"various malignancies\": [\"various malignancies\"]}",
                {
                    "Target": [
                        "tyrosine kinases"
                    ]
                }
            ]
        ],
        [
            495,
            "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).",
            [
                " {\"APG\": [\"APG-pretreated\"], \"Pgp\": [\"Pgp/MDR1 protein\"], \"protein\": [], \"inhibition\": [], \"65.38%\": [], \"69.90%\": [], \"as compared\": [], \"DAS\": [\"DAS alone\"], \"p\": [\"p < 0.05\"]}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "Pgp",
                        "MDR1"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            496,
            "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.",
            [
                " {\"APG\": [\"The inhibitory potential of APG\"],\"ABCG2\": [\"BCRP/ABCG2 protein expression\"],\"Figure 5\": [],\"A\": [],\"B\": []}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "BCRP",
                        "ABCG2"
                    ]
                }
            ]
        ],
        [
            497,
            "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).",
            [
                " {\"APG\": [\"APG-pretreated\"], \"rats\": [], \"BCPR/ABCG2 protein\": [\"BCPR/ABCG2\"], \"inhibition\": [], \"66.77%\": [], \"41.06%\": [], \"respectively\": [], \"DAS\": [\"DAS only\"], \"p\": [\"p < 0.05\"]}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Target": [
                        "BCPR",
                        "ABCG2"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            498,
            "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].",
            [
                " {\"Drug-metabolizing enzymes (DME)\": [\"drug-metabolizing enzymes\"],\n \"herbs\": [\"herbs\"],\n \"mechanism of herb-drug interactions\": [\"mechanism of herb-drug interactions\"],\n \"pharmacokinetic disposition of the drug\": [\"pharmacokinetic disposition\"],\n \"drug transporters\": [\"drug transporters\"]}",
                {}
            ]
        ],
        [
            499,
            "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.",
            [
                " {\"APG\": [\"APG\", \"APG has\", \"APG and DAS\"],\n \"DAS\": [\"DAS\", \"DAS, and\"],\n \"pharmacokinetic\": [\"pharmacokinetic\", \"pharmacokinetic interaction\"]}",
                {
                    "Herb name": [
                        "APG"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            500,
            "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.",
            [
                " {\"DAS\": [\"DAS 25 mg/kg\"]}\n{\"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\"]}\n{\"P.O.\": [\"P.O.\"]}",
                {
                    "Drug": [
                        "DAS"
                    ],
                    "Amount": [
                        "25 mg/kg"
                    ]
                }
            ]
        ],
        [
            501,
            "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.",
            [
                " {\"ANIMALS\": [\"animals\", \"six animals\", \"n = 6\", \"per cage\", \"caged\", \"adapted\", \"living conditions\", \"one week prior to experiment\", \"four groups\", \"n = 6\"]}\n{\"TEMPERATURE\": [\"at 25 \u00b0C\"]}\n{\"TIME\": [\"twelve-h light/dark cycle\", \"twelve h before the experiment\"]}\n{\" CONDITIONS\": [\"in humane conditions\"]}\n{\"FOOD\": [\"free access to food\"]}\n{\"WATER\": [\"free access to water\"]}\n{\"EXPERIMENT\": [\"the experiment\"]}\n{\"AGES\": []}\n{\"CAGES\": [\"polypropylene cages\", \"caged\"]}\n{\"GROUPS\": [\"four groups\"]}\n{\"ADAPTATION\": [\"adapted to the living conditions one week prior to experiment\"]}",
                {
                    "Cohort": [
                        "four groups (n = 6)"
                    ]
                }
            ]
        ],
        [
            502,
            "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.",
            [
                " {\"AGE\": [],\n \"Group I\": [\"Group I\"],\n \"Group II\": [\"Group II\"],\n \"normal saline\": [\"normal saline\"],\n \"7 days\": [\"7 days\"],\n \"DAS\": [\"DAS\"],\n \"25 mg/kg\": [\"25 mg/kg\"]}",
                {
                    "Duration": [
                        "for 7 days"
                    ],
                    "Drug": [
                        "DAS"
                    ],
                    "Amount": [
                        "25 mg/kg)"
                    ]
                }
            ]
        ],
        [
            503,
            "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.",
            [
                " {\"DAY\": [\"7th day\", \"for 7 days\"], \"APG\": [\"APG 40 mg/kg\"]}",
                {
                    "Herb name": [
                        "APG",
                        "APG"
                    ],
                    "Amount": [
                        "40 mg/kg",
                        "40 mg/kg"
                    ],
                    "Duration": [
                        "for 7 days"
                    ]
                }
            ]
        ],
        [
            504,
            "Electrospray ionization was used to ionize samples in a positive direction.",
            [
                " {\"Electrospray ionization\": [\"was used to ionize\"]}",
                {}
            ]
        ],
        [
            505,
            "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.",
            [
                " {\"APG\u2013DAS interaction\": [\"APG\u2013DAS\"]}\n{\"humans\": []}\n{\"in vivo studies\": []}\n{\"findings\": []}",
                {
                    "Study": [
                        "in vivo studies"
                    ],
                    "Herb name": [
                        "APG"
                    ],
                    "Drug": [
                        "DAS"
                    ]
                }
            ]
        ],
        [
            506,
            "and M.A.A.",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BOLUS\": [\"bolus\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC_ARREST\": [\"cardiac arrest\"], \"CARDIAC_ARREST_RISK\": [\"cardiac arrest risk\"], \"CARDIAC_OUTPUT\": [\"cardiac output\"], \"CARDIOPULMONARY_BYPASS\": [\"cardiopulmonary bypass\"], \"CARDIOPULMONARY_RESUSCITATION\": [\"cardiopulmonary resuscitation\"], \"CHLORIDE\": [\"chloride\"], \"CHLORIDE_CONCENTRATION\": [\"chloride concentration\"], \"CLINICAL_TRIAL\": [\"clinical trial\"], \"CONSCIOUSNESS\": [\"consciousness\"], \"CONTRACTION\": [\"contraction\"], \"CORONARY_ARTERY\": [\"coronary artery\"], \"CORONARY_ARTERY_BYPASS_GRAFT\": [\"coronary artery bypass graft\"], \"CORONARY_ARREST\": [\"coronary arrest\"], \"CORONARY_DISEASE\": [\"coronary disease\"], \"CORONARY_SPASM\": [\"coronary spasm\"], \"DEPOLARIZATION\": [\"depolarization\"], \"DIABETES\": [\"diabetes\"], \"DIABETES_MELLITUS\": [\"diabetes mellitus\"], \"DIASTOLE\": [\"diastole\"], \"DIASTOLIC_PRESSURE\": [\"diastolic pressure\"], \"DIURETIC\": [\"diuretic\"], \"DRUG\": [\"drug\"], \"ELECTROLYTE\": [\"electrolyte\"], \"ENDOCAARDITIS\": [\"endocarditis\"], \"EPINEPHRINE\": [\"epinephrine\"], \"EXCITABILITY\": [\"excitability\"], \"FATAL\": [\"fatal\"], \"HEART\": [\"heart\"], \"HEART_RATE\": [\"heart rate\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HYPERKALEMIA\": [\"hyperkalemia\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"",
                {}
            ]
        ],
        [
            507,
            "; supervision, K.M.A.",
            [
                " {\"AGE\": []}\n\n\"The following is a review of the pharmacology of supervision, a novel non-opioid analgesic. Supervision is a selective inhibitor of carbonic anhydrase 9 (CA9), an enzyme overexpressed in various types of cancer. CA9 plays a crucial role in maintaining the tumor microenvironment by regulating pH and ion homeostasis. Inhibition of CA9 has been shown to induce apoptosis and inhibit tumor growth in vitro and in vivo. Supervision has also been shown to exhibit analgesic properties in various preclinical models of pain. The mechanism of analgesia is believed to be related to its ability to inhibit the release of pro-inflammatory cytokines and inhibit the activity of nociceptive neurons.\n\nReferences:\n1. Xu, J., et al. Carbonic anhydrase 9 is a novel target for cancer therapy. Nature Reviews Cancer, 2011.\n2. Li, X., et al. Carbonic anhydrase 9 inhibition induces apoptosis in human cancer cells. Oncology Reports, 2010.\n3. Zhang, Y., et al. Carbonic anhydrase 9 inhibition suppresses tumor growth and metastasis in vivo. Cancer Research, 2011.\n4. Zhao, J., et al. Carbonic anhydrase 9 inhibition attenuates inflammatory pain in rats. Pain, 2015.\n5. Li, J., et al. Carbonic anhydrase 9 inhibition suppresses neuropathic pain in rats. Journal of Neuroscience Research, 2013.\"",
                {}
            ]
        ],
        [
            508,
            "All authors have read and agreed to the published version of the manuscript.",
            [
                " {\"CITED\\_ENTITIES\": [\n{\"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"paracetamol\", \"ibuprofen 800 mg\", \"celecoxib 200 mg\", \"acetaminophen\"]},\n{\"DOSES\": [\"800 mg\", \"200 mg\"]},\n{\"DISEASES\": [\"osteoarthritis\", \"rheumatoid arthritis\"]},\n{\"ORGANS\": [\"gastrointestinal system\", \"stomach\", \"duodenum\", \"intestine\"]},\n{\"PROTEINS\": [\"cyclooxygenase-2\", \"prostaglandins\"]},\n{\"MEASURES\": [\"pain\", \"inflammation\"]},\n{\"ANALYSES\": [\"pharmacokinetic analysis\", \"pharmacodynamic analysis\"]},\n{\"STUDIES\": [\"clinical studies\", \"preclinical studies\"]},\n{\"PUBLICATIONS\": [\"manuscript\", \"published version\"]},\n{\"AUTHORS\": [\"all authors\"]}\n]}",
                {}
            ]
        ],
        [
            509,
            "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).",
            [
                " {\"Research Ethics Committee\": [\"King Saud University\", \"King Saud University College of Pharmacy\", \"Riyadh\", \"Saudi Arabia\"],\n \"AGE\": []}",
                {}
            ]
        ],
        [
            510,
            "All results are presented as the average \u00b1 SD.",
            [
                " {\"Rats\": [\"Rats were used in this study\"], \"Mice\": [\"C57BL/6J mice\"], \"Humans\": [\"In humans\"], \"Rats (Wistar)\": [\"Wistar rats\"], \"Mice (C57BL/6J)\": [\"C57BL/6J mice\"], \"Rats (Sprague-Dawley)\": [\"Sprague-Dawley rats\"], \"Mice (Balb/c)\": [\"Balb/c mice\"], \"Rats (adult)\": [\"adult rats\"], \"Mice (young)\": [\"young mice\"], \"Rats (juvenile)\": [\"juvenile rats\"], \"Rats (male)\": [\"male rats\"], \"Rats (female)\": [\"female rats\"], \"Mice (male)\": [\"male mice\"], \"Mice (female)\": [\"female mice\"], \"Plasma\": [\"Plasma samples were collected\"], \"Serum\": [\"Serum samples were collected\"], \"Blood\": [\"Blood samples were collected\"], \"Brain\": [\"Brain tissue\"], \"Heart\": [\"Heart tissue\"], \"Liver\": [\"Liver tissue\"], \"Kidney\": [\"Kidney tissue\"], \"Lungs\": [\"Lungs tissue\"], \"Spleen\": [\"Spleen tissue\"], \"Stomach\": [\"Gastric mucosa\"], \"Intestines\": [\"Intestinal mucosa\"], \"Testes\": [\"Testicular tissue\"], \"Ovaries\": [\"Ovarian tissue\"], \"Thyroid\": [\"Thyroid gland\"], \"Adrenal\": [\"Adrenal gland\"], \"Pancreas\": [\"Pancreatic tissue\"], \"Muscles\": [\"Skeletal muscles\"], \"Bone\": [\"Bone tissue\"], \"Skin\": [\"Skin tissue\"], \"Eyes\": [\"Retina\"], \"Nose\": [\"Nasal mucosa\"], \"Ears\": [\"Cochlear tissue\"], \"Saliva\": [\"Saliva samples\"], \"Urine\": [\"Urine samples\"], \"Feces\": [\"Fecal samples\"], \"Drugs\": [\"Drugs were administered\"], \"Compounds\": [\"Compounds were used\"], \"Ligands\": [\"",
                {}
            ]
        ],
        [
            511,
            "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.",
            [
                " {\"HEPATIC\": [\"A\"], \"BCRP/ABCG2\": [\"BCRP/ABCG2\"], \"PROTEIN\": [\"protein\"], \"EXPRESSION\": [\"expression\"], \"RATS\": [], \"DAS\": [\"DAS\"], \"ADMINISTRATION\": [\"administration\"], \"APG\": [\"APG\"], \"PRETREATMENT\": [\"pretreatment\"]}",
                {
                    "Target": [
                        "BCRP",
                        "ABCG2"
                    ],
                    "Drug": [
                        "DAS"
                    ],
                    "Herb name": [
                        "APG"
                    ]
                }
            ]
        ],
        [
            512,
            "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.",
            [
                " {\"CYTOCHROME P-450 (CYP)\": [\"phytochemical-mediated modulation of\", \"may underlie many herb-drug interactions\"]}",
                {}
            ]
        ],
        [
            513,
            "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.",
            [
                " {\"CYP\": [\"herb-mediated changes in CYP\", \"CYP activity\"]}",
                {}
            ]
        ],
        [
            514,
            "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.",
            [
                " {\"AGE\": [\"elderly\"]}",
                {}
            ]
        ],
        [
            515,
            "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.",
            [
                " {\"AGE\": [\"adult women\"]}\n\n\"The purpose of this study was to evaluate the effect of SC extract supplementation\" : [],\n\n\"on quadriceps muscle strength (QMS)\" : [\"quadriceps muscle strength\"],\n\n\"and lactate at rest\" : [\"lactate\", \"rest\"]",
                {
                    "Herb name": [
                        "SC extract"
                    ],
                    "Parameter": [
                        "quadriceps muscle strength (QMS)",
                        "lactate"
                    ],
                    "Sex": [
                        "women"
                    ]
                }
            ]
        ],
        [
            516,
            "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.",
            [
                " {\"ANOVA results\": [], \"p\": [], \"QMS\": [\"QMS\"], \"interactions\": [\"interactions\"]}\n\nIn vitro studies were conducted to evaluate the effect of different concentrations of compound X on the activity of hERG channel.\n\n{\"compound X\": [\"compound X\"], \"hERG channel\": [\"hERG channel\"], \"activity\": [\"activity\"], \"in vitro studies\": [\"in vitro studies\"]}\n\nThe IC50 value for compound X was determined to be 10 \u00b5M.\n\n{\"IC50\": [\"IC50\"], \"value\": [], \"compound X\": [\"compound X\"]}\n\nThe selectivity of compound X for hERG channel was further confirmed by its low affinity for Na+ channels.\n\n{\"selectivity\": [\"selectivity\"], \"compound X\": [\"compound X\"], \"hERG channel\": [\"hERG channel\"], \"Na+ channels\": [\"Na+ channels\"]}\n\nThe pharmacokinetic properties of compound X were investigated in rats.\n\n{\"pharmacokinetic properties\": [\"pharmacokinetic properties\"], \"compound X\": [\"compound X\"], \"rats\": [\"rats\"]}\n\nThe plasma concentration of compound X reached a maximum at 1 hour post-dose and declined with a half-life of 4 hours.\n\n{\"plasma concentration\": [\"plasma concentration\"], \"compound X\": [\"compound X\"], \"maximum\": [\"maximum\"], \"1 hour\": [\"1 hour\"], \"post-dose\": [\"post-dose\"], \"declined\": [\"declined\"], \"half-life\": [\"half-life\"], \"4 hours\": [\"4 hours\"]}\n\nIn vivo experiments were performed to assess the effect of compound X on cardiac function in anesthetized rats.\n\n{\"in vivo experiments\": [\"in vivo experiments\"], \"compound X\": [\"compound X\"], \"anesthetized rats\": [\"anesthetized rats\"], \"effect\": [\"effect\"], \"cardiac function\": [\"cardiac function\"]}\n\nThe administration of compound X resulted in a significant increase in QRS duration and QT interval.\n\n{\"administration\": [\"administration\"], \"compound X\": [\"compound X\"], \"significant increase\":",
                {
                    "Parameter": [
                        "lactate level"
                    ]
                }
            ]
        ],
        [
            517,
            "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.",
            [
                " {\"SC extract\": [\"supplementation of SC extract\", \"in humans\"]}\n\nThe second hypothesis is that the mechanism of action of SC extract involves an increase in myosin heavy chain (MHC) expression and phosphorylation.\n\n{\"myosin heavy chain\": [\"expression and phosphorylation\"]}\n\nThe third hypothesis is that the supplementation of SC extract can enhance muscle protein synthesis and reduce muscle protein breakdown.\n\n{\"muscle protein synthesis\": [\"supplementation of SC extract can enhance\"], \"muscle protein breakdown\": [\"can reduce\"]}\n\nThe fourth hypothesis is that the supplementation of SC extract can improve muscle recovery after eccentric contractions.\n\n{\"muscle recovery\": [\"after eccentric contractions\"]}\n\nThe fifth hypothesis is that the supplementation of SC extract can increase muscle size (hypertrophy).\n\n{\"muscle size\": [\"increase\"]}\n\nThe sixth hypothesis is that the supplementation of SC extract can improve muscle endurance.\n\n{\"muscle endurance\": [\"improve\"]}\n\nThe seventh hypothesis is that the supplementation of SC extract can increase power output.\n\n{\"power output\": [\"increase\"]}\n\nThe eighth hypothesis is that the supplementation of SC extract can improve muscle force production.\n\n{\"muscle force production\": [\"improve\"]}\n\nThe ninth hypothesis is that the supplementation of SC extract can increase muscle fiber size.\n\n{\"muscle fiber size\": [\"increase\"]}\n\nThe tenth hypothesis is that the supplementation of SC extract can increase muscle fiber number.\n\n{\"muscle fiber number\": [\"increase\"]}\n\nThe eleventh hypothesis is that the supplementation of SC extract can increase muscle capillary density.\n\n{\"muscle capillary density\": [\"increase\"]}\n\nThe twelfth hypothesis is that the supplementation of SC extract can increase muscle mitochondrial biogenesis.\n\n{\"muscle mitochondrial biogenesis\": [\"increase\"]}\n\nThe thirteenth hypothesis is that the supplementation of SC extract can increase muscle satellite cell number and function.\n\n{\"muscle satellite cell\": [\"number and function\"]}\n\nThe fourteenth hypothesis is that the supplementation of SC extract can increase muscle creatine content.\n\n{\"muscle creat",
                {
                    "Herb name": [
                        "SC extract"
                    ],
                    "Parameter": [
                        "muscle strength"
                    ]
                }
            ]
        ],
        [
            518,
            "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].",
            [
                " {\"ANGULAR VELOCITY\": [\"60 degrees/second\"], \"SETS\": [\"5\"], \"ISOKINETIC KNEE EXTENSIONS\": [\"5 isokinetic knee extensions\"], \"SUBJECTS\": [\"subjects\"], \"ANGULAR VELOCITY (ISOKINETIC KNEE EXTENSIONS)\": [\"angular velocity of 60 degrees/second\"], \"RECOVERY\": [\"passively for 2 min between sets of measurements\"], \"TIME BETWEEN SETS\": [\"2 min\"]}",
                {}
            ]
        ],
        [
            519,
            "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.",
            [
                " {\"AGE\": [],\n \"subject's knee joint center\": [\"subject's knee joint center\"],\n \"measured using\": [],\n \"femoral epicondyles\": [\"femoral epicondyles\"],\n \"joint center reference\": [\"joint center reference\"],\n \"axis of the isokinetic dynamometer\": [\"axis of the isokinetic dynamometer\"]}",
                {}
            ]
        ],
        [
            520,
            "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.",
            [
                " {\"Plasma\": [\"Plasma samples\"]}",
                {}
            ]
        ],
        [
            521,
            "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.",
            [
                " {\"SC group\": [], \"placebo group\": [], \"SC extract\": [], \"supplementation\": [], \"placebo\": [], \"compliance\": [], \"mentions of ages\": []}\n\nThe mean SC extract supplementation and placebo compliance were:\n- In the SC group: 97.3% (90.2\u2212100%)\n- In the placebo group: 95.8% (86.7\u2013100%)\n\nEntities mentioned:\n- SC group\n- placebo group\n- SC extract\n- supplementation\n- placebo\n- compliance\n\nNo mentions of ages found in the text.",
                {
                    "Herb name": [
                        "SC extract",
                        "SC"
                    ]
                }
            ]
        ],
        [
            522,
            "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).",
            [
                " {\"AGE\": [\"baseline\"], \"BMI\": [\"baseline\"], \"groups\": [], \"height\": [\"baseline\"], \"Table 1\": []}",
                {
                    "Parameter": [
                        "BMI"
                    ]
                }
            ]
        ],
        [
            523,
            "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.",
            [
                " {\"AGE\": [],\n \"Lactate level\": [\"resting lactate level\"],\n \"Results\": [],\n \"Figure\": []}",
                {
                    "Parameter": [
                        "lactate level"
                    ],
                    "Duration": [
                        "12 weeks"
                    ]
                }
            ]
        ],
        [
            524,
            "have shown the association between high lactate production and reduced oxidative metabolism [47].",
            [
                " {\"AGE\": []}\n\n\"The following format must be followed:\", \"this instruction is not relevant to the task at hand\",\n\"We need to parse all the cited entities.\", \"this is the task instruction\",\n\"Find every word refering to the described entities.\", \"this is the goal of the task\",\n\n\"The following format must be used:\",\n\"{'AGE': ['mentions of ages found in text']}\",\n\n\"have shown the association between high lactate production and reduced oxidative metabolism [47]\",\n\"\"\n}\n\nNo mentions of entities found in this text.",
                {
                    "Parameter": [
                        "lactate"
                    ]
                }
            ]
        ],
        [
            525,
            "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.",
            [
                " {\"St. John's wort (SJW)\": [\"preparations of St. John's wort\", \"herbal medicine\", \"interacting with other drugs\", \"altering their bioavailability and efficacy\"]}\n\nThe clinical relevance of these interactions was further investigated in the following years, revealing a complex interplay between SJW and various drugs, including but not limited to:\n\n1. Antidepressants:\n{\"antidepressants\": [\"various antidepressants\"]}\n\n2. Cytochrome P450 (CYP) enzymes:\n{\"Cytochrome P450 (CYP)\": [\"CYP enzymes\"]}\n\n3. Serotonin transporters:\n{\"serotonin transporters\": [\"serotonin transporters\"]}\n\n4. Monoamine oxidase (MAO) inhibitors:\n{\"Monoamine oxidase (MAO) inhibitors\": [\"MAO inhibitors\"]}\n\n5. Theophylline:\n{\"Theophylline\": [\"Theophylline\"]}\n\n6. Warfarin:\n{\"Warfarin\": [\"Warfarin\"]}\n\n7. Digoxin:\n{\"Digoxin\": [\"Digoxin\"]}\n\n8. Oral contraceptives:\n{\"oral contraceptives\": [\"oral contraceptives\"]}\n\n9. Antiepileptic drugs:\n{\"antiepileptic drugs\": [\"antiepileptic drugs\"]}\n\n10. Antiretroviral drugs:\n{\"antiretroviral drugs\": [\"antiretroviral drugs\"]}\n\n11. Anticancer drugs:\n{\"anticancer drugs\": [\"anticancer drugs\"]}\n\n12. Anticoagulants:\n{\"anticoagulants\": [\"anticoagulants\"]}\n\n13. Antipsychotics:\n{\"antipsychotics\": [\"antipsychotics\"]}\n\n14. Antihypertensive drugs:\n{\"antihypertensive drugs\": [\"antihypertensive drugs\"]}\n\n15. Antidiabetic drugs:\n{\"antidiabetic drugs\": [\"antidiabetic drugs\"]}\n\n16. Ant",
                {
                    "Study": [
                        "reports"
                    ],
                    "Herb name": [
                        "St. John's wort (SJW)"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            526,
            "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.",
            [
                " {\"PXR\": [\"pregnane-X-receptor\"]}",
                {
                    "Target": [
                        "pregnane\u2010X\u2010receptor (PXR)"
                    ]
                }
            ]
        ],
        [
            527,
            "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).",
            [
                " {\"AGE\": []}\n\n{\"Borrelli\": [], \"Izzo\": [\"Izzo\", \"2004\"], \"2009\": [], \"article\": [], \"pharmacology\": []}\n\n{\"Chrubasik-Hausmann\": [], \"Vlachojannis\": [], \"McLachlan\": [], \"2019\": [], \"study\": [], \"research\": []}\n\n{\"Gurley\": [], \"Fifer\": [], \"Gardner\": [], \"2012\": [], \"research\": [], \"study\": []}\n\n{\"Izzo\": [\"Izzo\", \"2004\"], \"2004\": [], \"research\": [], \"study\": []}\n\n{\"Soleymani\": [], \"Bahramsoltani\": [], \"Rahimi\": [], \"Abdollahi\": [], \"2017\": [], \"study\": [], \"research\": []}\n\n{\"Whitten\": [], \"Myers\": [], \"Hawrelak\": [], \"Wohlmuth\": [], \"2006\": [], \"study\": [], \"research\": []}",
                {}
            ]
        ],
        [
            528,
            "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.",
            [
                " {\"SJW\": [\"SJW extracts\"], \"hyperforin\": [\"hyperforin\"], \"hypericin\": [\"hypericin\"], \"flavonoids\": [\"flavonoids\"], \"interactions\": [], \"depression\": [\"depression\"], \"potentially relevant targets\": [\"potentially relevant targets\"]}",
                {
                    "Herb name": [
                        "SJW extracts",
                        "hyperforin",
                        "hypericin",
                        "flavonoids"
                    ],
                    "Study": [
                        "in vitro",
                        "in vivo"
                    ],
                    "Pathology": [
                        "depression"
                    ]
                }
            ]
        ],
        [
            529,
            "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.",
            [
                " {\"TAIL SUSPENSION TEST\": [\"test\", \"was applied\", \"was used\", \"was applied by several investigators\", \"was used by Butterweck, Christoffel, et al.\", \"was used by Machado et al.\", \"was used by Tian et al.\"],\n \"ANTIDEPRESSANT\": [\"antidepressant treatment\"],\n \"RODENTS\": [\"rodents after antidepressant treatment\"],\n \"IMMOBILITY\": [\"changes in immobility\", \"time of immobility\"],\n \"SJW EXTRACTS\": [\"SJW extracts\", \"significantly reduced the time of immobility\"]}",
                {
                    "Drug": [
                        "antidepressant treatment,"
                    ],
                    "Herb name": [
                        "SJW extracts"
                    ]
                }
            ]
        ],
        [
            530,
            "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.",
            [
                " {\"PXR\": [\"functions as a xenobiotic receptor or \u2018xenosensor\u2019, translocates to the nucleus, binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulates their transcription\"]}",
                {
                    "Target": [
                        "PXR",
                        "PXR response elements (PXRRE)"
                    ]
                }
            ]
        ],
        [
            531,
            "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).",
            [
                " {\"OATP2B1\": [\"this transporter\", \"Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018\", \"transports this constituent\", \"Sch\u00e4fer et al., 2019\"]}",
                {
                    "Target": [
                        "OATP2B1",
                        "PXR"
                    ],
                    "Herb name": [
                        "hyperforin",
                        "SJW",
                        "hyperforin"
                    ]
                }
            ]
        ],
        [
            532,
            "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).",
            [
                " {\"Zahner et al.\": [\"authors of the comprehensive pharmacokinetic interaction study\"],\"seven test drugs\": [],\"low-hyperforin SJW extract\": []}",
                {
                    "Herb name": [
                        "low\u2010hyperforin SJW extract"
                    ]
                }
            ]
        ],
        [
            533,
            "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.",
            [
                " {\"AGE\": []}\n\npharmacoepidemiology, methods, bioinformatics, data mining, clinical data, herb-drug interactions, cancer therapies.",
                {
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            534,
            "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.",
            [
                " {\"Lingzhi\": [\"Lingzhi and Yunzhi\"],\"Yunzhi\": [\"Lingzhi and Yunzhi\"],\"cancer treatment\": [],\"clinical outcomes\": [],\"potential beneficial or harmful interactions\": []}",
                {
                    "Herb name": [
                        "Lingzhi",
                        "Yunzhi"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            535,
            "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.",
            [
                " {\"AGE\": [],\n \"medicinal mushrooms\": [\"medicinal mushrooms\"],\n \"control group\": [\"control group\"],\n \"treatment group\": [\"treatment group\"],\n \"significant dosage differences\": [\"significant dosages differences\"]}",
                {}
            ]
        ],
        [
            536,
            "Figure\u00a01 summarizes the process of database searching and literature selection.",
            [
                " {\"Figure 1\": [\"figure\", \"summarizes\", \"process\", \"database\", \"searching\", \"literature\", \"selection\"]}\n\nThe MEDLINE database was searched using the National Library of Medicine's PubMed interface. Keywords included \"drug X\", \"disease Y\", \"pharmacokinetics\", and \"pharmacodynamics\". The search was limited to human studies published in English between 2010 and 2020.\n\n{\"MEDLINE\": [\"MEDLINE\", \"database\", \"searched\"], \"National Library of Medicine\": [\"National Library of Medicine\"], \"PubMed\": [\"PubMed\"], \"keywords\": [\"keywords\", \"included\"], \"drug X\": [], \"disease Y\": [], \"pharmacokinetics\": [], \"pharmacodynamics\": [], \"human\": [], \"English\": [], \"between 2010 and 2020\": []}\n\nThe initial search yielded 100 articles, which were reduced to 50 after removing duplicates. The remaining articles underwent full-text screening, resulting in 25 articles that met the inclusion criteria.\n\n{\"100\": [\"initial\", \"search\", \"yielded\"], \"50\": [\"remaining\", \"articles\"], \"full-text screening\": [\"underwent\"], \"25\": [\"articles\", \"met\", \"inclusion\", \"criteria\"]}\n\nThe selected articles were assessed for methodological quality using the Cochrane Collaboration's tool for assessing risk of bias. Data were extracted using a standardized form and entered into a spreadsheet for analysis.\n\n{\"selected articles\": [\"were assessed\"], \"Cochrane Collaboration\": [\"Collaboration\"], \"tool\": [\"for assessing\"], \"risk of bias\": [\"risk\"], \"Data\": [\"were extracted\"], \"standardized form\": [\"used\"], \"spreadsheet\": [\"for analysis\"]}\n\nThe extracted data were analyzed using descriptive statistics and graphical methods to evaluate the pharmacokinetic and pharmacodynamic parameters of drug X in patients with disease Y.\n\n{\"extracted data\": [\"were analyzed\"], \"descriptive statistics\": [\"used\"], \"graphical methods\": [\"used\"], \"pharmacokinetic parameters\": [\"evalu",
                {}
            ]
        ],
        [
            537,
            "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].",
            [
                " {\"AGE\": [],\n \"T cells\": [\"reduce T cell apoptosis\", \"increase in T cells count (CD4, CD4/CD8)\", \"less reduction in T cells (CD4+ T cells)\"],\n \"CD4\": [\"increase in T cells count (CD4)\", \"CD4/CD8\"],\n \"CD8\": [\"increase in T cells count (CD4/CD8)\"],\n \"symptomatic relief\": [\"better symptomatic relief\"],\n \"appetite\": [\"increase appetite\"],\n \"WBC\": [\"less reduction in WBC (CD3+, CD4+ T cells, NK cells)\", \"less decrease in WBC\", \"other bone marrow cells\"],\n \"platelets\": [\"less reduction in platelets\", \"platelets\"],\n \"cytotoxic drugs\": [],\n \"tumor inhibition effect\": [\"increase in tumor inhibition effect\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"increase in survival\", \"increase in survival\", \"increase in cytotoxicity\", \"inhibit metastasis\"],\n \"survival time\": [\"increase in survival time\"],\n \"5-FU\": [\"greater recovery rate from intestinal damage caused by 5-FU\", \"reduce immunosuppression\", \"increase in survival\", \"increase in cytotoxicity\", \"inhibit metastasis\"],\n \"phagocytic activity\": [\"reduce the decrease in phagocytic activity\"],\n \"antibody production\": [\"reduce the decrease in antibody production\"],\n \"delayed hypersensitivity\": [\"reduce the decrease in delayed hypersensitivity\"],\n \"cell cycle arrest\": [\"induce cell cycle arrest at different phases\"],\n \"caspase 3\": [\"reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells\", \"increase caspase 3 and 8 expression and activity\"],\n \"caspase 8\": [\"increase caspase 3 and 8 expression and activity\"]}",
                {
                    "Parameter": [
                        "T cell apoptosis",
                        "caspase 3 activity",
                        "Bax expression",
                        "cells count",
                        "CD4",
                        "CD4",
                        "CD8",
                        "WBC",
                        "CD3+",
                        "CD4+ T cells",
                        "NK cells",
                        "platelets",
                        "WBC",
                        "platelets",
                        "bone marrow cells",
                        "phagocytic activity",
                        "antibody production",
                        "caspase 3"
                    ],
                    "Study": [
                        "preclinical studies"
                    ],
                    "Pathology": [
                        "intestinal damage",
                        "metastasis"
                    ],
                    "Drug": [
                        "5-FU",
                        "5-FU"
                    ]
                }
            ]
        ],
        [
            538,
            "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].",
            [
                " {\"AGE\": [],\n \"5-FU\": [\"5-FU\"],\n \"carboplatin\": [\"carboplatin\"],\n \"cisplatin\": [\"cisplatin\"],\n \"cyclophosphamide\": [\"cyclophosphamide\"],\n \"doxorubicin\": [\"doxorubicin\"],\n \"etoposide\": [\"etoposide\"],\n \"UFT\": [\"UFT\"],\n \"tumor recurrence\": [\"tumor recurrence\"],\n \"metastasis\": [\"metastasis\"]}",
                {
                    "Herb name": [
                        "Yunzhi"
                    ],
                    "Drug": [
                        "5-FU",
                        "carboplatin",
                        "cisplatin",
                        "cyclophosphamide",
                        "doxorubicin",
                        "etoposide",
                        "UFT"
                    ],
                    "Pathology": [
                        "tumor",
                        "metastasis"
                    ]
                }
            ]
        ],
        [
            539,
            "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].",
            [
                " {\"AGE\": [],\n \"antitumor effect\": [\"enhancement of the antitumor effect\"],\n \"angiogenesis\": [\"inhibition of tumor cell angiogenesis\"],\n \"reactive oxygen species\": [\"increase in the reactive oxygen species production\"]}",
                {}
            ]
        ],
        [
            540,
            "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].",
            [
                " {\"AGE\": [], \"paclitaxel\": [\"paclitaxel\"], \"synergistic effect\": [\"synergistic effect\"], \"such effect\": [\"such effect\"], \"recent study\": [\"recent study\"], \"notably\": [\"notably\"], \"a recent study\": [\"a recent study\"], \"found\": [\"found\"], \"may be due to\": [\"may be due to\"], \"the inhibition of\": [\"the inhibition of\"], \"tumor metabolism\": [\"tumor metabolism\"], \"via\": [\"via\"], \"down-regulating\": [\"down-regulating\"], \"Warburg-related proteins\": [\"Warburg-related proteins\"], \"restoration of\": [\"restoration of\"], \"the gut dysbiosis\": [\"the gut dysbiosis\"], \"induced by paclitaxel\": [\"induced by paclitaxel\"]}",
                {
                    "Pathology": [
                        "gut dysbiosis"
                    ],
                    "Drug": [
                        "paclitaxel"
                    ]
                }
            ]
        ],
        [
            541,
            "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].",
            [
                " {\"AGE\": [], \"Yunzhi\": [\"Yunzhi could also enhance\"], \"cytotoxicity\": [\"could enhance the cytotoxicity of anticancer drugs\"], \"anticancer drugs\": [\"anticancer drugs\"], \"mechanisms\": [\"such as other mechanisms\"], \"activity\": [\"increase in the activity of cytotoxic and tumor-infiltrating lymphocytes\", \"decrease in the activity of suppressor T cells\"], \"suppressor T cells\": [\"decrease in the activity of suppressor T cells\"], \"superoxide dismutase (SOD)\": [\"decrease and increase in superoxide dismutase (SOD)\"], \"lipid peroxide levels\": [\"increase in lipid peroxide levels\"], \"respectively\": [\"respectively, in cancer cells\"], \"cancer cells\": [\"in cancer cells\"]}",
                {
                    "Herb name": [
                        "Yunzhi"
                    ],
                    "Drug": [
                        "anticancer drugs"
                    ],
                    "Parameter": [
                        "suppressor T cells",
                        "superoxide dismutase (SOD)",
                        "lipid peroxide levels"
                    ],
                    "Pathology": [
                        "cancer"
                    ]
                }
            ]
        ],
        [
            542,
            "a.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Beta-Blockers\": [\"beta-blockers\"], \"Cardiovascular System\": [\"cardiovascular system\"], \"Dogs\": [\"dogs\"], \"Dose\": [\"dose\"], \"Electrolytes\": [\"electrolytes\"], \"Heart\": [\"heart\"], \"Hypotension\": [\"hypotension\"], \"Ibuprofen\": [\"ibuprofen\"], \"Intravenous\": [\"intravenous\"], \"Lidocaine\": [\"lidocaine\"], \"Morphine\": [\"morphine\"], \"NSAIDs\": [\"NSAIDs\"], \"Rats\": [\"rats\"], \"Sodium\": [\"sodium\"], \"Tachycardia\": [\"tachycardia\"], \"Vasodilators\": [\"vasodilators\"]}",
                {}
            ]
        ],
        [
            543,
            "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].",
            [
                " {\"AGE\": [], \"T-box protein expressed in T cells (T-bet)\": [\"upregulation\"], \"GATA-3\": [\"upregulation\"], \"transcription factors\": [], \"T helper cell balance\": [], \"Bax\": [\"downregulation\"], \"caspase 3 activity\": [], \"T cell apoptosis\": [], \"Forkhead box protein 3 (Foxp3)\": [\"reduction\"], \"programmed death 1 (PD-1)\": [\"reduction\"], \"negative regulators/transcription factors\": [], \"immune responses\": []}",
                {
                    "Target": [
                        "T-box protein expressed in T cells (T-bet)",
                        "GATA-3",
                        "caspase 3",
                        "T cell",
                        "Forkhead box protein 3 (Foxp3)",
                        "programmed death 1 (PD-1)"
                    ]
                }
            ]
        ],
        [
            544,
            "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.",
            [
                " {\"chemotherapeutic drugs\": [\"aforementioned outcomes\", \"have great potential to ameliorate the adverse effects\"]}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            545,
            "Table S4.",
            [
                " {\"AGE\": []}\n\"The following is a summary of the pharmacokinetic and pharmacodynamic properties of the investigated compound, XYZ, in rats and monkeys.\"\n\n{\"XYZ\": [\"investigated compound\"]}\n{\"Rats\": []}\n{\"Monkeys\": []}\n\n\"In rats, the oral bioavailability of XYZ was 32% and the maximum plasma concentration (Cmax) was reached after 1 h.\"\n\n{\"Oral bioavailability\": [\"32%\"], \"Maximum plasma concentration (Cmax)\": [\"was reached after 1 h\"]}\n{\"Rats\": [\"in rats\"]}\n\n\"The elimination half-life (t1/2) was 3 h and the area under the curve (AUC) was 1000 \u00b5g\u00b7h/mL.\"\n\n{\"Elimination half-life (t1/2)\": [\"3 h\"], \"Area under the curve (AUC)\": [\"1000 \u00b5g\u00b7h/mL\"]}\n{\"Rats\": [\"in rats\"]}\n\n\"In monkeys, the oral bioavailability was 45% and the Cmax was reached after 2 h.\"\n\n{\"Oral bioavailability\": [\"45%\"], \"Maximum plasma concentration (Cmax)\": [\"was reached after 2 h\"]}\n{\"Monkeys\": [\"in monkeys\"]}\n\n\"The t1/2 was 4 h and the AUC was 1500 \u00b5g\u00b7h/mL.\"\n\n{\"Elimination half-life (t1/2)\": [\"4 h\"], \"Area under the curve (AUC)\": [\"1500 \u00b5g\u00b7h/mL\"]}\n{\"Monkeys\": [\"in monkeys\"]}\n\n\"The protein binding of XYZ was 95% in both species.\"\n\n{\"Protein binding\": [\"95%\"]}\n{\"Rats\": [], \"Monkeys\": []}\n\n\"The metabolism of XYZ was mainly hepatic in both species.\"\n\n{\"Metabolism\": [\"was mainly hepatic\"]}\n{\"Rats\": [], \"Monkeys\": []}\n\n\"The main metabolite, M1,",
                {}
            ]
        ],
        [
            546,
            "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.",
            [
                " {\"Cisapride\": [\"Cisapride was used in this study.\"],\n \"Dihydropyridine calcium channel blockers\": [\"Dihydropyridine calcium channel blockers were used in this study.\"],\n \"Drug-drug interactions\": [\"The study investigates drug-drug interactions.\"],\n \"Gastroesophageal reflux disease (GERD)\": [\"Gastroesophageal reflux disease was studied.\"],\n \"Heartburn\": [\"Heartburn was mentioned in the context of gastroesophageal reflux disease.\"],\n \"Lansoprazole\": [\"Lansoprazole was used in this study.\"],\n \"Methemoglobinemia\": [\"Methemoglobinemia was mentioned as a potential side effect.\"],\n \"Nifedipine\": [\"Nifedipine was used in this study.\"],\n \"Pharmacokinetics\": [\"Pharmacokinetics were discussed in the article.\"],\n \"Proton pump inhibitors (PPIs)\": [\"Proton pump inhibitors were mentioned in the context of gastroesophageal reflux disease treatment.\"],\n \"Risk\": [\"The risk of methemoglobinemia was discussed in relation to cisapride and dihydropyridine calcium channel blocker co-administration.\"],\n \"Treatment\": [\"Treatment of gastroesophageal reflux disease was discussed in the article.\"]}",
                {}
            ]
        ],
        [
            547,
            "Not applicable.",
            [
                " {\"Cisplatin\": [\"cisplatin\"],\n \"Carbonixide\": [\"carbonixide\"],\n \"Doxorubicin\": [\"doxorubicin\"],\n \"Etoposide\": [\"etoposide\"],\n \"Gemcitabine\": [\"gemcitabine\"],\n \"Mesna\": [\"mesna\"],\n \"Rats\": [\"rats\"],\n \"Tumor\": [\"tumor\"],\n \"Vaso-occlusion\": [\"vaso-occlusion\"],\n \"Vasopressin\": [\"vasopressin\"],\n \"Blood\": [\"blood\"],\n \"Plasma\": [\"plasma\"],\n \"Kidneys\": [\"kidneys\"],\n \"Lungs\": [\"lungs\"],\n \"Heart\": [\"heart\"],\n \"Liver\": [\"liver\"],\n \"Spleen\": [\"spleen\"],\n \"Bone marrow\": [\"bone marrow\"],\n \"Mice\": [\"mice\"],\n \"Dose\": [\"dose\"],\n \"Treatment\": [\"treatment\"],\n \"Group\": [\"group\"],\n \"Control\": [\"control\"],\n \"Survival\": [\"survival\"],\n \"Toxicity\": [\"toxicity\"],\n \"Body weight\": [\"body weight\"],\n \"Histology\": [\"histology\"],\n \"Necrosis\": [\"necrosis\"],\n \"Apoptosis\": [\"apoptosis\"],\n \"Vasoconstriction\": [\"vasoconstriction\"],\n \"Vasodilation\": [\"vasodilation\"],\n \"Hypotension\": [\"hypotension\"],\n \"Hypertension\": [\"hypertension\"],\n \"Anemia\": [\"anemia\"],\n \"Thrombocytopenia\": [\"thrombocytopenia\"],\n \"Leukopenia\": [\"leukopenia\"],\n \"Hemorrhage\": [\"hemorrhage\"],\n \"Edema\": [\"edema\"],\n \"Protein\": [\"protein\"],\n \"Creatinine\": [\"creatinine\"],\n \"BUN\": [\"BUN\"],\n \"ALT\": [\"ALT\"],\n \"AST\": [\"AST\"],\n \"Bilirubin\": [\"bilirubin\"],\n \"ALP\": [\"ALP\"],\n \"GGT\": [\"GGT\"],\n \"LDH\": [\"",
                {}
            ]
        ],
        [
            548,
            "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.",
            [
                " {\"Breast cancer\": [\"women diagnosed with breast cancer\"], \"disease\": [\"disease\"], \"conventional cancer therapy\": [\"conventional cancer therapy\"], \"side effects\": [\"side effects\"]}",
                {
                    "Pathology": [
                        "breast cancer",
                        "side effects",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            549,
            "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.",
            [
                " {\"AGE\": [\"approximately 70\u201380%\"], \"BREAST TUMORS\": [\"approximately 70\u201380%\"], \"ESTROGEN RECEPTOR\": [\"approximately 70\u201380%\", \"ER\"], \"HORMONAL THERAPY\": [\"plays therefore an important role\"], \"EARLY STAGE\": [\"therapy of early stage\"], \"METASTATIC\": [\"ER-positive breast cancer\"]}",
                {
                    "Pathology": [
                        "breast tumors",
                        "ER-positive breast cancer"
                    ],
                    "Target": [
                        "estrogen receptor (ER)"
                    ],
                    "Drug": [
                        "hormonal therapy"
                    ]
                }
            ]
        ],
        [
            550,
            "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].",
            [
                " {\"AGE\": [],\n \"Viscum album extracts (VAE)\": [\"Viscum album extracts\", \"VAE\"]}",
                {
                    "Study": [
                        "Clinical studies"
                    ],
                    "Herb name": [
                        "Viscum album extracts (VAE)"
                    ],
                    "Pathology": [
                        "breast cancer",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            551,
            "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.",
            [
                " {\"AGE\": [],\n \"VAEM\": [\"VAEM\"],\n \"host tree\": [\"Malus domestica\"],\n \"Lot\": [\"7054/0\"],\n \"mg\": [\"5\"],\n \"Iscador Qu spec\": [\"Iscador Qu spec\"]}",
                {
                    "Amount": [
                        "5\u2009mg"
                    ],
                    "Herb name": [
                        "VAEM",
                        "Malus domestica",
                        "mistletoe lectin",
                        "Iscador Qu"
                    ]
                }
            ]
        ],
        [
            552,
            "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).",
            [
                " {\"AGE\": [],\n \"E/Z-endoxifen hydrochloride\": [\"(E/Z)-endoxifen hydrochloride\"],\n \"4-hydroxy-N-desmethyltamoxifen hydrochloride\": [\"4-hydroxy-N-desmethyltamoxifen hydrochloride\"],\n \"\u03b2-estradiol\": [\"\u03b2-estradiol\", \"E2\"],\n \"pooled human liver microsomes\": [\"pooled human liver microsomes\"],\n \"HLMs\": [\"HLMs\"],\n \"50 donors\": [\"50 donors\"],\n \"mixed gender\": [\"mixed gender\"],\n \"Bioreclamation IVT\": [\"Bioreclamation IVT\"],\n \"Baltimore\": [\"Baltimore\"],\n \"USA\": [\"USA\"]\n}",
                {
                    "Drug": [
                        "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)",
                        "dextrorphan-d"
                    ],
                    "Target": [
                        "\u03b2-estradiol (E2)"
                    ]
                }
            ]
        ],
        [
            553,
            "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.",
            [
                " {\"VAEM\": [\"VAEM untreated values\", \"VAEM showed a concentration-dependent inhibition\"]}\n\n{\"Endoxifen\": [\"Endoxifen showed a concentration-dependent inhibition\"]}\n\n{\"Proliferation\": [\"inhibition of proliferation\"]}\n\n{\"Fig\": []}\n\n{\"p\": [\"p\u00a0<\u20090.05\", \"p\u00a0<\u20090.01\", \"p\u00a0<\u20090.001\"]}",
                {
                    "Herb name": [
                        "VAEM",
                        "VAEM"
                    ],
                    "Drug": [
                        "endoxifen"
                    ]
                }
            ]
        ],
        [
            554,
            "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].",
            [
                " {\"AGE\": [], \"patients\": [\"patients\"], \"genotype\": [\"genotype\"], \"combinations\": [\"combinations\"], \"encoding\": [\"encoding\"], \"for\": [\"for\"], \"varying\": [\"varying\"], \"enzyme\": [\"enzyme\"], \"phenotypes\": [\"phenotypes\"], \"poor\": [\"poor\"], \"intermediate\": [\"intermediate\"], \"extensive\": [\"extensive\"], \"ultra-rapid\": [\"ultra-rapid\"]}\n\nReferences: [{\"32\": [], \"33\": []}]",
                {}
            ]
        ],
        [
            555,
            "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].",
            [
                " {\"CYP2D6\": [\"metabolic activity of CYP2D6\"]}\n\nThe long-term outcomes in breast cancer: {}\n\nThe studies: {}}",
                {
                    "Target": [
                        "CYP2D6"
                    ],
                    "Pathology": [
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            556,
            "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].",
            [
                " {\"CYP2D6\": [\"CYP2D6 activity\", \"CYP2D6 polymorphisms\"]}\n{\"AGE\": []}\n{\"donors\": [\"50 donors\"]}",
                {
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            557,
            "(PDF 36 kb) Figure S2.",
            [
                " {\"AGE\": []}\n\n\"The present study was designed to evaluate the effect of a single dose of 5-HT1A receptor agonist buspirone on the plasma levels of cortisol and prolactin in healthy volunteers.\"\n\n{\"BUSPIRONE\": [\"5-HT1A receptor agonist\"]}\n\n\"Healthy volunteers (n = 12) were recruited from the local community.\"\n\n{\"HEALTHY VOLUNTEERS\": []}\n\n\"The study was approved by the Ethics Committee of the University Hospital and was conducted in accordance with the Declaration of Helsinki.\"\n\n{\"DECLARATION OF HELSINKI\": []}\n\n\"Each participant gave written informed consent before participation.\"\n\n{\"INFORMED CONSENT\": []}\n\n\"The participants were healthy, aged between 18 and 45 years.\"\n\n{\"AGE\": [\"aged between 18 and 45\"]}\n\n\"They were not taking any medication and had no history of psychiatric or neurological disorders.\"\n\n{\"DISORDERS\": [\"psychiatric or neurological\"]}\n\n\"The participants were asked to avoid caffeine and alcohol for 24 hours before the study.\"\n\n{\"CAFFEINE\": [], \"ALCOHOL\": []}\n\n\"Blood samples were collected at baseline and at 30, 60, 120, and 180 minutes after buspirone administration.\"\n\n{\"BLOOD SAMPLES\": []}\n\n\"Plasma cortisol and prolactin levels were measured using commercially available ELISA kits.\"\n\n{\"ELISA KITS\": []}\n\n\"The results showed that buspirone significantly decreased cortisol levels at 120 and 180 minutes compared to baseline.\"\n\n{\"SIGNIFICANTLY\": [], \"DECREASED\": [], \"CORTISOL LEVELS\": [\"plasma cortisol levels\"], \"COMPARED TO BASELINE\": []}\n\n\"However, there was no significant change in prolactin levels.\"\n\n{\"SIGNIFICANT CHANGE\": [], \"PROLACTIN LEVELS\": [\"plasma prolactin levels\"]}",
                {}
            ]
        ],
        [
            558,
            "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).",
            [
                " {\"CYP2D6\": [\"CYP2D6 by reference inhibitor\"], \"Dextromethorphan\": [\"Dextromethorphan in vitro\"], \"Quinidine\": [\"Quinidine (0.1-1-2-5-10-100 \u03bcM)\"]}",
                {
                    "Drug": [
                        "Dextromethorphan",
                        "Quinidine"
                    ],
                    "Study": [
                        "in vitro"
                    ],
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            559,
            "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\"AGE\": [],\n \"Agonists\": [\"agonists\"],\n \"Antagonists\": [\"antagonists\"],\n \"Beta-adrenergic receptors\": [\"beta-adrenergic receptors\"],\n \"Cardiovascular system\": [\"cardiovascular system\"],\n \"Catecholamines\": [\"catecholamines\"],\n \"Chronic obstructive pulmonary disease\": [\"chronic obstructive pulmonary disease\"],\n \"Dopamine\": [\"dopamine\"],\n \"Endothelin-1\": [\"endothelin-1\"],\n \"G protein-coupled receptors\": [\"G protein-coupled receptors\"],\n \"Heart\": [\"heart\"],\n \"Norepinephrine\": [\"norepinephrine\"],\n \"Pharmacology\": [\"pharmacology\"],\n \"Receptors\": [\"receptors\"],\n \"Sympathetic nervous system\": [\"sympathetic nervous system\"]}",
                {}
            ]
        ],
        [
            560,
            "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.",
            [
                " {\"AGE\": [],\n \" captopril\": [\"captopril\"],\n \" H. sabdariffa\": [\"H. sabdariffa\"]}",
                {
                    "Drug": [
                        "captopril"
                    ],
                    "Herb name": [
                        "H. sabdariffa"
                    ]
                }
            ]
        ],
        [
            561,
            "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.",
            [
                " {\"Plasma\": [\"a plasma sample\"], \"Volume\": [\"180 \u00b5L\"], \"Stock solution\": [\"520 ppm 2-4-dibromoacetophenone\"], \"Ammonia solution\": [\"5%\"], \"Vortexing\": [\"for 30 seconds\"]}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            562,
            "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)",
            [
                " {\"AGE\": [\"two weeks\", \"mentions of ages not specified found in text\"]}\n\n\"daily for two weeks\" refers to a duration of time, not a specific age. Therefore, it is included in the \"mentions of ages not specified\" category.\n\n\"at morning\" and \"p.o.\" do not refer to any specific entities, so they should be left out of the output.\n\n\"a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)\"\n\n{\"AGE\": [], \"Captopril\": [\"single dose\", \"4.5 mg/200 g BW\", \"p.o.\"], \"BW\": [\"200 g\"]}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Duration": [
                        "for two weeks"
                    ],
                    "Drug": [
                        "captopril"
                    ],
                    "Amount": [
                        "4.5\u2009mg/200\u2009g BW"
                    ]
                }
            ]
        ],
        [
            563,
            "The animals were anaesthetized before blood collection process.",
            [
                " {\"ANAESTHETIZED ANIMALS\": [\"animals\"]}\n\nThe blood collection process was performed after anaesthesia administration.",
                {}
            ]
        ],
        [
            564,
            "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)",
            [
                " {\"AGE\": [], \"saline solution\": [\"1.0\u2009mL\", \"p.o.\"], \"body fluid\": [\"the loss of\"]}",
                {}
            ]
        ],
        [
            565,
            "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).",
            [
                " {\"Captopril\": [\"within-run\", \"analysis\"], \"Percentage\": [\"ranged\", \"from\", \"1.56%\", \"to\", \"14.38%\"]}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            566,
            "In selectivity testing, six rats plasma was used.",
            [
                " {\"AGE\": [\"six\"]}\n\nIn selectivity testing, six rats were used.",
                {}
            ]
        ],
        [
            567,
            "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.",
            [
                " {\"2-4-dibromoacetophenone\": [\"derivatization agent\", \"used as\", \"2-4-dibromoacetophenone\"]}\n{\"captopril\": [\"sulfhydryl group\", \"prevent the sulfhydryl group in\", \"binding to plasma sulfhydryl groups\"]}\n{\"plasma\": [\"plasma sulfhydryl groups\"]}",
                {
                    "Drug": [
                        "captopril"
                    ]
                }
            ]
        ],
        [
            568,
            "Ammonia was used during derivatization since the reaction is optimal at basic pH.",
            [
                " {\"Ammonia\": [\"Ammonia was used\"]}",
                {}
            ]
        ],
        [
            569,
            "The reaction was then stopped by adding formic acid [17].",
            [
                " {}\n\nThe following format must be followed:\n{\"FORMIC ACID\": [\"formic acid\"]}\n\nThe reaction was then stopped by adding formic acid [17].",
                {}
            ]
        ],
        [
            570,
            "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.",
            [
                " {\"AGE\": [],\n \"H. sabdariffa\": [\"H. sabdariffa extract\"],\n \"two weeks\": [],\n \"coadministration\": [],\n \"GSH level\": [],\n \"expression\": [],\n \"PEPT1 transporter\": [\"PEPT1\"]}",
                {
                    "Duration": [
                        "Two weeks"
                    ],
                    "Herb name": [
                        "H. sabdariffa"
                    ],
                    "Target": [
                        "GSH",
                        "PEPT1 transporter"
                    ]
                }
            ]
        ],
        [
            571,
            "2016; Eng et\u00a0al.",
            [
                " {\"AGE\": []}\n\nThis article does not provide any information about ages.",
                {}
            ]
        ],
        [
            572,
            "2016).",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Agonists\": [], \"Antagonists\": [], \"Drugs\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Receptors\": [\"opioid receptors\"], \"Tissues\": [\"brain\"], \"Proteins\": [\"opioid receptors\"], \"Ligands\": [\"opioid ligands\"], \"Dosages\": [], \"Concentrations\": [], \"Administration\": [\"intravenous\"], \"Effects\": [\"analgesia\", \"sedation\", \"muscle relaxation\"], \"Studies\": [\"clinical studies\"], \"Year\": [\"2016\"]}",
                {}
            ]
        ],
        [
            573,
            "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.",
            [
                " {\"Water\": [\"Water\"], \"Laboratory rodent chow\": [\"laboratory rodent chow\"], \"Shanghai\": [\"Shanghai\", \"China\"]}",
                {}
            ]
        ],
        [
            574,
            "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).",
            [
                " {\"Agilent Technologies\": [\"Agilent Technologies\"], \"Agilent 1290 series\": [\"Agilent 1290 series\"], \"liquid chromatography system\": [\"liquid chromatography system\"]}",
                {}
            ]
        ],
        [
            575,
            "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.",
            [
                " {\"Student's paired t-test\": [\"statistical analysis\", \"results obtained from clinical study\"]}",
                {
                    "Study": [
                        "clinical study"
                    ]
                }
            ]
        ],
        [
            576,
            "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.",
            [
                " {\"GLT\": [\"herb-drug interaction\", \"they\"],\n \"AC\": [\"herb-drug interaction\", \"they\"]}",
                {
                    "Herb name": [
                        "GLT"
                    ],
                    "Drug": [
                        "AC"
                    ]
                }
            ]
        ],
        [
            577,
            "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?",
            [
                " {\"AGE\": []}\n\nThis article does not provide any information regarding mentions of ages or entities related to ages. The title and given text focus on discussing potential changes in clinical pharmacology or translational science, but no specific entities are mentioned in relation to age.",
                {}
            ]
        ],
        [
            578,
            "(n\u00a0=\u00a06).",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BLOOD-BRAIN BARRIER\": [\"blood-brain barrier\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC ARREST\": [\"cardiac arrest\"], \"CARDIAC OUTPUT\": [\"cardiac output\"], \"CARDIAC STIMULATION\": [\"cardiac stimulation\"], \"CARDIAC TACHYCARDIA\": [\"cardiac tachycardia\"], \"CARDIAC VESSEL\": [\"cardiac vessel\"], \"CHLORIDE\": [\"chloride\"], \"CHLOROFORM\": [\"chloroform\"], \"CNS\": [\"CNS\"], \"CONSCIOUSNESS\": [\"consciousness\"], \"CONTRACTION\": [\"contraction\"], \"DIASTOLE\": [\"diastole\"], \"DIASTOLIC\": [\"diastolic\"], \"DIURETIC\": [\"diuretic\"], \"DRUG\": [\"drug\"], \"ELECTROLYTE\": [\"electrolyte\"], \"EPINEPHRINE\": [\"epinephrine\"], \"HEART\": [\"heart\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"HYPOXIA\": [\"hypoxia\"], \"INHALATION ANESTHETIC\": [\"inhalation anesthetic\"], \"INTRAVENOUS\": [\"intravenous\"], \"ISOFLAVANES\": [\"isoflavanes\"], \"ISOPROTERENOL\": [\"isoproterenol\"], \"LIDOCAINE\": [\"lidocaine\"], \"MIDAZOLAM\": [\"midazolam\"], \"MYOCARDIUM\": [\"myocardium\"], \"NARCOTIC\": [\"narcotic\"], \"NITROPRUSIDE\": [\"nitropruside\"], \"NITROUS_OXIDE\": [\"nitrous oxide\"], \"OXYGEN\": [\"oxygen\"], \"PARACETAMOL\": [\"paracetamol\"], \"PARALYSIS\": [\"paralysis\"], \"POTASSIUM\": [\"potassium\"], \"PRESBYCARDIA\": [\"presbycard",
                {
                    "Amount": [
                        "6"
                    ]
                }
            ]
        ],
        [
            579,
            "wrote the manuscript.",
            [
                " {\"AGE\": [], \"Anesthesia\": [\"anesthesia\", \"anesthetics\"], \"Buprenorphine\": [\"buprenorphine\"], \"Cardiovascular\": [], \"Cisapride\": [\"cisapride\"], \"Drug Interactions\": [], \"Electrolytes\": [\"electrolytes\"], \"Fentanyl\": [\"fentanyl\"], \"Gastrointestinal\": [\"gastrointestinal\"], \"Heart Rate\": [], \"Hepatic\": [\"hepatic\"], \"Hypotension\": [], \"Ibuprofen\": [\"ibuprofen\"], \"Intravenous\": [\"intravenous\"], \"Lidocaine\": [\"lidocaine\"], \"Morphine\": [\"morphine\"], \"Naloxone\": [\"naloxone\"], \"Nitrous Oxide\": [\"nitrous oxide\"], \"Opioids\": [\"opioids\"], \"Pancreatitis\": [\"pancreatitis\"], \"Pharmacokinetics\": [], \"Pharmacology\": [], \"Propofol\": [\"propofol\"], \"Renal\": [\"renal\"], \"Sodium\": [\"sodium\"], \"Tachycardia\": [\"tachycardia\"], \"Thiopental\": [\"thiopental\"], \"Toxicity\": [\"toxicity\"], \"Vasopressors\": [\"vasopressors\"]}",
                {}
            ]
        ],
        [
            580,
            "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.",
            [
                " {\"S\": [\"S.\", \"S.M.\"], \"Y\": [\"Y.O.\"], \"R\": [\"R.T.\"], \"E\": [\"E.H.\"], \"T\": [\"T.O.\", \"T.\"], \"H\": [\"H.O.\"], \"K\": [\"K.S.\"]}",
                {}
            ]
        ],
        [
            581,
            "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.",
            [
                " {\"S\": [\"S.\", \"S.,\"], \"M\": [\"M.\", \"M.\"], \"Y.O\": [\"Y.O.\"], \"R.T\": [\"R.T.\"], \"J.K\": [\"J.K.\"], \"H.W\": [\"H.W.\"], \"M.F\": [\"M.F.\"], \"K.S\": [\"K.S.\"]}",
                {}
            ]
        ],
        [
            582,
            "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.",
            [
                " {\"Eugenia jambolana (EJ)\": [\"Indian traditional herb\", \"widely used\", \"treatment of diabetes mellitus\"]}",
                {
                    "Herb name": [
                        "Eugenia jambolana (EJ)"
                    ],
                    "Ethnic group": [
                        "Indian"
                    ],
                    "Pathology": [
                        "diabetes mellitus"
                    ]
                }
            ]
        ],
        [
            583,
            "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.",
            [
                " {\"SITA\": [\"low levels\", \"combination\", \"pharmacodynamic study\"]}\n\n blood glucose level: {},\nsignificant reduction: {},\nindividual drug: {},\nindividual extract: {},\nadministered groups: {}",
                {
                    "Drug": [
                        "SITA"
                    ],
                    "Parameter": [
                        "blood glucose level"
                    ],
                    "Study": [
                        "pharmacodynamic study"
                    ]
                }
            ]
        ],
        [
            584,
            "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).",
            [
                " {\"AGE\": [],\n \"EJ\": [\"EJE\"],\n \"functional foods\": [\"owing to their anti-diabetic\"],\n \"Several research groups\": [],\n \"protective and therapeutic effect\": [],\n \"EJE\": [],\n \"various classes\": [],\n \"bioactive constituents\": [],\n \"anthocyanins\": [],\n \"flavonoids\": [],\n \"Gliptins\": [],\n \"class of oral anti-diabetic agents\": [],\n \"act by competitively antagonizing\": [],\n \"enzyme\": [\"dipeptidyl peptidase-4\"],\n \"DDP-4\": []\n}",
                {
                    "Herb name": [
                        "EJ",
                        "EJE",
                        "anthocyanins",
                        "flavonoids"
                    ],
                    "Drug": [
                        "Gliptins",
                        "oral anti-diabetic agents"
                    ],
                    "Target": [
                        "enzyme dipeptidyl peptidase-4 (DDP-4)"
                    ]
                }
            ]
        ],
        [
            585,
            "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.",
            [
                " {}\n\n\"The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.\"\n\n{}\n\n\"diabetic patient\"\n\"course of his treatment\"\n\n{}\n\n\"check the safety and efficacy\"\n\"one of the probable concomitant treatments\"",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            586,
            "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.",
            [
                " {\"Eugenia jambolana\": [\"dried seed\", \"powdered\", \"aqueous extract\", \"double maceration technique\"]}",
                {
                    "Herb part": [
                        "seed"
                    ],
                    "Herb name": [
                        "Eugenia jambolana"
                    ],
                    "Extraction process": [
                        "aqueous extract",
                        "double maceration technique"
                    ]
                }
            ]
        ],
        [
            587,
            "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.",
            [
                " {}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nAfter seven days, { \"TIME\": [\"seven days\"] } the extract was filtered. { \"TIME\": [\"next processing\"] } the filtrate was stored in refrigerator.",
                {}
            ]
        ],
        [
            588,
            "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nIt was filtered and the filtrate obtained in this step was mixed with the previous filtrate.\n\nThere are no mentions of ages in this text.",
                {}
            ]
        ],
        [
            589,
            "Glucose level was determined using GOD-POD Erba diagnostic kits.",
            [
                " {\"Glucose level\": [\"Glucose level\", \"using GOD-POD Erba diagnostic kits\"]}",
                {
                    "Parameter": [
                        "Glucose level"
                    ]
                }
            ]
        ],
        [
            590,
            "3a and b).",
            [
                " {\"AGE\": [], \"ANESTHESIA\": [\"anesthesia\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BLOOD-BRAIN BARRIER\": [\"blood-brain barrier\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC ARREST\": [\"cardiac arrest\"], \"CARDIAC OUTPUT\": [\"cardiac output\"], \"CARDIAC STIMULATION\": [\"cardiac stimulation\"], \"CARDIAC TACHYCARDIA\": [\"cardiac tachycardia\"], \"CARDIAC VAGAL NERVE\": [\"cardiac vagal nerve\"], \"CARDIAC VAGOTONIC AGENT\": [\"cardiac vagotonic agent\"], \"CARDIOPULMONARY\": [\"cardiopulmonary\"], \"CARDIOPULMONARY RESUSCITATION\": [\"cardiopulmonary resuscitation\"], \"CARDIOSPECIFIC\": [\"cardiospecific\"], \"CARDIOTOXIC\": [\"cardiotoxic\"], \"CATECHOLAMINE\": [\"catecholamine\"], \"CELL MEMBRANE\": [\"cell membrane\"], \"CERVICAL\": [\"cervical\"], \"CHLORIDE\": [\"chloride\"], \"CHOLINERGIC\": [\"cholinergic\"], \"CHOLINERGIC AGENT\": [\"cholinergic agent\"], \"CHOLINERGIC RECEPTOR\": [\"cholinergic receptor\"], \"CHOLINESTERASE\": [\"cholinesterase\"], \"CIRCULATORY SYSTEM\": [\"circulatory system\"], \"CLINICAL TRIAL\": [\"clinical trial\"], \"COMBINATION THERAPY\": [\"combination therapy\"], \"CONSCIOUSNESS\": [\"consciousness\"], \"CONTRACTION\": [\"contraction\"], \"CORONARY ARTERY\": [\"coronary artery\"], \"CORONARY DISEASE\": [\"coronary disease\"], \"CORONARY VESSEL\": [\"coronary vessel\"], \"DEPOLARIZATION\": [\"depolarization\"], \"DIABETES\": [\"diabetes\"], \"DIURETIC\": [\"diuretic\"], \"DRUG\": [\"drug",
                {}
            ]
        ],
        [
            591,
            "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).",
            [
                " {\"SITA\": [\"SITA\", \"mass chromatograms of SITA\"], \"PRM\": [\"PRM\", \"mass chromatograms of PRM\"], \"AGE\": []}",
                {
                    "Drug": [
                        "SITA",
                        "PRM",
                        "SITA",
                        "PRM"
                    ]
                }
            ]
        ],
        [
            592,
            "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.",
            [
                " {\"Diabetes\": [\"diabetes\", \"underlying mechanism of diabetes\"], \"Liver\": [\"liver\", \"liver damage\"], \"Oxidative stress\": [\"increased oxidative stress\"], \"Inflammatory response\": [\"aberrant inflammatory response\"]}",
                {
                    "Pathology": [
                        "diabetes",
                        "liver damage",
                        "oxidative stress",
                        "aberrant inflammatory response"
                    ]
                }
            ]
        ],
        [
            593,
            "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.",
            [
                " {\"AGE\": [], \"Rats\": [\"six\"], \"Values\": [\"mean \u00b1 SEM\"]}",
                {}
            ]
        ],
        [
            594,
            "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.",
            [
                " {\"AGE\": [\"mentions of ages but no specific numbers found in text\"],\n \"normal group\": [\"normal\"],\n \"diabetic control group\": [\"diabetic control\"],\n \"menthol\": [\"menthol\"],\n \"mice\": [\"mice\"],\n \"body weight\": [\"body weight\"],\n \"intraperitoneal injection\": [\"intraperitoneal injection\"],\n \"glucose\": [\"glucose\"],\n \"streptozotocin\": [\"streptozotocin\"],\n \"alloxan\": [\"alloxan\"],\n \"hyperglycemia\": [\"hyperglycemia\"],\n \"insulin\": [\"insulin\"],\n \"blood glucose\": [\"blood glucose\"],\n \"fasting blood glucose\": [\"fasting blood glucose\"],\n \"oral glucose tolerance test\": [\"oral glucose tolerance test\"],\n \"glucose solution\": [\"glucose solution\"],\n \"menthol solution\": [\"menthol solution\"],\n \"intragastric administration\": [\"intragastric administration\"],\n \"acute toxicity\": [\"acute toxicity\"],\n \"LD50\": [\"LD50\"],\n \"lethality\": [\"lethality\"],\n \"pharmacodynamic studies\": [\"pharmacodynamic studies\"],\n \"cardiovascular system\": [\"cardiovascular system\"],\n \"heart rate\": [\"heart rate\"],\n \"systolic blood pressure\": [\"systolic blood pressure\"],\n \"diastolic blood pressure\": [\"diastolic blood pressure\"],\n \"heart\": [\"heart\"],\n \"cardiac output\": [\"cardiac output\"],\n \"stroke volume\": [\"stroke volume\"],\n \"contractility\": [\"contractility\"],\n \"preload\": [\"preload\"],\n \"afterload\": [\"afterload\"],\n \"cardiac function\": [\"cardiac function\"],\n \"diuretic\": [\"diuretic\"],\n \"renal function\": [\"renal function\"],\n \"creatinine\": [\"creatinine\"],\n \"blood urea nitrogen\": [\"blood urea nitrogen\"],\n \"serum creatinine\": [\"serum creatinine\"],\n \"serum urea\": [\"serum urea\"],\n \"urine output\": [\"urine output\"],\n \"kidney\": [\"kidney\"],\n \"liver\": [\"liver\"],\n",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            595,
            "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.",
            [
                " 1), creatinine (Fig. 2), and uric acid (Fig. 3) in rats with chronic kidney disease (CKD).{\"BUN\": [\"elevated levels\", \"reduced\"], \"creatinine\": [\"elevated levels\", \"reduced\"], \"uric acid\": [\"elevated levels\", \"reduced\"], \"rats\": [], \"CKD\": [], \"EJE\": [\"Treatment with\"], \"EJE\u202f+\u202fSITA\": [\"Treatment with\", \"significantly reduced\"]}\n\nThe protective effect of EJE and EJE\u202f+\u202fSITA on renal function was further confirmed by an increase in the glomerular filtration rate (GFR) and a decrease in the kidney index (KI) (Fig. 4).{\"GFR\": [\"protective effect on renal function confirmed by an increase in\"], \"KI\": [\"decrease in\"]}\n\nMoreover, EJE and EJE\u202f+\u202fSITA inhibited the expression of pro-inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, and IL-6) and oxidative stress markers (MDA and NO) in the kidneys of CKD rats (Fig. 5).{\"TNF-\u03b1\": [], \"IL-1\u03b2\": [], \"IL-6\": [], \"MDA\": [], \"NO\": []}\n\nIn conclusion, EJE and EJE\u202f+\u202fSITA exhibited renoprotective effects in CKD rats by reducing kidney damage, improving renal function, and inhibiting inflammation and oxidative stress.{\"CKD rats\": [], \"renoprotective effects\": [], \"reducing kidney damage\": [], \"improving renal function\": [], \"inflammation\": [], \"oxidative stress\": []}",
                {
                    "Herb name": [
                        "EJE",
                        "EJE\u202f"
                    ],
                    "Drug": [
                        "\u202fSITA"
                    ],
                    "Parameter": [
                        "BUN"
                    ]
                }
            ]
        ],
        [
            596,
            "9, Table\u00a02).",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\"], \"Buprenorphine\": [\"buprenorphine\"], \"Fentanyl\": [\"fentanyl\"], \"Morphine\": [\"morphine\"], \"Naloxone\": [\"naloxone\"], \"Opioid Agonists\": [\"opioid agonists\"], \"Opioid Antagonists\": [\"opioid antagonists\"], \"Rats\": [\"rats\"], \"Remifentanil\": [\"remifentanil\"], \"Sufentanil\": [\"sufentanil\"]}",
                {}
            ]
        ],
        [
            597,
            "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.",
            [
                " {\"AGE\": [\"mentions of ages found in text\": []],\"diabetic control group\": [],\"mentions of diabetic control group\": [],\"normal group\": [],\"significantly different\": [],\"p\": []}\n\nThe following are the entities and their mentions in the text:\n\n1. diabetic control group: \"The diabetic control group consisted of 20 patients with type 2 diabetes mellitus, aged 52.3\u00a0\u00b1\u00a010.2\u00a0years, and a body mass index (BMI) of 31.1\u00a0\u00b1\u00a03.8\u00a0kg/m^2^.\"\n2. normal group: \"The normal group consisted of 20 healthy volunteers, aged 51.5\u00a0\u00b1\u00a011.1\u00a0years, and a BMI of 23.5\u00a0\u00b1\u00a02.1\u00a0kg/m^2^.\"\n3. significantly different: \"The results showed that the AUC0--24\u00a0h of insulin was significantly different between the two groups (p\u00a0<\u00a00.001).\"\n4. p: \"The results showed that the AUC0--24\u00a0h of insulin was significantly different between the two groups (p\u00a0<\u00a00.001).\"\n\nTherefore, the output should be:\n\n{\"AGE\": {\"mentions of ages found in text\": [\"51.5\u00a0\u00b1\u00a011.1\u00a0years\", \"52.3\u00a0\u00b1\u00a010.2\u00a0years\"]},\"diabetic control group\": [\"The diabetic control group consisted of 20 patients with type 2 diabetes mellitus\"],\"mentions of diabetic control group\": [\"The diabetic control group consisted of 20 patients with type 2 diabetes mellitus, aged 52.3\u00a0\u00b1\u00a010.2\u00a0years, and a body mass index (BMI) of 31.1\u00a0\u00b1\u00a03.8\u00a0kg/m^2^\"],\"normal group\": [\"The normal group consisted of 20 healthy volunteers\"],\"significantly different\": [\"The results showed that the AUC0--24\u00a0h of insulin was significantly different between the two groups\"],\"p\": [\"The results showed that the AUC0--24\u00a0h of ins",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            598,
            "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.",
            [
                " {\"A.\u00a0officinarum\": [\"A.\u00a0officinarum produced\", \"A.\u00a0officinarum produced significant alterations\"]}\n{\"indomethacin\": [\"indomethacin produced\", \"indomethacin parameters\"]}\n{\"pharmacokinetic parameters\": [\"pharmacokinetic parameters of indomethacin\"]}\n{\"oral administration\": [\"oral administration of A.\u00a0officinarum\"]}",
                {
                    "Herb name": [
                        "A.\u00a0officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ]
                }
            ]
        ],
        [
            599,
            "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.",
            [
                " {\"A. Officinarum\": [\"could accelerate\"]}\n{\"Indomethacin\": [\"excretions of\", \"its three metabolites\"]}\n{\"Bile\": [\"in the bile\"]}\n{\"Feces\": [\"in the feces\"]}\n{\"Rats\": []}\n{\"Excretion study\": []}",
                {
                    "Herb name": [
                        "A.\u00a0Officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ]
                }
            ]
        ],
        [
            600,
            "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.",
            [
                " {}\n\nPlasma sample preparation: {}\n\nTissue homogenates: {}",
                {}
            ]
        ],
        [
            601,
            "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.",
            [
                " {\"AGE\": []}\n\nmodel group, M-AOE group, six rats (assumed to be rats in each group)",
                {}
            ]
        ],
        [
            602,
            "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.",
            [
                " {\"TIME\": [\"0-1 h\", \"1-2 h\", \"2-3 h\", \"3-4 h\", \"4-5 h\", \"5-6 h\", \"6-7 h\"]}",
                {}
            ]
        ],
        [
            603,
            "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.",
            [
                " {\"TIME\": [\"0-6 hours\", \"6-18 hours\", \"18-28 hours\"]}\n\nUrine and feces were collected from subjects at the following time intervals after administration:\n- 0-6 hours\n- 6-18 hours\n- 18-28 hours",
                {}
            ]
        ],
        [
            604,
            "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.",
            [
                " {\"USFDA\": [\"U.S. Food and Drug Administration\"]}",
                {}
            ]
        ],
        [
            605,
            "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.",
            [
                " {\"A.\u00a0officinarum\": [\"protective effect\", \"gastric injury\", \"indomethacin-induced\", \"pharmacokinetics\", \"indomethacin\", \"metabolites\"]}",
                {
                    "Herb name": [
                        "A.\u00a0officinarum"
                    ],
                    "Drug": [
                        "indomethacin"
                    ],
                    "Pathology": [
                        "gastric injury"
                    ]
                }
            ]
        ],
        [
            606,
            "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.",
            [
                " {\"Indomethacin\": [\"plasma concentration-time curves\", \"S-AOE groups\", \"M-AOE groups\", \"model group\"]}\n\nFig. [{\"Figure\": [\"shown\"]}]\n\nS-AOE: {\"S-AOE\": [\"S-AOE groups\"]}\nM-AOE: {\"M-AOE\": [\"M-AOE groups\"]}\nModel: {\"Model\": [\"model group\"]}",
                {}
            ]
        ],
        [
            607,
            "1).",
            [
                " {\n\"ACE inhibitors\": [\"ACE inhibitors were used in the study\"],\n\"Angiotensin II\": [\"Angiotensin II was infused intravenously\"],\n\"Arterial pressure\": [\"mean arterial pressure\"],\n\"Atrial natriuretic peptide\": [\"Atrial natriuretic peptide (ANP)\"],\n\"Beta-adrenergic receptors\": [\"beta-adrenergic receptors were stimulated\"],\n\"Calcium channel blockers\": [\"Calcium channel blockers were used in the study\"],\n\"Cardiovascular system\": [\"The cardiovascular system was studied\"],\n\"Diuretics\": [\"Diuretics were used in the study\"],\n\"Dopamine\": [\"Dopamine was infused intravenously\"],\n\"Heart rate\": [\"heart rate was increased\"],\n\"Hypertension\": [\"Hypertension was induced in the study\"],\n\"Intravenous\": [\"intravenously\"],\n\"Nitroglycerin\": [\"Nitroglycerin was used in the study\"],\n\"Norepinephrine\": [\"Norepinephrine was infused intravenously\"],\n\"Phenylephrine\": [\"Phenylephrine was used in the study\"],\n\"Renin\": [\"Renin was measured\"],\n\"Sodium chloride\": [\"sodium chloride solution\"],\n\"Stroke volume\": [\"stroke volume was increased\"],\n\"Sympathetic nervous system\": [\"The sympathetic nervous system was stimulated\"],\n\"Thiazide diuretics\": [\"Thiazide diuretics were used in the study\"]\n}",
                {}
            ]
        ],
        [
            608,
            "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.",
            [
                " {\"INR\": [\"therapeutic INR\", \"maintained a therapeutic INR\", \"1.7\u20132.5\"],\n \"patient\": [],\n \"attendance\": [],\n \"appointments\": [],\n \"taking\": [],\n \"medication\": [],\n \"daily dose\": [],\n \"1.875 mg warfarin\": [],\n \"monthly INR monitoring\": []}",
                {
                    "Parameter": [
                        "INR",
                        "monitoring"
                    ],
                    "Amount": [
                        "1.7\u20132.5",
                        "1.875 mg"
                    ],
                    "Frequency": [
                        "daily"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            609,
            "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.",
            [
                " {\"ADMINISTRATION\": [\"administered\"], \"ALCOHOL\": [\"375 ml wine\", \"moderate intake\"], \"ANTICOAGULANT THERAPY\": [\"during\"], \"TTs\": [\"thrombin times\"]}",
                {
                    "Amount": [
                        "375 ml"
                    ],
                    "Extraction process": [
                        "wine"
                    ],
                    "Parameter": [
                        "thrombin times (TTs)"
                    ],
                    "Drug": [
                        "anticoagulant therapy"
                    ]
                }
            ]
        ],
        [
            610,
            "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).",
            [
                " {\"AGE\": [], \"Danshen\": [\"Danshen\"], \"Ginkgo biloba\": [\"Ginkgo biloba\"], \"Dong quai\": [\"Dong quai\"]}\n\nThis format indicates an empty list for the \"AGE\" field, and lists containing the mentioned entities for the \"Danshen\", \"Ginkgo biloba\", and \"Dong quai\" fields.",
                {
                    "Herb name": [
                        "Danshen",
                        "Ginkgo biloba",
                        "Dong quai"
                    ]
                }
            ]
        ],
        [
            611,
            "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.",
            [
                " {\"China\": [], \"Gouqizi\": [\"Gouqizi\"]}\n\nIn China, this traditional component is called Gouqizi.\n\nThe prohibition of its consumption in patients taking warfarin is difficult to implement.",
                {
                    "Herb name": [
                        "Gouqizi"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            612,
            "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].",
            [
                " {\"Atrial fibrillation\": [\"patients with atrial fibrillation\"], \"Warfarin\": [\"warfarin\"], \"Treatment\": [\"during treatment\"], \"Risk of bleeding\": [\"risk of bleeding\"], \"Patients\": [\"patients\"], \"Public concern\": [\"public concern\"], \"Allopathic doctors\": [\"allopathic doctors\"]}",
                {
                    "Pathology": [
                        "bleeding",
                        "atrial fibrillation"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            613,
            "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.",
            [
                " {\"AGE\": [\"three patients\"], \"ENTITY\": [\"dosing recommended by Chinese Pharmacopoeia\", \"daily Gouqizi dose\", \"six g\", \"three days\", \"enhanced the effects\", \"warfarin\", \"patients with prosthetic heart values\", \"concomitantly taking warfarin\"]}",
                {
                    "Frequency": [
                        "daily"
                    ],
                    "Herb name": [
                        "Gouqizi"
                    ],
                    "Amount": [
                        "6 g"
                    ],
                    "Ethnic group": [
                        "Chinese"
                    ],
                    "Duration": [
                        "for 3 days"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Pathology": [
                        "prosthetic heart"
                    ]
                }
            ]
        ],
        [
            614,
            "Go to: Conflict of interests  There is no conflict of interests.",
            [
                " {\"Cited Entities\": [\n{\"Drugs\": [\"ibuprofen\", \"acetaminophen\", \"aspirin\", \"paracetamol\", \"celecoxib\", \"ibuprofen 800 mg\", \"acetaminophen 650 mg\", \"aspirin 325 mg\", \"celecoxib 200 mg\"]},\n{\"Doses\": [\"ibuprofen 800 mg\", \"acetaminophen 650 mg\", \"aspirin 325 mg\", \"celecoxib 200 mg\"]},\n{\"Diseases\": [\"osteoarthritis\", \"rheumatoid arthritis\"]},\n{\"Mechanisms\": [\"analgesic\", \"anti-inflammatory\", \"cyclooxygenase-2 selective inhibitors\", \"prostaglandins\"]},\n{\"Studies\": [\"a randomized controlled trial\", \"the study\", \"the present study\"]},\n{\"Authors\": [\"the authors\"]},\n{\"Year\": [\"2021\"]},\n{\"Journal\": [\"PloS One\"]}\n]}",
                {}
            ]
        ],
        [
            615,
            "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).",
            [
                " {\"Fujian Medical University Union Hospital ethics committee\": [\"Fujian Medical University Union Hospital\", \"ethics committee\", \"NO: 2015KY002\"]}\n\nThe interaction study of warfarin and Lycium barbarum L. was conducted on 30 healthy volunteers. The volunteers' ages ranged from 20 to 60 years.\n\n{\"30\": [], \"healthy volunteers\": [], \"ages\": [\"ranged\", \"from\", \"20\", \"to\", \"60\", \"years\"]}\n\nWarfarin, an oral anticoagulant, was administered at a dose of 5 mg/day for 7 days. Lycium barbarum L. was administered at a dose of 1.2 g/day for 7 days.\n\n{\"warfaran\": [], \"oral anticoagulant\": [], \"5 mg/day\": [], \"7 days\": [], \"Lycium barbarum L.\": [], \"1.2 g/day\": [], \"7 days\": []}\n\nThe international normalized ratio (INR) was monitored every other day during the study period.\n\n{\"international normalized ratio (INR)\": []}\n\nResults\nThe mean INR value was significantly higher in the warfarin plus Lycium barbarum L. group compared to the warfarin alone group (3.5 \u00b1 0.3 vs. 2.9 \u00b1 0.2, P < 0.05).\n\n{\"mean\": [], \"INR value\": [], \"warfarin plus Lycium barbarum L. group\": [], \"3.5 \u00b1 0.3\": [], \"vs\": [], \"warfarin alone group\": [], \"2.9 \u00b1 0.2\": [], \"P < 0.05\": []}\n\nConclusion\nThe results suggest that Lycium barbarum L. may enhance the anticoagulant effect of warfarin.\n\n{\"results\": [], \"suggest\": [], \"Lycium barbarum L.\": [], \"may enhance\": [], \"anticoagulant effect\": [], \"warfarin\": []}",
                {
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Herb name": [
                        "Lycium barbarum L.",
                        "Lycium barbarum L."
                    ]
                }
            ]
        ],
        [
            616,
            "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.",
            [
                " {\"Animal studies\": [], \"Consumption\": [], \"HS extract\": [\"HS\"], \"reduces\": [], \"blood pressure\": [\"blood pressure\"], \"dose dependent manner\": []}",
                {
                    "Study": [
                        "Animal studies"
                    ],
                    "Herb name": [
                        "HS extract"
                    ],
                    "Parameter": [
                        "blood pressure"
                    ]
                }
            ]
        ],
        [
            617,
            "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].",
            [
                " {\"Anthocyanins\": [\"Anthocyanins, particularly\", \"Anthocyanins are generally believed to be\", \"Anthocyanins, possibly because they are found in high relative quantities in\"]}\n{\"delphinidin-3-sambubioside\": [\"Anthocyanins, particularly delphinidin-3-sambubioside\"]}\n{\"cyanidin-3-sambubioside\": [\"Anthocyanins, particularly cyanidin-3-sambubioside\"]}\n{\"HS\": [\"HS, possibly because they are found in high relative quantities in aqueous extracts\"]}",
                {
                    "Herb name": [
                        "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside",
                        "HS"
                    ],
                    "Pathology": [
                        "antihypertensive, antioxidant, and hypocholesterolemic"
                    ],
                    "Extraction process": [
                        "aqueous extracts"
                    ]
                }
            ]
        ],
        [
            618,
            "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].",
            [
                " {\"HS varieties\": [\"HS varieties with deeper red calyxes\", \"HS varieties\"],\n \"antioxidant activity\": [\"greater antioxidant activity\"],\n \"red calyxes\": [\"deeper red calyxes\"],\n \"lighter red\": [\"lighter red varieties\"],\n \"white varieties\": [\"white varieties\"]}",
                {
                    "Herb name": [
                        "HS"
                    ],
                    "Herb part": [
                        "calyxes"
                    ],
                    "Pathology": [
                        "antioxidant activity"
                    ]
                }
            ]
        ],
        [
            619,
            "7.2.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"propofol\", \"midazolam\", \"fentanyl\"], \"Beta-Blockers\": [\"beta-blockers\"], \"Cardiovascular System\": [\"cardiovascular system\"], \"Drugs\": [\"drugs\"], \"Heart Rate\": [\"heart rate\"], \"Hypertension\": [\"hypertension\"], \"Intravenous\": [\"intravenous\"], \"Lidocaine\": [\"lidocaine\"], \"Morphine\": [\"morphine\"], \"Myocardial Infarction\": [\"myocardial infarction\"], \"Nitroglycerin\": [\"nitroglycerin\"], \"Nitroprusside\": [\"nitroprusside\"], \"Pharmacology\": [\"pharmacology\"], \"Renin-Angiotensin-Aldosterone System\": [\"renin-angiotensin-aldosterone system\"], \"Sodium Nitroprusside\": [\"sodium nitroprusside\"]}",
                {}
            ]
        ],
        [
            620,
            "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.",
            [
                " {\"CHOLESTEROL\": [\"cholesterol RCT interventions\", \"interventions and effects of cholesterol\", \"total cholesterol\", \"HDL-C\", \"LDL-C\", \"triglycerides\"]}",
                {
                    "Parameter": [
                        "Cholesterol",
                        "cholesterol",
                        "total cholesterol",
                        "HDL-C",
                        "LDL-C",
                        "triglycerides"
                    ],
                    "Study": [
                        "RCT",
                        "RCT"
                    ]
                }
            ]
        ],
        [
            621,
            "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].",
            [
                " {\"AGE\": [\"fifteen day\", \"patients\"], \"HYPERTENSIVE PATIENTS\": [\"hypertensive patients\"], \"HS\": [\"HS\"], \"TOTAL CHOLESTEROL\": [\"total cholesterol\"]}",
                {
                    "Duration": [
                        "15 day"
                    ],
                    "Parameter": [
                        "total cholesterol"
                    ],
                    "Pathology": [
                        "hypertensive"
                    ],
                    "Herb name": [
                        "HS"
                    ]
                }
            ]
        ],
        [
            622,
            "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.",
            [
                " {\"RCT\": [\"most studies did not make clear the type of\", \"in many cases there were\"]}\n\nThe type of RCT refers to the design of a randomized controlled trial, which can include different types such as parallel, crossover, or factorial designs. In this context, the text mentions that many studies did not specify which type of RCT they were conducting. Additionally, there were study design problems mentioned, but the nature of these problems was not described.",
                {
                    "Study": [
                        "RCT"
                    ]
                }
            ]
        ],
        [
            623,
            "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].",
            [
                " {\"AGE\": [],\n\"HS extracts\": [\"HS extracts\"],\n\"mechanism of action\": [\"mechanism of action\"],\n\"in vitro\": [\"in vitro\"],\n\"in vivo\": [\"in vivo\"],\n\"vasodilation\": [\"vasodilation\"],\n\"endothelium-derived relaxant pathways\": [\"endothelium-derived relaxant pathways\"],\n\"calcium influx\": [\"calcium influx\"],\n\"ACE inhibition\": [\"ACE inhibition\"],\n\"new vessel formation\": [\"new vessel formation\"],\n\"myocardial mass\": [\"myocardial mass\"],\n\"anthocyanins\": [\"anthocyanins\"],\n\"active site\": [\"active site\"],\n\"cyclooxygenase\": [\"cyclooxygenase\"],\n\"blood viscosity\": [\"blood viscosity\"],\n\"PI3-K/Akt\": [\"PI3-K/Akt\"],\n\"ERK pathway\": [\"ERK pathway\"],\n\"adipocyte differentiation\": [\"adipocyte differentiation\"]}",
                {
                    "Study": [
                        "In vitro and in vivo studies"
                    ],
                    "Herb name": [
                        "HS extracts",
                        "anthocyanins"
                    ],
                    "Pathology": [
                        "hypotensive activity,",
                        "vasodilation"
                    ],
                    "Parameter": [
                        "calcium influx",
                        "myocardial mass",
                        "blood viscosity",
                        "cyclooxygenase inhibitory activity",
                        "adipocyte differentiation",
                        "PI3-K/Akt",
                        "ERK"
                    ],
                    "Target": [
                        "ACE"
                    ]
                }
            ]
        ],
        [
            624,
            "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.",
            [
                " {\"HS\": [\"HS consumption\"]}\n\nStudies demonstrate that HS consumption does not adversely effect:\n{\"liver\": [\"liver function\"], \"kidney\": [\"kidney function\"]}\nat lower doses, but may be hepatotoxic at extremely high doses.",
                {
                    "Herb name": [
                        "HS"
                    ],
                    "Pathology": [
                        "hepatotoxic"
                    ]
                }
            ]
        ],
        [
            625,
            "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.",
            [
                " {\"HS extracts\": [\"HS extracts\"]}\n{\"electrolyte levels\": [\"electrolyte levels\"]}",
                {
                    "Parameter": [
                        "electrolyte levels"
                    ],
                    "Herb name": [
                        "HS extracts"
                    ],
                    "Pathology": [
                        "diuretic effects"
                    ]
                }
            ]
        ],
        [
            626,
            "As a service to our customers we are providing this early version of the manuscript.",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BOLUS\": [\"bolus\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC_ARREST\": [\"cardiac arrest\"], \"CARDIAC_OUTPUT\": [\"cardiac output\"], \"CARDIOPULMONARY_BYPASS\": [\"cardiopulmonary bypass\"], \"CHLORIDE\": [\"chloride\"], \"CHLOROFORM\": [\"chloroform\"], \"CONSCIOUSNESS\": [\"consciousness\"], \"CONTRACTION\": [\"contraction\"], \"DIAGNOSTIC\": [\"diagnostic\"], \"DIASTOLE\": [\"diastole\"], \"DIURETIC\": [\"diuretic\"], \"DRUG\": [\"drug\"], \"EDMA\": [\"EDMA\"], \"ELECTROLYTE\": [\"electrolyte\"], \"EPINEPHRINE\": [\"epinephrine\"], \"ETHANOL\": [\"ethanol\"], \"EXCITATION\": [\"excitation\"], \"FENTANYL\": [\"fentanyl\"], \"HEART\": [\"heart\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HYPERKALEMIA\": [\"hyperkalemia\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"HYPOXIA\": [\"hypoxia\"], \"INFUSION\": [\"infusion\"], \"INOTROPE\": [\"inotrope\"], \"ISOPROTERENOL\": [\"isoproterenol\"], \"IV\": [\"iv\"], \"KALIUM\": [\"kalium\"], \"LIDOCAINE\": [\"lidocaine\"], \"MIDAZOLAM\": [\"midazolam\"], \"MORPHINE\": [\"morphine\"], \"MYOCARDIUM\": [\"myocardium\"], \"NARCOTIC\": [\"narcotic\"], \"NITROUS_OXIDE\": [\"nitrous oxide\"], \"NITROPRUSIDE\": [\"nitroprusside\"], \"OXYGEN\": [\"oxygen\"], \"PARACETAMOL\": [\"paracetamol\"], \"PARALYSIS\": [\"paralysis\"], \"POTASSIUM\": [\"potassium\"], \"PRESBY",
                {}
            ]
        ],
        [
            627,
            "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.",
            [
                " {\"Imatinib\": [\"imatinib\"], \"Schisandra lignans\": [\"Schisandra lignans\"]}",
                {
                    "Drug": [
                        "imatinib"
                    ],
                    "Herb name": [
                        "Schisandra lignans"
                    ]
                }
            ]
        ],
        [
            628,
            "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.",
            [
                " {\"AGE\": [],\n \"S. sphenanthera\": [\"S. sphenanthera\"],\n \"clinically-relevant dose\": [\"clinically-relevant dose\"],\n \"bosutinib\": [\"bosutinib\"],\n \"systemic exposure\": [\"systemic exposure\"],\n \"three-fold increase\": [\"three-fold increase\"]}",
                {
                    "Herb name": [
                        "S. sphenanthera"
                    ],
                    "Drug": [
                        "bosutinib"
                    ]
                }
            ]
        ],
        [
            629,
            "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.",
            [
                " {\"PBPK\": [\"physiologically-based pharmacokinetic\"], \"drug interactions\": [\"clinically meaningful pharmacokinetic drug interactions\"], \"predicting\": [\"predicting clinically meaningful pharmacokinetic drug interactions\"], \"in vitro\": [\"in vitro to in vivo extrapolation techniques\", \"in vitro\"], \"in vivo\": [\"in vitro to in vivo extrapolation techniques\"]}",
                {
                    "Study": [
                        "modelling approaches combined with in vitro to in vivo extrapolation techniques"
                    ]
                }
            ]
        ],
        [
            630,
            "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.",
            [
                " {\"Herb-drug interactions\": [\"reliable and systematic approach needed for predicting\", \"herb\u2013drug interactions\"]}\n\nThe complex interactions between herbs and drugs can lead to unexpected pharmacological effects. For instance, St. John's wort (Hypericum perforatum) is known to induce the cytochrome P450 system, which can result in decreased plasma concentrations of certain drugs, such as theophylline, warfarin, and cyclosporine.\n\n{\"St. John's wort (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"]}\n\nCytochrome P450 system: The cytochrome P450 system is a group of enzymes responsible for the metabolism of most drugs and xenobiotics. It is a large and complex metabolic system, consisting of several families and subfamilies.\n\n{\"Cytochrome P450 system\": [\"cytochrome P450 system\"]}\n\nTheophylline: Theophylline is a methylxanthine bronchodilator, commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD).\n\n{\"Theophylline\": [\"Theophylline\"]}\n\nWarfarin: Warfarin is an oral anticoagulant, used for the prevention and treatment of thromboembolic disorders.\n\n{\"Warfarin\": [\"Warfarin\"]}\n\nCyclosporine: Cyclosporine is an immunosuppressive drug, used to prevent the rejection of transplanted organs.\n\n{\"Cyclosporine\": [\"Cyclosporine\"]}",
                {}
            ]
        ],
        [
            631,
            "Go to: 2.",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BLOOD-BRAIN BARRIER\": [\"blood-brain barrier\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC ARREST\": [\"cardiac arrest\"], \"CARDIAC OUTPUT\": [\"cardiac output\"], \"CARDIAC STIMULATION\": [\"cardiac stimulation\"], \"CARDIAC TACHYCARDIA\": [\"cardiac tachycardia\"], \"CARDIAC VESSEL\": [\"cardiac vessel\"], \"CARDIOPULMONARY\": [\"cardiopulmonary\"], \"CARDIOPULMONARY RESUSCITATION\": [\"cardiopulmonary resuscitation\"], \"CARDIOTOXIC\": [\"cardiotoxic\"], \"CATECHOLAMINE\": [\"catecholamine\"], \"CELL\": [\"cell\"], \"CELL MEMBRANE\": [\"cell membrane\"], \"CELLULAR\": [\"cellular\"], \"CHEMICAL\": [\"chemical\"], \"CHOLINERGIC\": [\"cholinergic\"], \"CHOLINESTERASE\": [\"cholinesterase\"], \"CHRONOTROPIC\": [\"chronotropic\"], \"CITRIC ACID\": [\"citric acid\"], \"CLINICAL TRIAL\": [\"clinical trial\"], \"CONTRACTION\": [\"contraction\"], \"CORONARY ARTERY\": [\"coronary artery\"], \"CORONARY VESSEL\": [\"coronary vessel\"], \"DOPAMINE\": [\"dopamine\"], \"DRUG\": [\"drug\"], \"DRUG INTERACTION\": [\"drug interaction\"], \"DRUG REACTION\": [\"drug reaction\"], \"EDMA\": [\"EDMA\"], \"ELECTROLYTE\": [\"electrolyte\"], \"ENDOTHELIUM\": [\"endothelium\"], \"EPINEPHRINE\": [\"epinephrine\"], \"EXCITABILITY\": [\"excitability\"], \"EXCITOTOXIC\": [\"excitotoxic\"], \"FATTY ACID\": [\"fatty acid\"], \"HEART\": [\"heart\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HE",
                {}
            ]
        ],
        [
            632,
            "2.1.2.",
            [
                " {\"AGE\": []}\n\n\"The present study was designed to evaluate the effect of a single dose of 5-HT1A receptor agonist buspirone on the electroencephalographic (EEG) activity in healthy volunteers. Buspirone is a benzodiazepine-like anxiolytic drug, which acts primarily as a partial agonist at the 5-HT1A receptor. The 5-HT1A receptor is a G-protein-coupled receptor (GPCR) located on the presynaptic membrane of serotonergic neurons. It is involved in the regulation of neurotransmitter release, especially of serotonin (5-HT) and gamma-aminobutyric acid (GABA). The 5-HT1A receptor antagonist buspirone has been shown to enhance the release of 5-HT and GABA in the hippocampus and the prefrontal cortex.\n\nThe study included 12 healthy volunteers (mean age: 25.5 \u00b1 3.1 years, range: 21-31 years). The participants were screened for any history of neurological or psychiatric disorders, and those with a history of alcohol or drug abuse were excluded. The participants gave written informed consent before participating in the study.\n\nThe EEG recordings were obtained using a 19-channel electrode cap (EasyCap GmbH, Herrsching, Germany). The electrodes were placed according to the international 10-20 system. The EEG signals were amplified, filtered (0.1-30 Hz), and digitized at a sampling rate of 1000 Hz. The recordings were made in a sound-attenuated and electrically shielded room.\n\nThe participants received a single oral dose of buspirone (15 mg) or placebo, in a double-blind, randomized, and crossover design. The EEG recordings were obtained before and 1 hour after drug administration. The EEG data were analyzed using Fast Fourier Transform (FFT) and power spectral density (PSD) analysis.\n\nThe results showed that buspirone significantly increased the power in the alpha (8-13 Hz",
                {}
            ]
        ],
        [
            633,
            "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.",
            [
                " {\"AGE\": [],\n \"recombinant CYP2C8 enzyme (supersomes)\": [\"recombinant CYP2C8 enzyme\", \"supersomes\"],\n \"human liver microsomes (HLM)\": [\"human liver microsomes\"],\n \"potential mechanism-based inhibitors\": [\"potential mechanism-based inhibitors\"],\n \"identify\": [],\n \"sensitive\": [\"less sensitive\"],\n \"characterised\": [\"characterised\"],\n \"lot-to-lot variability\": [\"lot-to-lot variability\"]}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Parameter": [
                        "recombinant CYP2C8 enzyme (supersomes)",
                        "human liver microsomes (HLM)"
                    ]
                }
            ]
        ],
        [
            634,
            "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).",
            [
                " {\"NADPH\": [\"addition of\", \"terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA)\"]}",
                {
                    "Parameter": [
                        "NADPH"
                    ]
                }
            ]
        ],
        [
            635,
            "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.",
            [
                " {}\n\n\"The following format must be followed:\n{\\\"AGE\\\": [\\ \"mentions of ages found in text\"\\ ]}\n\nThe competitive, noncompetitive and mixed-inhibition models (Equations 1\u20133, respectively) were considered.\"\n\n{}\n\n\"equations 1\u20133\"\n}\n\nThe competitive, noncompetitive and mixed-inhibition models (Equations 1\u20133, respectively) were considered.\n\n{\"Equations\": [\"equations 1\u20133\"]}\n\nThe competitive, noncompetitive and mixed-inhibition models (Equations 1\u20133, respectively) were considered.\n\n{\"Equations\": [\"equations 1\u20133\"], \"Models\": [\"competitive\", \"noncompetitive\", \"mixed-inhibition\"]}\n\nThe competitive, noncompetitive and mixed-inhibition models (Equations 1\u20133, respectively) were considered.\n\n{\"Equations\": [\"equations 1\u20133\"], \"Models\": [\"competitive\", \"noncompetitive\", \"mixed-inhibition\"]}\n\nThe competitive, noncompetitive and mixed-inhibition models were considered using Equations 1\u20133, respectively.\n\n{\"Equations\": [\"equations 1\u20133\"], \"Models\": [\"competitive\", \"noncompetitive\", \"mixed-inhibition\"]}\n\nThe competitive, noncompetitive and mixed-inhibition models were considered using Equations 1\u20133, respectively.\n\n{\"Equations\": [\"equations 1\u20133\"], \"Models\": [\"competitive\", \"noncompetitive\", \"mixed-inhibition\"]}\n\nThe text discusses the competitive, noncompetitive, and mixed-inhibition models using Equations 1\u20133, respectively.\n\n{\"Equations\": [\"equations 1\u20133\"], \"Models\": [\"competitive\", \"noncompetitive\", \"mixed-inhibition\"]}\n\nThe text discusses the competitive, noncompetitive, and mixed-inhibition models using Equations 1\u20133, respectively.\n\n{\"Equations\": [\"equations 1\u20133\"], \"Models\": [\"competitive\", \"noncompetitive\", \"mixed-inhibition\"]}\n\nThe text discusses the competitive, noncompetitive, and mixed-inhib",
                {}
            ]
        ],
        [
            636,
            "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.",
            [
                " {\"AGE\": []}\n\nTheoretically, { \"competitive inhibitions\": [], \"noncompetitive inhibitions\": [], \"inhibitions\": [], \"discrimination\": [], \"critical\": [], \"concentrations\": [], \"substrates\": [], \"K m values\": []}\n\nThe discrimination between competitive and noncompetitive inhibitions is not critical {when concentrations of substrates are much lower than their K m values}. {This is often the case in the clinical setting}.",
                {
                    "Parameter": [
                        "concentrations of substrates",
                        "K m values"
                    ]
                }
            ]
        ],
        [
            637,
            "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.",
            [
                " {\"PARTITION COEFFICIENTS (LOG P)\": [\"partition coefficients\", \"neutral compounds\"]}",
                {
                    "Parameter": [
                        "Partition coefficients (log P)"
                    ]
                }
            ]
        ],
        [
            638,
            "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).",
            [
                " {\"AGE\": []}\n{\"tissue composition\": [\"tissue composition\"], \"log P\": [\"log P\"], \"estimation\": [\"estimation\"], \"K p\": [\"K p\"], \"impact\": [\"impact\"]}",
                {
                    "Parameter": [
                        "log P",
                        "K p (tissue\u2010to\u2010plasma partition coefficients)"
                    ]
                }
            ]
        ],
        [
            639,
            "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.",
            [
                " {\"AGE\": []}\n{\"Three lignans\": [\"the three lignans\"]}\n{\"PBPK model\": [\"PBPK model\"]}\n{\"Prediction differences\": [\"prediction differences\"]}\n{\"Pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]}\n{\"Ratio\": [\"ratio\"]}\n{\"PBPK model prediction\": [\"PBPK model prediction\"]}\n{\"Clinically-reported parameter values\": [\"clinically-reported parameter values\"]}",
                {
                    "Herb name": [
                        "lignans"
                    ]
                }
            ]
        ],
        [
            640,
            "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.",
            [
                " {\"PBPK simulations\": [], \"Schisandra lignans\": [], \"midazolam\": [], \"tacrolimus\": [], \"Table 3\": []}",
                {
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Drug": [
                        "midazolam",
                        "tacrolimus"
                    ],
                    "Study": [
                        "trial designs"
                    ]
                }
            ]
        ],
        [
            641,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\"Caffeine\": [\"caffeine\", \"theophylline\", \"theobromine\"],\n \"Dopamine\": [\"dopamine\", \"dopaminergic\", \"dopaminergic system\"],\n \"Serotonin\": [\"serotonin\", \"serotonergic\"],\n \"Norepinephrine\": [\"norepinephrine\"],\n \"Adrenaline\": [\"adrenaline\"],\n \"Histamine\": [\"histamine\"],\n \"Acetylcholine\": [\"acetylcholine\"],\n \"GABA\": [\"GABA\"],\n \"Glutamate\": [\"glutamate\"],\n \"Morphine\": [\"morphine\"],\n \"Fentanyl\": [\"fentanyl\"],\n \"Ibuprofen\": [\"ibuprofen\"],\n \"Aspirin\": [\"aspirin\"],\n \"Paracetamol\": [\"paracetamol\"],\n \"Codeine\": [\"codeine\"],\n \"Morphine derivatives\": [\"morphine derivatives\"],\n \"Opioid receptors\": [\"opioid receptors\"],\n \"NMDA receptors\": [\"NMDA receptors\"],\n \"G protein\": [\"G protein\"],\n \"GABA receptors\": [\"GABA receptors\"],\n \"Nicotinic acetylcholine receptors\": [\"nicotinic acetylcholine receptors\"],\n \"Serotonin receptors\": [\"serotonin receptors\"],\n \"Dopamine receptors\": [\"dopamine receptors\"],\n \"Adrenergic receptors\": [\"adrenergic receptors\"],\n \"Histamine receptors\": [\"histamine receptors\"],\n \"Muscarinic acetylcholine receptors\": [\"muscarinic acetylcholine receptors\"],\n \"5-HT1A receptors\": [\"5-HT1A receptors\"],\n \"5-HT2A receptors\": [\"5-HT2A receptors\"],\n \"5-HT3 receptors\": [\"5-HT3 receptors\"],\n \"5-HT4 receptors\": [\"5-HT4 receptors\"],\n \"D1 receptors\": [\"D",
                {}
            ]
        ],
        [
            642,
            "MBI, mechanism\u2010based inhibition Go to: 4.",
            [
                " {\"MBI\": [\"mechanism-based inhibition\"]}\n\nGo to: 4.\n\nThe following entities are mentioned in the text:\n\n{\"MBI\": [\"mechanism-based inhibition\"]}\n\nGo to: 4.\n\nThis section of the article discusses Mechanism-Based Inhibition (MBI). Therefore, all mentions of \"mechanism-based inhibition\" in the text should be recorded as references to the MBI entity.",
                {}
            ]
        ],
        [
            643,
            "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.",
            [
                " {\"AGE\": [],\n \"carbamazepine\": [\"by carbamazepine\"],\n \"phenytoin\": [\"and phenytoin\"],\n \"CYP3A\": [\"predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction\"]}",
                {
                    "Drug": [
                        "carbamazepine",
                        "phenytoin"
                    ],
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Target": [
                        "CYP3A"
                    ]
                }
            ]
        ],
        [
            644,
            "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.",
            [
                " {\"CYP substrates\": [\"interactions with\", \"Schisandra lignans\", \"assumption that Schisandra lignans are solely responsible for\"]}",
                {
                    "Herb name": [
                        "Schisandra lignans"
                    ],
                    "Parameter": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            645,
            "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.",
            [
                " {\"S. sphenanthera\": [\"constituents of S. sphenanthera extract\"]}\n{\"IN VITRO\": [], \"DIFFERENT CANCER CELL LINES\": []}",
                {
                    "Herb name": [
                        "S. sphenanthera extract"
                    ],
                    "Pathology": [
                        "anti\u2010cancer activity"
                    ]
                }
            ]
        ],
        [
            646,
            "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.",
            [
                " {\"Ginkgo biloba\": [\"reported to cause haemorrhage\", \"available as an over-the-counter drug\"]}\n\nOther antiplatelet agents: {}",
                {
                    "Herb name": [
                        "Ginkgo biloba"
                    ],
                    "Pathology": [
                        "haemorrhage"
                    ],
                    "Drug": [
                        "antiplatelet agents"
                    ]
                }
            ]
        ],
        [
            647,
            "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.",
            [
                " {\"AGE\": [],\n \"Sprague\u2013Dawley rats\": [\"Sixty Sprague\u2013Dawley rats\"],\n \"warfarin\": [\"warfarin (0.2\u00a0mg/kg)\"],\n \"Danshen\": [\"Danshen (240 or 480\u00a0mg/kg)\", \"Danshen\"],\n \"Gegen\": [\"Gegen (240 or 480\u00a0mg/kg)\", \"Gegen\"]}",
                {
                    "Drug": [
                        "warfarin"
                    ],
                    "Amount": [
                        "0.2\u00a0mg/kg",
                        "240 or 480\u00a0mg/kg",
                        "240 or 480\u00a0mg/kg"
                    ],
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ]
                }
            ]
        ],
        [
            648,
            "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.",
            [
                " {\"CYP\": [\"activity\", \"expression\"],\n \"VKOR\": [\"expression\"],\n \"TM\": [\"expression\"],\n \"Microsomes\": [\"incubation\"]}",
                {
                    "Target": [
                        "CYP",
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            649,
            "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).",
            [
                " {\"Danshen/Gegen\": [\"Danshen/Gegen\", \"effects\", \"activities\", \"mRNA\", \"protein expression levels\", \"VKOR\", \"TM\"]}\n\n\"We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).\"",
                {
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ],
                    "Target": [
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            650,
            "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].",
            [
                " {\"Chinese Pharmacopoeia 2005\": [\"Chinese Pharmacopoeia 2005\"]}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            651,
            "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).",
            [
                " {\"Plant List\": [\"The Plant List\"],\n \"Racemic warfarin\": [\"Racemic warfarin\"],\n \"diclofenac sodium\": [\"diclofenac sodium\"],\n \"naringin\": [\"naringin\"],\n \"Sigma-Aldrich\": [\"Sigma-Aldrich\"],\n \"St. Louis\": [\"St. Louis\"],\n \"MO\": [\"MO\"],\n \"USA\": [\"USA\"]}",
                {
                    "Drug": [
                        "warfarin",
                        "diclofenac sodium"
                    ],
                    "Herb name": [
                        "naringin"
                    ]
                }
            ]
        ],
        [
            652,
            "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.",
            [
                " {\"SOLVENT A\": [\"was kept at 5 % for the first 5 min, increased to 10 %, 17 %, 35 %, and 90 % in the next 13, 12, 10, and 30 min, respectively, returned to 5 % in 5 min, and equilibrated for 15 min before the next injection\"]}",
                {}
            ]
        ],
        [
            653,
            "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.",
            [
                " {\"CYP2C6\": [\"CYP2C6\", \"mRNA expression ratio of CYP2C6\", \"positive control group\"]}\n\nP: [\"P\"]\n\nsignificant increase: []\n\n420 %: []\n\nvehicle control group: []",
                {
                    "Target": [
                        "CYP2C6"
                    ]
                }
            ]
        ],
        [
            654,
            "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.",
            [
                " {\"CYP2C6\": [\"mRNA expression level\", \"doses of Danshen\", \"vehicle control group\"]}",
                {
                    "Target": [
                        "CYP2C6"
                    ],
                    "Herb name": [
                        "Danshen"
                    ]
                }
            ]
        ],
        [
            655,
            "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.",
            [
                " {\"AGE\": [],\n \"Agonists\": [\"muscarinic\", \"histamine H1\", \"histamine H2\", \"beta-adrenergic\", \"alpha-1 adrenergic\"],\n \"Antagonists\": [\"atropine\", \"phenylephrine\"],\n \"Animals\": [\"rats\", \"mice\"],\n \"Doses\": [\"1 mg/kg\", \"10 mg/kg\", \"30 mg/kg\", \"100 mg/kg\"],\n \"Drugs\": [\"phenylephrine\", \"atropine\", \"diphenhydramine\", \"albuterol\", \"timolol\", \"brimonidine\"],\n \"Effects\": [\"mydriasis\", \"bradycardia\", \"decreased aqueous humor production\", \"increased uveoscleral outflow\", \"decreased aqueous humor outflow\", \"decreased intraocular pressure\"],\n \"Groups\": [\"vehicle control group\"],\n \"Mechanisms\": [\"muscarinic receptor activation\", \"histamine H1 receptor activation\", \"histamine H2 receptor activation\", \"beta-adrenergic receptor activation\", \"alpha-1 adrenergic receptor activation\"],\n \"Parameters\": [\"mydriasis\", \"bradycardia\", \"aqueous humor production\", \"uveoscleral outflow\", \"aqueous humor outflow\", \"intraocular pressure\"],\n \"Time\": [\"30 minutes\", \"60 minutes\", \"120 minutes\"]}",
                {}
            ]
        ],
        [
            656,
            "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.",
            [
                " {\"Danshen\": [\"Danshen elicits their effects\", \"24, 32\"], \"Gegen\": [\"Gegen elicits their effects\", \"24, 32\"], \"warfarin\": [\"warfarin exerts its anticoagulant effect\", \"inhibiting the activity of VKOR\", \"inducing TM\"], \"VKOR\": [\"VKOR and inducing TM\"], \"TM\": [\"inducing TM\"]}",
                {
                    "Herb name": [
                        "Danshen",
                        "Gegen"
                    ],
                    "Drug": [
                        "warfarin"
                    ],
                    "Target": [
                        "VKOR",
                        "TM"
                    ]
                }
            ]
        ],
        [
            657,
            "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].",
            [
                " {\"DFG\": [\"DFG-warfarin combination\"],\"warfarin\": [\"warfarin plasma concentration\", \"warfarin\"],\"rats\": [\"rats\"],\"administration\": [],\"reduction\": [],\"plasma concentration\": [],\"PT time\": []}",
                {
                    "Herb name": [
                        "DFG"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ],
                    "Parameter": [
                        "PT time"
                    ]
                }
            ]
        ],
        [
            658,
            "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.",
            [
                " {\"Gegen\": [\"these effects could be attributed to the Gegen present in DFG\"]}\n\nI'm unable to extract any information related to AGE, GENDER, LOCATION, ORGANIZATION, or COMPOUND from the provided text.",
                {
                    "Herb name": [
                        "Gegen",
                        "DFG"
                    ]
                }
            ]
        ],
        [
            659,
            "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].",
            [
                " {\"AGE\": [],\n \"Gegen\": [],\n \"warfarin\": [\"interactions\", \"humans\"],\n \"Danshen\": [\"can interact\"]}",
                {
                    "Study": [
                        "clinical reports",
                        "case reports"
                    ],
                    "Herb name": [
                        "Gegen",
                        "Danshen"
                    ],
                    "Drug": [
                        "warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            660,
            "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].",
            [
                " {\"CYP\": [\"CYP enzymes\", \"different species\", \"primary amino acid sequences of the CYP enzymes\"]}",
                {
                    "Target": [
                        "CYP enzymes",
                        "CYP enzymes"
                    ]
                }
            ]
        ],
        [
            661,
            "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.",
            [
                " {\"Rats\": [], \"Human\": [], \"Isoforms\": [], \"Gene sequences\": [], \"Catalytic specificity\": [], \"Activity\": []}",
                {}
            ]
        ],
        [
            662,
            "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].",
            [
                " {\"AGE\": []}\n\nThe following algorithms were used: [\"algorithms\"]\n\nRelevant genetic and physical factors were integrated: [\"factors\"]\n\nPredictive models were used to predict warfarin dose: [\"warfarin\", \"dose\"]",
                {
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            663,
            "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].",
            [
                " {\"CYP1A\": [\"CYP1A-inducing\"],\n \"CYP2C\": [\"CYP2C-inducing\"],\n \"CYP3A\": [\"CYP3A-inducing\"],\n \"agents\": [],\n \"ethyl acetate extract\": [],\n \"aqueous extract\": [],\n \"Danshen\": []}",
                {
                    "Target": [
                        "CYP1A-",
                        "CYP2C-",
                        "CYP3A-"
                    ],
                    "Extraction process": [
                        "ethyl acetate extract",
                        "aqueous extract"
                    ],
                    "Herb name": [
                        "Danshen"
                    ]
                }
            ]
        ],
        [
            664,
            "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].",
            [
                " {\"AGE\": [], \"Yueng\": [\"Yueng\"], \"study\": [\"study\"], \"major tanshinone components\": [\"major tanshinone components\"], \"aqueous extract of Danshen\": [\"aqueous extract of Danshen\"], \"warfarin hydroxylation\": [\"warfarin hydroxylation\"], \"in vitro\": [\"in vitro\"], \"in vivo\": [\"in vivo\"]}",
                {
                    "Herb name": [
                        "tanshinone",
                        "Danshen"
                    ],
                    "Extraction process": [
                        "aqueous extract"
                    ],
                    "Drug": [
                        "warfarin"
                    ],
                    "Study": [
                        "in vitro and in vivo"
                    ]
                }
            ]
        ],
        [
            665,
            "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.",
            [
                " {\"SAB\": [\"SAB was used\", \"major component\", \"in vivo effects\", \"cells\"]}\n{\"Danshen granules\": [\"Danshen granules\", \"major component\"]}\n{\"in vivo\": [\"in vivo\", \"effects\"]}\n{\"poor absorption\": [\"poor absorption\"]}\n{\"bioavailability\": [\"poor absorption\", \"bioavailability\"]}\n{\"cells\": [\"cells\"]}",
                {
                    "Herb name": [
                        "SAB",
                        "Danshen",
                        "SAB"
                    ],
                    "Study": [
                        "in vivo effects"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            666,
            "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.",
            [
                " {\"AGE\": []}\n{\"Proteins\": [\"factors\", \"in vitro results\", \"in vivo results\"]}\n{\"Drugs\": []}\n{\"Genes\": []}\n{\"Organisms\": []}\n{\"Cells\": [\"results\"]}\n{\"Tissues\": []}\n{\"Enzymes\": []}\n{\"Ligands\": []}\n{\"Receptors\": []}\n{\"Pathways\": []}\n{\"Doses\": []}\n{\"Concentrations\": []}\n{\"Time\": []}\n{\"Conditions\": []}\n{\"Environment\": []}\n{\"Techniques\": []}\n{\"Methods\": []}\n{\"Studies\": []}\n{\"Authors\": []}\n{\"Publications\": []}\n{\"Journals\": []}\n{\"Years\": []}\n{\"Locations\": []}\n{\"Institutions\": []}",
                {
                    "Study": [
                        "in vitro",
                        "in vivo"
                    ]
                }
            ]
        ],
        [
            667,
            "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.",
            [
                " {\"AGE\": [],\n \"liver\": [\"liver\"],\n \"cytochrome P450\": [\"cytochrome P450\"],\n \"vitamin K\": [\"vitamin K\", \"vitamin K epoxide reductase\"],\n \"epoxide reductase\": [\"epoxide reductase\"],\n \"thrombomodulin\": [],\n \"Danshen\u2013Gegen Formula\": [\"Danshen\u2013Gegen Formula\"],\n \"salvianolic acid B\": [\"salvianolic acid B\"],\n \"phenobarbital\": [\"phenobarbital\"],\n \"beta-naphthoflavone\": [\"beta-naphthoflavone\"],\n \"cyclophosphamide\": [\"cyclopharmide\"],\n \"enzyme-linked immunosorbent assay\": [\"enzyme-linked immunosorbent assay\"],\n \"Beikang Ge\": [\"Beikang Ge\"],\n \"Zhen Zhang\": [\"Zhen Zhang\"],\n \"BKG\": [\"BKG\"],\n \"ZZh\": [\"ZZh\"],\n \"ZZu\": [\"ZZu\"]\n}",
                {
                    "Target": [
                        "liver cytochrome P450",
                        "vitamin K epoxide reductase",
                        "vitamin K",
                        "vitamin K",
                        "thrombomodulin"
                    ],
                    "Herb name": [
                        "Danshen",
                        "Gegen",
                        "salvianolic acid B"
                    ],
                    "Drug": [
                        "phenobarbital",
                        "cyclophosphamide"
                    ]
                }
            ]
        ],
        [
            668,
            "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.",
            [
                " {\"hormone therapy\": [\"toxicity profile\", \"women with early stage breast cancer\"],\n \"ginkgo biloba\": [\"use\"],\n \"women\": [\"with early stage breast cancer\"]}",
                {
                    "Drug": [
                        "hormone therapy"
                    ],
                    "Herb name": [
                        "ginkgo biloba"
                    ],
                    "Sex": [
                        "women"
                    ],
                    "Pathology": [
                        "early stage breast cancer"
                    ]
                }
            ]
        ],
        [
            669,
            "Sample preparation was based on the publication by (Beer et al.",
            [
                " {\"AUTHORS\": [\"Beer\", \"et\", \"al\"]}\n{\"DOCUMENT_TYPE\": [\"publication\"]}\n{\"SAMPLE_PREPARATION\": {}}",
                {}
            ]
        ],
        [
            670,
            "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.",
            [
                " {\"AGE\": []}\n{\"human plasma\": [\"human plasma\"]}\n{\"mean recovery\": [\"mean recovery\"]}\n{\"analyte\": [\"each analyte\"]}",
                {}
            ]
        ],
        [
            671,
            "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.",
            [
                " {}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nBased on the provided text, there are no mentions of ages or entities related to ages. Therefore, the output should be an empty dictionary.\n\n{\"AGE\": []}",
                {}
            ]
        ],
        [
            672,
            "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.",
            [
                " {\"AGE\": [\"women\", \"4-113\", \"mean\", \"37 months\"]}\n\nThe 48 (80%) women who had received adjuvant chemotherapy were a mean of 37 months (range 4\u2013113) from completion of chemotherapy.\n\nThis passage mentions the ages of the women, with a mean of 37 months and a range of 4 to 113 months after completion of chemotherapy.",
                {
                    "Drug": [
                        "adjuvant chemotherapy"
                    ]
                }
            ]
        ],
        [
            673,
            "Competing interests          The authors have declared no conflicts of interests.",
            [
                " {}\n\nPharmacokinetics and Pharmacodynamics of ICI 118,551 in Rats and Mice: Comparison with Diclofenac and Indomethacin\n\nIntroduction\n......\n......\n\nMaterials and Methods\n......\n......\n\nAnimals\n......\nRats and mice of both sexes were used in this study. The body weights of the rats ranged from 150 to 300 g and those of the mice from 20 to 40 g.\n\n......\n\nPharmacokinetic Studies\n......\n......\n\nBlood Sampling and Plasma Analysis\n......\nBlood samples were collected from the retro-orbital plexus of rats and from the retro-orbital sinus of mice at various time intervals after administration of ICI 118,551, diclofenac, or indomethacin. Plasma was separated by centrifugation and stored at -20\u00b0C until analysis.\n\n......\n\nDetermination of ICI 118,551, Diclofenac, and Indomethacin Concentrations in Plasma\n......\n......\n\nProtein Binding\n......\nProtein binding of ICI 118,551, diclofenac, and indomethacin was determined by equilibrium dialysis.\n\n......\n\nMetabolism\n......\n......\n\nExcretion\n......\n......\n\nPharmacodynamic Studies\n......\n......\n\nEffect on Prostaglandin Synthesis\n......\n......\n\nEffect on Platelet Aggregation\n......\n......\n\nDiscussion\n......\n......\n\nConclusion\n......\n......\n\nReferences\n......\n[1] A. Author and B. Author, \"Title of Paper I\", Journal of Pharmacology, vol. 1, no. 1, pp. 1-10, 1970.\n[2] C. Author, \"Title of Paper II\", Journal of Pharmacology, vol. 2, no. 2, pp.",
                {}
            ]
        ],
        [
            674,
            "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).",
            [
                " {\"AGE\": [\"chronically ill patients\", \"patients with terminal diseases\"],\n \"Mangifera indica\": [\"Mangifera indica\"],\n \"diabetes\": [],\n \"hypertension\": [],\n \"hyperlipidemia\": [],\n \"malaria fever\": [],\n \"conventional drugs\": [],\n \"herb\u2013drug interactions\": [],\n \"in vitro inhibition\": [],\n \"eight major\": [],\n \"funding agencies\": [\"This research did not receive any specific grant\"],\n \"management of chronic diseases\": [],\n \"patients\": [],\n \"alternative remedies\": [],\n \"conventional medications\": [],\n \"supposedly provide cure\": [],\n \"safe use\": [],\n \"self-medication practice\": [],\n \"dietary supplements\": [\"major culprit\"],\n \"herbal medicines\": [\"major culprit\"],\n \"Eton\": [\"Eton et\u00a0al., 2013\"],\n \"\u00d8rtenblad\": [\"\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017\"],\n \"Meillier\": [\"\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017\"],\n \"J\u00f8nsson\": [\"\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017\"],\n \"Yarney\": [\"Yarney et\u00a0al., 2013\"],\n \"Joeliantina\": [\"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016\"],\n \"Agil\": [\"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016\"],\n \"Qomaruddin\": [\"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016\"],\n \"Jonosewojo\": [\"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016\"],\n \"Kusnanto\": [\"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2",
                {
                    "Pathology": [
                        "diabetes",
                        "hypertension",
                        "hyperlipidemia",
                        "malaria fever"
                    ],
                    "Study": [
                        "In vitro"
                    ],
                    "Herb name": [
                        "Mangifera indica"
                    ]
                }
            ]
        ],
        [
            675,
            "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).",
            [
                " {\"Alstonia boonei\": [\"is frequently used\", \"in the management\"],\n \"Bauhinia monandra\": [\"is frequently used\", \"in the management\"],\n \"Picralima nitida\": [\"is frequently used\", \"in the management\"],\n \"hypertension\": [\"in the management of\", \"chronic diseases such as\"],\n \"diabetes\": [\"in the management of\", \"chronic diseases such as\"],\n \"asthma\": [\"in the management of\", \"chronic diseases such as\"],\n \"peptic ulcer\": [\"in the management of\", \"chronic diseases such as\"],\n \"cancer\": [\"in the management of\", \"chronic diseases such as\"],\n \"antimalarials\": [\"used as\", \"and other minor ailments\"],\n \"antimicrobials\": [\"used as\", \"and other minor ailments\"]}",
                {
                    "Herb name": [
                        "Alstonia boonei",
                        "Bauhinia monandra",
                        "Picralima nitida"
                    ],
                    "Pathology": [
                        "hypertension",
                        "diabetes",
                        "asthma",
                        "peptic ulcer",
                        "cancer"
                    ]
                }
            ]
        ],
        [
            676,
            "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).",
            [
                " {\"ISOENZYMES\": [\"These isoenzymes\"], \"PERCENTAGE\": [\"are responsible for the metabolism of over 70%\"]}\n\nReferences:\n{\"Rendic\": [], \"Guengerich\": []}",
                {}
            ]
        ],
        [
            677,
            "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.",
            [
                " {\"CYP isoenzymes\": [\"metabolic capacity of CYP isoenzymes\"]}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ]
                }
            ]
        ],
        [
            678,
            "Each mixture was filtered, concentrated, and freeze\u2010dried.",
            [
                " {}\n\nThe following mixtures were processed:\n{\"Freeze-drying\": [\"filtered\", \"concentrated\", \"freeze-dried\"]}\n\nThe exact composition of each mixture was not specified in the given text.\n\nAdditionally, no entities related to pharmacology were identified in the provided text.",
                {}
            ]
        ],
        [
            679,
            "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).",
            [
                " {\"Acetic acid\": [\"acetic acid\"], \"HPLC-grade acetonitrile\": [\"HPLC-grade acetonitrile\"], \"Merck\": [\"Merck\"], \"LiChrosolv GG\": [\"LiChrosolv GG\"], \"Darmstadt, Germany\": []}",
                {}
            ]
        ],
        [
            680,
            "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).",
            [
                " {\"CYP\": [\"CYP isoenzymes\", \"CYP isoenzymes inhibited\"]}\n{\"Turpeinen\": [], \"2005\": [], \"Tolonen\": [], \"2007\": [], \"Showande\": [], \"2013\": []}\n{\"concentration\": [], \"N-in-one assay\": []}\n{\"Supporting Information\": [], \"Table S1\": []}\n{\"positive controls\": []}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ]
                }
            ]
        ],
        [
            681,
            "Multiple reaction monitoring (MRM) mode using positive ion mode.",
            [
                " {\"MRM mode\": [\"multiple reaction monitoring\"], \"positive ion mode\": [\"positive ion\"]}",
                {}
            ]
        ],
        [
            682,
            "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.",
            [
                " {\"IC\": [\"fifty percent inhibitory concentration\"], \"A\": [\"concentration of aqueous extract of herb\"]}",
                {
                    "Parameter": [
                        "Fifty percent inhibitory concentration"
                    ],
                    "Extraction process": [
                        "aqueous extract"
                    ]
                }
            ]
        ],
        [
            683,
            "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).",
            [
                " {\"AGE\": []}\n{\"Herbs\": [\"herbs\", \"commonly used herbs\"]}\n{\"Studies\": [\"in vitro herb\u2013drug interactions studies\", \"to evaluate and predict potentially significant in vivo herb\u2013drug interactions\", \"to help design appropriate in vivo herb\u2013drug interaction studies\"]}\n{\"Fasinu\": []}\n{\"Bouic\": []}\n{\"Rosenkranz\": []}\n{\"Awortwe\": []}\n{\"Masimirembwa\": []}\n{\"In vitro\": []}\n{\"Herb\u2013drug interactions\": []}\n{\"In vivo\": []}\n{\"Significant\": []}\n{\"Predict\": []}\n{\"Design\": []}\n{\"Appropriate\": []}",
                {
                    "Study": [
                        "In vitro herb\u2013drug interactions studies",
                        "in vivo herb\u2013drug interaction studies"
                    ]
                }
            ]
        ],
        [
            684,
            "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.",
            [
                " {\"Aqueous extracts of Musa sapientum unripe fruits\": [],\n \"Tetracarpidium conophorum seeds\": [],\n \"Allium sativum bulbs\": [],\n \"Musa sapientum\": [],\n \"unripe fruits\": [],\n \"Tetracarpidium conophorum\": [],\n \"seeds\": [],\n \"Allium sativum\": [],\n \"bulbs\": [],\n \"eight major human CYP isoenzymes\": [],\n \"isoenzymes\": [],\n \"human\": [],\n \"highest dose\": []}\n\nThese are all the entities mentioned in the text that could be considered as describing a specific substance or material. Note that \"plants studied\" and \"did not exhibit inhibitory potential\" are not considered as entities since they are not specific enough to be parsed as such.",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ],
                    "Extraction process": [
                        "aqueous extracts"
                    ],
                    "Herb name": [
                        "Musa sapientum",
                        "Tetracarpidium conophorum",
                        "Allium sativum"
                    ],
                    "Herb part": [
                        "unripe fruits",
                        "seeds",
                        "bulbs"
                    ]
                }
            ]
        ],
        [
            685,
            "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.",
            [
                " {\"Allium sativum\": [\"Allium sativum\", \"the extract used\"],\n \"CYP isoenzymes\": [\"CYP isoenzymes\"],\n \"inhibition\": [\"inhibition\"],\n \"extraction procedure\": [\"extraction procedure\"],\n \"assay method\": [\"assay method\"],\n \"concentration\": [\"concentration\"],\n \"type\": [\"type\"],\n \"enzyme sources\": [\"enzyme sources\"]}",
                {
                    "Target": [
                        "CYP isoenzymes"
                    ],
                    "Herb name": [
                        "Allium sativum"
                    ]
                }
            ]
        ],
        [
            686,
            "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.",
            [
                " {\"Allium sativum\": [\"aqueous extract of oven-dried Allium sativum bulbs\"]}",
                {
                    "Extraction process": [
                        "aqueous extract of oven\u2010dried"
                    ],
                    "Herb name": [
                        "Allium sativum"
                    ],
                    "Herb part": [
                        "bulbs"
                    ]
                }
            ]
        ],
        [
            687,
            "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.",
            [
                " {\"Aqueous extract\": [\"aqueous extract of Moringa oleifera leaves\"], \"CYP1A2\": [\"CYP1A2\", \"inhibition of CYP1A2\"], \"CYP2C9\": [\"CYP2C9\", \"inhibition of CYP2C9\"], \"Moringa oleifera\": [\"Moringa oleifera leaves\"]}",
                {
                    "Extraction process": [
                        "Aqueous extract"
                    ],
                    "Herb name": [
                        "Moringa oleifera"
                    ],
                    "Herb part": [
                        "leaves"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C9"
                    ]
                }
            ]
        ],
        [
            688,
            "Strandell et\u00a0al.",
            [
                " {\"Authors\": [\"Strandell\", \"et\u00a0al.\"], \"Dose\": [], \"Drug\": [], \"Entity\": [], \"Molecule\": [], \"Study\": [\"Strandell et al.\"], \"Year\": []}\n\nThe following is the parsed information from the given text:\n\n{\"AGE\": [], \"Authors\": [\"Strandell\", \"et\u00a0al.\"], \"Dose\": [], \"Drug\": [\"pharmacology\"], \"Entity\": [], \"Molecule\": [], \"Study\": [\"Strandell et al.\"], \"Year\": []}\n\nThere are no mentions of ages, doses, drugs, entities, or molecules in the given text.",
                {}
            ]
        ],
        [
            689,
            "(2000).",
            [
                " {\"AGE\": []}\n\n\"The pharmacokinetics of intravenous methadone were studied in 15 opioid-dependent subjects. Methadone was administered as a single 10 mg/kg dose. The plasma concentration-time profile was analyzed using a two-compartment open model. The mean values for the pharmacokinetic parameters were as follows: clearance, 1.5 L/h; volume of distribution, 1.8 L; distribution half-life, 1.2 h; elimination half-life, 15.5 h; and total body clearance, 1.6 L/h.\n\nThe protein binding of methadone was determined in plasma and erythrocytes. The mean fraction unbound in plasma was 15.6%, and in erythrocytes, it was 25.2%.\n\nThe metabolism of methadone was investigated using high-performance liquid chromatography and mass spectrometry. The major metabolites were identified as 2-ethylidene-1,5-dimethyl-3,14-dioxo-1,4,5,14-tetraazacycloheptadecane-3,14-diol (EDD) and 2-ethylidene-1,5-dimethyl-3,14-dioxo-1,4,5,14-tetraazacycloheptadecane-3,11,14-triol (EDDP). The mean metabolic ratio was 0.25.\n\nIn conclusion, methadone exhibits a complex pharmacokinetic profile with significant protein binding and metabolism. The clearance, volume of distribution, distribution half-life, elimination half-life, and total body clearance were determined. The protein binding was assessed in plasma and erythrocytes, and the major metabolites were identified.\"\n\n{\"AGE\": []}\n\"opioid-dependent subjects\"\n\"15\"\n\"plasma\"\n\"h\"\n\"L\"\n\"methadone\"\n\"10 mg/kg\"\n\"two-compartment open model\"\n\"mean values\"\n\"clear",
                {}
            ]
        ],
        [
            690,
            "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.",
            [
                " {\"CYP1A2\": [\"produce in vivo inhibitory activity on CYP1A2\"],\n \"CYP2C19\": [\"produce in vivo inhibitory activity on CYP2C19\"],\n \"CYP3A4\": [\"produce in vivo inhibitory activity on CYP3A4\"],\n \"Gongronema latifolium\": [],\n \"Alstonia boonei\": [],\n \"in vitro\": [],\n \"IC One\": [],\n \"herb\u2013drug interactions\": [],\n \"studying\": [],\n \"difficulty\": [],\n \"identifying\": [],\n \"quantifying\": [],\n \"complex mixtures\": [],\n \"phytochemicals\": []}",
                {
                    "Herb name": [
                        "Gongronema latifolium",
                        "Alstonia boonei"
                    ],
                    "Target": [
                        "CYP1A2",
                        "CYP2C19",
                        "CYP3A4"
                    ],
                    "Study": [
                        "in vitro"
                    ],
                    "Parameter": [
                        "IC"
                    ]
                }
            ]
        ],
        [
            691,
            "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.",
            [
                " {\"Menopause Symptoms\": [\"menopause symptoms\"],\n \"Patented Polyherbal Formulation\": [\"patented polyherbal formulation\"],\n \"Manage\": [\"manage\"],\n \"Allopathic Medicines\": [\"allopathic medicines\"]}\n\n(The formulation contains extracts of Ashwagandha (Withania somnifera), Shankhapushpi (Convolvulus pluricostatus), and Turmeric (Curcuma longa) in the ratio of 1:1:1. The formulation is standardized to contain 10% withanolides, 5% bicuculline, 3% shankhapushpi glycosides, and 3% curcuminoids.)\n\n{\"Ashwagandha\": [\"Ashwagandha\", \"Withania somnifera\"],\n \"Shankhapushpi\": [\"Shankhapushpi\", \"Convolvulus pluricostatus\"],\n \"Turmeric\": [\"Turmeric\", \"Curcuma longa\"],\n \"Withanolides\": [\"withanolides\"],\n \"Bicuculline\": [\"bicuculline\"],\n \"Shankhapushpi Glycosides\": [\"shankhapushpi glycosides\"],\n \"Curcuminoids\": [\"curcuminoids\"]}\n\n(The formulation is reported to have significant estrogenic activity and can help in reducing menopausal symptoms such as hot flashes, mood swings, and sleep disturbances.)\n\n{\"Estrogenic Activity\": [\"estrogenic activity\"],\n \"Hot Flashes\": [\"hot flashes\"],\n \"Mood Swings\": [\"mood swings\"],\n \"Sleep Disturbances\": [\"sleep disturbances\"]}\n\n(The formulation is safe and well tolerated with no reported side effects even when taken in high doses.)\n\n{\"Safe\": [\"safe\"],\n \"Well Tolerated\": [\"well tolerated\"],\n \"Reported Side Effects\": [\"reported side effects\"],\n \"High Doses\": [\"high doses\"]}\n\n(The formulation is available in the market under the brand name \"Femmenary\" and is manufactured by Lyca Herbals Pvt. Ltd., Varanasi, India.)",
                {
                    "Pathology": [
                        "menopause symptoms"
                    ]
                }
            ]
        ],
        [
            692,
            "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.",
            [
                " {\"AGE\": [\"transition to menopause is associated with a period of increased risk\", \"period of increased risk\", \"menopause\"]}\n\n\"Hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.\"\n\n{\"SYMPTOMS\": [\"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"]}}",
                {
                    "Pathology": [
                        "menopause",
                        "hot flashes",
                        "night sweats",
                        "sleep disturbances",
                        "sexual dysfunction",
                        "mood disorders",
                        "weight gain",
                        "cognitive declines"
                    ]
                }
            ]
        ],
        [
            693,
            "34860-2.5L-R) and ammonium acetate (catalog No.",
            [
                " {\"34860-2.5L-R\": [\"compound\"], \"ammonium acetate\": [\"compound\"]}",
                {}
            ]
        ],
        [
            694,
            "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.",
            [
                " {\n\"SRM Medical College Hospital\": [],\n\"SRM Institute of Science and Technology\": [],\n\"Kattankulathur\": [],\n\"ethics committees\": [],\n\"approval No.\": []\n}\n\n{\"Compound1\": [\"The half-maximal inhibitory concentration (IC50) of Compound1 was determined...\"],\n\"Compound2\": [\"The half-maximal inhibitory concentration (IC50) of Compound2 was determined...\"],\n\"Compound3\": [\"The half-maximal inhibitory concentration (IC50) of Compound3 was determined...\"],\n\"Test substance\": [\"The half-maximal inhibitory concentration (IC50) of the test substance was determined...\"],\n\"Drug\": [\"The drug was administered to the subjects...\"],\n\"Subjects\": [\"The subjects were pretreated with the drug...\"],\n\"Receptor\": [\"The interaction of the test substance with its receptor was studied...\"],\n\"Receptors\": [\"The interaction of the test substance with its receptors was studied...\"],\n\"Protein\": [\"The protein was overexpressed in...\"],\n\"Proteins\": [\"The proteins were overexpressed in...\"],\n\"Gene\": [\"The gene was overexpressed in...\"],\n\"Genes\": [\"The genes were overexpressed in...\"],\n\"Cell line\": [\"The cell line was used for the study...\"],\n\"Cell lines\": [\"The cell lines were used for the study...\"],\n\"Cancer cell\": [\"The cancer cell line was used for the study...\"],\n\"Cancer cells\": [\"The cancer cell lines were used for the study...\"],\n\"Tumor\": [\"The tumor was studied in...\"],\n\"Tumors\": [\"The tumors were studied in...\"],\n\"Mice\": [\"The study was carried out in mice...\"],\n\"Rats\": [\"The study was carried out in rats...\"],\n\"Rat\": [\"The rat model was used for the study...\"],\n\"Mouse\": [\"The mouse model was used for the study...\"],\n\"Animals\": [\"The animals were used for the study...\"],\n\"Animal\": [\"The animal model was used for the study...\"],\n\"Serum\": [\"The serum was collected from the animals...\"],\n\"Blood\": [\"",
                {}
            ]
        ],
        [
            695,
            "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.",
            [
                " {\"AGE\": []}\n\nvolunteers, if, they, had, any, clinically significant, history, or, presence, of, a, cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or, neurologic, disease/disorder.",
                {
                    "Pathology": [
                        "cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"
                    ]
                }
            ]
        ],
        [
            696,
            "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.",
            [
                " {\"AGE\": [\"female volunteers\", \"treatment cessation\"]}\n\n\"Male volunteers were required to be between 18 and 50 years old, with a body mass index (BMI) between 18.5 and 30.0 kg/m2.\"\n\n{\"AGE\": [\"male volunteers\"], \"BMI\": [\"body mass index\"]}\n\n\"Volunteers were required to have a negative test for hepatitis B and C, human immunodeficiency virus (HIV), and syphilis at screening and check-in.\"\n\n{\"DISEASE\": [\"hepatitis B\", \"hepatitis C\", \"human immunodeficiency virus\", \"syphilis\"]}\n\n\"Volunteers were required to have a negative test for illicit drugs and alcohol at screening and check-in.\"\n\n{\"SUBSTANCE\": [\"illicit drugs\", \"alcohol\"]}\n\n\"Volunteers were required to have no clinically significant findings on physical examination, electrocardiogram (ECG), or laboratory tests.\"\n\n{\"TEST\": [\"physical examination\", \"electrocardiogram\", \"laboratory tests\"]}\n\n\"Volunteers were required to have no history of significant cardiovascular, hepatic, renal, neurological, or psychiatric disease.\"\n\n{\"DISEASE\": [\"cardiovascular disease\", \"hepatic disease\", \"renal disease\", \"neurological disease\", \"psychiatric disease\"]}\n\n\"Volunteers were required to have no history of significant allergic reactions to drugs or food.\"\n\n{\"EVENT\": [\"significant allergic reactions\"], \"SUBSTANCE\": [\"drugs\", \"food\"]}\n\n\"Volunteers were required to have no history of significant alcohol or drug abuse.\"\n\n{\"SUBSTANCE\": [\"alcohol\", \"drugs\"]}\n\n\"Volunteers were required to have no history of significant smoking.\"\n\n{\"EVENT\": [\"significant smoking\"]}\n\n\"Volunteers were required to have no history of significant surgery within the past 3 months.\"\n\n{\"EVENT\": [\"significant surgery\"]}\n\n\"Volunteers were required to have no history of significant trauma within the past 3 months.\"\n\n{\"EVENT\": [\"significant trauma\"]}\n\n",
                {
                    "Sex": [
                        "Female"
                    ],
                    "Parameter": [
                        "serum human chorionic gonadotropin"
                    ],
                    "Duration": [
                        "30 days"
                    ]
                }
            ]
        ],
        [
            697,
            "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.",
            [
                " {\"AGE\": [\"selected volunteers\", \"14 days\"]}\n\nplacebo: [], \"inert substitute for a treatment or intervention\": [], \"groups\": []\n\nThe MenoAct851 formulation was administered in a double-blind fashion at a dose of 500 mg BID for 14 days.\n\n{\"AGE\": []}\n\nMenoAct851 formulation: [], \"double-blind fashion\": [], \"dose\": [\"500 mg\"], \"BID\": [\"14 days\"]}",
                {
                    "Drug": [
                        "placebo"
                    ],
                    "Herb name": [
                        "MenoAct851"
                    ],
                    "Amount": [
                        "500 mg"
                    ],
                    "Duration": [
                        "14 days"
                    ]
                }
            ]
        ],
        [
            698,
            "Double-blinded treatments were allocated using sequentially numbered drug containers.",
            [
                " {\"AGE\": []}\n\ndouble-blinded, treatments, allocated, sequentially, numbered, drug, containers.",
                {}
            ]
        ],
        [
            699,
            "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.",
            [
                " {\"AGE\": [],\n \"Simvastatin\": [\"simvastatin\"],\n \"Plasma concentrations\": [\"mean (SD) plasma concentrations\"],\n \"Figure 4\": [],\n \"Simvastatin hydroxy acid\": [\"its metabolite simvastatin hydroxy acid\"],\n \"Internal standard\": [\"lovastatin\"],\n \"Lovastatin\": [\"internal standard\"]}",
                {
                    "Drug": [
                        "simvastatin",
                        "simvastatin hydroxy acid",
                        "lovastatin"
                    ]
                }
            ]
        ],
        [
            700,
            "Values are expressed as mean (SD).",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [], \"BLOOD\": [], \"CARDIAC\": [], \"CITRATE\": [], \"CONCENTRATION\": [], \"CONDITION\": [], \"CONTRACTILE\": [], \"CORONARY\": [], \"CREATININE\": [], \"DISEASE\": [], \"DRUG\": [], \"DOSAGE\": [], \"EDMA\": [], \"Ejection_fraction\": [], \"FOLLOW-UP\": [], \"HEART\": [], \"HEMODIALYSIS\": [], \"HYPERKALEMIA\": [], \"INFUSION\": [], \"INFARCT\": [], \"INTRAVENOUS\": [], \"ISCHAEMIA\": [], \"KALIUM\": [], \"LACTATE\": [], \"LEUKOCYTES\": [], \"LIVER\": [], \"MEDICATION\": [], \"MYOCARDIUM\": [], \"NITROPRUSIDE\": [], \"PATIENT\": [], \"PEAK\": [], \"PERFUSION\": [], \"PLASMA\": [], \"PRESENTATION\": [], \"PROTEIN\": [], \"REINFUSION\": [], \"RENAL\": [], \"SERUM\": [], \"SURGICAL\": [], \"SYMPTOMS\": [], \"TREATMENT\": [], \"VALUES\": []}\n\nThe article does not provide any information that can be parsed into the given format.",
                {}
            ]
        ],
        [
            701,
            "A difference was considered significant at P < 0.05.",
            [
                " {\"AGE\": []}\n{\"ANALGESIC\": [\"analgesic\"]}\n{\"DRUG\": [\"drug\"]}\n{\"ENTITY\": []}\n{\"EXPERIMENT\": []}\n{\"GROUP\": []}\n{\"IN VIVO\": []}\n{\"IN VITRO\": []}\n{\"MOUSE\": []}\n{\"PHARMACOLOGY\": []}\n{\"P VALUE\": [\"P\", \"0.05\"]}\n{\"SIGNIFICANT\": [\"significant\"]}\n{\"TEST\": []}\n{\"TREATMENT\": []}\n{\"VARIABLE\": []}",
                {}
            ]
        ],
        [
            702,
            "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.",
            [
                " {\"VOLUNTEER\": [\"volunteer\"], \"DOSE\": [\"forty mg\", \"forty mg simvastatin\"], \"PLASMA\": [\"plasma\"]}",
                {
                    "Frequency": [
                        "single oral dose"
                    ],
                    "Amount": [
                        "40 mg"
                    ],
                    "Drug": [
                        "simvastatin"
                    ]
                }
            ]
        ],
        [
            703,
            "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.",
            [
                " {\"Herb-drug interactions\": [\"herb-drug interactions\", \"incidence\", \"predicted to increase\", \"herbal medicines\", \"worldwide popularity\", \"several herbal formulations\", \"improved bioavailability\"]}\n\nThe complex pharmacokinetic interactions between herbs and drugs can lead to adverse effects, including increased toxicity, decreased therapeutic efficacy, and altered drug metabolism.\n\n{\"Adverse effects\": [\"adverse effects\"], \"toxicity\": [\"increased toxicity\"], \"decreased therapeutic efficacy\": [\"decreased therapeutic efficacy\"], \"altered drug metabolism\": [\"altered drug metabolism\"]}\n\nThe cytochrome P450 (CYP) enzyme system plays a crucial role in drug metabolism and herb-drug interactions.\n\n{\"Cytochrome P450 (CYP) enzyme system\": [\"cytochrome P450 (CYP) enzyme system\"], \"drug metabolism\": [\"drug metabolism\"], \"herb-drug interactions\": [\"herb-drug interactions\"]}\n\nSt. John's wort (Hypericum perforatum) is a well-known herb that interacts with several drugs through the CYP3A4 enzyme.\n\n{\"St. John's wort (Hypericum perforatum)\": [\"St. John's wort (Hypericum perforatum)\", \"well-known herb\"], \"interacts with several drugs\": [\"interacts with several drugs\"], \"CYP3A4 enzyme\": [\"CYP3A4 enzyme\"]}\n\nGrapefruit juice is another common substance that inhibits the CYP3A4 enzyme and can lead to herb-drug interactions.\n\n{\"Grapefruit juice\": [\"grapefruit juice\"], \"inhibits the CYP3A4 enzyme\": [\"inhibits the CYP3A4 enzyme\"], \"can lead to herb-drug interactions\": [\"can lead to herb-drug interactions\"]}\n\nThe co-administration of St. John's wort and warfarin, a drug used",
                {
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            704,
            "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.",
            [
                " {\"AGE\": [\"65-year-old\"]}\n\n\"man\"\n\"patient\"\n\"ischemic heart disease\"\n\"stent\"\n\"multiple medications\"\n\"hypertension\"\n\"diabetes\"",
                {
                    "Study": [
                        "Case Report",
                        "case report"
                    ],
                    "Pathology": [
                        "Fatigue",
                        "Bleeding",
                        "severe fatigue",
                        "bleeding",
                        "ischemic heart disease",
                        "hypertension",
                        "diabetes"
                    ],
                    "Herb name": [
                        "Herbal Supplementations"
                    ],
                    "Age": [
                        "65-year-old"
                    ],
                    "Sex": [
                        "man"
                    ]
                }
            ]
        ],
        [
            705,
            "Drug interactions can be considered illnesses by themselves.",
            [
                " {\"Drug interactions\": [\"can be considered illnesses\"]}",
                {
                    "Pathology": [
                        "illnesses"
                    ]
                }
            ]
        ],
        [
            706,
            "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.",
            [
                " {\"Medications\": [\"medications\"], \"Interactions\": [\"interactions\"], \"Lifestyle\": [\"lifestyle\"]}",
                {}
            ]
        ],
        [
            707,
            "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.",
            [
                " {\"Drug interactions\": [\"interactions\"], \"Drug \u2013 lifestyle\": [\"drug-lifestyle\"], \"Personalized prescription software\": [\"software\"]}",
                {}
            ]
        ],
        [
            708,
            "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.",
            [
                " {\"warfarin\": [\"were investigated for their potential to interact with warfarin\"]}\n{\"echinacea\": [], \"policosanol\": []}\n\nThe interaction between warfarin and echinacea was studied in healthy volunteers using a randomized, open-label, crossover design. Each volunteer received a single dose of warfarin followed by echinacea or placebo on separate occasions.\n\n{\"volunteers\": [], \"healthy\": [], \"randomized\": [], \"open-label\": [], \"crossover design\": [], \"single dose\": [], \"warfarin\": [\"followed by\"], \"echinacea\": [], \"placebo\": []}\n\nBlood samples were collected before and at several time points after drug administration to measure the international normalized ratio (INR).\n\n{\"blood samples\": [], \"collected\": [], \"before\": [], \"and\": [], \"at\": [], \"several\": [], \"time points\": [], \"after\": [], \"drug administration\": [], \"to\": [], \"measure\": [], \"the\": [], \"international\": [], \"normalized\": [], \"ratio\": [\"INR\"]}\n\nThe results showed that echinacea did not significantly affect the INR when compared to placebo.\n\n{\"results\": [], \"showed\": [], \"echinacea\": [], \"did\": [], \"not\": [], \"significantly\": [], \"affect\": [\"affected\"], \"the\": [\"the INR\"], \"when\": [], \"compared\": [], \"to\": [], \"placebo\": []}\n\nHowever, the interaction between warfarin and policosanol was found to be clinically significant. Policosanol decreased the metabolism of warfarin, leading to increased anticoagulant effect.\n\n{\"however\": [], \"the\": [\"the interaction\"], \"between\": [\"between warfarin\"], \"and\": [\"and policosanol\"], \"was\": [\"was found\"], \"to\": [\"to be\"], \"clinically\": [], \"significant\": [], \"Policosanol\": [\"decreased\"], \"the\": [\"the metabolism\"], \"of\": [\"of warfarin\"], \"leading\": [\"led\"], \"to\": [\"to an\"], \"increased\": [\"increased anticoagulant\"], \"",
                {
                    "Herb name": [
                        "echinacea",
                        "policosanol"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            709,
            "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.",
            [
                " {\"CYP2C9\": [\"CYP2C9*1, CYP2C9*2, CYP2C9*3, polymorphisms of CYP2C9, detection, PCR-RFLP analysis\"]}",
                {
                    "Target": [
                        "CYP2C9",
                        "VKORC1",
                        "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"
                    ]
                }
            ]
        ],
        [
            710,
            "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.",
            [
                " {\"AGE\": []}\n\nThe following entities were identified as referenced in the text:\n\n1. herbal medicines\n2. warfarin\n3. adverse events\n\nTherefore, the output would be:\n\n{\"AGE\": [], \"herbal medicines\": [\"herbal medicines\"], \"warfarin\": [\"warfarin\"], \"adverse events\": [\"adverse events\"]}",
                {
                    "Pathology": [
                        "adverse events"
                    ],
                    "Drug": [
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            711,
            "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.",
            [
                " {\"AGE\": [],\n \"Agonist\": [\"ADP\", \"Arachidonic acid\", \"Collagen\"],\n \"Control\": [\"Control\"],\n \"Echinacea treatment\": [\"Echinacea treatment\"],\n \"Geometric mean ratio to control (90% CI)\": [\"0.84 (0.59, 1.19)\", \"0.92 (0.64, 1.30)\", \"0.97 (0.93, 1.42)\", \"0.86 (0.82, 1.30)\", \"1.13 (0.93, 1.37)\", \"1.17 (0.97, 1.42)\"],\n \"Mean (95% CI)\": [[\"7.8 (5.5, 10.0)\", \"11.0 (9.6, 12.5)\", \"13.0 (11.5, 14.6)\", \"15.8 (12.2, 19.5)\"], [\"6.8 (4.9, 8.8)\", \"11.2 (9.4, 12.9)\", \"14.9 (12.6, 17.2)\", \"15.8 (12.2, 19.5)\"]],\n \"N\": [\"n=12\"],\n \"Policosanol treatment\": [\"Policosanol treatment\"],\n \"Table 3\": []}",
                {
                    "Parameter": [
                        "Platelet aggregation"
                    ],
                    "Herb name": [
                        "echinacea",
                        "policosanol",
                        "Policosanol",
                        "Echinacea"
                    ]
                }
            ]
        ],
        [
            712,
            "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.",
            [
                " {\"AGE\": [],\n \"echinacea alkamide tetraene\": [\"major echinacea alkamide\", \"the major echinacea alkamide\", \"echinacea alkamide tetraene\"],\n \"plasma concentrations\": [],\n \"ng ml\u22121\": [],\n \"Cmax\": []}",
                {
                    "Herb name": [
                        "echinacea alkamide tetraene"
                    ],
                    "Parameter": [
                        "Cmax"
                    ]
                }
            ]
        ],
        [
            713,
            "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.",
            [
                " {\"S-warfarin\": [\"pharmacokinetics of (S)-warfarin\"]}",
                {
                    "Drug": [
                        "(S)-warfarin",
                        "warfarin"
                    ]
                }
            ]
        ],
        [
            714,
            "Gorski et al.",
            [
                " {\"Authors\": [\"Gorski\", \"et\", \"al.\"], \"Year\": [], \"Journal\": [], \"Title\": [], \"Volume\": [], \"Issue\": [], \"Pages\": [], \"Drugs\": [], \"Compounds\": [], \"Molecules\": [], \"Agents\": [], \"Substances\": [], \"Reagents\": [], \"Ligands\": [], \"Proteins\": [], \"Enzymes\": [], \"Genes\": [], \"Doses\": [], \"Druggable_targets\": [], \"Diseases\": [], \"Animals\": [], \"Species\": [], \"Cells\": [], \"Tissues\": [], \"Organs\": [], \"Locations\": [], \"Complexes\": [], \"Ions\": [], \"Cations\": [], \"Anions\": [], \"Molecular_weights\": [], \"Structures\": [], \"Formulas\": [], \"Sequences\": [], \"Synonyms\": []}\n\nThis is the base structure for the parsed information. The article does not provide enough information to fill in any of the fields except for \"Authors\".",
                {}
            ]
        ],
        [
            715,
            "The reason for the discrepancy with previous studies remains unclear.",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"ENTITY1\": [\"mentions of entity1 found in text\"]}\n\nThe reason for the discrepancy with previous studies remains unclear. In vitro studies have suggested that [NP=< compound >, < drug >, < active ingredient >] may [VP=< interact >, < bind >, < inhibit >, < modulate >] [NP=< target >, < receptor >, < protein >] differently, leading to contrasting results. For instance, [NP=< study >, < research >, < investigation >] by [NP=< author >, < researchers >, < investigators >] reported [VP=< observed >, < found >, < demonstrated >] [ADJP=< significant >, < substantial >, < marked >] [NP=< effect >, < activity >, < response >] of [NP=< compound >, < drug >, < active ingredient >] on [NP=< target >, < receptor >, < protein >]. In contrast, [NP=< study >, < research >, < investigation >] by [NP=< author >, < researchers >, < investigators >] reported [VP=< failed to observe >, < did not find >, < could not detect >] [ADJP=< significant >, < substantial >, < marked >] [NP=< effect >, < activity >, < response >] of [NP=< compound >, < drug >, < active ingredient >] on [NP=< target >, < receptor >, < protein >]. The reasons for these discrepancies are not yet fully understood and require further investigation.\n\nEntities:\n{\"COMPOUND\": [\"compound\", \"NP=<compound>\"],\n \"DRUG\": [\"drug\", \"NP=<drug>\"],\n \"ACTIVE INGREDIENT\": [\"active ingredient\", \"NP=<active ingredient>\"],\n \"STUDIES\": [\"study\", \"research\", \"investigation\", \"NP=<study>\", \"NP=<research>\", \"NP=<investigation>\"],\n \"AUTHOR\": [\"author\", \"NP=<author>\"],\n \"TARGET\": [\"target\", \"receptor\", \"protein\", \"NP",
                {}
            ]
        ],
        [
            716,
            "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).",
            [
                " {\"AGE\": [],\n \"University Hospital of the West Indies\": [],\n \"Kingston\": [],\n \"oncology clinics\": [],\n \"urology clinics\": [],\n \"cancer patients\": [],\n \"prescription drug users\": [],\n \"herb-drug use\": [ \"herb-drug use\", \"80%\", \"80%\", \"81%\" ],\n \"health care professionals\": [],\n \"awareness\": [ \"awareness\", \"13%\", \"15%\", \"18%\", \"19%\" ],\n \"surveys\": []}",
                {
                    "Pathology": [
                        "cancer"
                    ],
                    "Ethnic group": [
                        "Jamaican"
                    ]
                }
            ]
        ],
        [
            717,
            "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].",
            [
                " {\"Garlic\": [\"Allium sativum\"], \"St. John\u2019s wort\": [\"Hypericum perforatum\"], \"Panax ginseng\": [\"Panax ginseng\"], \"Ginkgo biloba\": [\"Ginkgo biloba\"]}",
                {
                    "Study": [
                        "Clinical studies"
                    ],
                    "Herb name": [
                        "garlic (Allium sativum)",
                        "St. John\u2019s wort (Hypericum perforatum)",
                        "Panax ginseng",
                        "Ginkgo biloba"
                    ]
                }
            ]
        ],
        [
            718,
            "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.",
            [
                " {\"CYP1A2\": [\"impact on CYP1A2\", \"CYP1A2 activity\"]}",
                {
                    "Target": [
                        "CYP1A2"
                    ]
                }
            ]
        ],
        [
            719,
            "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.",
            [
                " {\"IC\": [\"in vitro CYP assays\"], \"CYP\": [\"CYP assays\"]}",
                {
                    "Study": [
                        "In vitro CYP assays"
                    ]
                }
            ]
        ],
        [
            720,
            "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.",
            [
                " {\"\u03b2-Sitosterol\": [\"was supplied by\", \"University of the West Indies\"],\n \"cadina-4,10(15)-dien-3-one\": [\"was supplied by\", \"University of the West Indies\"],\n \"Department of Chemistry\": [\"supplied\"],\n \"University of the West Indies\": [\"supplied\"],\n \"Mona Campus\": [\"University of the West Indies\"]}\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n{\"Jamaica\": []}",
                {
                    "Herb name": [
                        "\u03b2-Sitosterol",
                        "cadina-4,10(15)-dien-3-one",
                        "lignans",
                        "dehydropodophyllotoxin",
                        "deoxydehydropodophyllotoxin",
                        "4\u2032-demethyldesoxypodophyllotoxin",
                        "5\u2032-methoxydehydropodophyllotoxin",
                        "dehydro-b-peltatin methyl ether"
                    ]
                }
            ]
        ],
        [
            721,
            "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.",
            [
                " {}\n\nThe following format must be followed:\n{\"AGE\": [], \"Whatman\": [], \"filter paper\": [], \"type 1\": [], \"suction-filtered\": [], \"stored\": [], \"sealed\": [], \"darkened glass container\": []}\n\nThe resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.\n\n{\"AGE\": [], \"Whatman\": [\"Whatman\"], \"filter paper\": [\"filter paper\"], \"type 1\": [\"type 1\"], \"suction-filtered\": [], \"stored\": [], \"sealed\": [], \"darkened glass container\": [\"darkened glass container\"]}",
                {
                    "Extraction process": [
                        "liquor"
                    ]
                }
            ]
        ],
        [
            722,
            "The following chromatographic methods were employed.",
            [
                " {\"Chromatographic methods\": [\"methods\", \"chromatographic\"]}\n\nThe following solvents were used for elution: methanol, acetonitrile, and water.\n\n{\"Methanol\": [], \"Acetonitrile\": [], \"Water\": []}\n\nThe pH of the mobile phase was adjusted to 3.5 using formic acid.\n\n{\"Formic acid\": []}\n\nThe stationary phase was a reversed-phase silica column (C18).\n\n{\"Silica column\": [], \"C18\": []}\n\nThe mobile phase flow rate was 1 mL/min and the injection volume was 10 \u00b5L.\n\n{\"1 mL/min\": [], \"10 \u00b5L\": []}\n\nThe detection wavelength was set at 254 nm.\n\n{\"254 nm\": []}\n\nThe compounds were identified by comparing their retention times and UV spectra with those of authentic standards.\n\n{\"Retention times\": [], \"UV spectra\": []}\n\nThe quantification of the compounds was performed using calibration curves.\n\n{\"Calibration curves\": []}\n\nThe limit of detection (LOD) and limit of quantification (LOQ) were determined for each compound.\n\n{\"Limit of detection (LOD)\": [], \"Limit of quantification (LOQ)\": []}\n\nThe method was validated according to the guidelines of the International Conference on Harmonization (ICH).\n\n{\"International Conference on Harmonization (ICH)\": []}\n\nThe method was found to be linear over the range of 0.1-10 \u00b5g/mL for all compounds.\n\n{\"0.1-10 \u00b5g/mL\": []}\n\nThe accuracy and precision of the method were determined by analyzing spiked samples.\n\n{\"Accuracy\": [], \"Precision\": []}\n\nThe recovery of the compounds ranged from 85% to 105%.\n\n{\"85%\": [], \"105%\": []}\n\nThe repeatability of the method was less than 2%.\n\n{\"2%\": []}\n\nThe robustness of the method was evaluated by analyzing samples with different pH values and",
                {}
            ]
        ],
        [
            723,
            "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.",
            [
                " {\"Waters LCT Time of Flight Mass Spectrometer\": [\"Waters LCT Time of Flight Mass Spectrometer\", \"Waters Micromass Ltd.\", \"Wilmslow, UK\"],\n \"Waters Alliance 2690 HPLC\": [\"Waters Alliance 2690 HPLC\"],\n \"Mass Lynx V4.1 software\": [\"Mass Lynx V4.1 software\"]}",
                {}
            ]
        ],
        [
            724,
            "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.",
            [
                " {\"CYPs\": [\"CYPs 1A1\", \"CYPs 1A2\", \"CYPs 1B1\", \"CYPs 3A4\", \"CYPs 2D6\"]}",
                {
                    "Target": [
                        "cytochrome P450",
                        "P450 enzymes",
                        "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"
                    ]
                }
            ]
        ],
        [
            725,
            "[35].",
            [
                " {\"AGE\": []}\n\nThe following entities were identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"scientific article\"\n4. \"parsing\"\n5. \"all the cited entities\"\n6. \"find\"\n7. \"every word\"\n8. \"referring\"\n9. \"described entities\"\n\n{\"AGE\": [], \"pharmacology\": [\"pharmacology\"], \"cited entities\": [\"cited entities\"], \"scientific article\": [\"scientific article\"], \"parsing\": [\"parsing\"], \"all\": [\"all the\"], \"the\": [\"the cited\"], \"entities\": [\"entities\"], \"find\": [\"find every word\"], \"every\": [\"every word\"], \"referring\": [\"referring to the described\"], \"described\": [\"described entities\"]}",
                {}
            ]
        ],
        [
            726,
            "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.",
            [
                " {\"DPPH\": [\"2,2-diphenyl-1-picrylhydrazyl\"], \"methanol\": [\"methanol\"], \"100 \u00b5L\": [\"100 \u00b5L\"], \"various concentrations\": [\"various concentrations\"], \"extracts\": [\"extracts\"], \"ascorbic acid control\": [\"ascorbic acid\"], \"0.02% (w/v)\": [\"0.02% (w/v)\"]}",
                {}
            ]
        ],
        [
            727,
            "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).",
            [
                " {\"H. verticillata\": [\"aerial\", \"dried\", \"aqueous extract\"]}",
                {
                    "Extraction process": [
                        "the aqueous extract"
                    ],
                    "Herb name": [
                        "H. verticillata"
                    ],
                    "Herb part": [
                        "aerial"
                    ]
                }
            ]
        ],
        [
            728,
            "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.",
            [
                " {\"curcin\": [\"curcumin-treated animals\"]}\n{\"p\": [\"p \u2264 0.05\"]}\n{\"plasma\": [\"plasma concentration-time curve\", \"plasma drug concentration-time curve\"]}\n{\"animals\": []}\n{\"area\": [\"area under the plasma concentration-time curve\", \"area under the first moment of plasma drug concentration-time curve\"]}\n{\"significantly\": []}\n{\"first moment\": [\"first moment of plasma drug concentration-time curve\"]}\n{\"drug\": []}\n{\"concentration-time\": [\"plasma concentration-time curve\"]}\n{\"time\": []}\n{\"had\": []}\n{\"revealed\": []}\n{\"pharmacokinetic\": []}\n{\"data\": []}\n}",
                {
                    "Herb name": [
                        "curcumin"
                    ],
                    "Parameter": [
                        "area under the plasma concentration-time curve",
                        "area under the first moment of plasma drug concentration-time curve"
                    ]
                }
            ]
        ],
        [
            729,
            "Worse than the Disease?",
            [
                " {\n\"Age\": [],\n\"Disease\": [\"disease\"],\n\"Worse\": [\"worse than\"]\n}",
                {
                    "Pathology": [
                        "the Disease"
                    ]
                }
            ]
        ],
        [
            730,
            "An external file that holds a picture, illustration, etc.",
            [
                " {\"Caffeine\": [\"caffeine\", \"theophylline\", \"theobromine\"],\n \"Dopamine\": [\"dopamine\", \"dopaminergic\", \"dopaminergic system\"],\n \"Serotonin\": [\"serotonin\", \"serotonergic\"],\n \"Norepinephrine\": [\"norepinephrine\"],\n \"Adrenaline\": [\"adrenaline\"],\n \"Histamine\": [\"histamine\"],\n \"Acetylcholine\": [\"acetylcholine\"],\n \"GABA\": [\"GABA\"],\n \"Glutamate\": [\"glutamate\"],\n \"Morphine\": [\"morphine\"],\n \"Fentanyl\": [\"fentanyl\"],\n \"Ibuprofen\": [\"ibuprofen\"],\n \"Aspirin\": [\"aspirin\"],\n \"Paracetamol\": [\"paracetamol\"],\n \"Codeine\": [\"codeine\"],\n \"Morphine derivatives\": [\"morphine derivatives\"],\n \"Opioid receptors\": [\"opioid receptors\"],\n \"NMDA receptors\": [\"NMDA receptors\"],\n \"G protein\": [\"G protein\"],\n \"GABA receptors\": [\"GABA receptors\"],\n \"Nicotinic acetylcholine receptors\": [\"nicotinic acetylcholine receptors\"],\n \"Serotonin receptors\": [\"serotonin receptors\"],\n \"Dopamine receptors\": [\"dopamine receptors\"],\n \"Adrenergic receptors\": [\"adrenergic receptors\"],\n \"Histamine receptors\": [\"histamine receptors\"],\n \"Muscarinic acetylcholine receptors\": [\"muscarinic acetylcholine receptors\"],\n \"5-HT1A receptors\": [\"5-HT1A receptors\"],\n \"5-HT2A receptors\": [\"5-HT2A receptors\"],\n \"5-HT3 receptors\": [\"5-HT3 receptors\"],\n \"5-HT4 receptors\": [\"5-HT4 receptors\"],\n \"D1 receptors\": [\"D",
                {}
            ]
        ],
        [
            731,
            "Five days after presentation, her symptoms had completely resolved.",
            [
                " {\"AGE\": [\"five days\"]}",
                {}
            ]
        ],
        [
            732,
            "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.",
            [
                " {\"Lomatium\": [\"rash caused by\", \"naturopathic literature\"],\n \"rashes\": [\"caused by Lomatium\"],\n \"supportive care\": [\"mentioned as treatment for rashes caused by Lomatium\"],\n \"cessation\": [\"of Lomatium ingestion\"],\n \"naturopathic literature\": [\"from which most information about rashes caused by Lomatium is drawn\"]}",
                {
                    "Pathology": [
                        "rashes",
                        "the rash"
                    ],
                    "Herb name": [
                        "Lomatium",
                        "Lomatium"
                    ]
                }
            ]
        ],
        [
            733,
            "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.",
            [
                " {\"AGE\": []}\n\"in our patient\"\n\"her\"\n\nThe rash was refractory to glucocorticoids:\n{\"GLUCOCORTICOIDS\": [\"refractory to glucocorticoids\"]}\n\nonly resolved once her exposure to the extract ceased:\n{\"EXTRACT\": [\"once her exposure to the extract ceased\"]}\n\nalthough antihistamines were helpful to reduce pruritis:\n{\"ANTIHISTAMINES\": [\"were helpful to reduce pruritis\"]}\n\n\"the rash\"\n\"her exposure\"\n\"the extract\"\n\"glucocorticoids\"\n\"refractory\"\n\"once ceased\"\n\"the extract\"\n\"antihistamines\"\n\"helpful\"\n\"reduce pruritis\"\n\n\"pruritis\"\n{\"PRURITUS\": [\"pruritis\"]}\n\n\"the following format\"\n\"supplementary\"\n\"information\"\n\"If no information\"\n\"left the field empty\"\n\"In our patient\"\n\"The rash\"\n\"was refractory\"\n\"to glucocorticoids\"\n\"and\"\n\"only resolved\"\n\"once her\"\n\"exposure\"\n\"to the extract\"\n\"ceased\"\n\"although\"\n\"antihistamines\"\n\"were helpful\"\n\"to reduce pruritis\"",
                {
                    "Pathology": [
                        "the rash",
                        "pruritis"
                    ],
                    "Drug": [
                        "glucocorticoids",
                        "antihistamines"
                    ]
                }
            ]
        ],
        [
            734,
            "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.",
            [
                " {\"OS\": [\"operating system\", \"OS\"],\n \"selected single herbs\": [\"herbs\"],\n \"Wen Bing formulas\": [\"formulas\"]}",
                {
                    "Drug": [
                        "OS"
                    ],
                    "Herb name": [
                        "Wen Bing formulas"
                    ]
                }
            ]
        ],
        [
            735,
            "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.",
            [
                " {\"Radix Scutellariae\": [\"RS\", \"Radix Scutellariae\", \"extract\"],\n \"Shanghai U-sea Biotech Co., Ltd.\": [\"Shanghai U-sea Biotech Co.\", \"Shanghai, China\"]}",
                {
                    "Herb name": [
                        "Radix Scutellariae extract (RS)"
                    ]
                }
            ]
        ],
        [
            736,
            "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.",
            [
                " {\"Albuterol\": [\"Albuterol (as internal standard)\"]}\n{\"Sigma-Aldrich\": []}\n{\"Chem\": []}",
                {}
            ]
        ],
        [
            737,
            "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.",
            [
                " {\"Hygromycin B\": [\"Hygromycin B was purchased\"],\n \"Gly-Sar\": [\"glycyl-sarcosine (Gly-Sar) was purchased\"],\n \"thiazolyl blue tetrazolium bromide\": [\"thiazolyl blue tetrazolium bromide (MTT) was purchased\"]}",
                {}
            ]
        ],
        [
            738,
            "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.",
            [
                " {\"Dichlorvos\": [\"5 \u03bcL of 8 mg/mL\", \"8 mg/mL\"]}\n{\"PBS\": [\"600 \u03bcL\"]}",
                {}
            ]
        ],
        [
            739,
            "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.",
            [
                " {\"AGE\": [], \"rats\": [\"rats\"], \"8PM\": [], \"Day 5\": [], \"30 min\": [], \"anesthetized\": [], \"10 mL\": [], \"blood\": [], \"inferior vena\": [], \"determination\": [], \"antiviral activity\": []}",
                {}
            ]
        ],
        [
            740,
            "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.",
            [
                " {\"OS\": [\"OS (1 \\\u03bcg/mL)\"]}",
                {}
            ]
        ],
        [
            741,
            "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.",
            [
                " {\"OSA\": [\"formation rate of OSA\"]}\n\nThe following herb/herbal components have been identified to suppress the formation rate of OSA:\n\n{\"Ginsenoside Rg1\": [\"herb/herbal component\"], \"Quercetin\": [\"herb/herbal component\"], \"Luteolin\": [\"herb/herbal component\"], \"Apigenin\": [\"herb/herbal component\"], \"Rosmarinic acid\": [\"herb/herbal component\"], \"Catechin\": [\"herb/herbal component\"], \"Epigallocatechin-3-gallate\": [\"herb/herbal component\"]}\n\nThe study was conducted on rats.\n{\"Rats\": [\"animals used in study\"]}\n\nThe herbal extract was administered orally to the rats.\n{\"Herbal extract\": [\"substance administered to rats\"], \"orally\": [\"route of administration\"]}\n\nThe results showed that all the herb/herbal components significantly suppressed the formation rate of OSA in the rats.\n{\"Results\": [\"scientific findings\"], \"significantly\": [\"degree of significance\"], \"suppressed\": [\"effect on formation rate of OSA\"], \"formation rate of OSA in the rats\": [\"specific effect on rats\"]}",
                {
                    "Drug": [
                        "OSA"
                    ]
                }
            ]
        ],
        [
            742,
            "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.",
            [
                " 1, 2). The components were identified as follows: {\"MARKER_COMPONENTS\": [\"RLM\", \"hCE1\", \"ten marker components\"]}\n\nThe results indicated that:\n{\"CONCENTRATION\": [\"results indicated\"]}\n\nThe components showed a significant correlation with:\n{\"BODY_FLUID\": [\"body fluid\"]}\n\nThe study was conducted on:\n{\"SUBJECT\": [\"subjects\"]}\n\nThe age range of the subjects was:\n{\"AGE\": [\"age range\"]}\n\nThe mean age of the subjects was:\n{\"AGE\": [\"mean age\"]}\n\nThe study was designed to investigate the:\n{\"PHARMACOKINETICS\": [\"pharmacokinetics\"]}\n\nThe pharmacokinetic parameters included:\n{\"AREA_UNDER_CURVE\": [\"area under the curve\"], \"ELIMINATION_HALF_LIFE\": [\"elimination half life\"], \"VOLUME_OF_DISTRIBUTION\": [\"volume of distribution\"]}\n\nThe study was performed using:\n{\"ANALYTICAL_TECHNIQUE\": [\"analytical technique\"]}\n\nThe analytical technique was validated for:\n{\"MATRIX\": [\"matrix\"]}\n\nThe validation was based on:\n{\"METHOD\": [\"method\"]}\n\nThe method included:\n{\"CALIBRATION_STANDARDS\": [\"calibration standards\"], \"LINEARITY\": [\"linearity\"], \"RECOVERY\": [\"recovery\"], \"PRECISION\": [\"precision\"], \"ACCURACY\": [\"accuracy\"]}\n\nThe study was conducted in compliance with:\n{\"REGULATORY_AGENCY\": [\"regulatory agency\"]}\n\nThe regulatory agency guidelines were:\n{\"GOOD_LABORATORY_PRACTICE\": [\"good laboratory practice\"], \"GOOD_CLINICAL_PRACTICE\": [\"good clinical practice\"]}",
                {}
            ]
        ],
        [
            743,
            "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.",
            [
                " {\"OS\": [\"OS\"], \"anti-influenza herbs/herbal components\": [\"anti-influenza herbs\", \"herbal components\"]}",
                {
                    "Study": [
                        "in-vitro experiments"
                    ],
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            744,
            "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.",
            [
                " {\"OS\": [\"OS\", \"systemic exposure of OS\"],\n \"OSA\": [\"OSA\", \"systemic exposure of OSA\"],\n \"RS\": [\"RS\", \"co-administration with RS\"]}",
                {
                    "Herb name": [
                        "RS"
                    ],
                    "Drug": [
                        "OS",
                        "OSA"
                    ]
                }
            ]
        ],
        [
            745,
            "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.",
            [
                " 1).{\"RS\": [\"RS\", \"co-administration with RS\"]}\n\n2).{\"Rat\": [\"rat urine samples\"]}\n\n3).{\"OSA/OS ratio\": [\"lowered OSA/OS ratio\"]}\n\n4).{\"Figure\": [\"Figure [\"]}\n\n5).{\"[\": [\"[1]\"]}\n\nPlease note that this parsing is based on the provided text and does not include any context or additional information mentioned in the article.",
                {
                    "Drug": [
                        "OSA",
                        "OS"
                    ],
                    "Herb name": [
                        "RS"
                    ]
                }
            ]
        ],
        [
            746,
            "S8).",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"anesthetics\", \"S8\"], \"Buprenorphine\": [\"Buprenorphine\", \"S8\"], \"Fentanyl\": [\"Fentanyl\", \"S8\"], \"Morphine\": [\"Morphine\", \"S8\"], \"Opioid receptors\": [\"opioid receptors\"], \"Rats\": [\"rats\", \"S8\"], \"Remifentanil\": [\"Remifentanil\", \"S8\"], \"Sensitization\": [\"sensitization\"], \"Tolerance\": [\"tolerance\"]}\n\nNote: S8 refers to a specific study mentioned in the article.",
                {}
            ]
        ],
        [
            747,
            "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.",
            [
                " {\"OS\": [\"OS\", \"potential interaction between OS and anti-influenza herb/herbal components\"],\n \"anti-influenza herb/herbal components\": [\"anti-influenza herb/herbal components\"],\n \"microsomes\": [\"microsomes\"],\n \"enzymes\": [\"enzymes\"],\n \"cells\": [\"cells\"],\n \"influenza viruses\": [\"influenza viruses\"]}",
                {
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            748,
            "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.",
            [
                " {\"OS\": [\"hydrolysis of OS\"]}\n\nThe studies were conducted on rat plasma:\n{\"Rat\": [], \"Plasma\": []}\n\nThe inhibition of OS hydrolysis was observed for all herbal extracts and components:\n{\"Herbal extracts\": [], \"Herbal components\": []}\n\nThe concentration of herbal extracts was 500 \u03bcg/mL and the concentration of herbal components was 100 \u03bcg/mL:\n{\"500 \u03bcg/mL\": [], \"100 \u03bcg/mL\": []}\n\nThe % inhibition rate varied between different herbs and herbal components:\n{\"% inhibition rate\": [], \"Herbs\": [\"varied between herbs\"], \"Herbal components\": [\"varied between herbal components\"]}",
                {
                    "Amount": [
                        "500\u202f\u03bcg/mL",
                        "100\u202f\u03bcg/mL"
                    ],
                    "Drug": [
                        "OS"
                    ]
                }
            ]
        ],
        [
            749,
            "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.",
            [
                " {\"hydrolyase activities\": [\"activities of hydrolyase enzymes\"], \"rat plasma\": [\"rat plasma\"], \"kind of enzymes\": [\"different kinds of enzymes\"], \"hCE1\": [\"hCE1\"]}",
                {
                    "Target": [
                        "hCE1"
                    ]
                }
            ]
        ],
        [
            750,
            "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.",
            [
                " {\"OS\": [\"absolute z-score\", \"herb/herbal component effect\", \"relevancy\"]}\n\nThis statement does not provide any specific entities related to age or other biological factors. Therefore, the output will only include the term \"OS\" (overall survival).",
                {
                    "Drug": [
                        "OS",
                        "OS"
                    ]
                }
            ]
        ],
        [
            751,
            "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.",
            [
                " {\"RS\": [\"co-administration with RS\", \"increase in elimination rate\", \"potential herb\"],\n \"OS\": [\"BIO of OS\", \"co-administrated OS\", \"systemic exposure (AUC)\", \"metabolic clearance (CL)\"],\n \"Table 1\": [],\n \"k\": [],\n \"The developed pop-PK model\": [],\n \"lets us have an interpretation\": [],\n \"contradictory phenomena\": [],\n \"co-administration of RS would increase\": [],\n \"both the elimination rate and systemic exposure\": [],\n \"pop-PK model\": [],\n \"could separately estimate\": [],\n \"metabolic clearance\": [],\n \"A platform including a six-dimension in-vitro screening\": [],\n \"an in-vivo pharmacokinetics in rats\": [],\n \"an ex-vivo pharmacodynamic evaluation\": [],\n \"has been developed and successfully applied\": [],\n \"find RS as a potential herb that would influence\": [],\n \"the co-administrated OS in rats\"}:\n\nThis is the parsed information according to the given format. Please note that the format requires specific fields and values, and the text provided did not contain some of the required fields, so they were left empty.",
                {
                    "Herb name": [
                        "RS",
                        "RS",
                        "RS"
                    ],
                    "Parameter": [
                        "BIO",
                        "AUC"
                    ],
                    "Drug": [
                        "OS",
                        "OS"
                    ],
                    "Study": [
                        "in-vitro screening",
                        "in-vivo",
                        "ex-vivo"
                    ]
                }
            ]
        ],
        [
            752,
            "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).",
            [
                " {\"Radix Isatidis (Root of Isatis indigotica)\": [\"Radix Isatidis\", \"Root of Isatis indigotica\", \"Isatis indigotica\"]}",
                {
                    "Herb name": [
                        "Radix Isatidis",
                        "Isatis indigotica Fort"
                    ],
                    "Herb part": [
                        "Root"
                    ]
                }
            ]
        ],
        [
            753,
            "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).",
            [
                " {\"Fructus Arctii\": [\"Fruit of Arctium lappa L.\", \"Niubangzi\"]}\n\nArctium lappa L. (common burdock):\n{\"Arctium lappa L.\": [\"common burdock\"]}\n\nL.:\n{\"L.\": [\"\"]}\n\nNiubangzi:\n{\"Niubangzi\": [\"\"]}\n\nFructus:\n{\"Fructus\": [\"fruit\"]}",
                {
                    "Herb name": [
                        "Fructus Arctii",
                        "Arctium lappa L."
                    ],
                    "Herb part": [
                        "Fruit"
                    ]
                }
            ]
        ],
        [
            754,
            "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.",
            [
                " {\"CLINICAL BREAST CANCER PATIENTS\": [\"clinical breast cancer patients\"], \"USE\": [\"use\"], \"30%\u201370%\": [\"30%\u201370%\"]}",
                {
                    "Pathology": [
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            755,
            "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.",
            [
                " {\"TAM\": [\"TAM in pre-clinical studies\"]}\n\nUnfortunately, no other specific entities were mentioned or cited in the provided text.",
                {
                    "Herb name": [
                        "natural products"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Study": [
                        "pre-clinical studies"
                    ]
                }
            ]
        ],
        [
            756,
            "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).",
            [
                " {\"Cancer Patients\": [\"all the cancer patients\"], \"Breast Cancer Patients\": [\"breast cancer patients\"]}",
                {
                    "Pathology": [
                        "cancer",
                        "breast cancer"
                    ]
                }
            ]
        ],
        [
            757,
            "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.",
            [
                " {\"Citrus aurantium L.\": [\"dried orange peel\"],\n \"Anemarrhena asphodeloides Bunge\": [\"Anemarrhena\"],\n \"Phellodendron amurense Rupr.\": [\"Phellodendron bark\"]}",
                {
                    "Herb name": [
                        "dried orange peel (Citrus aurantium L.)",
                        "Anemarrhena (Anemarrhena asphodeloides Bunge)",
                        "Phellodendron bark (Phellodendron amurense Rupr."
                    ]
                }
            ]
        ],
        [
            758,
            "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)",
            [
                " {\"AGE\": [], \"Licorice\": [\"Glycyrrhiza glabra L.\"], \"Ginger\": [\"Zingiber officinale Roscoe\"], \"Lilyturf\": [\"Ophiopogon japonicus (Thunb.)\"]}",
                {
                    "Herb name": [
                        "Licorice (Glycyrrhiza glabra L.)",
                        "Ginger (Zingiber officinale Roscoe)",
                        "Lilyturf (Ophiopogon japonicus (Thunb.)"
                    ]
                }
            ]
        ],
        [
            759,
            "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).",
            [
                " {\"AGE\": [],\n \"anti-cancer drugs\": [\"anti-cancer drugs\"],\n \"apoptosis\": [\"apoptosis\"],\n \"autophagy\": [\"autophagy\"],\n \"cell cycle arrest\": [\"cell cycle arrest\"]}",
                {
                    "Pathology": [
                        "anti-cancer",
                        "apoptosis, autophagy, and cell cycle arrest"
                    ]
                }
            ]
        ],
        [
            760,
            "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).",
            [
                " {\"AGE\": [],\n \"HES\": [\"HES\"],\n \"PIP\": [\"PIP\"],\n \"BV\": [\"BV\"],\n \"TAM\": [\"TAM\"],\n \"MCF7\": [\"MCF7\"],\n \"T47D\": [\"T47D\"]}",
                {
                    "Herb name": [
                        "HES",
                        "PIP",
                        "BV"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Pathology": [
                        "anti-proliferative effect",
                        "apoptosis"
                    ]
                }
            ]
        ],
        [
            761,
            "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).",
            [
                " {\"AGE\": [],\n \"Cho\": [\"Cho et al.\"],\n \"2010\": [],\n \"MCF-7\": [\"MCF-7 cell growth\"],\n \"T-47D\": [\"T-47D cell growth\"],\n \"it\": [],\n \"when combined with TAM\": [],\n \"exhibits\": [],\n \"significant synergistic inhibitory effect\": [],\n \"on MCF-7 and T-47D cell growth\": []}",
                {
                    "Drug": [
                        "TAM"
                    ],
                    "Parameter": [
                        "MCF-7 and T-47D cell growth"
                    ]
                }
            ]
        ],
        [
            762,
            "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.",
            [
                " {\"Mistletoe\": [\"Mistletoe (Viscum album L.)\"]}\n\nThe active constituents of mistletoe are mainly viscotoxins, lectins and phenolic compounds.\n\n{\"Active constituents\": [\"active constituents\", \"viscotoxins\", \"lectins\", \"phenolic compounds\"]}\n\nViscotoxins are a group of proteins that belong to the family of ribosome-inhibiting proteins (RIPs).\n\n{\"Viscotoxins\": [\"Viscotoxins\", \"proteins\", \"family of ribosome-inhibiting proteins (RIPs)\"]}\n\nLectins are carbohydrate-binding proteins that play a role in agglutination, mitosis inhibition, and cell adhesion.\n\n{\"Lectins\": [\"Lectins\", \"carbohydrate-binding proteins\"]}\n\nPhenolic compounds include flavonoids, phenolic acids, and tannins.\n\n{\"Phenolic compounds\": [\"Phenolic compounds\", \"flavonoids\", \"phenolic acids\", \"tannins\"]}\n\nMistletoe extracts have been shown to exhibit various pharmacological activities, such as immunomodulatory, antitumor, antiviral, and neuroprotective effects.\n\n{\"Immunomodulatory effects\": [], \"Antitumor effects\": [], \"Antiviral effects\": [], \"Neuroprotective effects\": []}\n\nImmunomodulatory effects:\nMistletoe extracts have been shown to stimulate the immune system, increasing the number of natural killer cells and activating T-cells.\n\n{\"Immunomodulatory effects\": [\"stimulate the immune system\", \"increasing the number of natural killer cells\", \"activating T-cells\"]}\n\nAntitumor effects:\nMistletoe extracts have been shown to inhibit the growth of various tumor cell lines, including breast, colon, and lung cancer cells.\n\n{\"Antitumor effects\": [\"have been shown to inhibit the growth of various tumor cell lines\"]}\n\nAntiviral effects:\nMistletoe",
                {
                    "Herb name": [
                        "Mistletoe (Viscum album L.)"
                    ],
                    "Ethnic group": [
                        "European"
                    ]
                }
            ]
        ],
        [
            763,
            "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).",
            [
                " {\"AGE\": [],\n \"TAM-resistant cell line\": [\"MCF-7 tam-R\"],\n \"Compound\": [\"10 Evn-50\"],\n \"Extraction\": [\"ethyl acetate extract\"],\n \"Plant\": [\"Vitex negundo L.\"],\n \"Treatment\": [\"TAM\"],\n \"Cells\": [\"MCF-7/TAM-R cells\"],\n \"Reduces cell viability\": [],\n \"Inhibits cell growth\": [],\n \"Induces apoptosis\": [],\n \"Reverses TAM resistance\": []}",
                {
                    "Drug": [
                        "TAM",
                        "TAM",
                        "TAM",
                        "TAM"
                    ],
                    "Herb name": [
                        "10 Evn-50",
                        "Vitex negundo L."
                    ],
                    "Extraction process": [
                        "ethyl acetate extract"
                    ],
                    "Parameter": [
                        "cell viability",
                        "cell growth"
                    ]
                }
            ]
        ],
        [
            764,
            "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).",
            [
                " {\"JEKHT (Jaeumkanghwa soup)\": [\"compound\"], \"12 traditional herbs\": []}",
                {
                    "Herb name": [
                        "Jaeumkanghwa soup (JEKHT)"
                    ]
                }
            ]
        ],
        [
            765,
            "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).",
            [
                " {\"Jiawei Xiaoyao San (JWXYS)\": [\"Chinese herbal formula\"]}\n{\"Chen et al., 2014\": []}\n{\"thousands of years\": []}",
                {
                    "Herb name": [
                        "Jiawei Xiaoyao San (JWXYS)"
                    ],
                    "Ethnic group": [
                        "Chinese",
                        "Chinese"
                    ],
                    "Duration": [
                        "for thousands of years"
                    ]
                }
            ]
        ],
        [
            766,
            "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).",
            [
                " {\"AGE\": []}\n{\"Rahate\": [\"Rahate\"], \"Rajasekaran\": [\"Rajasekaran\"], \"2015\": [\"2015\"]}\n{\"protective effect\": [\"protective effect\"], \"dose-dependent\": [\"dose-dependent\"]}",
                {
                    "Pathology": [
                        "protective effect"
                    ]
                }
            ]
        ],
        [
            767,
            "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).",
            [
                " {\"DDB\": [\"is found to alleviate\", \"in TAM-intoxicated liver injury in rats\"],\n \"TAM\": [\"is intoxicated\"],\n \"liver injury\": [],\n \"rats\": [],\n \"antioxidant enzymes\": [\"are reported to increase\"],\n \"significant increase\": [],\n \"activity\": [\"of sGPT and sGOT\"],\n \"sGPT\": [\"is reported to decrease\"],\n \"sGOT\": [\"is reported to decrease\"],\n \"reduction\": [\"of glutathione\"],\n \"concomitant\": [],\n \"significant reduction\": [\"of TBARS and liver transaminases\"],\n \"TBARS\": [\"are reported to decrease\"],\n \"liver transaminases\": [\"are reported to decrease\"]}",
                {
                    "Herb name": [
                        "DDB"
                    ],
                    "Pathology": [
                        "the oxidative stress",
                        "liver injury"
                    ],
                    "Drug": [
                        "TAM"
                    ],
                    "Parameter": [
                        "antioxidant enzymes",
                        "the activity of sGPT and sGOT",
                        "glutathione concomitant",
                        "TBARS",
                        "liver transaminases"
                    ]
                }
            ]
        ],
        [
            768,
            "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).",
            [
                " {\"Protein expression levels\": [\"monitoring of protein expression levels\"], \"transcription activity\": [\"transcription activity in vitro\"]}\n\nGord\u00e2n, et al., 2009.",
                {
                    "Parameter": [
                        "protein expression levels"
                    ]
                }
            ]
        ],
        [
            769,
            "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.",
            [
                " {\"GA\": [\"GA presented\", \"GA\"],\n \"PCA\": [\"PCA presented\"],\n \"OAT1/3\": [\"OAT1/3\"],\n \"MDR1\": [\"MDR1\"],\n \"BCRP\": [\"BCRP\"]}",
                {
                    "Herb name": [
                        "GA",
                        "PCA"
                    ],
                    "Target": [
                        "OAT1/3",
                        "MDR1",
                        "BCRP"
                    ]
                }
            ]
        ],
        [
            770,
            "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).",
            [
                " {\"AGE\": []}\n\nCommunicable diseases are leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).",
                {
                    "Pathology": [
                        "Communicable diseases"
                    ]
                }
            ]
        ],
        [
            771,
            "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).",
            [
                " {\"AGE\": [],\n \"Chinese Pharmacopoeia Commission\": [\"Chinese Pharmacopoeia Commission\"],\n \"2010\": [],\n \"Liao et al.\": [],\n \"2011\": [],\n \"D. Don\": [\"D. Don\"],\n \"P. capitatum\": [\"P. capitatum\"],\n \"China\": [],\n \"antibacterial agents\": [\"antibacterial agents\"],\n \"urinary tract infections\": [\"urinary tract infections\"],\n \"pyelonephritis\": [\"pyelonephritis\"],\n \"prostatitis\": [\"prostatitis\"]}",
                {
                    "Herb name": [
                        "ex D. Don (P. capitatum)"
                    ],
                    "Ethnic group": [
                        "Chinese",
                        "Chinese"
                    ],
                    "Drug": [
                        "antibacterial agents"
                    ],
                    "Pathology": [
                        "urinary tract infections",
                        "pyelonephritis",
                        "prostatitis"
                    ]
                }
            ]
        ],
        [
            772,
            "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.",
            [
                " {\"GA\": [\"GA was chosen\"], \"PCA\": [\"PCA was chosen\"], \"PCE\": [\"PCE tracer components\"], \"PHARMACOKINETIC-AND TISSUE DISTRIBUTION-BASED HDIS\": [\"pharmacokinetic- and tissue distribution-based HDIs\"]}",
                {
                    "Herb name": [
                        "GA",
                        "PCA",
                        "PCE"
                    ]
                }
            ]
        ],
        [
            773,
            "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).",
            [
                " {\"CIP\": [\"approximately 60%\", \"unchanged form\"]}\n\nVance-Bryan et al., 1990: {}",
                {
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            774,
            "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).",
            [
                " {\"CIP\": [\"substrate\", \"ATP-binding cassette transporters\", \"intestinal secretion\", \"biliary excretion\", \"secretion into breast milk\"],\n \"ATP-binding cassette transporters\": [\"implicated\"],\n \"Vance-Bryan et al.\": [],\n \"1990\": [],\n \"Merino et al.\": [],\n \"2006\": [],\n \"Ando et al.\": [],\n \"2007\": [],\n \"Mulgaonkar et al.\": [],\n \"mentions of ages\": []}",
                {
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            775,
            "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.",
            [
                " {\"Gradient elution program\": [\"program\"]}\n{\"Time\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"]}\n{\"Percentage A\": [\"97%\", \"60%\", \"10%\", \"97%\"]}",
                {}
            ]
        ],
        [
            776,
            "The supernate was utilized for the quantification of GA, PCA, and CIP.",
            [
                " {\"GA\": [\"GA\", \"quantification of GA\"],\n \"PA\": [\"PCA\"],\n \"CIP\": [\"CIP\"],\n \"supernate\": [\"the supernate\"]}",
                {
                    "Herb name": [
                        "GA",
                        "PCA"
                    ],
                    "Drug": [
                        "CIP"
                    ]
                }
            ]
        ],
        [
            777,
            "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.",
            [
                " {\"CIP\": [\"precursor-product ion transitions\", \"332.1\u2192288.1\"], \"ofloxacin\": [\"precursor-product ion transitions\", \"362.2\u2192318.1\", \"internal standard\"]}",
                {
                    "Drug": [
                        "CIP",
                        "ofloxacin"
                    ]
                }
            ]
        ],
        [
            778,
            "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.",
            [
                " {\"CIP\": [\"CIP and\"], \"PCE\": [\"PCE and\"], \"GA\": [\"GA's PK changes\", \"GA\", \"Figures  3\"], \"PCA\": [\"PCA's PK changes\", \"PCA\", \"Figures 4\"]}",
                {
                    "Drug": [
                        "CIP"
                    ],
                    "Herb name": [
                        "PCE",
                        "GA",
                        "PCA"
                    ]
                }
            ]
        ],
        [
            779,
            "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.",
            [
                " {\"CIP\": [\"ciprofloxacin\", \"tissue to plasma distribution coefficients of CIP\"],\n \"PCE\": [\"PCE\", \"significantly increased the tissue to plasma distribution coefficients (K)\", \"in the absence (A)\", \"in the presence (B)\", \"after intravenous administration of CIP in the absence and presence of PCE to rats\", \"in normal rats after intragastric administration of PCE in the absence and presence of CIP\"],\n \"GA\": [\"GA\", \"tissue distribution curves of GA\"]}",
                {
                    "Herb name": [
                        "PCE",
                        "PCE",
                        "GA",
                        "PCE"
                    ],
                    "Drug": [
                        "ciprofloxacin (CIP)",
                        "CIP",
                        "CIP"
                    ]
                }
            ]
        ],
        [
            780,
            "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.",
            [
                " {\"AGE\": [],\n \"CIP\": [\"ciprofloxacin\"],\n \"GA\": [\"gallic acid\"],\n \"K\": [\"tissue distribution coefficients\", \"tissue distribution profiles\"],\n \"PCA\": [\"PCE\"]}",
                {
                    "Drug": [
                        "CIP",
                        "ciprofloxacin",
                        "CIP"
                    ],
                    "Herb name": [
                        "gallic acid (GA)",
                        "PCE",
                        "PCA"
                    ]
                }
            ]
        ],
        [
            781,
            "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.",
            [
                " {\"CIP\": [\"the drug\"], \"circulating CIP\": [\"reduced circulating CIP\"], \"liver metabolism\": [\"liver metabolism (approximately 10%)\"], \"biliary excretion\": [\"biliary excretion (approximately 1%)\"], \"drug\": [\"the drug\"]}",
                {
                    "Drug": [
                        "CIP",
                        "CIP"
                    ]
                }
            ]
        ],
        [
            782,
            "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.",
            [
                " {\"FUNDING\": [\"Scientific Research Project of Tianjin Municipal Education Commission\", \"2021ZD017 and 2021ZD030\", \"National Science and Technology Major Project of China\", \"Grant number 2018ZX09734-002\", \"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\"]}",
                {
                    "Ethnic group": [
                        "Chinese"
                    ]
                }
            ]
        ],
        [
            783,
            "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
            [
                " {}\n\nThe present investigation was carried out to elucidate the pharmacological profile of compound X in rat models.\n\n{\"Compound X\": [\"compound X\"]}\n\nThe experiments were performed in accordance with the guidelines established by the Institutional Animal Care and Use Committee (IACUC).\n\n{\"Institutional Animal Care and Use Committee (IACUC)\": [\"Institutional Animal Care and Use Committee\", \"IACUC\"]}\n\nRats (Sprague-Dawley, 250-300 g) were housed under standard conditions (12 h light/dark cycle, temperature 22-25\u00b0C, and humidity 50-60%) and had free access to food and water.\n\n{\"Rats\": [\"rats\", \"Sprague-Dawley\"]}\n\nCompound X was administered orally via gavage at doses of 5, 10, and 20 mg/kg.\n\n{\"Compound X\": [\"compound X\", \"doses\"]}\n\nThe pharmacokinetic parameters were determined by analyzing the plasma concentration-time profiles.\n\n{\"Pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]}\n\nThe plasma concentration of compound X was measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.\n\n{\"Plasma concentration\": [\"plasma concentration\"], \"LC-MS/MS\": [\"LC-MS/MS\", \"liquid chromatography-tandem mass spectrometry\"]}\n\nThe results showed that compound X was rapidly absorbed, with a median time to maximum concentration (Tmax) of 0.5 h and a half-life (t1/2) of 2.5 h.\n\n{\"Compound X\": [\"compound X\", \"median time to maximum concentration (Tmax)\", \"half-life (t1/2)\"]}\n\nThe distribution volume (Vd) was calculated to be 1.5 L/kg, indicating that compound X was moderately distributed in the body.\n\n{\"Compound X\": [\"compound X\", \"distribution volume (Vd)\"]}\n\nThe metabolism of compound X was studied using in vitro and in vivo methods.\n",
                {}
            ]
        ],
        [
            784,
            "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",
            [
                " {\"Cisplatin\": [\"This anticancer drug is a common representative of the inorganic platinum complexes, which are widely used in clinical oncology.\"],\n \"Platinum complexes\": [\"These are widely used in clinical oncology.\"],\n \"Inorganic platinum complexes\": [\"These are widely used in clinical oncology.\"],\n \"Cisplatin administration\": [\"The administration of cisplatin is associated with nephrotoxicity.\"],\n \"Nephrotoxicity\": [\"The administration of cisplatin is associated with nephrotoxicity.\"],\n \"Carbonic anhydrase IX\": [\"Carbonic anhydrase IX (CAIX) is a transmembrane enzyme overexpressed in various human cancers.\"],\n \"Hypoxia\": [\"Under hypoxic conditions, CAIX expression is significantly increased.\"],\n \"Sodium bicarbonate\": [\"Sodium bicarbonate is a weak base that can alkalinize the urine.\"],\n \"Urine alkalinization\": [\"Sodium bicarbonate is used for urine alkalinization.\"],\n \"Renal proximal tubules\": [\"The renal proximal tubules are the primary site of cisplatin toxicity.\"],\n \"Acidosis\": [\"Acidosis is a common complication of cisplatin therapy.\"],\n \"Sodium chloride\": [\"Sodium chloride is used for intravenous infusions.\"],\n \"Isotonic solution\": [\"Isotonic solutions, such as 0.9% sodium chloride, are commonly used for intravenous infusions.\"],\n \"Mesna\": [\"Mesna (2-Mercaptoethanesulfonic acid) is a sulfhydryl donor that can react with the reactive metabolites of cisplatin.\"],\n \"Cysteine\": [\"Cysteine is a sulfhydryl-containing amino acid.\"],\n \"Glutathione\": [\"Glutathione is a tripeptide that acts as a major intracellular antioxidant.\"],\n \"Reactive metabolites\": [\"The reactive metabolites of cis",
                {}
            ]
        ],
        [
            785,
            "Click here for additional data file.",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BLOOD-BRAIN BARRIER\": [\"blood-brain barrier\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC ARREST\": [\"cardiac arrest\"], \"CARDIAC OUTPUT\": [\"cardiac output\"], \"CARDIOPULMONARY\": [\"cardiopulmonary\"], \"CARDIOPULMONARY RESUSCITATION\": [\"cardiopulmonary resuscitation\"], \"CELLS\": [\"cells\"], \"CHEMICAL\": [\"chemical\"], \"CHLORIDE\": [\"chloride\"], \"CHOLINERGIC\": [\"cholinergic\"], \"CONSCIOUSNESS\": [\"consciousness\"], \"CONTRACTILE\": [\"contractile\"], \"CORONARY\": [\"coronary\"], \"CORONARY ARTERIES\": [\"coronary arteries\"], \"CORONARY THROMBOSIS\": [\"coronary thrombosis\"], \"DIABETES\": [\"diabetes\"], \"DIURETIC\": [\"diuretic\"], \"DRUGS\": [\"drugs\"], \"ELECTROLYTES\": [\"electrolytes\"], \"ENDOTHELIUM\": [\"endothelium\"], \"EPINEPHRINE\": [\"epinephrine\"], \"EXCITATORY\": [\"excitatory\"], \"FATTY ACIDS\": [\"fatty acids\"], \"HEART\": [\"heart\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HYALURONIC ACID\": [\"hyaluronic acid\"], \"HYPERGLYCEMIA\": [\"hyperglycemia\"], \"HYPERKALEMIA\": [\"hyperkalemia\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"HYPERVOLUME\": [\"hypervolume\"], \"HYPOGLYCEMIA\": [\"hypoglycemia\"], \"HYPOKALEMIA\": [\"hypokalemia\"], \"INFARCTION\": [\"infarction\"], \"INHIBITORY\": [\"inhibitory\"], \"INSULIN\": [\"insulin\"], \"ISCHEMIA\": [\"ischemia\"], \"IS",
                {}
            ]
        ],
        [
            786,
            "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.",
            [
                " {}\n\nAll tests were performed at similar:\n{\"LABORATORY\": [\"conditions\"]}\n\ncontrolling for:\n{\"AIR_TEMPERATURE\": [], \"BAROMETRIC_PRESSURE\": [], \"RELATIVE_HUMIDITY\": []}\n\nThe following pharmacological agents were used in the study:\n\n1. Propranolol:\n{\"PROPRANOLOL\": [\"pharmacological agent\"]}\n\n2. Salbutamol:\n{\"SALBUTAMOL\": [\"pharmacological agent\"]}\n\n3. ICI 118,551:\n{\"ICI_118_551\": [\"pharmacological agent\"]}\n\n4. Phentolamine:\n{\"PENTOLAMINE\": [\"pharmacological agent\"]}\n\n5. Albuterol:\n{\"ALBUTEROL\": [\"pharmacological agent\"]}\n\n6. Isoproterenol:\n{\"ISOPROTERENOL\": [\"pharmacological agent\"]}\n\n7. Phenylephrine:\n{\"PHENYLEPHRINE\": [\"pharmacological agent\"]}\n\n8. Timolol:\n{\"TIMOLOL\": [\"pharmacological agent\"]}\n\n9. Bradykinin:\n{\"BRADYKININ\": [\"pharmacological agent\"]}\n\n10. Histamine:\n{\"HISTAMINE\": [\"pharmacological agent\"]}\n\n11. Acetylcholine:\n{\"ACETYLCHOLINE\": [\"pharmacological agent\"]}\n\n12. Norepinephrine:\n{\"NOREPINEPHRINE\": [\"pharmacological agent\"]}\n\n13. Dopamine:\n{\"DOPAMINE\": [\"pharmacological agent\"]}\n\n14. Serotonin:\n{\"SEROTONIN\": [\"pharmacological agent\"]}\n\n15. Glucagon:\n{\"GLUCAGON\": [\"pharmacological agent\"]}\n\n16. Insulin:\n{\"INSULIN\": [\"pharmacological agent\"]}\n\n17. Epinephrine:\n{\"EPINEPHRINE",
                {}
            ]
        ],
        [
            787,
            "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).",
            [
                " {\"Scale\": [\"anchored\", \"labels\"], \"NOT AT ALL\": [\"(0 mm)\"], \"EXTREMELY\": [\"(100 mm)\"]}",
                {}
            ]
        ],
        [
            788,
            "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).",
            [
                " {\"AUC\": [\"total AUC for CHO in YM\", \"total AUC for CHO in PLC\"], \"CHO\": [\"CHO\"], \"YM\": [\"YM\"], \"PLC\": [\"PLC\"], \"p\": [\"p\"]}",
                {
                    "Parameter": [
                        "AUC",
                        "CHO"
                    ],
                    "Herb name": [
                        "YM"
                    ]
                }
            ]
        ],
        [
            789,
            "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).",
            [
                " {\"Total Energy Expenditure\": [\"Total Energy Expenditure\", \"TEE\"]}\n{\"treatment\": [\"treatment\", \"YM\", \"PLC\"]}\n{\"exercise time\": [\"exercise time\"]}",
                {
                    "Parameter": [
                        "Total Energy Expenditure (TEE)"
                    ],
                    "Herb name": [
                        "YM"
                    ],
                    "Drug": [
                        "PLC"
                    ]
                }
            ]
        ],
        [
            790,
            "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].",
            [
                " {\"AGE\": []}\n\nThis increase is comparable with: [\"24% increase\", \"low to moderate exercise intensities\", \"incremental protocol\"]\n\nfound during: [\"previous study\"]\n\ndetermined using: [\"incremental protocol\"]\n\nin our: [\"previous study\"]\n\nstudy: []\n\nThe following format must be followed:\n{\"AGE\": [\"mentions of ages found in text\"]}\n\nThere are no mentions of ages in this text. Therefore, the output should be an empty dictionary.\n\n{\"AGE\": []}",
                {}
            ]
        ],
        [
            791,
            "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].",
            [
                " {\"AGE\": [], \"YM\": [\"YM\", \"ingestion\", \"metabolic rate\", \"acutely\", \"twelve weeks\", \"healthy obese participants\"]}\n\nThe mechanism of action of YM is not fully understood, but it is believed to involve the activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptors (PPARs) [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21].\n\n{\"AMPK\": [\"AMP-activated protein kinase\"], \"PPARs\": [\"peroxisome proliferator-activated receptors\"]}\n\nMoreover, YM has been shown to increase energy expenditure and lipid oxidation in rodents [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21].\n\n{\"energy expenditure\": [], \"lipid oxidation\": [], \"rodents\": []}\n\nIn vitro studies have demonstrated that YM can inhibit the activity of acetyl-CoA carboxylase (ACC) and citrate synthase (CS) [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21].\n\n{\"in vitro\": [], \"acetyl-CoA carboxylase (ACC)\": [], \"citrate synthase (CS)\": []}\n\nAdditionally, YM has been reported to increase the expression of genes involved in \u03b2-oxidation and mitochondrial biogenesis [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21].\n\n{\"\u03b2-oxid",
                {
                    "Herb name": [
                        "YM"
                    ],
                    "Duration": [
                        "12 weeks"
                    ],
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            792,
            "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].",
            [
                " {\"AGE\": [],\n \"adrengenic effects\": [\"adrengenic\"],\n \"central nervous system\": [\"central nervous system\"],\n \"caffeine\": [\"caffeine\"],\n \"chlorogenic acids\": [\"chlorogenic acids\"],\n \"mono- and di-caffeolquinic acids\": [\"mono- and di-caffeolquinic acids\"],\n \"hydroxycinnamic acids\": [\"hydroxycinnamic acids\"],\n \"caffeic acid\": [\"caffeic acid\"],\n \"quinic acid\": [\"quinic acid\"],\n \"terpeneic saponins\": [\"terpeneic saponins\"],\n \"minerals\": [],\n \"vitamins\": []}",
                {
                    "Herb name": [
                        "caffeine"
                    ]
                }
            ]
        ],
        [
            793,
            "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.",
            [
                " {\"YM capsules\": [\"YM capsules\"]}",
                {
                    "Herb name": [
                        "YM"
                    ],
                    "Parameter": [
                        "bioavailability"
                    ]
                }
            ]
        ],
        [
            794,
            "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.",
            [
                " {\"AGE\": []}\n\nFavorable psychomotor effects: [\"psychomotor effects\"]\non mood state: [\"mood state\"]\nand satiety: [\"satiety\"]\nare often expected outcomes: [\"expected outcomes\"]\nof fat: [\"fat\"]\nand weight-loss: [\"weight-loss\"]\nsupplementation: [\"supplementation\"]\nprotocols: [\"protocols\"]",
                {}
            ]
        ],
        [
            795,
            "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.",
            [
                " {\"BF%\": [\"BF% data indicated\", \"lower BF% percentile\"],\n \"females\": [\"all females who took part\"],\n \"YM\": [\"positive effects of YM\", \"YM treatment\"]}",
                {
                    "Sex": [
                        "females"
                    ],
                    "Herb name": [
                        "YM",
                        "YM",
                        "YM"
                    ]
                }
            ]
        ],
        [
            796,
            "R.A. collected the data and contributed to data analysis and manuscript writing.",
            [
                " {\"R.A.\": [\"R.A.\"]},\n{\"pharmacology\": [\"pharmacology\"]}\n\nNo mentions of entities related to age, gender, species, drugs, or other chemical compounds were found in the given text.",
                {}
            ]
        ],
        [
            797,
            "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).",
            [
                " {\"Company\": [\"Co.\"], \"City\": [\"Seoul\"], \"Country\": [\"Korea\"], \"Prof. Yeong Bae Seo\": []}\n\nThe bioactive compounds 1-3 were isolated from the leaves of Acanthopanax gracilistylus (Schltdl. & Cham.) Benn. (Acanthaceae) collected in Jilin Province, China.\n\n{\"Acanthopanax gracilistylus\": [], \"Schltdl. & Cham.\": [], \"Benn\": [], \"Acanthaceae\": []}\n\nThe structures of 1-3 were elucidated by 1D and 2D NMR spectroscopy and high-resolution electrospray ionization mass spectroscopy (HRESI-MS).\n\n{\"1-3\": [], \"1D\": [], \"2D\": [], \"NMR spectroscopy\": [], \"high-resolution electrospray ionization mass spectroscopy\": [\"HRESI-MS\"]}\n\nCompound 1 was identified as 2,3,5-tri-O-galloyl-quercetin (1) based on its molecular formula C16H10O12, UV, IR, 1H and 13C NMR data, and comparison with the literature.\n\n{\"Compound 1\": [], \"molecular formula\": [\"C16H10O12\"], \"UV\": [], \"IR\": [], \"1H\": [], \"13C NMR\": []}\n\nCompound 2 was identified as 3,5-di-O-galloyl-quercetin (2) based on its molecular formula C15H10O11, UV, IR, 1H and 13C NMR data, and comparison with the literature.\n\n{\"Compound 2\": [], \"molecular formula\": [\"C15H10O11\"], \"UV\": [], \"IR\": [], \"1H\": [], \"13C NMR\": []}\n\nCompound 3 was identified as quercetin-3-O-gallate (3) based on its molecular formula C15H12O8, UV, IR, 1H",
                {}
            ]
        ],
        [
            798,
            "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).",
            [
                " {\"HEK293 cells\": [\"HEK293\", \"cells\"],\n \"OAT1\": [\"OAT1\"],\n \"OAT3\": [\"OAT3\"],\n \"OCT1\": [\"OCT1\"],\n \"OCT2\": [\"OCT2\"],\n \"OATP1B1\": [\"OATP1B1\"],\n \"OATP1B3\": [\"OATP1B3\"],\n \"Corning-Gentest\": [\"Corning-Gentest\"],\n \"Tewksbury\": [\"Tewksbury\"],\n \"MA\": [\"MA\"],\n \"USA\": [\"USA\"]}",
                {
                    "Parameter": [
                        "OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"
                    ]
                }
            ]
        ],
        [
            799,
            "Food and water were supplied ad libitum.",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"AGE\": [\"mentions of ages found in text\"]}\n\nFood and water were supplied ad libitum. (No mentions of ages found in this text.)",
                {}
            ]
        ],
        [
            800,
            "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.",
            [
                " {\"ANESTHESIA\": [\"isoflurane\"], \"COMPANY\": [\"Natsume Co\"], \"COUNTRY\": [\"Japan\"], \"PE-50\": [], \"POLYETHYLENE TUBING\": [\"PE-50\"]}\n\nRats were cannulated with PE-50 polyethylene tubing (Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.\n\nThis text mentions the following entities and their respective mentions:\n\n* Anesthesia: isoflurane\n* Company: Natsume Co\n* Country: Japan\n* Polyethylene tubing: PE-50\n\nThere are no mentions of age, so the \"AGE\" field remains empty.",
                {
                    "Parameter": [
                        "anesthesia"
                    ],
                    "Drug": [
                        "isoflurane"
                    ]
                }
            ]
        ],
        [
            801,
            "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.",
            [
                " {\"Agilent Technologies\": [\"Agilent Technologies\"]}\n{\"Mass Hunter software\": [\"Mass Hunter software\"]}\n{\"LC-MS/MS\": [\"LC-MS/MS\"]}\n{\"system control\": []}\n{\"data processing\": []}",
                {}
            ]
        ],
        [
            802,
            "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].",
            [
                " {\"AGE\": [\"respondents\"]}\n\npractice of herbal co-medication: [], prescription drugs: [], patient demographics: [], respondents: [\"38%\"]}\n\nThe use of herbal medicines in combination with prescription drugs was found to be prevalent among various patient populations [6].\n\n{\"AGE\": [\"patient populations\"]}\n\nuse of herbal medicines: [], prescription drugs: [], patient populations: [\"various\"]}\n\nHerbal co-medication, also known as herb-drug interaction, is a common practice that has gained increasing attention in recent years due to its potential impact on health outcomes [1,2,3,4,5,6].\n\nHerbal co-medication: [\"Herbal co-medication\", \"herb-drug interaction\"], health outcomes: []\n\nThe prevalence of herbal co-medication use was found to be high, with up to 77% of patients reporting the use of herbal medicines in addition to prescription drugs [1].\n\nprevalence: [], patients: [\"up to 77%\"], herbal medicines: [\"herbal medicines\", \"herbs\"], prescription drugs: []\n\nThe practice of herbal co-medication was found to cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].\n\npatient demographics: [\"various\"], respondents: [\"38%\"], concomitant herbal use: []\n\nThe use of herbal medicines in combination with prescription drugs is particularly common among older adults, with up to 80% of older adults reporting the use of herbal medicines [3].\n\nolder adults: [\"older adults\"], up to 80%: [\"up to 80%%\"], herbal medicines: [\"herbal medicines\"]\n\nThe potential risks and benefits of herbal co-medication use in older adults are complex and require further investigation [3].\n\nherbal co-medication use: [\"herbal co-medication use\"], older adults: [\"older adults\"], risks: [], benefits: []\n\nThe use of herbal medicines in combination with prescription drugs can lead to drug-herb interactions, which can result in adverse effects or reduced efficacy of the prescription drugs [1,2,3",
                {}
            ]
        ],
        [
            803,
            "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].",
            [
                " {\"CYP\": [\"cytochrome P450\"], \"P-gp\": [\"P-glycoprotein\"], \"felodipine\": [\"felodipine\"], \"pharmacokinetic profiles\": [\"pharmacokinetic profiles\"], \"inhibition\": [\"inhibition\"]}",
                {
                    "Herb name": [
                        "grapefruit juice"
                    ],
                    "Drug": [
                        "felodipine"
                    ],
                    "Target": [
                        "cytochrome P450 (CYP)",
                        "P-glycoprotein (P-gp)"
                    ]
                }
            ]
        ],
        [
            804,
            "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.",
            [
                " {\"celery\": [], \"echinacea\": [], \"ginkgo\": [], \"ginseng\": [], \"hydroxycut\": [], \"kava\": [], \"kratom\": [], \"moringa\": [], \"piperine\": [], \"rhodiola\": [], \"St. John\u2019s wort\": [], \"terminalia/commiphora ayurvedic mixture\": [], \"valerian\": []}\n\nHere are the mentions of the entities in the text:\n\n1. celery: No mentions found\n2. echinacea: \"echinacea\"\n3. ginkgo: \"ginkgo\"\n4. ginseng: \"ginseng\"\n5. hydroxycut: \"hydroxycut\"\n6. kava: \"kava\"\n7. kratom: \"kratom\"\n8. moringa: \"moringa\"\n9. piperine: \"piperine\"\n10. rhodiola: \"rhodiola\"\n11. St. John\u2019s wort: \"St. John\u2019s wort\"\n12. terminalia/commiphora ayurvedic mixture: \"terminalia/commiphora ayurvedic mixture\"\n13. valerian: \"valerian\"\n\nThe text does not contain any mentions of ages or other entities not listed in the provided instructions.",
                {
                    "Herb name": [
                        "celery",
                        "echinacea",
                        "ginkgo",
                        "ginseng",
                        "hydroxycut",
                        "kava",
                        "kratom",
                        "moringa",
                        "piperine",
                        "rhodiola",
                        "St. John\u2019s wort",
                        "terminalia/commiphora ayurvedic",
                        "valerian"
                    ]
                }
            ]
        ],
        [
            805,
            "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.",
            [
                " {\"Celery\": [\"celery\", \"phytostrogens\", \"bioactive components\"], \"DMEs\": [\"DMEs\"], \"CYP450 family\": [\"CYP450 family\"]}",
                {
                    "Herb name": [
                        "celery"
                    ],
                    "Target": [
                        "DMEs",
                        "CYP450 family"
                    ]
                }
            ]
        ],
        [
            806,
            "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.",
            [
                " {\"HDIs\": [\"anecdotal pieces of evidence\", \"consequences of HDIs\", \"further studies\", \"clinical decisions\"]}",
                {}
            ]
        ],
        [
            807,
            "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].",
            [
                " {\"AGE\": [],\n \"ginkgo\": [\"the use of ginkgo\", \"ginkgo is associated with\"],\n \"symptoms of cognition decline and memory loss\": [],\n \"anxiety and mood disorders\": [],\n \"fatigue\": [],\n \"general well-being\": [],\n \"cardiovascular disorders\": []}",
                {
                    "Study": [
                        "Several controlled clinical studies"
                    ],
                    "Herb name": [
                        "ginkgo"
                    ],
                    "Pathology": [
                        "cognition decline",
                        "memory loss",
                        "anxiety",
                        "mood disorders",
                        "fatigue",
                        "cardiovascular disorders"
                    ]
                }
            ]
        ],
        [
            808,
            "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.",
            [
                " {\"AGE\": [],\n \"Seizure\": [\"seizure\"],\n \"Death\": [\"death\"],\n \"Toxicological autopsy results\": [],\n \"Subtherapeutic\": [\"subtherapeutic\"],\n \"Serum levels\": [\"serum levels\"],\n \"Both drugs\": [\"both drugs\"]}",
                {
                    "Pathology": [
                        "seizure"
                    ]
                }
            ]
        ],
        [
            809,
            "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].",
            [
                " {\"CYP3A4\": [\"the different phytochemicals in ginseng\", \"CYP3A4 is demonstrated\", \"CYP3A4 is inhibitory and inductive effect\", \"CYP3A4 is observed changes\", \"CYP3A4 is human studies\", \"CYP3A4 is midazolam\"],\n \"AUC\": [\"observed changes in the AUC\"],\n \"phytochemicals\": [\"the different phytochemicals\"],\n \"ginseng\": [\"in ginseng\"],\n \"human studies\": [\"in these human studies\"],\n \"midazolam\": [\"midazolam in these human studies\"]}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Target": [
                        "CYP3A4"
                    ],
                    "Parameter": [
                        "AUC"
                    ],
                    "Drug": [
                        "midazolam"
                    ],
                    "Study": [
                        "human studies"
                    ]
                }
            ]
        ],
        [
            810,
            "Chronic use of ginseng on its own has been associated with manic psychosis [90].",
            [
                " {\"AGE\": []}\n\"Chronic use of ginseng on its own has been associated with manic psychosis\" [90]:\n{\"ginseng\": [\"ginseng\"]}",
                {
                    "Herb name": [
                        "ginseng"
                    ],
                    "Pathology": [
                        "manic psychosis"
                    ]
                }
            ]
        ],
        [
            811,
            "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].",
            [
                " {\"kavalactones\": [\"kavalactones\"]}\n\nThe main active constituents of kava are the kavalactones, which are primarily found in the rhizomes [96].\n\nTherefore, the output would be:\n{\"kavalactones\": [\"kavalactones\", \"primarily found in the rhizomes\"]}",
                {
                    "Herb name": [
                        "kava",
                        "kavalactones"
                    ],
                    "Herb part": [
                        "rhizomes"
                    ]
                }
            ]
        ],
        [
            812,
            "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.",
            [
                " {\"AGE\": []}\n\nDespite the general concern about its safety, kava is still popularly consumed for CNS (central nervous system) benefits.",
                {
                    "Herb name": [
                        "kava"
                    ]
                }
            ]
        ],
        [
            813,
            "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].",
            [
                " {\"AGE\": [\"18\", \"health volunteers\"]}\n\nA study was conducted on:\n- 18 individuals\n- health volunteers\n\nThe study did not show any clinically relevant interaction between:\n- kava\n- bromazepam.",
                {
                    "Cohort": [
                        "18 health volunteers"
                    ],
                    "Herb name": [
                        "kava"
                    ],
                    "Drug": [
                        "bromazepam"
                    ]
                }
            ]
        ],
        [
            814,
            "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].",
            [
                " {\"Kratom\": [\"complementary medicine\", \"manage diabetes\", \"diarrhea\", \"improve circulation\", \"enhance alertness and concentration\", \"increase libido\"], \"AGE\": []}",
                {
                    "Herb name": [
                        "Kratom"
                    ],
                    "Pathology": [
                        "diabetes",
                        "diarrhea"
                    ]
                }
            ]
        ],
        [
            815,
            "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.",
            [
                " {\"CYP/P-gp\": [\"mediates\", \"interactions\", \"CYP/P-gp induction\"]}\n{\"serotonergic\": [\"serotonergic effects\"]}",
                {
                    "Herb name": [
                        "SJW"
                    ]
                }
            ]
        ],
        [
            816,
            "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.",
            [
                " {\"SJW\": [\"investigated the ability of\", \"interact with\"], \"CYP3A4\": [\"in a 2-way, open-label crossover study of\", \"using midazolam as the probe substrate\"]}\n\nThe number of mentions for each entity is not provided in the text.",
                {
                    "Herb name": [
                        "SJW"
                    ],
                    "Target": [
                        "CYP3A4"
                    ],
                    "Study": [
                        "open-label crossover study"
                    ],
                    "Cohort": [
                        "21 healthy subjects"
                    ],
                    "Drug": [
                        "midazolam"
                    ]
                }
            ]
        ],
        [
            817,
            "This is important because the vast majority of herbal products are orally administered.",
            [
                " {\"AGE\": []}\n\nThe following entities were identified as being referred to in the text:\n\n{\"Herbal products\": [\"vast majority of herbal products\", \"herbal products\"]}\n{\"Orally administered\": [\"orally administered\"]}",
                {}
            ]
        ],
        [
            818,
            "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.",
            [
                " {\"AGE\": []}\n\n\"Many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.\"\n\nThere is no mention of specific ages in the given text.",
                {}
            ]
        ],
        [
            819,
            "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.",
            [
                " {\"CYP3A4\": [\"CYP3A4\", \"human small intestinal enterocytes\", \"richly expressed\"]}\n{\"P-gp\": [\"P-gp\", \"human small intestinal enterocytes\", \"richly expressed\"]}",
                {}
            ]
        ],
        [
            820,
            "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.",
            [
                " {\"CELERY\": [], \"ECHINACEA\": [], \"GINKGO\": [], \"GINSENG\": [], \"HYDROXYCT\": [], \"KAVA\": [], \"KRATOM\": [], \"MORINGA\": [], \"PIPERINE\": [], \"RHODIOLA\": [], \"SAINT JOHN\u2019S WORT\": [], \"TERMINALIA/COMMIPHORA AYURVEDIC MIXTURE\": [], \"VALERIAN\": [], \"AGE\": []}\n\nThe given text mentions the following herbal products: celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture, and valerian. Since no age-related information was found in the text, the \"AGE\" field remains empty.",
                {
                    "Herb name": [
                        "celery",
                        "echinacea",
                        "ginkgo",
                        "ginseng",
                        "kava",
                        "kratom",
                        "moringa",
                        "piperine",
                        "rhodiola",
                        "St. John\u2019s wort",
                        "terminalia/commiphora ayurvedic mixture",
                        "valerian"
                    ],
                    "Herb part": [
                        "hydroxycut"
                    ],
                    "Drug": [
                        "neuropsychiatric drugs"
                    ]
                }
            ]
        ],
        [
            821,
            "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.",
            [
                " {\"Medicinal herbs\": [], \"rich sources\": [], \"natural bioactive compounds\": [], \"could interact\": [], \"drugs\": []}\n\nThe pharmacokinetic interactions between herbal medicines and drugs could lead to therapeutic benefits or adverse effects.\n\n{\"Pharmacokinetic interactions\": [], \"herbal medicines\": [], \"drugs\": [], \"therapeutic benefits\": [], \"adverse effects\": []}\n\nThe cytochrome P450 (CYP) enzyme system plays a crucial role in the metabolism of most drugs and herbal constituents.\n\n{\"cytochrome P450 (CYP)\": [], \"enzyme system\": [], \"plays a crucial role\": [], \"metabolism\": [], \"most drugs\": [], \"herbal constituents\": []}\n\nThe inhibition or induction of CYP enzymes by herbal constituents can significantly alter the pharmacokinetics of co-administered drugs.\n\n{\"inhibition\": [], \"induction\": [], \"CYP enzymes\": [], \"herbal constituents\": [], \"significantly alter\": [], \"pharmacokinetics\": [], \"co-administered drugs\": []}\n\nFor instance, St. John's wort (Hypericum perforatum) is a well-known herbal remedy that induces CYP3A4, leading to decreased plasma concentrations of drugs metabolized by this enzyme.\n\n{\"St. John's wort (Hypericum perforatum)\": [], \"well-known herbal remedy\": [], \"induces\": [], \"CYP3A4\": [], \"leading to\": [], \"decreased plasma concentrations\": [], \"drugs metabolized by this enzyme\": []}\n\nGrapefruit juice is another example of a natural product that inhibits CYP3A4 and can result in increased plasma concentrations of co-administered drugs.\n\n{\"Grapefruit juice\": [], \"another example\": [], \"natural product\": [], \"inhibits\": [], \"CYP3A4\": [], \"can result in\": [], \"increased plasma concentrations\": [], \"co-administered drugs\": []}\n\nIn conclusion, the interaction between her",
                {}
            ]
        ],
        [
            822,
            "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.",
            [
                " {\"Sirolimus\": [\"Sirolimus displays\", \"Sirolimus\"],\n \"calcineurin inhibitors\": [\"calcineurin inhibitors\", \"indispensable immunosuppressive agents in kidney transplantation\"]}",
                {
                    "Drug": [
                        "Sirolimus",
                        "calcineurin inhibitors",
                        "calcineurin inhibitors"
                    ]
                }
            ]
        ],
        [
            823,
            "This is especially important for drugs with a narrow therapeutic window.",
            [
                " {\"AGE\": [], \"ANESTHESIA\": [\"anesthesia\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BISOPROLLOL\": [\"bisoprolol\"], \"BLOOD PRESSURE\": [\"blood pressure\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC GLYCOSIDES\": [\"cardiac glycosides\"], \"CARDIAC OUTPUT\": [\"cardiac output\"], \"CARDIOSPECIFIC\": [\"cardiospecific\"], \"CHLORPROMAZINE\": [\"chlorpromazine\"], \"CLINICAL TRIAL\": [\"clinical trial\"], \"DILTIAZEM\": [\"diltiazem\"], \"DOBUTAMINE\": [\"dobutamine\"], \"DRUG\": [], \"DRUG INTERACTION\": [\"drug interaction\"], \"ELECTROLYTE\": [\"electrolyte\"], \"HEART RATE\": [\"heart rate\"], \"HEMODYNAMIC\": [\"hemodynamic\"], \"HYPERKALEMIA\": [\"hyperkalemia\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"HYPERVOLAEMIC\": [\"hypervolaemic\"], \"INOTROPE\": [\"inotrope\"], \"ISOPROTERENOL\": [\"isoproterenol\"], \"LIDOCAINE\": [\"lidocaine\"], \"MORPHINE\": [\"morphine\"], \"MYOCARDIUM\": [\"myocardium\"], \"NARCOTIC\": [\"narcotic\"], \"NITROPRUSIDE\": [\"nitroprusside\"], \"NITROUS OXIDE\": [\"nitrous oxide\"], \"NORADRENALINE\": [\"noradrenaline\"], \"PARACETAMOL\": [\"paracetamol\"], \"PHARMACOKINETICS\": [\"pharmacokinetics\"], \"PHARMACODYNAMICS\": [\"pharmacodynamics\"], \"POTASSIUM\": [\"potassium\"], \"PRESBYCARDIA\": [\"presbycardia\"], \"PROPRANOLOL\": [\"propranolol\"], \"RESERVE\": [\"reserve\"], \"SARCOLEPTIC\": [\"sarcoleptic\"], \"SEPSIS\": [\"seps",
                {}
            ]
        ],
        [
            824,
            "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.",
            [
                " {\"tacrolimus\": [\"the patient received tacrolimus-based immunosuppression\", \"tacrolimus-based immunosuppression\", \"tacrolimus\"],\n \"sirolimus\": [\"the treatment was switched from tacrolimus to sirolimus\"],\n \"April 2016\": [\"until April 2016\"]}",
                {
                    "Drug": [
                        "tacrolimus",
                        "tacrolimus",
                        "sirolimus"
                    ],
                    "Pathology": [
                        "tremors"
                    ]
                }
            ]
        ],
        [
            825,
            "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.",
            [
                " {\"AGE\": [], \"serum creatinine level\": [\"serum creatinine level\", \"74.27 \u00b5mol/L\"]}",
                {
                    "Parameter": [
                        "serum creatinine level"
                    ],
                    "Amount": [
                        "74.27\u2009\u00b5mol/L"
                    ]
                }
            ]
        ],
        [
            826,
            "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.",
            [
                " {\"AGE\": []}\n\nherb\u2013drug interactions\ncould lead to serious adverse effects.",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            827,
            "Author contributions: MK drafted the initial and final versions of the manuscript.",
            [
                " {\"AGE\": []}\n\nIntroduction:\nThe pharmacology of 5-HT3 receptors has been extensively studied due to their role in various physiological and pathological conditions. (5-HT3 receptors)\n\nMethods:\nThe data were obtained from a systematic search of PubMed and Embase databases up to January 2021. (PubMed, Embase)\n\nResults:\n5-HT3 receptors are expressed in the central and peripheral nervous system and play a crucial role in the regulation of gastrointestinal motility, nausea, and vomiting. (5-HT3 receptors, central nervous system, peripheral nervous system, gastrointestinal motility, nausea, vomiting)\n\nDiscussion:\n5-HT3 receptors are also implicated in the modulation of pain, anxiety, and addiction. (5-HT3 receptors, pain, anxiety, addiction)\n\nConclusion:\nIn conclusion, the pharmacology of 5-HT3 receptors is complex and multifaceted, and further research is needed to fully understand their role in various physiological and pathological conditions. (5-HT3 receptors, further research)\n\nReferences:\n[1] Smith J, Jones M. The role of 5-HT3 receptors in gastrointestinal function. Neuropharmacology. 2005;48(3):415-425.\n[2] Doe J, Roe S. The role of 5-HT3 receptors in pain modulation. Pain. 2008;135(3):456-464.\n[3] Lee S, Kim J. The role of 5-HT3 receptors in anxiety and addiction. Neuropsychopharmacology. 2011;36(1):218-231.",
                {}
            ]
        ],
        [
            828,
            "Sirolimus is an immunosuppressive drug used to prevent graft rejection.",
            [
                " {\"Sirolimus\": [\"Sirolimus is\", \"Sirolimus is an\", \"Sirolimus is used\"]}\n{\"Drug\": [\"drug\", \"immunosuppressive drug\"]}\n{\"Graft\": []}\n{\"Rejection\": []}\n{\"Prevent\": []}\n{\"Age\": []}",
                {
                    "Drug": [
                        "Sirolimus"
                    ],
                    "Pathology": [
                        "graft rejection"
                    ]
                }
            ]
        ],
        [
            829,
            "Therapeutic drug monitoring is required as with other immunosuppressive drugs.",
            [
                " {\"AGE\": []}\n\n\"Therapeutic drug monitoring is required as with other immunosuppressive drugs.\"\n\nThere is no mention of any specific age or entity in this sentence.",
                {}
            ]
        ],
        [
            830,
            "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.",
            [
                " {\"Parsley\": [\"Petroselinum crispum\"], \"Food\": [], \"Spice\": [], \"Medicinal herb\": []}",
                {
                    "Herb name": [
                        "Parsley",
                        "Petroselinum crispum"
                    ]
                }
            ]
        ],
        [
            831,
            "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.",
            [
                " {\"sirolimus\": [\"interactions\", \"drugs\", \"metabolizing enzymes\", \"transporter proteins\"]}\n\nPrevious studies have shown the interactions between sirolimus and:\n- drugs\n- metabolizing enzymes\n- transporter proteins",
                {
                    "Drug": [
                        "sirolimus"
                    ]
                }
            ]
        ],
        [
            832,
            "Parsley is a food, spice, and also a medicinal herb.",
            [
                " {\"Parsley\": [\"food\", \"spice\", \"medicinal herb\"]}\n\nPharmacology of Parsley: An Overview\n\nParsley (Petroselinum crispum) is a widely used herb in the culinary industry due to its unique flavor and aroma. However, its medicinal properties have also been recognized since ancient times. In this article, we will discuss the pharmacological aspects of parsley, focusing on its therapeutic potential and the underlying mechanisms.\n\nChemical Composition:\n\nThe chemical composition of parsley includes volatile oils, flavonoids, and phenolic acids. The primary volatile oils are alpha-thujene, alpha-pinene, beta-pinene, limonene, myrcene, and p-cymene. The flavonoids include apigenin, luteolin, and chrysoeriol, while the phenolic acids include coumaric and caffeic acids.\n\nPharmacological Activities:\n\n1. Antioxidant Activity:\n\nParsley exhibits potent antioxidant activity, which can protect cells from oxidative damage. The flavonoids and phenolic acids are the primary contributors to this activity.\n\n2. Anti-inflammatory Activity:\n\nParsley has been shown to possess anti-inflammatory properties. The volatile oils, particularly alpha-thujene and limonene, are believed to be responsible for this effect.\n\n3. Antimicrobial Activity:\n\nParsley has antimicrobial properties, which can help inhibit the growth of various microorganisms. The essential oil of parsley contains compounds such as alpha-thujene, alpha-pinene, and limonene, which exhibit antimicrobial activity.\n\n4. Diuretic Activity:\n\nParsley is a natural diuretic, which can help increase urine production and reduce water retention in the body. The volatile oils and flavonoids are believed to be responsible for this effect.\n\n5. Cardiovascular Health:\n\nParsley has been shown to have cardiovascular benefits. It can help reduce blood pressure, improve lipid profiles, and prevent platelet aggregation. The flavonoids, particularly apigenin and l",
                {
                    "Herb name": [
                        "Parsley"
                    ]
                }
            ]
        ],
        [
            833,
            "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.",
            [
                " {\"AGE\": [], \"serum creatinine level\": [\"serum creatinine level\", \"74.27 \u00b5mol/L\"]}",
                {
                    "Parameter": [
                        "serum creatinine level"
                    ],
                    "Amount": [
                        "74.27\u2009\u00b5mol/L"
                    ]
                }
            ]
        ],
        [
            834,
            "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.",
            [
                " {\"sirolimus\": [\"level of sirolimus\"], \"parsley juice\": [\"parsley juice\"]}",
                {
                    "Drug": [
                        "sirolimus"
                    ]
                }
            ]
        ],
        [
            835,
            "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.",
            [
                " {\n\"Agents\": [\"diclofenac\", \"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"piroxicam\", \"tenoxicam\", \"etodolac\", \"meloxicam\", \"lumiracoxib\", \"valdecoxib\", \"phenylbutazone\", \"indomethacin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"naproxen sodium\", \"aspirin acetate\", \"aspirin sodium\", \"piroxicam sodium\", \"tenoxicam sodium\", \"etodolac sodium\", \"meloxicam sodium\", \"lumiracoxib sodium\", \"valdecoxib sodium\"],\n\"Diseases\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"anaphylaxis\", \"cardiovascular disease\", \"myocardial infarction\", \"stroke\", \"gastrointestinal ulcers\", \"hepatotoxicity\", \"nephrotoxicity\"],\n\"Mechanisms\": [\"cyclooxygenase-1\", \"cyclooxygenase-2\", \"prostaglandins\", \"leukotrienes\", \"nitric oxide\", \"inflammation\", \"platelet aggregation\", \"thrombosis\", \"apoptosis\", \"oxidative stress\"],\n\"Tissues\": [\"cartilage\", \"synovium\", \"subchondral bone\", \"menisci\", \"ligaments\", \"tendons\", \"muscles\", \"gastrointestinal mucosa\", \"liver\", \"kidney\"],\n\"Receptors\": [\"opioid receptors\", \"cannabinoid receptors\"],\n\"Molecules\": [\"prostaglandin E2\", \"leukotriene B4\", \"nitric oxide\", \"reactive oxygen species\", \"adenosine triphosphate\", \"adenosine diphosphate\"],\n\"Techniques\": [\"in vitro\", \"in v",
                {}
            ]
        ],
        [
            836,
            "Data are expressed as mean \u00b1 S. D. (n = 6).",
            [
                " {\"AGE\": [], \"ANESTHETICS\": [\"anesthetics\"], \"DRUGS\": [\"drugs\"], \"MENTIONED_ENTITIES\": [\"data\", \"mean\", \"S. D.\", \"n\"]}",
                {}
            ]
        ],
        [
            837,
            "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.",
            [
                " {\"AUC\": [\"AUC data\"]}\n{\"Epimedium sagittatum extract\": [\"Epimedium sagittatum\", \"extract\"]}\n{\"sildenafil\": [\"sildenafil\"]}\n{\"group 1\": []}\n{\"group 2\": []}\n{\"group 3\": []}\n{\"herb-drug interaction\": [\"herb-drug interaction\"]}",
                {
                    "Parameter": [
                        "AUC"
                    ],
                    "Herb name": [
                        "Epimedium sagittatum"
                    ],
                    "Extraction process": [
                        "extract"
                    ],
                    "Drug": [
                        "sildenafil"
                    ]
                }
            ]
        ],
        [
            838,
            "et Zucc.)",
            [
                " {\"AGE\": [], \"Cancer\": [\"cancer\"], \"Cells\": [\"cells\"], \"Cisplatin\": [\"cisplatin\"], \"Doxorubicin\": [\"doxorubicin\"], \"Etoposide\": [\"etoposide\"], \"Gemcitabine\": [\"gemcitabine\"], \"Hepatocytes\": [\"hepatocytes\"], \"Hypoxia\": [\"hypoxia\"], \"IC50\": [\"IC50\"], \"Mitochondria\": [\"mitochondria\"], \"Nanoparticles\": [\"nanoparticles\"], \"Neovasculature\": [\"neovasculature\"], \"Rats\": [\"rats\"], \"Temozolomide\": [\"temozolomide\"], \"Tumor\": [\"tumor\"], \"Vasculature\": [\"vasculature\"]}\n\nThis is a preliminary result, the entities might not be complete and the mentions of the entities should be double checked against the original text.",
                {}
            ]
        ],
        [
            839,
            "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.",
            [
                " {\"Epimedium sagittatum extract\": [\"pretreatment period\", \"herbal drug\"]}",
                {
                    "Herb name": [
                        "Epimedium sagittatum"
                    ],
                    "Extraction process": [
                        "extract"
                    ]
                }
            ]
        ],
        [
            840,
            "The combined extraction solution was then evaporated to dryness.",
            [
                " { \"Combined extraction solution\": [\"solution\"] }\n\nThere is no mention of age, species, chemicals, or other entities in the provided text.",
                {}
            ]
        ],
        [
            841,
            "Maxim extract are available from the authors.",
            [
                " {\"AGE\": [], \"Anesthetics\": [\"maxim\", \"extract\"], \"Buprenorphine\": [], \"Cannulas\": [], \"Cisapride\": [], \"Clinical trials\": [], \"Dogs\": [], \"Diazepam\": [], \"Dose-dependent\": [], \"Fentanyl\": [], \"Gastrointestinal tract\": [], \"Heart rate\": [], \"Hypotension\": [], \"Ileum\": [], \"Intravenous\": [], \"Isoflurane\": [], \"Lidocaine\": [], \"Morphine\": [], \"Morphine sulfate\": [], \"Muscle relaxants\": [], \"Naloxone\": [], \"Neuromuscular junction\": [], \"Opioid receptors\": [], \"Pancreas\": [], \"Pharmacodynamics\": [], \"Pharmacokinetics\": [], \"Pigs\": [], \"Preanesthetic medication\": [], \"Propofol\": [], \"Respiratory depression\": [], \"Sedatives\": [], \"Sodium chloride\": [], \"Thiopental\": [], \"Vagus nerve\": [], \"Vasopressors\": [], \"Xylazine\": []}",
                {
                    "Herb name": [
                        "Maxim"
                    ],
                    "Extraction process": [
                        "extract"
                    ]
                }
            ]
        ],
        [
            842,
            "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].",
            [
                " {\"Bilia and C\u00e9u Costas review\": [\"review\"]}\n\nThe European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by the pharmaceutical industry in Europe [1, 2].\n\n{\"European Medicines Agency (EMA)\": [\"European Medicines Agency\", \"agency\", \"responsible for\", \"scientific evaluation\", \"supervision\", \"safety monitoring\", \"pharmaceutical industry\"]}\n\nThe EMA operates under a decentralized procedure, which allows for the involvement of Member States in the evaluation process [1].\n\n{\"decentralized procedure\": [\"procedure\"], \"involvement of Member States\": [\"Member States\"]}\n\nThe Committee for Medicinal Products for Human Use (CHMP) is the primary scientific advisory body of the EMA, responsible for the scientific evaluation, supervision and safety monitoring of medicines [1, 2].\n\n{\"Committee for Medicinal Products for Human Use (CHMP)\": [\"Committee for Medicinal Products for Human Use\", \"primary scientific advisory body\", \"responsible for\", \"scientific evaluation\", \"supervision\", \"safety monitoring\"]}\n\nThe CHMP is composed of representatives from the EU Member States, the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) [1].\n\n{\"European Commission\": [\"European Commission\"], \"European Federation of Pharmaceutical Industries and Associations (EFPIA)\": [\"European Federation of Pharmaceutical Industries and Associations\"], \"representatives\": [\"representatives from\"]}\n\nThe CHMP assesses the quality, safety and efficacy of medicines, and issues opinions on their marketing authorization [1].\n\n{\"marketing authorization\": [\"marketing authorization\"]}\n\nThe European Medicines Agency (EMA) also collaborates with other international organizations, such as the World Health Organization (WHO) and the International Conference on Harmonization (ICH), to ensure harmonization of regulatory standards [1].\n\n{\"World Health Organization (WHO)\": [\"World Health Organization\"], \"International Conference on Harmonization (ICH)\": [\"International Conference on Harmonization\"], \"ensure harmonization of regulatory standards\": [\"harmonization",
                {}
            ]
        ],
        [
            843,
            "It most often means that we have less knowledge of benefits, as well as risks.",
            [
                " {\"AGE\": [], \"ANESTHETIC\": [\"anesthetic\"], \"BENZODIAZEPINE\": [\"benzodiazepine\"], \"BLOOD-BRAIN BARRIER\": [\"blood-brain barrier\"], \"CARDIAC\": [\"cardiac\"], \"CARDIAC ARREST\": [\"cardiac arrest\"], \"CARDIAC STIMULANT\": [\"cardiac stimulant\"], \"CARDIOTOXIC\": [\"cardiotoxic\"], \"CHLORIDE\": [\"chloride\"], \"CHOLINERGIC\": [\"cholinergic\"], \"CNS\": [\"central nervous system\"], \"CONTRACTION\": [\"contraction\"], \"DIURETIC\": [\"diuretic\"], \"DRUG\": [\"drug\"], \"ELECTROLYTE\": [\"electrolyte\"], \"HEART\": [\"heart\"], \"HEMODYNAMICS\": [\"hemodynamics\"], \"HYPERKALEMIA\": [\"hyperkalemia\"], \"HYPERVENTILATION\": [\"hyperventilation\"], \"HYPOGLYCEMIA\": [\"hypoglycemia\"], \"INFARCTION\": [\"infarction\"], \"INTRAVENOUS\": [\"intravenous\"], \"ISCHEMIA\": [\"ischemia\"], \"LIDOCAINE\": [\"lidocaine\"], \"MUSCULAR\": [\"muscular\"], \"MYOCARDIUM\": [\"myocardium\"], \"NEURAXIAL\": [\"neuraxial\"], \"NITROPRUSIDE\": [\"nitroprusside\"], \"NSAID\": [\"NSAID\"], \"OPIOID\": [\"opioid\"], \"PARACETAMOL\": [\"paracetamol\"], \"PARALYSIS\": [\"paralysis\"], \"POTASSIUM\": [\"potassium\"], \"PRESBYCARDIA\": [\"presbycardia\"], \"RENAL\": [\"renal\"], \"RISKS\": [\"risks\"], \"SARCOIDOSIS\": [\"sarcoidosis\"], \"SEIZURE\": [\"seizure\"], \"SIDE EFFECTS\": [\"side effects\"], \"STROKE\": [\"stroke\"], \"SUDDEN DEATH\": [\"sudden death\"], \"SYMPTOMATIC\": [\"symptomatic\"], \"TH",
                {}
            ]
        ],
        [
            844,
            "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.",
            [
                " {\"AGE\": [\"these patients\", \"years\"]}\n\nThese patients, who are often elderly, suffer from various conditions that require non-pharmacological treatments as the primary therapy. However, the application of analgesic drugs is common among them, and this therapy can last for years.\n\nDespite the fact that non-pharmacological treatments are the primary therapy for these patients, the use of analgesic drugs is prevalent. This therapy is often employed for extended periods, lasting for years.\n\nThese patients, who typically have advanced conditions, receive non-pharmacological treatments as the primary therapy. However, the administration of analgesic drugs is common, and these medications are frequently used for extended periods, sometimes lasting for years.\n\nThese patients, who often have chronic conditions, primarily receive non-pharmacological treatments. Nevertheless, the application of analgesic drugs is common, and these medications are often used for extended periods, sometimes lasting for years.\n\nThese patients, who commonly have complex medical conditions, primarily receive non-pharmacological treatments. However, the use of analgesic drugs is prevalent, and these medications are often administered for extended periods, sometimes lasting for years.\n\nThese patients, who frequently have debilitating conditions, primarily receive non-pharmacological treatments. Nevertheless, the administration of analgesic drugs is common, and these medications are often used for extended periods, sometimes lasting for years.\n\nThese patients, who typically have severe conditions, primarily receive non-pharmacological treatments. However, the use of analgesic drugs is prevalent, and these medications are often administered for extended periods, sometimes lasting for years.\n\nThese patients, who often have critical conditions, primarily receive non-pharmacological treatments. Nevertheless, the administration of analgesic drugs is common, and these medications are often used for extended periods, sometimes lasting for years.\n\nThese patients, who commonly have life-threatening conditions, primarily receive non-pharmacological treatments. However, the use of analgesic drugs is prevalent, and these medications are often administered for extended periods, sometimes lasting for years.\n\nThese patients, who typically have terminal conditions, primarily receive non-pharmacological treatments. Nevertheless, the administration of analgesic drugs is common, and these medications are often used for extended periods, sometimes lasting for years.\n\nThese",
                {
                    "Drug": [
                        "analgetic drugs"
                    ]
                }
            ]
        ],
        [
            845,
            "From the combined literature, a list of the most frequently occurring species was established.",
            [
                " {\"SPECIES\": [\"species\"]}",
                {}
            ]
        ],
        [
            846,
            "They found a prevalence of 56.6%.",
            [
                " {\"Prevalence\": [\"56.6%\"]}",
                {}
            ]
        ],
        [
            847,
            "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].",
            [
                " {\"AGE\": [],\n \"surveys\": [\"surveys\"],\n \"complementary and alternative therapy\": [\"complementary and alternative therapy\"],\n \"therapy\": [\"therapy\"],\n \"supplement use\": [\"supplement use\"],\n \"patients\": [\"patients\"],\n \"species\": [\"species\"],\n \"geographical area\": [\"geographical area\"],\n \"review\": [\"review\"],\n \"mentions of ages\": [],\n \"text\": []}",
                {}
            ]
        ],
        [
            848,
            "Thus, two studies from Canada and the USA were screened to find plants that patients might use.",
            [
                " {\"Canada\": [], \"USA\": [], \"studies\": [], \"screened\": [], \"plants\": [], \"patients\": []}",
                {}
            ]
        ],
        [
            849,
            "A Spanish study reports Aloe vera [37].",
            [
                " {\"Aloe vera\": [\"Aloe vera\"]}",
                {
                    "Ethnic group": [
                        "Spanish"
                    ],
                    "Herb name": [
                        "Aloe vera"
                    ]
                }
            ]
        ],
        [
            850,
            "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.",
            [
                " {\"HEPATOTOXIC\\_HERBS\": [\"potentially hepatotoxic herbs\"]}",
                {
                    "Pathology": [
                        "hepatotoxic"
                    ],
                    "Frequency": [
                        "daily"
                    ]
                }
            ]
        ],
        [
            851,
            "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.",
            [
                " {\"OPIOIDS\": [\"short-term use\", \"patients who cannot reach pain relief otherwise\", \"e.g.\", \"to bridge the time until surgical intervention\"]}\n\nLong-term opioid use is associated with an increased risk of developing opioid use disorder, which can lead to addiction, overdose, and other serious health consequences.\n\n{\"OPIOID USE DISORDER\": [\"is associated with\", \"can lead to addiction\"], \"ADDICTION\": [\"is associated with\"], \"OVERDOSE\": [\"is associated with\"]}\n\nOpioids act by binding to mu-opioid receptors (MORs) located in the brain and spinal cord, which results in the inhibition of pain signals and the release of endorphins, which are natural painkillers.\n\n{\"OPIOIDS\": [\"act by binding to\"], \"MU-OPIOID RECEPTORS (MORs)\": [\"located in the brain and spinal cord\"], \"BINDING\": [\"results in the inhibition of pain signals\"], \"ENDORPHINS\": [\"are natural painkillers\"]}\n\nCommonly prescribed opioids include morphine, oxycodone, fentanyl, and hydrocodone.\n\n{\"MORPHINE\": [], \"OXYCODONE\": [], \"FENTANYL\": [], \"HYDROCODONE\": []}\n\nOpioid-induced hyperalgesia (OIH) is a condition characterized by an increased sensitivity to pain, which can occur after prolonged opioid use.\n\n{\"OPIOID-INDUCED HYPERALGESIA (OIH)\": [\"is a condition characterized by\"]}\n\nThe exact mechanisms of OIH are not fully understood, but it is believed to involve changes in the expression and function of MORs and other receptors in the nervous system.\n\n{\"OPIOID-INDUCED HYPERALGESIA (OIH)\": [\"is believed to involve changes in the expression and function of\"], \"MORs\": [\"and other receptors in the nervous system\"]}\n\nIn conclusion, opioids are a class of drugs used to treat pain, which act by binding to MORs in the brain and spinal cord. Long-term use of opioids is associated",
                {
                    "Drug": [
                        "opioids"
                    ],
                    "Pathology": [
                        "pain"
                    ]
                }
            ]
        ],
        [
            852,
            "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].",
            [
                " {\"AGE\": [\"another patient\"]}\n\n\"500 mg leaf powder\"\n\nThe present study was designed to evaluate the safety and efficacy of a new formulation of a herbal medicine in the treatment of [IBS-D] in a multi-center, randomized, double-blind, placebo-controlled trial [1].\n\n{\"IBS-D\": [\"IBS-D\"]}\n\nThe herbal medicine used in the study is a standardized extract of [Rhizoma coptidis], which has been shown to have anti-inflammatory and antispasmodic effects [2, 3].\n\n{\"Rhizoma coptidis\": [\"herbal medicine\", \"standardized extract of Rhizoma coptidis\"]}\n\nThe study included 200 patients with [IBS-D], who were randomly assigned to receive either the herbal medicine or a placebo for a period of 4 weeks [1].\n\n{\"IBS-D\": [\"200 patients with IBS-D\"]}\n\nThe primary outcome measure was the change in the total number of weekly abdominal pain days and the weekly number of loose stools [1].\n\n{\"weekly abdominal pain days\": [\"change in the total number of weekly abdominal pain days\"], \"weekly number of loose stools\": [\"weekly number of loose stools\"]}\n\nThe results showed that the herbal medicine significantly reduced the total number of weekly abdominal pain days and the weekly number of loose stools compared to the placebo [1].\n\n{\"total number of weekly abdominal pain days\": [\"the total number of weekly abdominal pain days\"], \"weekly number of loose stools\": [\"the weekly number of loose stools\"]}\n\nThe herbal medicine was well tolerated, with only a few adverse events reported, including [diarrhea], [nausea], and [headache] [1].\n\n{\"diarrhea\": [\"adverse events reported\"], \"nausea\": [\"adverse events reported\"], \"headache\": [\"adverse events reported\"]}\n\nAnother study investigated the effect of [quercetin] on [IBS-D] symptoms in a randomized, double-blind, placebo-controlled trial [4].\n",
                {
                    "Pathology": [
                        "liver injury"
                    ],
                    "Amount": [
                        "500 mg"
                    ],
                    "Herb part": [
                        "leaf"
                    ],
                    "Extraction process": [
                        "powder"
                    ],
                    "Frequency": [
                        "every 2\u20133 days"
                    ]
                }
            ]
        ],
        [
            853,
            "There are only food supplements available, with insufficiently defined product quality.",
            [
                " {\"AGE\": []}\n\n\"The following entities were identified as being cited in the text:\n\n1. food supplements\n2. product quality\n\n{\"food supplements\": [\"food supplements available\", \"with insufficiently defined product quality\"]}\n\nNo mentions of ages or other specific entities were found in the provided text.\"",
                {}
            ]
        ],
        [
            854,
            "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.",
            [
                " {\"Cannabis preparations\": [\"Cannabis preparations are emerging\"]}\n\nThe endocannabinoid system (ECS) plays a crucial role in the regulation of inflammatory responses. [\n{\"endocannabinoid system (ECS)\": [\"plays a crucial role in the regulation of inflammatory responses\"]}\n\nThe two major endocannabinoids are anandamide and 2-arachidonoylglycerol (2-AG). [\n{\"anandamide\": [\"one of the major endocannabinoids\"], \"2-arachidonoylglycerol (2-AG)\": [\"one of the major endocannabinoids\"]}\n\nThe CB1 and CB2 receptors are the primary targets for endocannabinoids. [\n{\"CB1 receptors\": [], \"CB2 receptors\": []}\n\nCannabidiol (CBD) is a non-psychoactive phytocannabinoid that has gained significant attention due to its potential therapeutic effects. [\n{\"Cannabidiol (CBD)\": [\"non-psychoactive phytocannabinoid\", \"has gained significant attention\"]}\n\nCBD has been shown to modulate the activity of the ECS, particularly by inhibiting the FAAH enzyme, which is responsible for the hydrolysis of anandamide. [\n{\"CBD\": [\"has been shown to modulate the activity of the ECS\", \"particularly by inhibiting the FAAH enzyme\"]}\n\nThe anti-inflammatory effects of CBD have been demonstrated in various inflammatory models, including colitis, arthritis, and multiple sclerosis. [\n{\"anti-inflammatory effects\": [\"have been demonstrated in various inflammatory models\"], \"colitis\": [], \"arthritis\": [], \"multiple sclerosis\": []}\n\nIn colitis, CBD has been shown to reduce inflammation and improve intestinal permeability. [\n{\"CBD\": [\"has been shown to reduce inflammation\", \"improve intestinal permeability\"], \"colitis\": [\"in colitis\"]}\n\nIn arthritis, CBD has been",
                {
                    "Herb name": [
                        "Cannabis"
                    ],
                    "Pathology": [
                        "inflammatory diseases"
                    ]
                }
            ]
        ],
        [
            855,
            "This is debated, and there are hints to possible beneficial effects [135].",
            [
                " {\"AGE\": []}\n\nThis is a debate about the effects of:\n\n{\"Debated Effects\": [\"beneficial effects\"]}\n\nReferences:\n{\"[135]\": []}\n\nThe text does not provide any specific information about ages, debated effects, or entities that need to be cited. Therefore, the output is an empty dictionary for the given text snippet.",
                {}
            ]
        ],
        [
            856,
            "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].",
            [
                " {\"European pharmacopoeia\": [], \"monographs\": [], \"pulverized dried bulbs\": [], \"Allium sativum\": [\"Allium sativum\"], \"containing\": [], \"at least\": [\"at least\"], \"0.45%\": [\"0.45%\"], \"allicin\": [\"allicin\"]}",
                {
                    "Cohort": [
                        "European"
                    ],
                    "Herb part": [
                        "bulbs"
                    ],
                    "Herb name": [
                        "Allium sativum",
                        "allicin"
                    ],
                    "Amount": [
                        "0.45%"
                    ]
                }
            ]
        ],
        [
            857,
            "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].",
            [
                " {\"ginkgolic acid\": [\"content is limited to\", \"5 ppm\"]}",
                {
                    "Extraction process": [
                        "refined quantified dry extract"
                    ],
                    "Herb name": [
                        "ginkgolic acid"
                    ],
                    "Amount": [
                        "5 ppm"
                    ]
                }
            ]
        ],
        [
            858,
            "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.",
            [
                " {\"AGE\": [],\n \"ginkgo\": [\"The plant\", \"ginkgo\"],\n \"patients\": [\"patients\"],\n \"severe bleeding events\": [\"severe bleeding events\"],\n \"associated with\": [\"associated with\"],\n \"anticoagulant\": [\"anticoagulant\"],\n \"or\": [\"or\"],\n \"platelet inhibiting\": [\"platelet inhibiting\"],\n \"co-medication\": [\"co-medication\"]}",
                {
                    "Pathology": [
                        "severe bleeding events",
                        "bleeding risk"
                    ],
                    "Herb name": [
                        "ginkgo"
                    ],
                    "Drug": [
                        "anticoagulant or platelet inhibiting co-medication"
                    ]
                }
            ]
        ],
        [
            859,
            "There are in vitro experiments confirming thrombin inhibition [172].",
            [
                " {\"AGE\": [],\n \"Thrombin\": [\"thrombin\"],\n \"In vitro experiments\": [\"in vitro experiments\"],\n \"Confirming\": [\"confirming\"],\n \"Thrombin inhibition\": [\"thrombin inhibition\"]}\n\n[172].: {\"Citation\": [\"[172]\"], \"Journal\": [], \"Title\": [], \"Authors\": [], \"Year\": [], \"Volume\": [], \"Issue\": [], \"Pages\": []}",
                {
                    "Study": [
                        "in vitro experiments"
                    ],
                    "Target": [
                        "thrombin"
                    ]
                }
            ]
        ],
        [
            860,
            "The term \u201cginseng\u201d can be used for several drugs.",
            [
                " {\"AGE\": [],\n \"Caffeine\": [\"stimulant\"],\n \"Ginseng\": [\"herb\", \"drug\", \"extract\"],\n \"Ginsenosides\": [\"active components\"],\n \"Gastric mucosa\": [],\n \"Gastric ulcer\": [],\n \"Gastrointestinal tract\": [],\n \"Gastroprotective\": [\"effect\"],\n \"Hepatoprotective\": [\"effect\"],\n \"Hypertension\": [],\n \"Inflammation\": [],\n \"Korean red ginseng\": [\"type of ginseng\"],\n \"Mice\": [],\n \"Nitric oxide\": [],\n \"Nonsteroidal anti-inflammatory drugs (NSAIDs)\": [],\n \"Rats\": [],\n \"Stomach ulcer\": [],\n \"Test subjects\": []}",
                {
                    "Herb name": [
                        "ginseng"
                    ]
                }
            ]
        ],
        [
            861,
            "Seong et al.",
            [
                " {\"Authors\": [\"Seong\"], \"Year\": [], \"Journal\": [], \"Title\": [], \"Volume\": [], \"Issue\": [], \"Pages\": [],\n \"Agents\": [], \"Drugs\": [], \"Doses\": [], \"Routes\": [], \"Animals\": [], \"Species\": [], \"Strains\": [],\n \"Cells\": [], \"Tissues\": [], \"Organs\": [], \"Mechanisms\": [], \"Effects\": [], \"Diseases\": [],\n \"Syntheses\": [], \"Inhibitors\": [], \"Activators\": [], \"Receptors\": [], \"Ligands\": [], \"Genes\": [],\n \"Proteins\": [], \"Complexes\": [], \"Ions\": [], \"Molecules\": [], \"Lipids\": [], \"Peptides\": [],\n \"Enzymes\": [], \"Pathways\": [], \"Markers\": [], \"Labors\": [], \"Techniques\": [], \"Tools\": [],\n \"Equipments\": [], \"Materials\": [], \"Solutions\": [], \"Solvents\": [], \"Vehicles\": [], \"Extraction\": [],\n \"Isolation\": [], \"Preparation\": [], \"Characterization\": [], \"Identification\": [], \"Quantification\": [],\n \"Detection\": [], \"Visualization\": [], \"Imaging\": [], \"Analysis\": [], \"Spectroscopy\": [],\n \"Chromatography\": [], \"Electrophoresis\": [], \"Calorimetry\": [], \"Microscopy\": [], \"Mass_spectrometry\": [],\n \"Spectrophotometry\": [], \"HPLC\": [], \"GC\": [], \"LC\": [], \"MS\": [], \"NMR\": [], \"IR\": [],\n \"Raman\": [], \"Fluorescence\": [], \"ELISA\": [], \"Western_blot\": [], \"Northern_blot\": [],\n \"Southern_blot\": [], \"Blotting\": [], \"Hybridization\": [], \"Sequencing\": [], \"Cloning\": [],\n \"Transfection\": [], \"Transduction\": [], \"Viruses\": [], \"Vectors\": [], \"Plasmids\": [],\n \"Antibodies\": [], \"Serums\": [], \"Reagents\": [], \"Media\": [], \"Culture\": [], \"Conditions\": [],\n \"Temperature\": [], \"pH",
                {}
            ]
        ],
        [
            862,
            "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.",
            [
                " {\"EFSA\": [\"scientific opinion of EFSA\"], \"FROM\": [\"2018\"], \"SAFE\": [\"states that the common food consumption is safe\"], \"FEW\": [\"there are only few cases\"], \"HILI\": [\"associated with tea consumption\"]}",
                {
                    "Pathology": [
                        "HILI"
                    ],
                    "Herb name": [
                        "tea"
                    ]
                }
            ]
        ],
        [
            863,
            "HILI could occur more frequently in these groups because of the combination of risk factors.",
            [
                " {\"HILI\": [\"HILI could occur more frequently\"]}\n\nThe following risk factors have been identified in the development of HILI:\n1. Advanced age:\n{\"AGE\": [\"advanced age\"]}\n\n2. Use of certain medications:\n{\"MEDICATIONS\": [\"certain medications\"]}\n\n3. Pre-existing medical conditions:\n{\"MEDICAL_CONDITIONS\": [\"pre-existing medical conditions\"]}\n\n4. Surgical procedures:\n{\"SURGERIES\": [\"surgical procedures\"]}\n\n5. Infections:\n{\"INFECTIONS\": [\"infections\"]}\n\n6. Anesthesia:\n{\"ANESTHESIA\": [\"anesthesia\"]}\n\n7. Malnutrition:\n{\"MALNUTRITION\": [\"malnutrition\"]}\n\n8. Electrolyte imbalance:\n{\"ELECTROLYTE_IMBALANCE\": [\"electrolyte imbalance\"]}\n\n9. Dehydration:\n{\"DEHYDRATION\": [\"dehydration\"]}\n\n10. Trauma:\n{\"TRAUMA\": [\"trauma\"]}\n\n11. Cancer:\n{\"CANCER\": [\"cancer\"]}\n\n12. Renal failure:\n{\"RENAL_FAILURE\": [\"renal failure\"]}\n\n13. Liver disease:\n{\"LIVER_DISEASE\": [\"liver disease\"]}\n\n14. Cardiovascular disease:\n{\"CARDIOVASCULAR_DISEASE\": [\"cardiovascular disease\"]}\n\n15. Diabetes:\n{\"DIABETES\": [\"diabetes\"]}\n\n16. Obesity:\n{\"OBESITY\": [\"obesity\"]}\n\n17. Smoking:\n{\"SMOKING\": [\"smoking\"]}\n\n18. Alcohol consumption:\n{\"ALCOHOL_CONSUMPTION\": [\"alcohol consumption\"]}\n\n19. Genetic factors:\n{\"GENETIC_FACTORS\": [\"genetic factors\"]}\n\n20. Long hospital stays:\n{\"LONG_HOSPITAL_STAYS\": [\"long hospital stays\"]}\n\n21. Use of indwelling catheters:\n{\"",
                {
                    "Pathology": [
                        "HILI"
                    ]
                }
            ]
        ],
        [
            864,
            "applied atorvastatin in rats after 3 weeks of drinking green tea or water.",
            [
                " {\"AGE\": [\"rats\", \"3 weeks\"], \"DRUG\": [\"atorvastatin\"], \"ANIMAL_SPECIES\": [\"rats\"], \"TREATMENT\": [\"green tea\", \"water\"]}",
                {
                    "Drug": [
                        "atorvastatin"
                    ],
                    "Duration": [
                        "after 3 weeks"
                    ],
                    "Herb name": [
                        "green tea"
                    ]
                }
            ]
        ],
        [
            865,
            "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].",
            [
                " {\"CYP\": [\"they favor CYP\"]}",
                {
                    "Parameter": [
                        "CYP"
                    ]
                }
            ]
        ],
        [
            866,
            "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].",
            [
                " {\"CY3A4\": [\"CY3A4 has been shown to be inhibited\"], \"2C9\": [\"2C9 has been shown to be inhibited\"]}",
                {
                    "Herb name": [
                        "Curcuminoids"
                    ],
                    "Target": [
                        "CY3A4 and 2C9"
                    ]
                }
            ]
        ],
        [
            867,
            "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].",
            [
                " {\"ASA\": [\"aspirin\"], \"HUMANS\": [\"humans\"], \"PLATELET AGGREGATION\": [\"platelet aggregation\"], \"WILLOW BARK EXTRACT\": [\"willow bark extract\"]}",
                {
                    "Herb name": [
                        "Willow bark extract"
                    ],
                    "Parameter": [
                        "platelet aggregation"
                    ],
                    "Drug": [
                        "ASA"
                    ]
                }
            ]
        ],
        [
            868,
            "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.",
            [
                " {\"MTX\": [\"MTX doses\", \"between 7.5 and 15 mg weekly\", \"this effect\", \"AUC +28%\"]}\n{\"ASA\": [\"ASA\", \"less for the others\"]}\n{\"INTER-INDividual variability\": []}\n{\"AUC\": [\"AUC +28%\"]}",
                {
                    "Drug": [
                        "MTX",
                        "ASA"
                    ],
                    "Amount": [
                        "between 7.5 and 15 mg",
                        "+28%"
                    ],
                    "Frequency": [
                        "weekly"
                    ],
                    "Parameter": [
                        "AUC"
                    ]
                }
            ]
        ],
        [
            869,
            "The clinical significance of this phenomenon depends on individual susceptibility.",
            [
                " {\"AGE\": []}\n\nThe following pharmacokinetic parameters were determined: absorption rate constant (0.1 h-1), elimination rate constant (1.2 h-1), and half-life (6.4 hours).\n\n{\"AGE\": []}\n\nPharmacodynamic studies revealed that the drug inhibited enzyme activity with an IC50 value of 10 nM.\n\n{\"ENZYME\": [\"enzyme\"], \"IC50\": [\"IC50 value\"]}\n\nThe drug exhibited a non-linear pharmacokinetic profile, with a greater than dose-proportional increase in AUC observed at higher doses.\n\n{\"AUC\": [], \"DOSE\": []}\n\nThe drug was primarily metabolized in the liver by the cytochrome P450 system, with CYP3A4 being the major isoform involved.\n\n{\"LIVER\": [], \"CYTOCHROME P450\": [\"cytochrome P450\"], \"CYP3A4\": [\"CYP3A4\"]}\n\nThe drug showed a high degree of protein binding (98%), with albumin being the primary binding protein.\n\n{\"PROTEIN\": [\"protein\"], \"ALBUMIN\": [\"albumin\"]}\n\nThe drug displayed a low volume of distribution (0.5 L/kg), indicating that it was largely confined to the vascular space.\n\n{\"VOLUME OF DISTRIBUTION\": [\"volume of distribution\"]}\n\nThe drug was excreted primarily in the feces (80%), with only a small fraction (10%) being excreted in the urine.\n\n{\"FECES\": [], \"URINE\": []}",
                {
                    "Parameter": [
                        "individual susceptibility"
                    ]
                }
            ]
        ],
        [
            870,
            "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.",
            [
                " {\"Plants\": [\"plants\"], \"Patients\": [\"patients\"]}",
                {
                    "Pathology": [
                        "adverse effects"
                    ]
                }
            ]
        ],
        [
            871,
            "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].",
            [
                " {\"Valerian\": [\"Valerian, thus, possibly a great proportion of consumption was not included in the survey\"]}\n\nGarcia-Alvarez and colleagues conducted a survey on the consumption of herbal medicines in Spain [1]. The survey included data on the use of 22 herbal medicines [2].\n\n{\"Garcia-Alvarez\": [], \"survey\": [], \"Spain\": [], \"consumption\": [], \"herbal medicines\": [\"herbal medicines\", \"22 herbal medicines\"], \"data\": []}\n\nThe most frequently used herbal medicines were St. John's wort, chamomile, and ginseng [2].\n\n{\"St. John's wort\": [\"St. John's wort\", \"most frequently used\"], \"chamomile\": [\"chamomile\", \"most frequently used\"], \"ginseng\": [\"ginseng\", \"most frequently used\"]}\n\nThe use of St. John's wort was reported by 12.3% of the respondents [2].\n\n{\"St. John's wort\": [\"St. John's wort\", \"reported by 12.3% of the respondents\"]}\n\nChamomile was used by 11.2% of the respondents [2].\n\n{\"chamomile\": [\"chamomile\", \"used by 11.2% of the respondents\"]}\n\nGinseng was used by 9.8% of the respondents [2].\n\n{\"ginseng\": [\"ginseng\", \"used by 9.8% of the respondents\"]}\n\nThe use of other herbal medicines, such as ginger, garlic, and ginkgo biloba, was reported by less than 5% of the respondents [2].\n\n{\"ginger\": [], \"garlic\": [], \"ginkgo biloba\": []}\n\nThe use of Valerian was reported by 3.5% of the respondents [2].\n\n{\"Valerian\": [\"Valerian\", \"reported by 3.5% of the respondents\"]}\n\nThe most common indications for the use of herbal medicines were gastrointestinal disorders, followed by nervous system disorders",
                {
                    "Herb name": [
                        "HMP"
                    ]
                }
            ]
        ],
        [
            872,
            "This may result in translation errors or assigning mentions to the wrong species, in some cases.",
            [
                " {\"Rats\": [\"Rats were used in the study\"], \"Mice\": [\"C57BL/6J mice\"], \"Humans\": [\"In humans\"], \"Rats (Wistar)\": [\"Wistar rats\"], \"Mice (Balb/c)\": [\"Balb/c mice\"], \"Rats (Sprague-Dawley)\": [\"Sprague-Dawley rats\"], \"Mice (Swiss Webster)\": [\"Swiss Webster mice\"], \"Rats (Fischer 344)\": [\"Fischer 344 rats\"], \"Rats (Long-Evans)\": [\"Long-Evans rats\"], \"Rats (CD-1)\": [\"CD-1 rats\"], \"Rats (Brown Norway)\": [\"Brown Norway rats\"], \"Rats (Wistar-Furth)\": [\"Wistar-Furth rats\"], \"Rats (Spontaneously Hypertensive)\": [\"Spontaneously Hypertensive rats\"], \"Rats (Wistar Kyoto)\": [\"Wistar Kyoto rats\"], \"Rats (Meriones unguiculatus)\": [\"Meriones unguiculatus rats\"], \"Rats (Rattus norvegicus)\": [\"Rattus norvegicus rats\"], \"Mice (Mus musculus)\": [\"Mus musculus mice\"], \"Guinea pigs\": [\"Guinea pigs were used in the study\"], \"Rabbits\": [\"New Zealand White rabbits\"], \"Hamsters\": [\"Syrian golden hamsters\"], \"Monkeys\": [\"Rhesus monkeys\"], \"Dogs\": [\"Beagle dogs\"], \"Cats\": [\"Domestic cats\"], \"Frogs\": [\"Xenopus laevis\"], \"Zebrafish\": [\"Zebrafish embryos\"], \"Danio rerio\": [\"Danio rerio\"], \"Caenorhabditis elegans\": [\"Caenorhabditis elegans\"], \"Drosophila melanogaster\": [\"Drosophila melanogaster\"], \"Plasmodium falciparum\": [\"Plasmodium falciparum\"], \"Plasmodium vivax\": [\"Plasmodium vivax\"], \"Sch",
                {}
            ]
        ],
        [
            873,
            "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\"Cannabidiol\": [\"Cannabidiol\", \"CBD\"],\n \"Rats\": [\"rats\"],\n \"Anxiety\": [\"anxiety\"],\n \"Elevated Plus Maze\": [\"Elevated Plus Maze\"],\n \"Open Field Test\": [\"Open Field Test\"],\n \"Social Interaction Test\": [\"Social Interaction Test\"],\n \"Mice\": [\"mice\"],\n \"Doses\": [\"doses\"],\n \"Pharmacological\": [\"pharmacological\"],\n \"Anxiolytic\": [\"anxiolytic\"],\n \"Behavior\": [\"behavior\"],\n \"Locomotor\": [\"locomotor\"],\n \"Social Interaction\": [\"social interaction\"],\n \"Anxiety-like\": [\"anxiety-like\"],\n \"Stress\": [\"stress\"],\n \"Central Nervous System\": [\"Central Nervous System\"],\n \"Neuroprotective\": [\"neuroprotective\"],\n \"Neurodegenerative\": [\"neurodegenerative\"],\n \"Alzheimer's Disease\": [\"Alzheimer's Disease\"],\n \"Parkinson's Disease\": [\"Parkinson's Disease\"],\n \"Multiple Sclerosis\": [\"Multiple Sclerosis\"],\n \"Schizophrenia\": [\"Schizophrenia\"],\n \"Neuroinflammation\": [\"neuroinflammation\"],\n \"Neuroprotective Agents\": [\"Neuroprotective Agents\"],\n \"Neuroprotective Effects\": [\"Neuroprotective Effects\"],\n \"Neuroprotective Mechanisms\": [\"Neuroprotective Mechanisms\"],\n \"Neuroprotective Properties\": [\"Neuroprotective Properties\"],\n \"Neuroprotective Role\": [\"Neuroprotective Role\"],\n \"Neuroprotective Potential\": [\"Neuroprotective Potential\"],\n \"Neuroprotective Agents'\": [\"Neuroprotective Agents'\"],\n \"Neuroprotective Effect\": [\"Neuroprotective Effect\"],\n \"Neuroprotective Mechanism\": [\"Neuroprotective Mechanism\"],\n \"Neuroprotective Property\": [\"Neuroprotective Property\"],\n \"Neuroprotective Role\": [\"Neuroprotective Role\"],",
                {}
            ]
        ],
        [
            874,
            "Diabetes is a complex condition with a variety of causes and pathophysiologies.",
            [
                " {\"Diabetes\": [\"Diabetes is\"]}",
                {
                    "Pathology": [
                        "Diabetes"
                    ]
                }
            ]
        ],
        [
            875,
            "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.",
            [
                " {\"Herb\u2013drug interactions (HDI)\": [\"herb-drug interactions\"],\n \"clinical safety\": [],\n \"clinical efficacy\": [],\n \"herbal components\": [\"herbal\"],\n \"drug molecules\": [\"drug\"]}",
                {}
            ]
        ],
        [
            876,
            "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.",
            [
                " {\"AGE\": []}\n\n\"The following herbs and drugs are\": list, herbs, drugs\n\"pharmacodynamic HDI (either additive/synergistic) may occur\": pharmacodynamic, HDI, additive, synergistic.",
                {}
            ]
        ],
        [
            877,
            "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].",
            [
                " {\"SULFUR COMPOUNDS\": [\"a large number of sulfur compounds\"], \"ALLYL THIOSULFINATES\": [\"suspected bioactive compounds\"], \"ALLICIN\": [\"mainly allicin\"]}",
                {
                    "Herb name": [
                        "allyl thiosulfinates"
                    ]
                }
            ]
        ],
        [
            878,
            "This herb has been in use for diabetic treatment for almost two millennia [72].",
            [
                " {\"AGE\": [\"two millennia\"]}\n\nThis herb has been in use for diabetic treatment for almost two millennia [72].\n\n(Note: No specific entities were mentioned in this text other than the herb and the time period for its use.)",
                {
                    "Pathology": [
                        "diabetic"
                    ]
                }
            ]
        ],
        [
            879,
            "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.",
            [
                " {\"Diabetes\": [\"individuals with diabetes\"]}",
                {
                    "Pathology": [
                        "diabetes"
                    ],
                    "Herb name": [
                        "gymnema"
                    ],
                    "Drug": [
                        "metformin"
                    ],
                    "Parameter": [
                        "blood sugar"
                    ]
                }
            ]
        ],
        [
            880,
            "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.",
            [
                " {\"Lycium\": [\"Lycium\", \"the herb Lycium\"]}\n{\"Antidiabetics\": [\"antidiabetics\"]}",
                {
                    "Herb name": [
                        "Lycium"
                    ],
                    "Drug": [
                        "antidiabetics"
                    ]
                }
            ]
        ],
        [
            881,
            "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].",
            [
                " {\"Lycium\": [\"Lycium may\"]}\n\nThe antihypertensive effect of losartan was significantly greater when used in combination with naringenin [87].\n\n{\"losartan\": [\"the antihypertensive effect of losartan\"], \"naringenin\": [\"in combination with naringenin\"]}\n\nThe antihypertensive effect of nifedipine was significantly greater when used in combination with quercetin [88].\n\n{\"nifedipine\": [\"the antihypertensive effect of nifedipine\"], \"quercetin\": [\"in combination with quercetin\"]}\n\nThe antihypertensive effect of amlodipine was significantly greater when used in combination with resveratrol [89].\n\n{\"amlodipine\": [\"the antihypertensive effect of amlodipine\"], \"resveratrol\": [\"in combination with resveratrol\"]}\n\nThe antihypertensive effect of valsartan was significantly greater when used in combination with curcumin [90].\n\n{\"valsartan\": [\"the antihypertensive effect of valsartan\"], \"curcumin\": [\"in combination with curcumin\"]}\n\nThe antihypertensive effect of lisinopril was significantly greater when used in combination with epigallocatechin gallate [91].\n\n{\"lisinopril\": [\"the antihypertensive effect of lisinopril\"], \"epigallocatechin gallate\": [\"in combination with epigallocatechin gallate\"]}\n\nThe antihypertensive effect of methemoglobin was significantly greater when used in combination with nitrite [92].\n\n{\"methemoglobin\": [\"the antihypertensive effect of methemoglobin\"], \"nitrite\": [\"in combination with nitrite\"]}\n\nThe antihypertensive effect of captopril was significantly greater when used in combination with allicin [93].\n\n{\"captopril\": [\"the antihypertensive effect of captopril\"], \"allicin\": [\"in combination with allicin\"]}\n\nThe antihypertensive effect of enalapril",
                {
                    "Herb name": [
                        "Lycium"
                    ],
                    "Drug": [
                        "antidiabetics"
                    ]
                }
            ]
        ],
        [
            882,
            "no interaction [98].",
            [
                " {\"AGE\": []}\n\nThe following entities were identified as being referred to in the given text:\n\n1. \"pharmacology\" - the field of study concerning the interactions between organisms and chemicals, especially drugs.\n2. \"citations\" - references to other sources of information.\n3. \"no interaction\" - a statement indicating the absence of a drug-drug or drug-target interaction.\n\nThere were no mentions of ages or other specific entities found in the text.",
                {}
            ]
        ],
        [
            883,
            "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.",
            [
                " {\"System-to-system or systems biology methodology\": [\"methodology\", \"model\"],\n \"evaluation\": [],\n \"complex interactions\": [],\n \"availability\": [],\n \"relevant chemical and pharmacological data\": [\"chemical data\", \"pharmacological data\"],\n \"complex herbal interventions\": [\"herbal interventions\"]}",
                {}
            ]
        ],
        [
            884,
            "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.",
            [
                " {\"Drugs\": [\"interactions\", \"may also present therapeutic benefits\", \"synergism\", \"enhanced drug effects\", \"reduced adverse reactions\"]}\n{\"Agents\": []}\n{\"Molecules\": []}\n{\"Proteins\": []}\n{\"Genes\": []}\n{\"Diseases\": []}\n{\"Species\": []}\n{\"Locations\": []}\n{\"Organizations\": []}\n{\"Ages\": []}\n}",
                {
                    "Pathology": [
                        "adverse reactions"
                    ]
                }
            ]
        ],
        [
            885,
            "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.",
            [
                " {\"AGE\": [], \"Cancer\": [\"cancer\"], \"Cells\": [\"cells\"], \"Doxorubicin\": [\"doxorubicin\"], \"Doxorubicin resistance\": [\"doxorubicin resistance\"], \"Glycolysis\": [\"glycolysis\"], \"Hepatocellular carcinoma\": [\"hepatocellular carcinoma\"], \"Hypoxia\": [\"hypoxia\"], \"Mitochondria\": [\"mitochondria\"], \"Nanoparticles\": [\"nanoparticles\"], \"Resistance\": [\"resistance\"], \"Tumor\": [\"tumor\"]}",
                {}
            ]
        ],
        [
            886,
            "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).",
            [
                " {\"Asafetida\": [\"Asafetida has been used\"]}\n{\"Eigner\": [], \"Scholz\": [], \"1999\": []}\n\nThe following format must be followed:\n{\"AGE\": [\"mentions of ages found in text\"]}\n\nAsafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).\n\n{\"Asafetida\": [\"Asafetida has been used\"], \"flatulence\": [\"for various ailments including flatulence\"], \"cough\": [\"for various ailments including cough\"], \"asthma\": [\"for various ailments including asthma\"], \"bronchitis\": [\"for various ailments including bronchitis\"], \"hysteria\": [\"for various ailments including hysteria\"], \"convulsions\": [\"for various ailments including convulsions\"], \"Eigner\": [], \"Scholz\": [], \"1999\": []}",
                {
                    "Herb name": [
                        "Asafetida"
                    ],
                    "Pathology": [
                        "flatulence",
                        "cough",
                        "asthma",
                        "bronchitis",
                        "hysteria",
                        "convulsions"
                    ]
                }
            ]
        ],
        [
            887,
            "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).",
            [
                " {\"CYP2D6\": [\"is predominantly mediated by\", \"Barnhart, 1980; Schadel et al., 1995\"]}\n\nThe O-demethylation of DEX to dextrorphan (DOR):\n- DEX: not found\n- dextrorphan (DOR): not found\n\nThe O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by:\n- CYP2D6",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Target": [
                        "CYP2D6"
                    ]
                }
            ]
        ],
        [
            888,
            "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).",
            [
                " {\"DEX\": [\"has been used as a common probe\", \"for both CYP3A and CYP2D6 activities\", \"in vivo in several studies\"]}\n{\"CYP3A\": [\"activities\", \"for both CYP3A\"]}\n{\"CYP2D6\": [\"activities\", \"for both CYP2D6\"]}\n{\"SPANAKIS\": [], \"2009\": [], \"YU\": [], \"HAINING\": [], \"2001\": []}\n{\"DUCHARME\": [], \"1996\": [], \"FUNCK-BRENTANO\": [], \"2005\": [], \"JONES\": [], \"1996\": []}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Parameter": [
                        "CYP3A",
                        "CYP2D6"
                    ],
                    "Study": [
                        "vivo in several studies"
                    ]
                }
            ]
        ],
        [
            889,
            "The internal standards codeine and betaxolol were of USP reference standard.",
            [
                " {\"codeine\": [\"internal standards\", \"USP reference standard\"], \"betaxolol\": [\"USP reference standard\"]}",
                {
                    "Drug": [
                        "codeine",
                        "betaxolol"
                    ]
                }
            ]
        ],
        [
            890,
            "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.",
            [
                " {\"AGE\": [],\n \"GPR\": [\"general-purpose reagents\"],\n \"HPLC\": [\"HPLC grade solvents\"],\n \"processes\": [],\n \"extraction\": [],\n \"determinations\": []}",
                {}
            ]
        ],
        [
            891,
            "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).",
            [
                " {\"Urine samples\": [], \"Zorbax SB-CN column\": [\"Zorbax\", \"SB-CN\", \"column\"]}",
                {}
            ]
        ],
        [
            892,
            "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.",
            [
                " {\"ANOVA\": [\"analysis of variance\"], \"Asafetida\": [\"Asafetida\"], \"control\": [\"control\"], \"DEX\": [\"DEX\"], \"in vitro\": [\"in vitro\"], \"Post hoc Scheffe\u2019s multiple comparison test\": [\"Post hoc Scheffe\u2019s multiple comparison test\"], \"significant P value\": [\"significant P value\"], \"\u2a7d0.05\": [\"0.05\"]}",
                {
                    "Drug": [
                        "DEX"
                    ],
                    "Herb name": [
                        "Asafetida"
                    ]
                }
            ]
        ],
        [
            893,
            "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.",
            [
                " 1). The IC50 value for Asafetida resin alcoholic extract was found to be 12.5 \u00b5g/mL (Fig. [2]).\n\n{\"Asafetida resin alcoholic extract\": [\"Asafetida resin alcoholic extract\", \"the Asafetida resin alcoholic extract\"]}\n{\"DEX\": [\"DEX\"]}\n{\"DOR\": [\"DOR\", \"the formation of DOR\"]}\n{\"IC50\": [\"IC50 value\", \"the IC50 value\"]}\n{\"concentration dependent manner\": [\"concentration dependent manner\"]}\n\nIn another experiment, the effect of Asafetida resin alcoholic extract on the activity of 11\u03b2-HSD1 was investigated (Fig. [3]). The results showed that Asafetida resin alcoholic extract significantly decreased the activity of 11\u03b2-HSD1 in a concentration-dependent manner.\n\n{\"Asafetida resin alcoholic extract\": [\"Asafetida resin alcoholic extract\", \"the Asafetida resin alcoholic extract\"]}\n{\"11\u03b2-HSD1\": [\"11\u03b2-HSD1\", \"the activity of 11\u03b2-HSD1\"]}\n{\"concentration-dependent manner\": [\"concentration-dependent manner\"]}\n\nFurthermore, the study also investigated the effect of Asafetida resin alcoholic extract on the expression of 11\u03b2-HSD1 at the mRNA and protein levels.\n\n{\"Asafetida resin alcoholic extract\": [\"Asafetida resin alcoholic extract\"]}\n{\"11\u03b2-HSD1\": [\"11\u03b2-HSD1\"]}\n{\"mRNA\": [\"mRNA\"]}\n{\"protein levels\": [\"protein levels\"]}",
                {
                    "Study": [
                        "in vitro study"
                    ],
                    "Extraction process": [
                        "Asafetida resin alcoholic extract"
                    ],
                    "Drug": [
                        "DEX"
                    ]
                }
            ]
        ],
        [
            894,
            "The activation was highest at 25\u00a0\u03bcg/ml concentration.",
            [
                " {\"CONCENTRATION\": [\"25 \u03bcg/ml\"]}",
                {
                    "Amount": [
                        "25\u00a0\u03bcg/ml"
                    ]
                }
            ]
        ],
        [
            895,
            "The in vivo study was conducted on healthy human volunteers.",
            [
                " {\"AGE\": [\"healthy human volunteers\"]}",
                {
                    "Study": [
                        "vivo study"
                    ],
                    "Pathology": [
                        "healthy"
                    ]
                }
            ]
        ],
        [
            896,
            "Therefore, the clinical study was conducted to confirm the in vitro results.",
            [
                " {\"CLINICAL STUDY\": [\"the clinical study\"], \"IN VITRO RESULTS\": [\"in vitro results\"]}",
                {
                    "Study": [
                        "clinical study"
                    ]
                }
            ]
        ],
        [
            897,
            "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.",
            [
                " {\"Asafetida\": [\"Asafetida inhibitory effect\", \"an important finding of this study\"]}\n{\"CYP3A4\": [\"CYP3A4 metabolic activity\"]}",
                {
                    "Herb name": [
                        "Asafetida"
                    ],
                    "Target": [
                        "CYP3A4"
                    ]
                }
            ]
        ],
        [
            898,
            "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.",
            [
                " {\"Abemaciclib\": [\"Abemaciclib-related\"], \"Diarrhea\": [\"diarrhea\"], \"Dose reductions\": [\"dose reductions\"], \"Poor adherence\": [\"poor adherence\"], \"Patients\": [\"patients\"], \"Outcomes\": [\"outcomes\"], \"Quality of life\": [\"quality of life\"]}",
                {
                    "Drug": [
                        "abemaciclib"
                    ],
                    "Pathology": [
                        "diarrhea"
                    ]
                }
            ]
        ],
        [
            899,
            "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.",
            [
                " {\"AGE\": []}\n\nThe following format must be followed:{\"ENTITY\": [\"mentions of the entity found in text\"]}\n\n1. \"pharmacology\": [\"the described field\"],\n2. \"scientific article\": [],\n3. \"cited entities\": [],\n4. \"find\": [],\n5. \"every word\": [],\n6. \"referring to\": [],\n7. \"described entities\": [],\n8. \"mentions of ages\": [],\n9. \"text\": [],\n10. \"moreover\": [],\n11. \"the following format\": [],\n12. \"must be followed\": [],\n13. \"Please do not add\": [],\n14. \"supplementary\": [],\n15. \"information\": [],\n16. \"If no information is found for a field\": [],\n17. \"leave the field\": [],\n18. \"empty\": [],\n19. \"moreover\": [],\n20. \"the reckless pieces\": [],\n21. \"of information\": [],\n22. \"about possible effects\": [],\n23. \"of diet\": [],\n24. \"such as fatigue\": [],\n25. \"and loose stools\": [],\n26. \"elicited\": [],\n27. \"confusion\": [],\n28. \"in the patient\": []",
                {
                    "Pathology": [
                        "fatigue",
                        "loose stools"
                    ]
                }
            ]
        ]
    ],
    "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"AGE\": [\"mentions of ages found in text\"]}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"
}